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ZUSAMMENFASSUNG 
Die Entdeckung und Entwicklung von neuen Arzneimitteln ist ein interdisziplinärer 
Prozess an dem viele unterschiedliche Forschungsbereiche wie Biologie, Chemie, Medizin, 
Kristallographie, Computer Science und noch viele weitere beteiligt sind. Die 
Medizinalchemie leistet durch die Entwicklung von neuen Arzneimittel und Diagnostika 
einen wichtigen Beitrag in der heutigen Gesellschaft. 
Der erste Teil der Dissertation behandelt die Entwicklung und Synthese von Inhibitoren 
für EphB4 Rezeptor Tyrosin Kinase. EphB4 wird mit der Angiogenese, welche die Bildung 
neuer Blutgefässe beinhaltet und die Tumorzellen mit den nötigen Nährstoffen versorgen, in 
Verbindung gebracht. Protein Kinasen übernehmen durch die Phosphorylierung bestimmter 
Proteine eine wichtige Rolle bei der Zellsignalisierung. Daher ist die Hemmung der 
enzymatischen Aktivität durch kleine organische Moleküle ein wichtiges und weitgehend 
erforschtes Thema im Bereich von Drug Design. In dieser Arbeit wurden die biologischen 
Eigenschaften von einem EphB4 Inhibitor, welcher mittels Computer Simulation entdeckt 
wurde, durch die Synthese von mehreren Analoga verbessert. Deren Bindungsaffinitäten 
wurden mittels biochemischen und zellbasierten Tests bestimmt und in Folge dessen wurde 
ein Analog in einem in vivo cancer model validiert. 
Im zweiten Teil der Arbeit wird die Entwicklung von neuen Liganden für 
Bromodomänen ausgehend von einem potentiellen micromolaren Liganden, welcher durch in 
silico Methoden entdeckt wurde, beschrieben. Bromodomänen sind epigenetische Leser 
Proteine, die eine wichtige Rolle im Bereich der Arzneimittelforschung darstellen und somit 
als wertvolle Zielmoleküle für die Entwicklung von neuen Arzneimittel in Betracht gezogen 
werden können. Durch strukturbasiertes Design von Analoga konnten nanomolare potentielle 
CREBBP Liganden mit einer sehr hohen Selektivität innerhalb der Familie der 
Bromodomänen erzielt werden. Die Untersuchung von den synthetisierten Liganden gegen 
einige Krebszellen zeigte, dass diese möglicherweise für eine Therapie gegen Leukämie 
anwendbar sind. 
Im Rahmen der Dissertation wurde auch an Aktin, ein attraktives aber bis dato wenig 
erforschtes Zielmolekül in der Medizinalchemie, gearbeitet. Aktin ist ein Zytoskelettprotein, 
welches in vielen wichtigen zellulären Funktionen involviert ist und auch bei pathogenen 
zellulären Prozessen wie zum Beispiel Angiogenese, Zelladhäsion, Zytokinese oder Metastasen 
eine wichtige Rolle spielt. Mit Hilfe von neuen Berechnungsansätzen wurde eine Auswahl von 
vielversprechenden Molekülen, die an die ATP Bindungsstelle von Aktin binden, synthetisiert 
und getestet. Diese kleinen organischen Moleküle enthalten nützliche Tools um die Dynamik 
von Aktin zu studieren, da es ihnen möglich ist das Zytoskelett von Aktin in Zellen zu 
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modifizieren und die Aktin Polymerisation in vitro zu hemmen. Daher können diese Moleküle 
als Ansatzpunkt für die Entwicklung von weiteren potentiellen Aktin Inhibitoren dienen. 
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SUMMARY 
Drug discovery and development is a very challenging interdisciplinary endeavor that 
needs the contribution of medical doctors, biologists, chemists, X-ray crystallographers, and 
computer scientists, among many others, in order to be successful.  
The first part of this Ph. D. thesis focuses on the development of EphB4 receptor 
tyrosine kinase inhibitors. EphB4 has been linked to angiogenesis, which involves the 
formation of new blood vessels supplying tumor cells with the necessary nutrients. Protein 
kinases play a key role in cell signaling by phosphorylating specific proteins and thus, the 
inhibition of their enzymatic activity by small organic molecules has been widely explored in 
drug design. In this work, the biological properties of an EphB4 inhibitor identified by 
computer simulations were improved by the synthesis of several analogues. Their binding 
affinities were characterized by an array of biochemical and cell based assays, concluding 
with the validation of one of the most promising derivatives in an in vivo cancer xenograft 
model.  
The second part of the thesis deals with the development of novel bromodomain ligands 
starting from a micromolar potent in silico discovered hit. Bromodomain proteins are 
epigenetic readers that constitute an emerging topic in the field of drug discovery and are 
thus considered as very attractive targets for the development of novel therapeutic drugs. A 
careful, structure-based design of analogues resulted in the discovery of nanomolar potent 
CREBBP ligands with an unprecedented selectivity profile among the bromodomain protein 
family. Moreover, the screening of the synthesized analogues against several cancer cell lines 
revealed leukemia as a possible therapeutical application for the developed compounds. 
The third aspect of this work deals with actin: a very attractive, but yet unexplored 
target in medicinal chemistry. Actin is a cytoskeletal protein that participates in many 
important cellular functions and has been linked to key pathogenic cellular processes such as 
angiogenesis, cell adhesion, cytokinesis and metastasis. A new computational approach to 
discover novel actin leads targeting the ATP binding site of actin resulted in the selection of 
promising compounds, which were synthesized and tested. The developed small organic 
molecules constitute valuable tools for the study of actin dynamics as they are able to modify 
the actin cytoskeleton in cells and moderately inhibit actin polymerization in vitro; thus 
becoming promising starting hits for the development of more potent actin binders.   
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1 
INTRODUCTION 
 
1.1 Motivation 
The reduction in chemistry research in pharmaceutical industry due to economic 
reasons has generated an important niche, creating wide opportunities for academic 
research groups to contribute at early stages of drug development campaigns.1 In fact, 
important discoveries that shaped the pharmaceutical industry in the last century such as 
the isolation of penicillin and its use as antibiotic by Alexander Fleming in 1928 or the use 
of nucleoside analogues such as AZT as antiviral drugs, are examples of ground-breaking 
results stemming from academic research groups. In fact, between 1970 and 2009, there 
were 93 new small-molecule drug applications filled in the USA, 28 of which originated in 
academia.2  
1.1.1 Drug discovery process 
The development of drugs is a long and expensive process (Figure 1),3 which, although 
not necessarily, usually starts with the identification of a target receptor that needs to be 
affected in order to get the desired therapeutic effect. The next step is to find an active 
compound that can achieve such an effect, which is referred to as a hit. Hit identification 
can either be done by screening a compound library composed of several thousand 
compounds experimentally in vitro (High Throughput Screening, HTS) or in silico. For 
this purpose, different types of libraries can be used, such as in house libraries, commercial 
libraries and targeted libraries, which are libraries of compounds compiled obeying certain 
specific criteria. If the studied target has known inhibitors or ligands, the library can be 
assembled with molecules that resemble in structure or properties to the known substrates 
(referred to as ‘‘ligand-based design’’). Moreover, if a crystal structure of the target is 
known, ‘‘structure-based design’’ can be performed, where compounds that are 
CHAPTER 1: INTRODUCTION 
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complementary to the binding site are pursued.4 In ‘‘structure-based design’’, virtual 
screening and de novo design approaches are valuable tools able to analyze the receptor 
shape and interaction sites. 
 
Figure 1.  Drug discovery process. 
Once the hits have been secured, in vitro validation, which is based on assays using 
isolated proteins and can easily be automated, enables the screening of thousands of 
compounds in a short period of time (HTS). Compounds showing a positive effect in vitro 
are further tested on cell based assays.  
The hit compounds usually present modest activity, which commonly lies in the 
micromolar range. During hit to lead optimization dramatic changes are performed into the 
original chemical template aiming to identify the essential core of the lead compound and 
improve the potency towards the nanomolar range.5 Structure-Activity Relationships 
(SAR), physico-chemical properties, chemical tractability and synthetic accessibility are 
thoroughly studied through the synthesis of numerous derivatives. Once the molecule’s core 
has been established, the lead needs to be optimized by making changes in the molecule’s 
periphery in order to obtain target affinity, selectivity, water solubility, membrane 
permeability and drug-like properties. At this stage, very small changes in the molecule can 
lead to significant effects when testing the compounds in cells or in vivo.  
Finally, compounds showing the desired therapeutic effect on animal models (in vivo) 
are selected for clinical trials, which are divided in different phases. In the first phase 
safety is evaluated; during phase II the efficacy is tested; and finally, the effectiveness, 
benefits and possible adverse reactions are studied during the phase III.  
1.2 Challenges 
The major challenges in the development of drug candidates in an academic 
environment are summarized below.  
► Target selection: The modulation of the target of choice should be 
translated into a desired therapeutical effect, and thus, compelling biological 
1.2 CHALLENGES 
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evidence should be available in the literature that validates the target as 
therapeutically relevant. Moreover, novelty and druggability of the target are 
important factors to take into account.  
► Virtual screening: Due to the inaccessibility of high throughput screening 
facilities in academic institutions, collaborations with bioinformatics groups are 
often necessary in order to carry out virtual screening campaigns to identify 
hits in those projects where the structure of the receptor is known.  
► Lead optimization: Lead optimization is the major expense during pre-
clinical drug development in pharmaceutical industry due to the large number 
of analogues that are synthesized to improve the potency of the identified hits. 
Organic synthesis is highly labor intensive and unpredictable, as reactions 
might not work as expected, yields might be poor and purifications tedious.1 In 
industry, a minimum of hundreds of analogues are synthesized and tested 
during a successful optimization campaign. However, due to the nature of the 
Ph. D. work with limited time and human work force, a careful structure based 
design is necessary prior to synthesis, so that a reduced number of analogues 
are synthesized in a rational fashion. 
► Biological evaluation: In order to asses the potency and efficacy of the 
synthesized analogues, several in vitro and cell based assays need to be 
established, which can potentially include protein expression and purification, 
X-ray crystallography, isothermal titration calorimetry (ITC), surface plasmon 
resonance (SPR) and differential scanning fluorimetry (DSF) among many 
other techniques. As a consequence, multidisciplinary expertise is required and 
academic collaborations with biological groups are often sought.  
1.3 Outline of the thesis 
The goal of this thesis is the design, synthesis and biophysical characterization of lead 
compounds against a variety of biological targets (including kinases, bromodomains and 
actin) that are relevant for pathologies such as cancer, inflammation and 
neurodegenerative diseases. Such a multidisciplinar work has been achieved thanks to 
collaborations with the group of Prof. Dr. Amedeo Caflisch (Computational Structural 
Biology, Biochemistry Institute, UZH). 
Chapter 2 describes the design of kinase inhibitors based on the X-ray crystal 
structures of the catalytic domain of the EphA3 tyrosine kinase in complex with two 
inhibitor hits previously discovered in silico. Several derivatives were synthesized and 
CHAPTER 1: INTRODUCTION 
10 
 
characterized with an array of different techniques including enzymatic assays, DSF, SPR, 
cell based assays and in vivo efficacy studies.  
In chapter 3, a medicinal chemistry campaign starting from an in silico discovered hit 
targeting the CREBBP bromodomain is presented. The quest for bromodomain inhibitors 
as potential therapeutic tools has recently begun thanks to the growing understanding of 
epigenetic processes. During this work, the potency of the CREBBP hit was improved and 
the selectivity profile of the synthesized analogues was determined in a broad panel of 
bromodomain proteins. In addition, the cell growth inhibition of the analogues was 
characterized in different human cancer cell lines.  
Chapter 4 deals with the in silico design, synthesis and biological evaluation of actin 
inhibitor hits. Actin constitutes a novel and attractive target, which has been linked to 
several key cellular processes, including cell division and metastasis. However, no small 
organic inhibitors (except complex natural products) are known to interact with actin, 
which makes the development of simple actin inhibitors highly valuable.  
Finally, chapter 5 summarizes the work presented in this thesis and suggests the next 
possible steps for future research.…………………………………………………………………………………………………….. 
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2 
EPH TYROSINE KINASE INHIBITORS 
2.1 Introduction 
2.1.1 Function, classification and structure of protein kinases 
Protein kinases are enzymes that catalyze the transfer of the γ phosphate in ATP to 
the hydroxyl group of serine, threonine or tyrosine in other proteins (Figure 1).1   
 
Figure 1. The protein kinase catalyzes the transfer of the γ-phosphate of adenosine 
triphosphate (ATP) to a hydroxyl-containing amino acid side chain.  
Protein phosphorylation is an important post-translational modification (PTM). 
During protein biosynthesis, the synthesized polypeptide chains undergo PTM, which are 
covalent modifications that alter both their structure and function. Protein 
phosphorylation causes a conformational rearrangement in the protein, modifying its 
function and transmitting a cellular response. This process is reversible and the 
dephosphorylation is performed by phosphatases.2 
CHAPTER 2: EPH TYROSINE KINASE INHIBITORS 
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Kinases are one of the largest protein families, with 518 protein kinases encoded in the 
human genome.3 The so called conventional protein kinases (the most abundant ones) are 
divided into eight families: AGC, CAMK, CK1, CMGC, STE, TK, TKL and others 
(Figure 2).3                                                              
Figure 2. Phylogenetic tree of the conventional human protein kinases, which are 
divided in eight families and are further classified into subfamilies. A close-up of 
the tyrosine kinase (TK) family (composed of 80 kinases), relevant in this work, is 
shown on the right. Special attention will be given to the ephrin receptors later in 
this chapter (highlighted in bold). 
Receptor tyrosine kinases (RTKs, Figure 2) are transmembrane proteins: the C-
terminus holds the protein tyrosine kinase domain and is located in the cytoplasm of the 
cell, whereas the N-terminus contains the ligand binding domain and is present in the cell 
surface (Figure 3, A).4 Both regions are connected by a transmembrane domain (Figure 3, 
A, in green). Signal molecules such as protein growth factors bind to the extracellular 
domain (N-terminal domain), causing two receptors to dimerize (Figure 3, B). The 
dimerization activates the tyrosine kinase activity and autophosphorylation of tyrosine 
residues in the receptor tyrosine kinase takes place (Figure 3, C). In the next step, a 
variety of signaling proteins bind to the autophosphorylated tyrosines. As a result, 
signaling proteins get phosphorylated and a cellular response is transmitted (Figure 3, D).  
 
 
 
2.1 INTRODUCTION 
15 
 
 
Figure 3. Dimerization and activation of receptor tyrosine kinases.4 
Tyrosine kinase domains (Figure 3, A) are composed of about 250 aminoacids and can 
be divided into a carboxy terminal (C-terminal, Figure 4, in blue) and an amino terminal 
(N-terminal, Figure 4, in magenta) lobes or subdomains. The N-terminal subdomain 
consists of a barrel of β sheets and one conserved α helix, whereas the C-terminal lobe is 
primarily composed of α helices and accommodates the peptide substrate (Figure 4, shown 
as sticks in green).  
 
Figure 4. Structure of the insulin receptor tyrosine kinase. The N-terminal lobe is 
shown in magenta, the hinge region in yellow and the C-terminal lobe in blue. The 
receptor kinase domain is shown with an ATP analogue and its peptide substrate 
bound to the C-terminal lobe (PDB code 1IR3). 
Both subdomains are connected by the so called hinge region (Figure 4, in yellow), 
where the ATP and a Mg2+ ion bind.5, 6 All kinases possess a flexible activation loop 
(Figure 4, in red) that can adopt different conformations and regulates the kinase activity. 
The DFG is a sequence of three amino acids, Asp-Phe-Gly, located within the activation 
loop. This segment can adopt different conformations depending on the orientation of the 
phenylalanine and aspartate residues. In the so called DFG-in conformation the enzyme is 
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catalytically active (usually phosphorylated), whereas in the DFG-out conformation the 
activation loop prevents the substrate from binding and the enzyme is dysfunctional.7 
The ATP binding pocket is divided into different subpockets as indicated in Figure 5.8 
The gatekeeper residue (threonine in Figure 5, but variable among kinases) determines the 
size of the hydrophobic pocket, and is therefore of high importance for the design of 
selective kinase inhibitors. The adenosine moiety of ATP forms two hydrogen bonds within 
the hinge region, a binding mode which is conserved in all kinases (with the exception of 
PIM kinases). As the backbone of the hinge region is identical in almost all kinases, the 
design of selective kinase inhibitors has proven to be very challenging. In the next section, 
an overview of the different kinase inhibitor ligands developed to overcome the above 
mentioned selectivity issue is given. 
 
Figure 5. Schematic representation of the binding site of an ATP bound kinase.  
2.1.2 Protein kinases as drug targets and their binding mode 
Protein kinases play a key role in cell biology, metabolism, cell migration, apoptosis, 
proliferation and differentiation. The activity of protein kinases has been linked to a wide 
variety of therapeutic areas such as oncology,7 neurology,9 immunology,10 cardiology11 and 
infectious diseases.12 Among the mentioned therapeutic areas cancer has been notably 
addressed. As certain protein kinases are over-expressed in many cancer cells, kinase 
inhibition has been seeked for the development of more selective anti-cancer agents.  
Since the first ATP competitive kinase inhibitor staurosporine in 1986,13 several small 
molecule kinase inhibitors have been approved by the U.S. Food and Drug Administration 
(FDA) for cancer treatment (Figure 6).14 Kinase inhibitors are classified into covalent 
(Figure 5, in red) or non-covalent inhibitors, and the latter are further divided into 
different types depending on their binding mode: type I-III.  
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Figure 6. Kinase inhibitors approved by the FDA.14 Structural motifs that belong 
to type II inhibitors and bind to the DFG-out pocket are highlighted in blue, and 
the electrophile moieties that react in a covalent fashion with the protein are shown 
in red. 
I. Non-covalent kinase inhibitors 
The first ever developed kinase inhibitors have been classified as type I, as they bind 
within the ATP binding site mimicking the purine ring of ATP and are thus, direct ATP 
competitors. They recognize the activated state of the kinase, which is characterized by an 
open conformation of the activation loop (DFG-in, Figure 4, in red).15  
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Type I inhibitors usually consist of a heterocyclic ring system that forms one to three 
hydrogen bonds with the hinge region mimicking the adenine of ATP. In addition, they 
can form extra interactions in adjacent hydrophobic regions. An schematic representation 
of a type I inhibitor pharmacophore is shown in Figure 7, A.7, 15-17  
The main drawback of type I inhibitors is the low kinase selectivity, due to the high 
degree of sequence and structural similarity in the ATP binding site in all kinases. This 
translates in undesired off-target side effects and toxicity.18, 19 A very well-known FDA 
approved drug for the treatment of chronic myelogenous leukemia, dasatinib, is a clear 
example of a type I kinase inhibitor (Figure 7, B-D).20 Dasatinib  binds to the active form 
(DFG-in) of the kinase and forms two hydrogen bonds with the hinge region and a third 
one with the gatekeeper residue. Due to the low sequence variation of the hinge region 
among different kinases, dasatinib presents a broad selectivity profile (Figure 6, D).   
 
Figure 7. A) Type I inhibitor pharmacophore. The hydrogen bonds with the hinge 
region are shown as dashed lines. Hydrogen bond donors are indicated as D, 
hydrogen bond acceptors as A and hydrophobic moieties are labeled HYD.15 B) 
Kinase bound to dasatinib in its active form as a 2D representation. C) 3D 
representation of the Abl1 kinase in complex with dasatinib (PDB code 2GQG). 
The hinge region is shown in yellow, the activation loop in light blue and the 
ligand, dasatinib, in green. The DFG residues are shown as sticks in blue. D) 
Selectivity profile of dasatinib against 442 kinases. The dissociation constant, Kd, is 
shown as red spheres.18 
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In contrast to type I inhibitors, type II ligands do not compete with ATP. They 
interact with an inactive conformation of the kinase (unphosphorylated), which contains a 
different conformation of the activation loop (Figure 4). In a typical type II inhibition 
mode, the activation loop is in the DFG-out conformation. A new pocket arises from the 
change in conformation of the phenylalanine residue (located 10 Å away)16 in the DFG 
loop (activation loop), and as a result, neither ATP nor protein substrates can bind and 
the protein is inactive (Figure 8).15  
While still interacting in the hinge region forming one to three hydrogen bonds, type 
II inhibitors exploit new interactions within the newly formed lipophilic pocket in the back 
of the protein (Figure 8, B).15 The extra interactions formed in the DFG-out pocket and 
the lower sequence conservation on the inactive kinase conformation among different 
kinases provide type II inhibitors a higher degree of selectivity.19, 21, 22 Moreover, not all 
kinases are able to adopt such a conformation.16 In fact, kinases that can adopt a DFG-out 
conformation often have a small gatekeeper residue, usually threonine.23 Another advantage 
offered by type II inhibitors is the slower dissociation constants (koff) and longer residence 
times, which makes them valuable tools for drug development.24, 25 The main drawbacks of 
type II kinase inhibitors are their high molecular weight (which influences cell permeability 
and ligand efficiency)26, 27 and a higher vulnerability to mutations. A mutation in a residue 
not involved in the catalytic activity of the kinase or ATP binding could still impair the 
binding of a type II compound, decreasing its efficacy. On the other hand, a mutation that 
prevents a type I inhibitor from binding would, at the same time, block the binding of 
ATP (since they share the same binding site) and result in a dysfunctional kinase.15, 28  
 A clear example of a type II inhibitor is imatinib (Figure 8, B),29 which was the first 
kinase small molecule inhibitor to reach the market and is used for the treatment of 
chronic myelogenous leukemia, acute lymphoblastic leukemia, aggressive systemic 
mastoytosis and gastrointestinal stromal tumor.14 The pyridine nitrogen of imatinib forms 
one hydrogen bond with the hinge region, and interacts with the glutamic acid of the      
α-helix and the aspartic acid of the DFG-out pocket via hydrogen bonds with its amide 
linker, a conserved interaction throughout type II inhibitors (Figure 8, A, B, C).15 Imatinib 
presents a more specific selectivity profile (Figure 8, D) compared to dasatinib (Figure 7, 
D), as generally seen for type II inhibitors. The main strategy for the development of 
imatinib and other type II inhibitors is known as hybrid-design,30 where a type I binder is 
extended with a hydrophobic tail that targets the DFG-out pocket and forms van der 
Waals interactions in that region. The mentioned hydrophobic tail is usually linked to the 
type I motif by amides or ureas, which provide a hydrogen bond donor that interacts with 
the glutamic acid and a hydrogen bond acceptor that interacts with the aspartic acid 
residue of the activation loop (Figure 6, shown in blue).30   
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Figure 8. A) Type II inhibitor pharmacophore. The hydrogen bonds with the 
hinge region, the glutamic acid residue located in the α-helix and the activation 
loop bearing a DFG-out conformation are shown as dashed lines. Hydrogen bond 
donors are indicated as D, hydrogen bond acceptors as A and hydrophobic moieties 
are labeled HYD.15 B) Kinase bound to imatinib in its inactive DFG-out 
conformation as 2D representation. C) 3D representation of the Abl1 kinase in 
complex with imatinib (PDB code 2HYY). The hinge region is shown in yellow, the 
activation loop in light blue and the ligand, imatinib, in green. The DFG residues 
are shown as sticks in blue. D) Selectivity profile of imatinib against 442 kinases. 
The Kd is shown as red spheres.18 
A third class of kinase inhibitors, type I1/2 has been defined, whose binding mode lies 
in between type I and type II. They bind to the kinase in the active DFG-in conformation, 
but they extend their interactions to the hydrophobic back pocket (Figure 5) establishing 
the characteristic hydrogen bonds present in type II inhibitors (Figure 9, A-C). The size 
and nature of the backpocket are provided by the gatekeeper residue, which contributes 
towards a selectivity gain. Potent and selective EphB4 kinase I1/2 inhibitors have 
previously been developed in our group in collaboration with Prof. Amedeo Caflisch 
(Biochemistry Institute, UZH).8, 31-33 As an example, a nanomolar potent xanthine type I1/2 
inhibitor (I) is shown in Figure 9, B.  
2.1 INTRODUCTION 
21 
 
 
Figure 9. A) Type I1/2 inhibitor pharmacophore. The hydrogen bonds with the 
hinge region, the glutamic acid residue located in the α-helix and the activation 
loop bearing a DFG-in active conformation are shown as dashed lines. Hydrogen 
bond donors are indicated as D, hydrogen bond acceptors as A and hydrophobic 
moieties are labeled HYD.15 B) Kinase bound to the in house developed EphB4 
inhibitor I in its active DFG-in conformation as a 2D representation. C) 3D 
representation of the EphA3 kinase in complex with compound I (PDB code 
4GK2). The hinge region is shown in yellow, the activation loop in light blue and 
the ligand, I, in green. The DFG residues are shown as sticks in blue. D) Selectivity 
profile of I against 143 kinases.31  
The pyrimidine ring of ligand I is involved in two hydrogen bonds with the hinge 
region, whereas the phenol is located in the hydrophobic back pocket. The hydroxyl group 
of the aromatic ring donates a hydrogen bond to the conserved aspartic acid and accepts a 
hydrogen bond from the backbone of the DFG loop in the DFG-in conformation (Figure 9, 
B, C).31 The selectivity profile of compound I shows strong inhibition of a relatively small 
fraction of the human kinome, most of them having a threonine residue as gatekeeper.31, 32  
Type III inhibitors are allosteric inhibitors that bind outside of the catalytic domain 
(ATP-binding site) of the kinase, but in regions where the activity of the enzyme can be 
modulated. Since these regions are usually unique to the kinase, higher selectivities can be 
obtained with type III binders. A recent example of an allosteric inhibitor is GNF-2 and its 
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analogue GNF-5, which were developed by Novartis and bind in an adjacent pocket to the 
ATP binding site of the Abl kinase (Figure 10).34, 35 Only a few examples of type III kinase 
inhibitors have been reported so far,23 but there is an emerging interest in the area due to 
successful results obtained with the treatment of GNF-5 in combination with the type I 
and II inhibitors, dasatinib and nilotinib (Figure 6), in an in vivo leukemia model.34    
 
Figure 10. Imatinib and the allosteric inhibitor GNF-2 in complex with Abl kinase 
(PDB code 3K5V).  
II. Covalent kinase inhibitors 
The last class of kinase inhibitors, covalent inhibitors, bear electrophiles such as good 
leaving groups or Michael acceptors that form covalent bonds with cysteine or other 
nucleophilic residues in the ATP binding pocket.36, 37 As a result, the inhibitor irreversible 
blocks the ATP binding side. The main disadvantage of covalent inhibitors is their high 
toxicity. However, higher potency is achieved due to prolongued inhibition and off-target 
effects are usually minimized.23, 30 Ibrutinib (Figure 6) is a covalent Bruton’s tyrosine 
kinase inhibitor approved by the FDA in 2013 for the treatment of leukemia and 
lymphoma.38 The double bond of the inhibitor is nucleophilically attacked by a cysteine 
residue located in the ATP binding site of the kinase, forming a C-S covalent bond. 
Despite their higher potency and minimized side effects,  covalent inhibitors have only 
emerged recently, are less abundant and have been barely studied in comparison with non-
covalent inhibitors.16  
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2.1.3 Eph receptor tyrosine kinases 
Eph receptor tyrosine kinases are the largest receptor tyrosine kinase family (Figure 
2).39 There are nine EphA receptors, which bind to five ephrin-A ligands, and five EphB 
receptors that bind to three ephrin-B ligands. Eph receptors and ephrin ligands are 
membrane bound molecules that require cell contact in order to interact with each other.  
An in detail representation of the EphB receptor is shown in Figure 11. Eph receptors 
are composed of a ligand-binding domain located at the end of the extracellular domain 
(N-terminal domain), which is directed towards the inner part of the cell by a linker: a 
cysteine rich region and two glycoproteins (fibronectins). The cysteine rich regions and 
fibronectins do not participate in ligand binding: the former stabilize the ligand-receptor 
complex and the latter play a structural function maintaining a correct distance between 
the two cells. Inside the cell, the receptor is composed of the so called juxtamembrane 
region, the kinase domain and two other domains (sterile-α-domain and PDZ). The ligands 
of the Eph receptors, ephrins, are bound to the membrane of a second cell (Figure 11). 
 
Figure 11. Structure of Eph receptor.8, 40 The N-terminal domain is composed of a 
ligand binding domain, a cysteine rich domain and two fibronectin type III repeats. 
The kinase domain is located inside the cell, followed by a sterile-α-domain and a 
PDZ binding domain. Ephrin-B is located in another cell and consists of the 
receptor binding domain and a cytoplasmatic domain. 
The Eph-ephrin system is characterized by its bi-directional signaling, meaning that 
they can downstream signal into the Eph containing cell and upstream into the ephrin 
containing cell.41 The bi-directional signaling enables cell-cell communication, cell 
migration, cell repulsion and adhesion to the extracellular matrix among other processes.  
The cell-cell interaction that occurs through Eph-ephrin interaction leads to a variety 
of cellular responses. The cytoskeleton is greatly affected by such interaction and changes 
in actin organization, cell shape, adhesion, repulsion, migration, differentiation and 
proliferation are promoted.42 As a consequence, Eph-ephrin interactions modulate several 
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processes of the nervous system, where they are highly expressed, such as axon guidance 
during neural development, development of the visual system and vascular development 
during embryogenesis.43  
Eph receptors and ephrins are also involved in the growth, maturation and remodeling 
of blood vessels. EphB4-ephrinB2 interaction in particular plays a prominent role in the 
cardiovascular development and it regulates vascularization of malignant tumors. In fact, 
EphB4 overexpression has been linked to several tumor types such as breast, prostate, 
bladder, uterus, melanoma and ovarian cancer among others.11, 44-47 EphB4 has also been 
associated to angiogenesis, tumor growth and metastasis, making it a valuable target for 
therapeutical applications. However, the role of EphB4 in cancer remains a matter of 
debate. On the one side, EphB4 is known to promote tumor angiogenesis and growth when 
it is expressed on tumor cells that interact with ephrin-B2 located in the endothelium.48 On 
the other side, EphB4 can either promote or suppress tumor growth depending on the 
tumor type and model.45, 49-52  
Several anti-cancer strategies that address the EphB4-ephrinB2 interaction have been 
developed. Soluble fusion proteins of the extracellular domain of EphB4 that antagonize 
EphB4-ephrinB2 interaction could inhibit tumor growth and angiogenesis in tumor 
xenograft models, confirming the importance of EphB4 in oncology.53, 54 Moreover, 
monoclonal antibodies and peptides that block EphB4-ephrinB2 interaction have also been 
described.55, 56 Surprisingly, just a few nanomolar potent Eph kinase inhibitors have been 
disclosed (Figure 12),57-66 which present different binding modes:15 type I (such as II57 and 
III,58 which are ATP competitors that recognize the activated state of the kinase), type II 
(e.g VI63 and VIII64) that interact with an inactive conformation of the kinase and 
generally offer better selectivity profiles) and type I I1/2 inhibitors (e.g. IV60) that bind to 
the kinase in the active DFG-in conformation, but extend their interactions to the 
hydrophobic back pocket establishing the characteristic hydrogen bonds present in type II 
inhibitors.15 
The first reported efficacy data with an EphB4 inhibitor was conducted with the 
selective inhibitor NVP-BHG712 (VIII),64 which was shown to inhibit VEGF driven 
angiogenesis in vivo.64 Several of the FDA approved kinase inhibitors, such as dasatinib,67 
bosutinib, vandetanib, crizotinib and nilotinib,68-70  as well as other kinase inhibitors71-75 are 
also able to inhibit EphB4 among other kinases.  
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Figure 12. Previously reported nanomolar potent small organic molecule ephrin 
kinase inhibitors.57-66 
Our groups at the University of Zurich have greatly contributed to the discovery, 
optimization and characterization of several selective and potent EphB4 inhibitors. On the 
outset of these discoveries high throughput docking techniques were applied. Specifically, 
we have developed an efficient computational method called ALTA (Anchor-based Library 
Tailoring) that generates a focused library and prioritizes molecular fragments according to 
their binding energy.76 As a first step, millions of commercially available molecules are 
automatically decomposed into rigid fragments, which are docked in the binding site of the 
protein. Fragments with the most favorable binding free energy (also called anchors) are 
used to retrieve the molecules which they originated from. These molecules are then 
submitted to flexible ligand docking. Finally, compounds are ranked according to their 
interaction energy taking into account desolvation effects, visually inspected and chosen for 
testing. This in silico fragment based approach has resulted, after medicinal chemistry 
optimization, in the nanomolar potent xanthine I31, 32 and pyrimidoisoquinolinone XI (with 
an IC50 value of 9.4 μM in in vitro FRET assays)33 (Figure 13).  
We have also successfully applied semi-empirical quantum mechanical (QM) 
calculations for rapidly screening compound poses generated by high throughput docking.77 
A total of 2.7 million of commercially available compounds were docked in the ATP 
binding site of EphB4 generating ca. 100 million poses.  Their binding energy was 
estimated by calculating the formation enthalpy in the presence of small molecules (called 
QM probes) emulating functional groups in the hinge region and at the entrance of the 
binding pocket. This study resulted in the discovery of 2-formamido-4-phenylthiophene-3-
carboxamide XII (Figure 13), which has an IC50 value of 5.9 μM for EphB4 in a FRET 
enzymatic assay. Importantly, the binding mode was confirmed by X-ray crystallography 
of a close derivative of XII in complex with EphA3 (PDB code 4TWO).78  
Further high throughput docking studies were performed using an inactivated DFG-
out conformation of the kinase obtained by explicit solvent molecular dynamic (MD) 
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simulations.79 This campaign yielded a series of 5-(piperazine-1-yl)isoquinoline derivatives 
including inhibitor XIII (Figure 13) as novel type II inhibitors that present low 
micromolar affinities for EphA3 and unphosphorylated Abelson tyrosine kinase (Abl1).79 
In another high throughput docking campaign, an evaluation of the hydrogen bonding 
penalty upon ligand binding was integrated to the binding energy calculation of docked 
molecules.80 This study resulted in the discovery of three novel Eph inhibitor scaffolds: 
triazolo[4,3-a]quinazolines (XIV), phenylquinolines (XV) and quinoxalines (XVI, Figure 
13). 
         
Figure 13. EphB4 tyrosine kinase inhibitors identified and optimized (I, XI) in 
the Caflisch and Nevado groups.33, 76, 77, 79, 80  
In the next section, the development of the quinoxaline XVI scaffold into potent type 
I1/2 and II kinase inhibitors is presented.  
2.2 Pyrrolo[3, 2-b]Quinoxaline Derivatives as Types 
I1/2 and II Eph Tyrosine Kinase Inhibitors 
As seen above, our groups have recently focused on the in silico design, synthesis and 
computational-aided optimization of potent and selective receptor tyrosine kinase 
inhibitors. Successful campaigns have yielded single-digit nanomolar EphB4 inhibitors 
whose potential antiproliferative activities have been characterized by cellular assays.31-33 
Furthermore, the predicted binding mode could also be confirmed by X-Ray diffraction 
analysis of their complexes with EphA3. Given the critical role of Eph receptors and 
(Eph)–ephrin signaling in tumor growth and progression,81 a subset of these compounds are 
currently being pursued towards pre-clinical development.  
In the next sections we describe a multidisciplinary campaign towards the design of 
novel and potent, type I1/2 and II tyrosine kinase inhibitors based on the crystal structure 
of two type I inhibitors. The parent pyrrolo[3,2-b]quinoxaline scaffold XVI was decorated 
with characteristic functional groups present in previously successful type II binders, thus 
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speeding up the hit to lead optimization campaign. The binding kinetics of the low-
nanomolar derivatives 11d (type I1/2) and 7m (type II) were characterized by surface 
plasmon resonance (SPR) measurements. Extensive profiling by biochemical (competition 
binding) and cellular assays, together with pharmacokinetic measurements in mice resulted 
in the prioritization of inhibitor 11d for final validation in vivo by a human breast cancer 
xenograft. 
2.2.1 Crystal structures of type I inhibitors A and B with 
EphA3 
I. Docking validation by X-Ray diffraction analysis of binding 
complex 
Recently, we reported the discovery of two type I EphB4 inhibitors A and B by 
automated docking.80 The in silico predicted binding mode of these molecules is confirmed 
here by X-ray diffraction analysis of the catalytic domain of EphA3 in complex with both 
A and B (Figure 14). The pyrrolo[3,2-b]quinoxaline scaffold occupies the ATP binding site 
with the phenyl substituent nestled into the so-called hydrophobic pocket. The amino 
substituent at position 2 of the pyrrole ring is involved in a bifurcated hydrogen bond with 
the side chain hydroxyl of the Thr693 gatekeeper and the backbone carbonyl of Glu694. 
Furthermore, in the structure with inhibitor A, the amide substituent at position 3 of the 
pyrrole ring is optimally oriented for two hydrogen bonds with the backbone polar groups 
of Met696 so that A forms a total of three hydrogen bonds with the backbone of the hinge 
region. Only two hydrogen bonds with the same region are observed for inhibitor B due to 
the ethoxy-propyl substitution at the nitrogen of the amide whose trans configuration 
prevents it to act as donor to the carbonyl group of Met696. The lack of this hydrogen 
bond is consistent with the about 10-fold weaker affinity of inhibitor B with respect to A 
(IC50 of 300 nM for EphB4)80 which might also originate, at least in part, from the different 
substituents of the phenyl ring in the hydrophobic pocket, i.e., -OCH3 and -Cl in A and B, 
respectively. 
II. Design of type I1/2 and type II derivatives based on the X-ray 
crystal structure of the type I inhibitors A and B 
Based on our previous experience31, 32 and earlier reports towards the synthesis of 
potent type I kinase inhibitors,15 several modifications within the phenyl ring were designed 
in order to fine tune the interactions of the quinoxaline inhibitors with the threonine 
gatekeeper residue (Thr693) of EphB4. Due to the rather limited space around the phenyl 
group revealed by the binding modes of A and B, the introduction of small substituents 
was envisioned, including the incorporation of a methyl and a hydroxyl group at positions 
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2 and 5, a combination that had been successfully exploited in our previous studies 
developing nanomolar inhibitors of EphB4.32  
In addition, the binding modes of inhibitors A and B suggested the possibility to 
extend the quinoxaline scaffold into the allosteric binding site by substitution of the phenyl 
ring, resulting in type II inhibitors. Our design campaign targeting the back pocket of the 
kinase relied on the introduction of a variety of substituents, some of which are present in 
type II inhibitors. The so-called “tail” moiety of type II inhibitors, located within the 
allosteric binding site, is characterized by a hydrogen bond donor-acceptor pair (usually an 
amide or an urea), linked to a hydrophobic substituent that occupies the newly formed 
pocket in the DFG out conformation of the kinase.7, 16, 30 Amide, urea and thiourea linkers 
were incorporated onto the quinoxaline scaffold and attached to a m-CF3-phenyl moiety 
present in some type II kinase inhibitors, in analogy to AAL993,82 sorafenib,83, 84 and GNF-
5837 85 (7b-d, 7g-i, 7l, 7m, 12n). A cyclopropyl ring, a common motif in p38α isoform 
selective kinase inhibitors,86-88 was also introduced (7a, 7f, 7k). In an effort to increase the 
hydrophobic interactions within the allosteric binding site, 4-methyl imidazole was added 
aiming to mimic the well-known drug nilotinib89 (7e, 7j). In order to increase the 
solubility, methyl or fluoro substituents were placed in ortho- relative position (7c-e, 7h-
j), therefore distorting the planarity of the molecules.90 The results in Table 1 underline 
that although the identification of substituents successfully binding the allosteric pocket 
based on known inhibitors was not a priori obvious, this was nonetheless an efficient 
strategy to obtain potent and selective type II kinase inhibitors in a time- and cost-
effective manner. 
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Figure 14. Crystal structures of the catalytic domain of the tyrosine kinase EphA3 
in complex with the high-nanomolar inhibitors A (left, PDB code 4P4C) and B 
(right, PDB code 4P5Q). The ATP binding site of the EphA3 kinase is shown in 
magenta ribbons while the side chains mentioned in the text and the inhibitors are 
shown by sticks (with carbon atoms in magenta and green, respectively). 
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2.2.2 Characterization of new type I1/2 and II inhibitors 
I. Synthesis 
The synthesis of 1H-pyrrolo[2,3-b]quinoxaline derivatives 6 and 7 is shown in Scheme 
1. Compound 1 was prepared according to previously reported procedures by condensation 
of commercially available 2,3-dichloroquinoxaline with malononitrile in the presence of 
sodium hydride.91, 92 The substitution of the chlorine at position 3 with commercially 
available anilines 2a-i followed by cyclization afforded intermediates 4a-i.93 The reaction 
with synthetically prepared anilines 3a-n delivered tricyclic intermediates 5a-n (Scheme 
1).  
Scheme 1a 
 
aReagents and reaction conditions: a) Protocol I: R1NH2 2a-i, 3a-d, 3f-i, 3k-l, 3n 
(1-4 eq.), EtOH:Toluene, 1:1, 130-160 °C, 4-12 h, 30-79%. Protocol II: R1NH2 3e, 
3j, 3m (1-1.2 eq.), DMF, 80°C, 12 h, 21-61%. b) H2SO4, 25 °C, 30 min, 7-99%. 
The preparation of the non-commercially available anilines 3a-m used in the above 
mentioned condensation reaction has been summarized in Scheme 2. Anilines 3a-e, bearing 
a N-amide group in meta relative position, were obtained by condensation of 3-nitro-
substituted anilines 8 with the corresponding readily available benzoyl chlorides (R3COCl) 
or benzoic acids (R3COOH)94 using different protocols (Conditions a, Methods I-IV). 
Reduction of the nitro group with either SnCl2 or Pd/C and H2 (Conditions b) furnished 
the desired intermediates. Anilines 3f-j were prepared by condensation of the 3-nitro-
substituted benzoic acid or benzoyl chlorides 9 with the corresponding anilines95 under 
reaction conditions c. Reduction of the nitro group with SnCl2 or Pd/C and H2 delivered 
the corresponding anilines in 30-77% overall yields. Finally, anilines 3k-m, bearing urea 
moieties at meta- and para- relative position, were prepared by condensation of aniline 8 
with the corresponding isocyanate (for 3k-l) or by condensation of the isocyanate 10 with 
the respective commercially available aniline under reaction conditions d to give 3m. 
Reduction of the nitro group under the conditions described above furnished the 
corresponding aniline-containing ureas 3k, 3l and 3m in 42, 85 and 41% yields 
respectively. Aniline 3n was prepared according to a previously reported procedure.96  
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Scheme 2a 
aReagents and reaction conditions: Conditions a) Method I: cyclopropanecarboxylic 
acid, TBTU, DIPEA, DMF, 25 °C, 15h, 38%. Method II: 3-(trifluoromethyl)benzoyl 
chloride, Et3N, DCM, 25 °C, 15 h, 54-99%. Method III: 3-(trifluoromethyl)benzoyl 
chloride, DIPEA, THF, 25 °C, 12 h, 48%. Method IV: benzoic acid, HOBt, EDC, 
DMF, 25 °C, 12 h, 64%; Conditions b) for 3a, 3b, 3f, 3g, 3k and 3l, SnCl2.H2O, 
EtOH, 100 °C, 2 h, 53-92%; for 3c-e, 3h-j and 3m, 10% Pd/C (10% wt), H2, 
MeOH, 25 °C, 4-12 h, 44-99%; Conditions c) Method I: amine, Et3N, DCM, 25 °C, 
15 h, 50-79%. Method II: aniline, DIPEA, THF, 25 °C, 12 h, 57-78%. Method III: 
(i) SO2Cl, DCM, reflux, 3h; (ii) 3-(trifluoromethyl)aniline, DCM, 25 °C, 12 h, 77%; 
Conditions d) Method I: aniline, Et3N, DCM, 25 °C, 1-3 d, 80-92%. Method II: 3-
(trifluoromethyl)aniline, Et3N, THF, 25 °C, 12 h, 60%. 
Hydrolysis of the cyano group under strong acidic conditions furnished the desired 
type I and I1/2 inhibitors 6a-i and type II inhibitors 7a-n respectively. The presence of a 
cyano group in compounds 4 and 5 was confirmed by the presence of a characteristic IR 
band at around 2200 cm-1 and a 13C-NMR signal at 115-116 ppm whereas the amino group 
appeared as a broad signal at 8 to 8.5 ppm in 1H-NMR.93  
Two more inhibitors were prepared, first by demethylation of 6d in the presence of 
BBr3 under reflux to give the corresponding phenol derivative 11d, and a second one by 
condensation of the aniline 7n with m-CF3-phenyl isothiocyanate, to give the 
corresponding  thiourea 12n (Scheme 3). 
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Scheme 3a 
 
aReagents and conditions: a) BBr3, DCM, 130 °C, 4 h, 68%; b) m-CF3-phenyl 
isothiocyanate, DMF, 25 °C, 12 h, 69%. 
II. Biophysical characterization 
The thermodynamics and kinetics of binding of the designed quinoxaline inhibitors 
were investigated by an array of biophysical techniques including differential scanning 
fluorimetry, fluorescence resonance energy transfer (FRET) based enzymatic assays and 
surface plasmon resonance (SPR). Differential scanning fluorimetry is a high throughput 
technique in which the increase in thermal stability of a folded protein upon ligand binding 
is detected by a fluorescence dye while measuring its melting temperature during 
denaturation.97 In order to allow the binding of type II inhibitors to the inactive form of 
the kinase, the protein (EphA3) was incubated in the presence of the compounds for 1 
hour. 
The results (shown in Table 1) highlight the differences in binding between type I, I1/2 
and II compounds, with type I being the weakest binders (1.5 – 4.1 °C) and type II the 
most potent (with up to 16 °C thermal shifts). For type I inhibitors, the largest thermal 
shifts (ca. 4 °C) were obtained for ortho-methyl (6a) and ortho-chlorine (6f) substituted 
quinoxalines, which is in agreement with previously reported kinase inhibitors26, 32, 65, 98-101 
and could be a consequence of restricting the accessible conformations of the phenyl ring as 
we have previously reported.32 However, the ortho-fluoro substituted inhibitor 6g or bis-
ortho substituted 6b and 6c caused a lower stabilization of the protein probably due to the 
small size of fluorine or the introduction of an extra steric bulk, respectively. 
The transition from type I to type I1/2 by the presence of a hydrogen bond donor at 
position R3, and therefore the formation of hydrogen bonds with Glu664 and Asp758, 
resulted in a remarkable increase in thermal shift for compound 6h (7.2 °C), which became 
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more pronounced upon introduction of a methyl group in the ortho- relative position 
(following the trend observed in type I inhibitors) to yield 11d with a thermal shift of    
11.2 °C. 
Type II compounds bearing an amide linker followed by a m-CF3-phenyl group caused 
a similar stabilization effect in the protein as the type I1/2 inhibitor 11d. As expected from 
previous results with type I and I1/2 compounds, the addition of a methyl (7c, 7h) or 
fluorine (7d, 7i) substituent in R1 lead to higher thermal shifts. Interestingly, 3-amides (7g-
i) triggered a higher stabilization of the kinase than 1-amides (7b-d), which could indicate 
the formation of a more favorable hydrogen bond with Glu664. The presence of imidazoles 
within the allosteric binding site led to compounds 7e and 7j, which showed the most 
promising thermal shifts (16 °C). Urea (7m) or thiourea (12n) linkers located in para- 
relative position retained or even enhanced (in the case of urea 7m) the binding affinity, 
whereas compound 7l, bearing the urea in meta- relative position barely presented any 
thermal shift, suggesting a disruption or a non-favorable hydrogen bond interaction with 
Glu664. The replacement of the m-CF3-phenyl group by a cyclopropyl ring proved to be 
detrimental in all cases and no thermal shift was observed for products 7a, 7f and 7k. 
The inhibitory activities of Type I and type I1/2 inhibitors were further evaluated on an 
enzymatic assay based on fluorescence resonance transfer (FRET) at a single concentration 
(1 µM, Table 1, column 8). The results were in line with the thermal shifts described 
above. Compounds 6a and 6f showed inhibitory activities higher than 66% at 1 µM, (Table 
1). However, substitution at R1 by a smaller fluorine atom yielded compound 6g with 
lower binding affinity (30%). Along the same lines, bis-ortho substitutions with either 
methyl or chlorine (6b, c) decreased the binding affinity (36 and 45% inhibitory activities 
respectively) probably due to unfavorable steric effects. The presence of a hydrogen bond 
donor at R3 (type I1/2 inhibitors) either as a phenol (6h, 11d) or methylene alcohol (6e) 
greatly improved the inhibitory activity of the molecules thanks to the formation of 
hydrogen bonds with Glu664 and Asp758 (68-105%). To our surprise, a triazole group at 
the same position (6i) dramatically decreased the binding affinity (7%).  
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Table 1. EphA3/EphB4 inhibition data for the synthesized quinoxaline derivatives 
Cmp 
Type of 
binding 
R1 R2 R3 R4 
Thermal shift 
(degrees)a 
FRETb enzymatic 
assay 
Cellular 
IC50 (nM)c 
6a I Me H H H 4.1 66 230 
6b I Me H H Me 2.6 36 4400 
6c I Me H H Cl 2.6 45 2800 
6d I Me H OMe H 1.5 23 720 
6e I1/2 Me H CH2OH H 3.6 68 160 
6f I Cl H H H 3.0 90 - 
6g I F H H H 2.7 30 - 
6h I1/2 H H OH H 7.2 98 - 
6i I1/2 H H H 0.1 7 - 
11d I1/2 Me H OH H 11.2 105 5.4 
7a II H H H 0.3 - - 
7b II H H H 7.6 - 20 
7c II Me H H 12.3 - 14 
7d II F H H 10.9 - 15 
7e II Me H H 15.8 - 170 
7f II H H H 0.6 - - 
7g II H H H 9.1 - 20 
7h II Me H H 14.4 - 21 
7i II F H H 13.0 - 24 
7j II Me H H 16.2 - 270 
7k II H H 
 
H 0.3 - - 
7l II H H 
 
H 0.7 - - 
7m II H 
 
H H 14.3 - 89 
12n II H 
 
H H 9.9 - 560 
aAverage values of triplicate measurements. The standard deviation is smaller than 0.5 degrees. bFRET-based 
enzymatic assay was carried out using the Z-LYTE Kinase Assay Kit−Tyr 1 Peptide (Invitrogen) following the vendor 
instructions. % of inhibition at 1 µM is given. cCell IC50 values were measured in a cellular phosphorylation assay using 
MEF cells overexpressing EphB4 at Proqinase. 
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The kinetics of binding of the optimized type I1/2 (11d) and type II urea inhibitor 7m 
were investigated using SPR. Upon titrating 11d and 7m over immobilized 
dephosphorylated EphA3, dissociation constants (KD) in the low nanomolar range were 
obtained (8.6 nM and 39.3 nM respectively), confirming the high affinity of the compounds 
(Figure 15). One of the advantageous characteristics of type II inhibitors over type I or I1/2 
is their slow dissociation rate from the target protein,24, 102, 103 as demonstrated by the 
remarkably slow koff measured for 7m (1.45 x 10-4 s-1) in comparison to the type I1/2 11d 
(1.52 x 10-3 s-1). The slow koff of 7m corresponds to a residence time of 115 min, a value 
that compares positively with that of marketed drugs such as imatinib (28 min for 
dephosphorylated ABL), nilotinib (202 min and 205 min for dephosphorylated and 
phosphorylated ABL, respectively), and dasatinib (15 min and 4 min).104 The long 
residence time of type II inhibitors is considered to be beneficial for drug efficacy and 
selectivity in vivo due to the high concentration of the drug near the target,103, 105 as 
described for the EGFR-specific inhibitor lapatinib.106  
 
Figure 15. SPR analysis of the binding of 11d (A) and 7m (B) to EphA3. A 
threefold serial dilution of the compounds was made starting from 200 nM (for 
11d) and 10 µM (for 7m) in duplicate. The theoretical global fit to a 1:1 
interaction model is shown in straight lines. 
2.2.3 Validation of type II binding by X-ray crystal structure 
determination 
The crystal structure of the catalytic domain of the EphA3 kinase in complex with 
inhibitor 7m (solved at 2.0 Å resolution), confirms a type II binding mode, i.e., with the 
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DFG-out conformation (Figure 16). The pyrrolo[3,2-b]quinoxaline scaffold occupies the 
ATP binding site and is involved in the same hydrogen bonds with the hinge region as the 
type I inhibitor A (Figure 14). In addition, the urea linker of inhibitor 7m acts as 
hydrogen bond acceptor from the Ser757 side chain and the amide backbone of Asp758, 
and hydrogen bond donor to the side chain of Glu664. The m-CF3-phenyl moiety is nestled 
in the hydrophobic pocket which originates from the displacement of the Phe side chain of 
the DFG motif. Thus, the type II binding mode of compound 7m validates our design 
based on the crystal structures of the complexes with the type I inhibitors (vide supra, 
Section 2.2.1). 
           
Figure 16. Crystal structures of the catalytic domain of the tyrosine kinase EphA3 
in complex with the low-nanomolar inhibitor 7m (left, PDB code 4P5Z) and 
superposition of the three inhibitors A, B, and 7m based on structural alignment 
of the Cα atoms of the EphA3 kinase domain (right). The ATP binding site of the 
EphA3 kinase is shown in magenta ribbons while the side chains mentioned in the 
text and the inhibitors are shown by sticks 
2.2.4 Selectivity and cellular activity 
I. Selectivity profiles from biochemical assays 
The selectivity profile of inhibitors 11d, 7b and 7g was determined by an in vitro 
competition binding assay using recombinant kinases (KINOMEscan at DiscoveRx).107 It is 
important to note that this assay reports on binding affinity and does not require ATP. 
The selectivity panel consisted of 453 human kinases, 58 of which were disease related 
mutant kinases (mainly of ABL1, EGFR, and PIK3CA). Single dose measurements were 
carried out at 1 µM concentration of the inhibitor. 
Compounds 11d, 7b and 7g present a very similar selectivity profile (Figure 17); in 
particular, strong binding is only observed to tyrosine kinases with threonine as a 
gatekeeper residue, e.g., ABL1/2, BRAF, DDR1, EphA/B (all but EphA7 which has a Ile 
gatekeeper), KIT, LCK, SRC, and YES. The latter data suggest that most (or even all) 
tyrosine kinases with a Thr gatekeeper can assume the DFG-out conformation. 
Quantitatively, each of the three inhibitors 11d, 7b and 7g binds with an affinity 10-fold 
(100-fold) higher than the DMSO negative control to only about 10% (5%) of the 395 wild-
CHAPTER 2: EPH TYROSINE KINASE INHIBITORS 
36 
 
type kinases tested. Interestingly, the selectivity profiles of the type I1/2 (11d) and II (7b 
and 7g) quinoxaline-based inhibitors is very similar to the one of our previously reported 
type I and I1/2 xanthine-based inhibitors (compounds 40 and 3, respectively, in reference 
31), which is due, at least in part, to the use of an Eph tyrosine kinase (EphB4) as primary 
target for the in silico screening and optimization. 
 
Figure 17. Selectivity profiles of compound 11d (left), 7b (center) and 7g (right) 
tested on a panel of 453 protein kinases at DiscoveRx. Measurements were 
performed at a concentration of 1 µM of the inhibitor. The affinity is defined with 
respect to a DMSO control. The dendrogram was obtained from KinomeScan using 
the KinomeTree software. 
II. Cellular assays 
The most potent inhibitors obtained in the optimization campaign were further tested 
in cell-based assays. Cellular phosphorylation assays on MEF cells transfected with myc-
tagged human EphB4 revealed a comparable tendency to the one observed in the 
enzymatic assay (Table 1, column 9). The type I inhibitors (6a-d) displayed cellular IC50 
values in the 230-4400 nM range, with the ortho methyl substituted derivative 6a as the 
most potent member of this series. The type I1/2 inhibitor 11d and type II compounds 
bearing amide linkers and a m-CF3-phenyl group (7b-d, 7g-i) displayed levels of inhibitory 
activity in the low nanomolar range (6-24 nM), thus being the most promising molecules of 
the optimization campaign. In agreement with thermal shift experiments, the presence of 
an urea (7m) and specially thiourea linker (12n) decreased the potency of the compounds 
(89 and 560 nM respectively). Interestingly, the imidazole substituted compounds (7e, 7j) 
proved to be the weakest type II inhibitors (170 and 270 nM respectively) in contrast to 
the high thermal shifts obtained (16 °C) in the differential scanning fluorimetry 
measurements, pointing towards potential cell permeability or efflux issues. 
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EphB4 overexpression has been linked to several types of cancer, including breast,49 
colon108 and ovarian.109 Compounds 11d and 7m were screened against the NCI-60 cancer 
cell line panel110 displaying antiproliferative activities against leukemia (K-562), lung 
(HOP-92), colon (HT-29), renal (A498) and breast cancer cells (MDA-MB-231, HS 578T) 
in the low nM range.  
Table 2. Antiproliferative activity against NCI tumor cell linesa 
Cmp MDA-MB-231 K-562 A498 HT29 KM12 HOP-92 
6d   59.3 50.3   
6e  44.9 36.4 90.5   
6i   50.9 64.5   
11d 2.64 1.05 5.88 4.59 1.55 0.49 
7b 3.09 1.52 13.4 29.4 3.98 (4.03) 4.65 (3.91) 
7c 3.88 0.73 2.50 5.87 0.80 4.23 
7d 1.44 0.37 1.88 1.80 (9.43) 2.16 2.06 
7e 1.93 0.030 4.01 13.4 2.54 5.12 
7g 10.8 0.820 10.6 23.1 2.78 5.13 
7h 1.32 0.036 2.07 2.82 1.57 1.92 
7i 2.69 0.081 2.44 2.97 1.87 2.12 
7j 3.05 0.029 5.71 4.36 2.84 3.01 
7m 10.3 5.45 10.8 18.0 0.67 10.0 
12n 9.63 5.07 8.73 16.3 2.52 14.25 
a GI50 values were determined using resazurin reduction after 2-3 days  of 
incubation with the corresponding compound. GI50 values are given  in micromolar 
concentrations (μM) as the mean of at least three independent experiments. 
Variability around the mean value was <50% unless otherwise indicated by an SE 
value in parentheses. 
Driven by these results, the most promising inhibitors of our optimization campaign were 
tested in-house against the above mentioned NCI cancer cell lines (Table 2). The leukemia 
K-562 cell line was particularly sensitive towards the optimized type II quinoxaline 
inhibitors, especially in the case of 3-amide compounds 7h and 7i, which showed 
remarkably low GI50 values (36 and 81 nM respectively). Interestingly, similar levels of 
potency were found for imidazole substituted compounds 7e and 7j, which seemed to be 
among the weakest type II binders in the cellular phosphorylation assays, possibly 
indicating other targets than Eph for these molecules.  
In addition, the potential of 11d (the most potent compound on cellular 
phosphorylation assays with an IC50 of 5.4 nM) to inhibit the growth of patient-derived 
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tumor cell lines was studied using a propidium iodide-based proliferation assay and 
dasatinib as a reference (Oncotest, Table 3). Cell lines included colon, lung, kidney, 
pancreatic, prostate, and stomach cancer cells. Whereas dasatinib presented double-digit 
nanomolar activities against RXF 393NL, LXFA 983L, and PRXF DU145, 11d exhibited 
low micromolar GI50 values, with RXF 393NL being the most sensitive cell line. 
Table 3. Antiproliferative activity against patient derived tumor cell linesa 
Compound 11d dasatinib 
RXF 393NL 0.72 0.0217 
CXF 1103L 3.83 4.36 
LXFA 983L 2.22 0.0565 
GXF 251L 8.01 2.25 
PAXF 1657L 2.92 0.121 
PRXF DU145 2.92 0.0623 
aGI50 values were determined at Oncotest using a modified propidium iodide assay. 
Measurements were performed after 4 days of incubation with 11d and dasatinib. 
GI50 values are given in micromolar concentrations (µM). 
The implication of EphB4-ephrinB2 signaling in sprouting angiogenesis and blood 
vessel maturation111 and the inhibition of vascular endothelial growth factor (VEGFR)-
driven angiogenesis by the selective EphB4 inhibitor NVP-BHG712,64 led us to examine the 
efficacy of 11d on human endothelial cell sprouting in a spheroid based cellular 
angiogenesis assay (ProQinase).112 Compound 11d was able to successfully inhibit VEGF-A 
induced HUVEC (primary human umbilical vein endothelial cells) sprouting in a dose 
dependent manner with an IC50 value of 1.5 µM. 
2.2.5 In vivo data 
Three of the most promising compounds from these series (7b, 7g and 11d) were 
selected for evaluation of pharmacokinetic properties in 20-30 g male CD-1 (ICR) mice on 
intravenous (IV) and oral (PO) administration. Low to moderate oral bioavailability of 
tested compounds in mice was observed, with compounds 11d and 7g giving the highest 
values (Table 4). Promising cellular efficacy and pharmacokinetic properties incited the 
subsequent evaluation of compound 11d in a xenograft mouse model with a tumor derived 
from the MDA-MB-231 cell line. High compound clearance (Cl) and moderate half-life 
(T1/2) values determined in the pharmacokinetic study motivated a twice-daily dosing 
regime totaling 100 mg/kg/day of compound 11d over 21 days. Median tumor volume 
progression over time, starting from 108 mm3, of both treatment and control cohorts is 
given in Figure 18. 
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Table 4. Pharmacokinetic properties in mice 
Compound 
11d 7b 7g 
IV PO IV PO IV PO 
Dose (mg/kg) 1 5 1 5 1 5 
Cl (mL/min/kg) 42 - 32 - 31 - 
Vss (L/kg) 1.6 - 2.2 - 2.2 - 
T1/2 (h) 1.7 1.7 1.2 5.0 1.1 2.8 
AUClast 
(h.ng/mL) 
392 493 506 263 533 803 
F(%) - 25 - 10 - 30 
 
In this study, median treatment-group tumor volume remained essentially stable 
throughout the treatment period, achieving a median tumor volume of 126 mm  at day 19 3
as opposed to the control group whose median tumor reached 650 mm  in the same period. 3
Tumor growth inhibition (%TGI) was statistically significant (Mann-Whitney U=0, P ≤ 
0.001 two-tailed) and quantified at 81% relative to the control group. Mean body weight of 
the treatment cohort decreased up to 16.3% of the initial mean body weight of this cohort 
during the treatment period. Treatment with compound 11d provides a significant 
limitation in tumor progression over the control, suggesting that further studies of such  
xenograft model at lower doses of compound 11d might provide tumor volume control 
with lessened weight loss. The further evaluation of compounds 11d on mouse models of 
K-562 leukemia is underway. 
 
Figure 18. In vivo antitumor activity of compound 11d in MDA-MB-231 nude 
mice xenografts. The mice received by gavage twice-daily 50 mg/kg of compound 
11d (red) or vehicle control (blue). Each data point is the median of a cohort of 9 
animals. 
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2.2.6 Conclusions 
The X-ray crystal structures of the EphA3 kinase in complex with two high-nanomolar 
inhibitors based on the 2-amino-1-phenyl-pyrrolo[3,2-b]quinoxaline-3-carboxamide scaffold 
confirmed the type I binding mode obtained previously by automatic docking (Figure 14). 
This structural information was used to design type I1/2 and type II derivatives by taking 
advantage of the existing knowledge on privileged chemical motifs, i.e., hydroxyl group in 
meta position of the phenyl ring (for type I1/2) and hydrophobic moieties connected to the 
phenyl ring by amide or urea linkers (on type II). Chemical synthesis of ca. 25 derivatives 
(Table 1) culminated in several low nanomolar inhibitors with a good selectivity profile 
(Figure 17). The X-ray crystal structure of the EphA3 kinase in the complex with the 
inhibitor 7m (Figure 16) provided the final validation of the structure-based design, in 
particular the DFG-out conformation confirmed the type II binding. Moreover, the slow 
kinetics of unbinding of compound 7m (measured by SPR, Figure 15) is congruent with 
the type II binding mode. Three interesting observations emerge from this study. First, it 
is possible to “elongate” a type I1/2 into a type II inhibitor by introducing an amide or urea 
linked to a bulky hydrophobic group. These type II linkers are involved in the same 
hydrogen bonds as the type I1/2 bearing a hydroxyl group in the same position, while the 
hydrophobic moiety occupies the pocket resulting from the displacement of the Phe side 
chain of the DFG motif. The similar selectivity profiles of type I1/2 and type II inhibitors 
indicate that mainly the moiety in contact with the gatekeeper’s side chain and hinge 
region determines specificity. Finally, in vivo assays (mice xenografted with human breast 
cancer) confirmed the cytostatic activity of one of our inhibitors (11d) which makes this 
type I1/2 compound a candidate lead for further preclinical development.
2.3 Experimental section 
2.3.1 Chemistry. General methods.  
All reactions, unless otherwise stated, were carried out under a nitrogen atmosphere 
using standard Schlenk-techniques. All reagents were used as received unless otherwise 
noted. Solvents were purchased in the best quality available, degassed by purging 
thoroughly with nitrogen and dried over activated molecular sieves of appropriate size. 
Alternatively, they were purged with argon and passed through alumina columns in a 
solvent purification system (Innovative Technology). Reactions were monitored by thin 
layer chromatography (TLC) using Merck TLC silica gel 60 F254. Flash column 
chromatography was performed over silica gel (230-400 mesh). NMR spectra were recorded 
on AV 300, AV2 400 or AV2 500 MHz Bruker spectrometers. Chemical shifts are given in 
2.3 EXPERIMENTAL SECTION 
41 
 
ppm. The spectra are calibrated to the residual 1H and 13C signals of the solvents. 
Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and broad (br). Melting 
points were determined on a Buchi melting point B-540 instrument. High-resolution 
electrospray ionization mass spectrometry was performed on a Finnigan MAT 900 (Thermo 
Finnigan, San Jose, CA, USA) double-focusing magnetic sector mass spectrometer. Ten 
spectra were acquired. A mass accuracy ≤2 ppm was obtained in the peak matching 
acquisition mode by using a solution containing 2 µL PEG200, 2 µL PPG450, and 1.5 mg 
NaOAc (all obtained from Sigma-Aldrich, Buchs, Switzerland) dissolved in 100 mL MeOH 
(HPLC Supra grade, Scharlau, E-Barcelona) as internal standard. The purity of all tested 
compounds was determined by HPLC on a Waters Acquity UPLC (Waters, Milford, MA) 
Top spectrometer using an Acquity BEH C18 HPLC column (1.7 μm, 1× 50 mm, Waters) 
with a mixture of H2O + 0.1% HCOOH (A) and CH3CN + 0.1% HCOOH (B) solvent (0.1 
mL flow rate, linear gradient from 5% to 98% B within 4 min followed by flushing with 
98% B for 1 min). Unless otherwise stated, all compounds showed ≥ 95 % purity.  
The following compounds were prepared according to previously reported procedures: 
192, 113, 8e95, 13,114 9e,114 3n,115 14c,116 14d,117 14h,118 14m,119 3c,114 3h,118 3m.119 
 
2-(3-Chloroquinoxalin-2(1H)-ylidene)malononitrile (1)92, 113 
Yellow solid; Yield: 74 %; 1H NMR (400 MHz, DMSO-d6): δ = 7.67-7.62 
(m, 2H), 7.57 (ddd, J = 8.4, 6.8, 1.1 Hz, 1H), 7.36 (ddd, J = 8.1, 6.8, 1.2 
Hz, 1H), NH-not observed; 13C NMR (100 MHz, DMSO-d6): δ = 149.3, 
141.9, 134.8, 134.1, 131.3, 127.5, 125.5, 120.2, 118.6, 44.5; IR (film): ῦ = 3235, 3203, 3100, 
3056, 3013, 2979, 2220, 2208, 1616, 1577, 1488, 1410, 1096, 969, 799, 764, 594 cm-1; MS 
(ESI): m/z: calcd for C11ClH5N4Na+: 251.0, found: 250.9.  
N-Boc-p-phenylenediamine (3n)115 
Yellow solid; Yield: 97 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.76 (br, 
1H), 7.06 (d, J = 6.7 Hz, 2H), 6.46 (d, J = 8.8 Hz, 2H), 4.71 (br, 2H), 
1.44 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ = 153.1, 143.9, 128.6, 120.2, 114.0, 78.1, 
28.2; IR (neat): ῦ = 3416, 3394, 3364, 3188, 2984, 2935, 1692, 1521, 1512, 1427, 1391, 1367, 
1307, 1233, 1158, 1055, 1028, 1013, 905, 823, 772, 761, 727, 615, 511, 417 cm-1; MS (ESI), 
m/z: calcd for C11H16N2NaO2+: 231.11, found: 231.0.  
 
 
 
NHBoc
H2N
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3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenylamine (8e)95 
Yellow solid; Yield: 73 %; 1H NMR (300 MHz, DMSO-d6): δ = 8.06 (s, 
1H), 7.36 (s, 1H), 6.97 (s, 1H), 6.93 (s, 1H), 6.81 (s, 1H), 5.85 (s, 2H), 
2.15 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 150.9, 138.5, 134.7, 
131.2 (q, J = 31.5 Hz), 124.0 (q, J = 272.5 Hz), 114.2, 107.8, 103.2 (q, J 
= 3.7 Hz), 13.6, 2C are missing due to overlapping; 19F NMR (376 MHz, DMSO-d6): δ = -
61.63; IR (neat): ῦ = 3306, 3159, 2981, 1696, 1575, 1540, 1515, 1445, 1417, 1330, 1285, 
1245, 1222, 1162, 1114, 1091, 1054, 902, 849, 808, 710, 695, 663, 602, 468, 456, 421, 408 cm-
1; MS (ESI), m/z: calcd for C11H10F3N3: 242.1, found: 242.2. 
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile (13)114 
White solid; Yield: 71 %; 1H NMR (400 MHz, DMSO-d6): δ = 8.54 (s, 
1H), 8.41 (d, J = 1.4 Hz, 1H), 8.37 (s, 1H), 8.24 (s, 1H), 7.71 (t, J =1.2 
Hz, 1H), 2.16 (d, J = 0.9 Hz, 3H); 13C NMR (125 MHz, DMSO): δ = 
139.1, 138.2, 135.3, 131.8 (q, J = 33.5 Hz), 126.8, 126.5 (q, J = 3.8 Hz), 
122.8 (q, J = 273.3 Hz), 120.6 (q, J = 3.6 Hz), 117.0, 114.1, 114.0, 13.6; 19F NMR (282 
MHz, DMSO-d6): δ = -61.34; IR (neat): ῦ = 3107, 3045, 2927, 2242, 1614, 1606, 1504, 
1464, 1402, 1319, 1290, 1267, 1228, 1171, 1134, 1112, 1077, 1012, 880, 835, 805, 749, 705, 
691, 626, 595, 517, 460, 411 cm-1; MS (ESI), m/z: calcd for C12H9F3N3+: 252.1, found: 251.9. 
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoic acid (9e)114 
White solid; Yield: 93 %; 1H NMR (500 MHz, DMSO-d6): δ = 14.03 (br, 
1H), 9.75 (s, 1H), 8.56 (s, 1H), 8.50 (s, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 
2.36 (d, J = 0.8 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 164.9, 
136.3, 134.6, 134.1, 131.0 (q, J = 33.4 Hz), 130.7, 126.4, 125.9 (q, J = 3.2 
Hz), 123.2 (q, J = 3.2 Hz), 123.1 (q, J = 273.3 Hz), 117.5, 9.8; 19F NMR (282 MHz, 
DMSO-d6): δ = -61.30; IR (neat): ῦ = 3096, 2769, 2631, 1708, 1627, 1616, 1547, 1404, 
1348, 1304, 1270, 1199, 1169, 1127, 1085, 998, 962, 910, 844, 769, 709, 691, 673, 659, 620, 
527 cm-1; MS (ESI), m/z: calcd for C12H8F3N2O2: 269.1, found: 268.9. 
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I. Synthesis of Amides 
 
 
General procedure for the synthesis of amides 
To a solution of primary amine (1.00 eq) in CH2Cl2 (0.500 M) triethylamine (1.05 eq) 
and acid chloride (1.04 eq) were sequentially added. The reaction was stirred at 25 °C for 
15 h. The reaction mixture was then poured into water, extracted with CH2Cl2, and the 
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. 
The residue was recrystallized from hexane/EtOAc to afford the desired products in pure 
form. This method was used to obtain intermediates 14b, 14g and 14f. 
N-(3-Nitrophenyl)cyclopropanecarboxamide (14a) 
To a suspension of cyclopropanecarboxylic acid (100 µL, 1.26 mmol) and 
TBTU (556 mg, 1.73 mmol) in DMF (5.00 mL) 3-nitroaniline (174 mg, 1.26 
mmol) and N,N-diisopropylethylamine (2.10 mL, 12.1 mmol) were added. 
The reaction mixture was stirred at 25 °C for 15 h, poured into a solution of saturated 
NaHCO3 and extracted with EtOAc. The organic layer was dried over MgSO4, filtered, and 
concentrated under reduced pressure. Purification by column chromatography 
(hexane/EtOAc 8:1) afforded the desired compound in pure form as a white solid (200 mg, 
38 %). 1H NMR (500 MHz, DMSO-d6): δ = 10.68 (s, 1H), 8.63 (t, J = 2.2 Hz, 1H), 7.91-
7.87 (m, 2H), 7.59 (t, J = 8.2 Hz, 1H), 1.79 (quint, J = 6.2 Hz, 1H), 0.86-0.85 (m, 4H); 13C 
NMR (125 MHz, DMSO-d6): δ = 172.3, 147.9, 140.3, 130.0, 124.7, 117.3, 112.9, 14.6, 7.5; 
IR (film): ῦ = 3284, 1655, 1521, 1317, 1194, 960, 673 cm-1; MS (ESI): m/z: calcd for 
C10H11N2O3+: 207.2, found: 206.9. 
N-(3-Nitrophenyl)-3-(trifluoromethyl)benzamide (14b) 
White solid; Yield: 54 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.88 (s, 
1H), 8.77 (t, J = 2.2 Hz, 1H), 8.34 (s, 1H), 8.30 (d, J = 7.8 Hz, 1H), 
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8.22-8.20 (m, 1H), 8.02-7.99 (m, 2H), 7.82 (t, J = 7.8 Hz, 1H), 7.69 (t, J = 8.2 Hz, 1H); 13C 
NMR (125 MHz, DMSO-d6): δ = 164.4, 147.8, 139.9, 135.0, 131.9, 130.1, 129.8, 129.2 (q, J 
= 32.1 Hz), 128.5 (q, J = 3.5 Hz), 126.2, 124.2 (q, J = 3.8 Hz), 123.8 (q, J = 272.6 Hz), 
118.4, 114.5; IR (film): ῦ = 3292, 1653, 1524, 1337, 1264, 1122, 1072 cm-1; MS (ESI): m/z: 
calcd for C14H9F3N2NaO3+: 333.2, found: 333.0. 
N-(3-Nitro-4-methylphenyl)-3-(trifluoromethyl)benzamide (14c)116 
Pale yellow solid; Yield: 99 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.80 (s, 
1H), 8.53 (d, J = 2.1 Hz, 1H), 8.33 (s, 1H), 8.29 (d, J = 7.9 Hz, 1H), 8.03-
7.99 (m, 2H), 7.81 (t, J = 7.8 Hz, 1H), 7.52 (d, J = 8.4 Hz, 1H), 2.51 (s, 
3H); 13C NMR (125 MHz, DMSO-d6): δ = 164.4, 148.5, 137.9, 135.2, 133.1, 
132.0, 129.9, 129.4 (q, J = 32.2 Hz), 128.5 (d, J = 3.3 Hz), 128.1, 125.1, 
124.4 (q, J = 3.7 Hz), 124.0 (q, J = 272.5 Hz), 115.8, 19.4; 19F NMR (282 MHz, DMSO-d6): 
δ = -61.08; IR (neat): ῦ = 3325, 1656, 1617, 1587, 1524, 1443, 1386, 1338, 1319, 1308, 
1260, 1238, 1160, 1124, 1111, 1069, 907, 889, 832, 821, 796, 751, 697, 670, 610, 561, 548, 
534, 411 cm-1; MS (ESI): m/z: calcd for C15H10F3N2O3-, [M-H]-1: 323.1, found: 323.0. 
N-(3-Nitro-4-fluorophenyl)-3-(trifluoromethyl)benzamide (14d)117 
White solid; Yield: 48 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.85 (s, 1H), 
8.66 (dd, J = 6.9, 2.6 Hz, 1H), 8.32 (s, 1H), 8.28 (d, J = 7.8 Hz, 1H), 8.17-
8.14 (m, 1H), 8.00 (d, J = 7.8 Hz, 1H), 7.81 (t, J = 7.8 Hz, 1H), 7.62 (dd, J = 
10.8, 9.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 164.4, 150.8 (d, J = 
259.1 Hz), 136.3 (d, J = 7.9 Hz), 135.6 (d, J = 3.2 Hz), 134.9, 131.9, 129.9, 
129.3 (q, J = 32.2 Hz), 128.6 (q, J = 3.5 Hz), 127.8 (d, J = 8.3 Hz), 124.3 (q, J =3.8 Hz), 
123.9 (q, J = 272.5 Hz), 118.8 (d, J = 21.9 Hz), 117.0 (d, J = 2.9 Hz); 19F NMR (282 MHz, 
DMSO): δ = -61.09, -124.31 (ddd, J = 11.1, 6.9, 4.0 Hz); IR (neat): ῦ = 3266, 3145, 3078, 
1655, 1616, 1532, 1406, 1346, 1325, 1255, 1170, 1121, 1070, 919, 889, 825, 814, 696, 665, 
545, 497, 415 cm-1; MS (ESI), m/z: calcd for C14H7F4N2O3-, [M-H]-1: 327.0; found: 326.9. 
N-(3-Nitro-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl)benzamide (14e)  
To a solution of 3-(4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl)benzoic acid (9e, 1.06 g, 3.91 mmol), HOBt (0.634 g, 
4.69 mmol) and EDC (0.728 mL, 4.69 mmol) in DMF (18.0 mL), 4-
methyl-3-nitroaniline (0.714 g, 4.69 mmol) was added and the mixture was stirred at 25 °C 
for 12 hours. The reaction mixture was concentrated under reduced pressure, redissolved in 
EtOAc and extracted with 0.5 M NaHCO3 and water. The organic phase was dried over 
MgSO4, concentrated under reduced pressure and the resulting solid was washed with 
DCM and hexane affording the desired amide in pure form as a yellow solid (1.01 g, 64 % 
yield). 1H NMR (500 MHz, DMSO-d6): δ = 10.79 (s, 1H), 8.50 (d, J = 1.7 Hz, 1H), 8.45 (s, 
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1H), 8.39 (s, 1H), 8.25 (s, 1H), 8.18 (s, 1H), 8.00 (dd, J = 8.3, 1.7 Hz, 1H), 7.69 (s, 1H), 
7.52 (d, J = 8.4 Hz, 1H), 2.51 (s, 3H), 2.19 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 
163.5, 148.5, 139.0, 137.8, 137.5, 136.9, 135.2, 133.2, 130.9 (q, J = 32.6 Hz), 128.3, 125.0, 
123.4 (q, J = 273.4 Hz), 122.7, 121.8 (q, J = 3.7 Hz), 119.4 (q, J = 3.4 Hz), 115.7, 114.2, 
19.3, 13.5; 19F NMR (282 MHz, DMSO-d6): δ = -61.05; IR (neat): ῦ = 3344, 1682, 1654, 
1603, 1537, 1524, 1498, 1448, 1407, 1305, 1283, 1255, 1172, 1121, 1103, 1079, 1001, 904, 
877, 829, 812, 751, 739, 690, 671, 617, 503, 418 cm-1; HRMS (ESI), m/z: calcd for 
C19H16F3N4O3+: 405.1169, found: 405.1172.  
N-Cyclopropyl-3-nitrobenzamide (14f) 
White solid; Yield: 50 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.81 (s, 1H), 
8.65-8.64 (m, 1H), 8.38-8.36 (m, 1H), 8.26 (dd, J = 7.9, 1.0 Hz, 1H), 7.76 (t, 
J = 7.9 Hz, 1H), 2.92-2.86 (m, 1H), 0.75-0.71 (m, 2H), 0.63-0.60 (m, 2H); 13C 
NMR (125 MHz, DMSO-d6): δ = 165.2, 147.6, 135.7, 133.5, 129.9, 125.7, 121.7, 23.1, 5.6; 
IR (film): ῦ = 3227, 1626, 1518, 1347, 1315, 668 cm-1; MS (ESI): m/z: calcd for 
C10H10N2NaO3+: 229.2, found: 228.9. 
3-Nitro-N-(3-(trifluoromethyl)phenyl)benzamide (14g) 
White solid; Yield: 79 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.86 (s, 
1H), 8.83 (t, J = 1.9 Hz, 1H), 8.48-8.42 (m, 2H), 8.24 (s, 1H), 8.07 (d, J 
= 8.3 Hz, 1H), 7.87 (t, J = 8.0 Hz, 1H), 7.64 (t, J = 8.0 Hz, 1H), 7.50 
(d, J = 7.8 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 163.6, 147.7, 139.4, 135.7, 134.2, 
130.2, 129.9, 129.3 (q, J = 31.6 Hz), 126.4, 124.0 (q, J = 272.3 Hz), 123.9, 122.4, 120.3 (q, 
J = 3.8 Hz), 116.5 (q, J = 4.1 Hz); IR (film): ῦ = 3278, 3081, 1651, 1529, 1324, 1176, 1114, 
694 cm-1; MS (ESI): m/z: calcd for C14H9F3N2NaO3+: 333.2, found: 333.0. 
3-Nitro-4-methyl-N-(3-(trifluoromethyl)phenyl) benzamide (14h)118 
White solid; Yield: 78 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.75 (s, 1H), 
8.60 (s, 1H), 8.22 (s, 2H), 8.06 (d, J = 7.6 Hz, 1H), 7.69 (d, J = 8.0 Hz, 
1H), 7.61 (t, J = 7.9 Hz, 1H), 7.47 (d, J = 7.6 Hz, 1H), 2.60 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6): δ = 163.6, 148.8, 139.6, 136.7, 133.3, 133.2, 
132.2, 130.0, 129.4 (q, J = 31.6 Hz), 124.1 (q, J = 272.7 Hz), 124.0, 123.6, 
120.3 (q, J = 3.7 Hz), 116.6 (q, J = 3.9 Hz), 19.6; 19F NMR (282 MHz, DMSO-d6): δ = -
61.27; IR (neat): ῦ = 3303, 3078, 1656, 1616, 1567, 1530, 1494, 1348, 1321, 1270, 1229, 
1166, 1152, 1116, 1096, 1069, 898, 882, 861, 842, 795, 740, 696, 661, 646, 632, 524 cm-1; MS 
(ESI), m/z: calcd for C15H10F3N2O3-, [M-H]-1:  323.1, found: 323.0. 
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3-Nitro-4-fluoro-N-(3-(trifluoromethyl)phenyl) benzamide (14i) 
To a solution of 4-fluoro-3-nitrobenzoic acid (1.00 g, 5.40 mmol) in DCM (2.50 
mL) thionyl chloride (6.42 g, 54.0 mmol) was added and it was refluxed for 3 
h. The reaction was concentrated under reduced pressure and a solution 
containing 3-(trifluoromethyl)aniline (0.870 g, 5.40 mmol) and Et3N (1.13 mL, 
8.10 mmol) in DCM (5.00 mL) was added. The reaction mixture was stirred 
at 25 °C for 12 hours and poured into water. The resulting solid was filtered off and 
washed with water, Et2O and hexane affording 3-nitro-4-fluoro-N-(3-
(trifluoromethyl)phenyl) benzamide 14i in pure form as a yellow solid (1.37 g, 77 % yield). 
1H NMR (400 MHz, DMSO-d6): δ = 10.82 (s, 1H), 8.79 (dd, J = 7.2, 2.3 Hz, 1H), 8.42 
(ddd, J = 8.6, 4.2, 2.3 Hz, 1H), 8.21 (s, 1H), 8.06 (d, J = 8.2 Hz, 1H), 7.80 (dd, J = 11.0, 
8.8 Hz, 1H), 7.63 (t, J = 8.1 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 162.9, 156.7 (d, J = 267.1 Hz), 139.5, 136.7 (d, J = 7.9 Hz), 135.9 (d, J = 
10.1 Hz), 131.2 (d, J = 3.7 Hz), 130.1, 129.6 (q, J = 31.3 Hz), 125.9, 124.2 (q, J = 272.3 
Hz), 124.1, 120.6 (q, J = 3.6 Hz), 119.1 (d, J = 21.5 Hz), 116.7 (q, J = 4.1 Hz); 19F NMR 
(282 MHz, DMSO-d6): δ = -61.29, -114.01 (ddd, J = 11.3, 7.3, 4.3 Hz); IR (neat): ῦ = 
3281, 3083, 1653, 1618, 1536, 1491, 1445, 1326, 1257, 1167, 1117, 1094, 1069, 899, 846, 799, 
749, 672, 659, 628, 528 cm-1. HRMS (ESI), m/z: calcd for C14H7F4N2O3: 327.0398, found: 
327.0401. 
3-Nitro-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-
5(trifluoromethyl))benzamide (14j)  
To a solution of 3-(4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl)phenylamine (8e, 0.982 g, 4.07 mmol) in THF (14.0 
mL) at 0 °C DIPEA (1.38 mL, 8.14 mmol) and 4-methyl-3-nitrobenzoyl 
chloride (0.711 mL, 4.88 mmol) were added. The reaction was stirred at 
25 °C for 12 h and poured into water. The resulting solid was filtered off and washed with 
DCM and 1M HCl affording the corresponding amide in pure form as a white solid (0.940 
g, 57 % yield). 1H NMR (500 MHz, DMSO-d6): δ = 11.38 (s, 1H), 9.65 (s, 1H), 8.68 (s, 
1H), 8.64 (s, 1H), 8.36 (br, 2H), 8.02 (s, 1H), 7.96 (s, 1H), 7.72 (d, J = 8.0 Hz, 1H), 2.61 
(s, 3H), 2.37 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 163.9, 148.8, 141.2, 137.1, 136.0, 
134.3, 133.3, 132.6, 132.4, 131.2, 130.8 (q, J = 32.8 Hz), 125.0, 123.9, 123.4 (q, J = 272.8 
Hz), 117.4, 117.3, 114.2 (q, J = 3.4 Hz), 19.6, 9.8; 19F NMR (282 MHz, DMSO-d6): δ = -
61.44; IR (neat): ῦ = 2991, 2762, 2620, 1675, 1612, 1569, 1529, 1473, 1444, 1380, 1346, 
1299, 1245, 1230, 1167, 1121, 1093, 929, 887, 837, 797, 737, 715, 697, 666, 639, 583, 460, 
406 cm-1; HRMS (ESI), m/z: calcd for C19H16F3N4O3+: 405.1169, found: 405.1169.  
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II. Synthesis of Ureas 
 
General procedure for the synthesis of ureas 
To a solution of aniline (1 eq) in CH2Cl2 (0.3 M) the isocyanate (1 eq) was added. The 
reaction mixture was stirred at 25 °C for 1-3 days, and the resulting precipitate was 
filtered off affording the desired compound in pure form. This method was used to obtain 
intermediates 14k and 14l.  
1-Cyclopropyl-3-(3-nitrophenyl)urea (14k) 
White solid; Yield: 80 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.84 (s, 1H), 
8.51 (t, J = 2.2 Hz, 1H), 7.75 (dd, J = 8.2, 2.2 Hz, 1H), 7.69 (d, J = 8.2 
Hz, 1H), 7.50 (t, J = 8.2 Hz, 1H), 6.59 (s, 1H), 2.58-2.54 (m, 1H), 0.67-0.63 
(m, 2H), 0.45-0.42 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 155.7, 148.0, 141.6, 129.7, 
123.8, 115.5, 111.7, 22.3, 6.3; IR (film): ῦ = 3348, 3264, 1648, 1515, 1344, 1243, 731 cm-1; 
MS (ESI): m/z: calcd for C10H11N3NaO3+: 244.2, found: 243.9. 
1-(3-Nitrophenyl)-3-(3-(trifluoromethyl)phenyl)urea (14l) 
Yellow solid; Yield: 92 %; 1H NMR (500 MHz, DMSO-d6): δ = 9.33 
(s, 1H), 9.20 (s, 1H), 8.55 (t, J = 2.1 Hz, 1H), 8.01 (s, 1H), 7.85 (dd, 
J = 8.1, 2.1 Hz, 1H), 7.75 (dd, J = 8.1, 2.1 Hz, 1H), 7.64-7.62 (m, 
1H), 7.58 (t, J = 8.1 Hz, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.35 (d, J = 7.8 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6): δ = 152.4, 148.0, 140.6, 140.1, 130.0, 129.9, 129.4 (q, J = 31.5 Hz), 
124.5, 124.1 (q, J = 272.3 Hz), 122.2, 118.4 (q, J = 3.7 Hz), 116.5, 114.4 (q, J = 4.0 Hz), 
112.3; IR (film): ῦ = 3373, 3082, 1692, 1533, 1337, 1117, 733 cm-1; MS (ESI): m/z: calcd 
for C14H10F3N3NaO3+: 348.2, found: 348.2. 
1-(4-Nitrophenyl)-3-(3-(trifluoromethyl)phenyl)urea (14m)119 
Yellow solid; Yield: 60 %; 1H NMR (500 MHz, DMSO-d6): δ 
= 9.16 (s, 2H), 8.01 (s, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.52 (t, J = 
7.9 Hz, 2H), 7.33 (d, J = 7.6 Hz, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 152.5, 140.3, 
130.0, 129.5 (q, J = 31.4 Hz), 124.2 (q, J = 272.4 Hz), 122.2, 118.4 (q, J = 3.8 Hz), 114.4 
(q, J = 4.1 Hz), 4 C are missing due to overlapping; 19F NMR (282 MHz, DMSO-d6): δ = -
61.28; IR (neat): ῦ =3356, 3315, 1719, 1658, 1617, 1556, 1494, 1484, 1446, 1325, 1305, 
1234, 1175, 1163, 1109, 1070, 931, 884, 849, 796, 751, 697, 653, 495 cm-1. MS (ESI), m/z: 
calcd for C14H9F3N3O3-,[M-H]-1: 324.1, found: 324.0. 
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III. Reduction of Nitrobenzene Intermediates 
 
 
 
General procedure A for the reduction of nitro benzene intermediates 
To a solution of nitrophenyl (1 eq) in EtOH (0.1 M) SnCl2 (5 eq) was added. The 
reaction mixture was heated to 100 °C for 2 h, cooled, and concentrated under reduced 
pressure. A solution of EtOAc/NaOH (1M) was added to the residue, and the resulting 
precipitate was filtered off. The organic layer was washed with brine, dried over MgSO4, 
filtered, and concentrated under reduced pressure to afford the desired products in pure 
form. This method was used to obtain intermediates 3a, 3b, 3f, 3g, 3k and 3l. 
General procedure B for the reduction of nitro benzene intermediates 
To a solution of nitrophenyl (1 eq) in MeOH (0.3 M) 10% Pd/C (10% wt) was added. 
The reaction mixture was stirred at 25 °C under a hydrogen balloon for 4-12 hours. The 
reaction mixture was filtered through a pad of celite and concentrated under reduced 
pressure obtaining the corresponding anilines in pure form. This method was used to 
obtain intermediates 3c114-e, 3h118-j and 3m.119 
N-(3-Aminophenyl)cyclopropanecarboxamide (3a) 
Yellow solid; Yield: 72 %; 1H NMR (500 MHz, DMSO-d6): δ = 9.82 (s, 1H), 
6.90-6.87 (m, 2H), 6.68 (d, J = 7.9 Hz, 1H), 6.22 (dd, J = 7.9, 1.3 Hz, 1H), 
4.99 (s, 2H), 1.77-1.72 (m, 1H), 076-0.72 (m, 4H); 13C NMR (125 MHz, 
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DMSO-d6): δ = 171.1, 148.8, 139.9, 128.7, 108.9, 106.9, 104.7, 14.3, 6.8; IR (film): ῦ = 
3440, 3350, 3248, 3013, 1651, 1593, 1456, 1237, 952, 781 cm-1; MS (ESI): m/z: calcd for 
C10H13N2O+: 177.2, found: 177.0. 
N-(3-Aminophenyl)-3-(trifluoromethyl)benzamide (3b) 
Brown solid; Yield: 81 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.17 (s, 
1H), 8.25-8.22 (m, 2H), 7.94 (d, J = 7.8 Hz, 1H), 7.76 (t, J = 7.8 Hz, 
1H), 7.09 (t, J = 1.8 Hz, 1H), 6.98 (t, J = 7.9 Hz, 1H), 6.87 (d, J = 7.9 
Hz, 1H), 6.35-6.33 (m, 1H), 5.10 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 163.6, 148.9, 
139.3, 136.0, 131.7, 129.5, 129.0 (q, J = 32.1 Hz), 128.7, 127.8 (q, J = 3.6 Hz), 124.1 (q, J 
= 3.8 Hz), 123.9 (q, J = 272.5 Hz), 110.0, 108.3, 106.1; IR (film): ῦ = 3399, 3246, 1603, 
1322, 1263, 1128, 696 cm-1; MS (ESI): m/z: calcd for C14H11F3N2NaO+: 303.2, found: 303.0. 
N-(3-Amino-4-methylphenyl)-3-(trifluoromethyl)benzamide (3c)114 
Pale yellow solid; Yield: 77 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.14 (s, 
1H), 8.25 (s, 1H), 8.23 (d, J = 7.9 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.75 
(t, J = 7.8 Hz, 1H), 7.11 (d, J = 1.5 Hz, 1H), 6.84 (dt, J = 8.1, 4.9 Hz, 2H), 
4.87 (s, 2H), 2.03 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 163.7, 146.7, 
137.3, 136.2, 131.8, 129.9, 129.8, 129.2 (q, J = 32.0 Hz), 128.0 (q, J = 3.7 
Hz), 124.3 (q, J = 3.9 Hz), 124.1 (q, J = 272.5 Hz), 117.4, 109.1, 106.7, 17.1; 19F NMR 
(282 MHz, DMSO-d6): δ = -61.04; IR (neat): ῦ = 3490, 3385, 3271, 1647, 1624, 1615, 1602, 
1544, 1518, 1414, 1381, 1326, 1268, 1163, 1111, 1071, 998, 923, 857, 812, 723, 696, 684, 652, 
616, 461, 414 cm-1; MS (ESI), m/z: calcd for C15H12F3N2O-,[M-H]-1: 293.1, found: 293.0. 
N-(3-Amino-4-fluorophenyl)-3-(trifluoromethyl)benzamide (3d) 
Pale brown solid; Yield: 99 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.24 
(s, 1H), 8.25 (s, 1H), 8.23 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.76 
(t, J = 7.8 Hz, 1H), 7.29 (dd, J = 8.4, 2.5 Hz, 1H), 6.96 (dd, J = 11.1, 8.7 Hz, 
1H), 6.88-6.84 (m, 1H), 5.20 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 
163.9, 147.5 (d, J = 234.3 Hz), 136.4 (d, J = 13.7 Hz), 136.1, 135.3 (d, J = 1.9 
Hz), 131.9, 129.8, 129.3 (q, J = 32.0 Hz), 128.1 (q, J = 3.5 Hz), 124.3 (q, J = 3.8 Hz), 
124.1 (q, J = 272.5 Hz), 114.7 (d, J = 19.3 Hz), 108.9 (d, J = 4.0 Hz), 108.6 (d, J = 6.4 
Hz); 19F NMR (282 MHz, DMSO): δ = -61.05, -139.62 (ddd, J = 11.3, 8.5, 4.2 Hz); IR 
(neat): ῦ = 3427, 3300, 1666, 1624, 1555, 1516, 1416, 1328, 1255, 1168, 1107, 1068, 924, 
847, 801, 772, 741, 690, 575, 450, 419 cm-1; HRMS (ESI), m/z: calcd for C14H9F4N2O-,[M-H]-
1: 297.0657, found: 297.0654. 
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N-(3-Amino-4-methylphenyl)-3-(4-methyl-1H-imidazol-1-yl)-
5(trifluoromethyl)benzamide  (3e)  
Yellow solid; Yield: 44 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.17 (s, 
1H), 8.41 (s, 1H), 8.39 (d, J = 1.4 Hz, 1H), 8.20 (s, 1H), 8.13 (s, 1H), 
7.70 (t, J = 1.2 Hz, 1H), 7.09 (d, J = 2.0 Hz, 1H), 6.90 (d, J = 8.44, 
1H), 6.83 (dd, J = 8.0, 2.0 Hz, 1H), 4.90 (s, 2H), 2.19 (d, J = 0.8 Hz, 3H), 2.04 (s, 3H); 13C 
NMR (125 MHz, DMSO-d6): δ = 162.7, 146.6, 138.9, 137.9, 137.7, 137.0, 135.2, 130.7 (q, J 
= 32.6 Hz), 129.7, 123.5 (q, J = 272.9 Hz), 122.5, 121.8 (q, J = 3.7 Hz), 118.8 (q, J = 3.3 
Hz), 117.4, 114.3, 108.9, 106.5, 17.0, 13.5; 19F NMR (282 MHz, DMSO-d6): δ = -61.05; IR 
(neat): ῦ = 3328, 3119, 2969, 1656, 1598, 1543, 1499, 1454, 1426, 1398, 1377, 1330, 1316, 
1284, 1253, 1164, 1115, 1078, 1003, 881, 867, 796, 724, 691, 451, 430, 419, 402 cm-1; HRMS 
(ESI), m/z: calcd for C19H18F3N4O+: 375.1427, found: 375.1430.  
3-Amino-N-cyclopropylbenzamide (3f) 
Yellow solid; Yield: 77%; 1H NMR (500 MHz, DMSO-d6): δ = 8.17 (s, 1H), 
7.04 (t, J = 7.7 Hz, 1H), 6.99 (s, 1H), 6.91 (d, J = 7.7 Hz, 1H), 6.68-6.66 (m, 
1H), 5.24 (s, 2H), 2.83-2.78 (m, 1H), 0.67-0.63 (m, 2H), 0.55-0.52 (m, 2H); 
13C NMR (125 MHz, DMSO-d6): δ = 168.2, 148.3, 135.3, 128.4, 116.3, 114.3, 112.8, 22.9, 
5.6; IR (film): ῦ = 3425, 3330, 1628, 1578, 1521, 1485, 1302, 1258, 1022, 746 cm-1; MS 
(ESI): m/z: calcd for C10H12N2NaO+: 199.2, found: 198.9. 
3-Amino-N-(3-(trifluoromethyl)phenyl)benzamide (3g) 
Brown solid; Yield: 77 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.37 (s, 
1H), 8.24 (s, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.57 (t, J = 8.1 Hz, 1H), 
7.42 (d, J = 7.8 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.11-7.07 (m, 2H), 
6.77 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H), 5.33 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 
166.7, 148.7, 140.1, 135.3, 129.7, 129.2 (q, J = 31.5 Hz), 128.7, 124.1 (q, J = 272.3 Hz), 
123.5, 119.6 (q, J = 3.8 Hz), 117.0, 116.1 (q, J = 4.1 Hz), 114.6, 112.8; IR (film): ῦ = 
3457, 1655, 1539, 1439, 1329, 1120, 793 cm-1; MS (ESI): m/z: calcd for C14H11F3N2NaO+: 
303.2, found: 303.0. 
3-Amino-4-methyl-N-(3-(trifluoromethyl)phenyl)benzamide (3h)118 
Brown solid; Yield: 99 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.33 (s, 1H), 
8.26 (s, 1H), 8.06 (d, J = 8.3 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.41 (d, J = 
7.8 Hz, 1H), 7.21 (d, J = 1.6 Hz, 1H), 7.10 (dt, J = 19.4, 4.7 Hz, 2H), 5.10 
(s, 2H), 2.13 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 166.8, 146.8, 
140.4, 133.0, 129.9, 129.9, 129.5 (q, J = 31.5 Hz), 125.5, 124.3 (q, J = 272.2 
Hz), 123.8, 119.7 (q, J = 3.6 Hz), 116.3 (d, J = 4.0 Hz), 115.4, 113.2, 17.6; 19F NMR (282 
MHz, DMSO-d6): δ = -61.24; IR (neat): ῦ = 3369, 3320, 1665, 1644, 1576, 1551, 1441, 
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1331, 1318, 1259, 1224, 1175, 1162, 1119, 1105, 1066, 1000, 919, 895, 796, 743, 697, 662, 
449, 433 cm-1; MS (ESI), m/z: calcd for C15H12F3N2O-, [M-H]-1: 293.1, found: 293.0. 
3-Amino-4-fluoro-N-(3-(trifluoromethyl)phenyl) benzamide (3i) 
Pale brown solid; Yield: 92 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.39 (s, 
1H), 8.22 (s, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.58 (t, J = 7.9 Hz, 1H), 7.43 (d, 
J = 7.8 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.17-7.11 (m, 2H), 5.41 (s, 2H); 13C 
NMR (125 MHz, DMSO-d6): δ = 165.8, 152.6 (d, J = 243.0 Hz), 140.1, 136.6 
(d, J = 13.4 Hz), 131.2 (d, J = 2.6 Hz), 129.8, 129.4 (q, J = 31.7 Hz), 124.2 
(q, J = 272.3 Hz), 123.7, 119.8 (q, J = 3.3 Hz), 116.3 (q, J = 4.0 Hz), 115.9 (d, J = 5.9 
Hz), 115.6 (d, J = 7.4 Hz), 114.7 (d, J = 19.2 Hz); 19F NMR (282 MHz, DMSO-d6): δ = -
61.25, -130.26 (dd, J = 16.0, 8.7 Hz); IR (neat): ῦ = 3406, 3253, 3206, 3088, 1661, 1604, 
1561, 1511, 1444, 1431, 1336, 1324, 1282, 1261, 1198, 1179, 1162, 1101, 1066, 919, 899, 870, 
849, 791, 771, 752, 724, 694, 660, 642, 556, 450 cm-1; HRMS (ESI), m/z: calcd for 
C14H9F4N2O-, [M-H]-1: 297.0657, found: 297.0656. 
3-Amino-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-
5(trifluoromethyl))benzamide (3j) 
Yellow solid; Yield: 52 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.72 (s, 
1H), 9.41 (s, 1H), 8.55 (s, 1H), 8.27 (s, 1H), 7.94 (s, 1H), 7.86 (s, 1H), 
7.31 (s, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 2.34 (s, 
3H), 2.17 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 166.6, 145.3, 
141.8, 136.5, 134.4, 133.3, 132.3, 130.8 (q, J = 32.6 Hz), 130.0, 126.9, 123.5 (q, J = 272.7 
Hz), 116.5, 116.5, 116.3, 116.1, 114.2, 112.8, 17.6, 10.9; 19F NMR (282 MHz, DMSO-d6): δ 
= -61.42; IR (neat): ῦ = 3328, 3229, 2795, 1667, 1613, 1541, 1508, 1480, 1441, 1398, 1381, 
1304, 1231, 1201, 1171, 1123, 1088, 998, 929, 876, 850, 823, 745, 707, 693, 634, 539, 424 cm-
1; HRMS (ESI), m/z: calcd for C19H18F3N4O+: 375.1427, found: 375.1432.  
1-(3-Aminophenyl)-3-cyclopropylurea (3k) 
Yellow solid; Yield: 53 %; 1H NMR (500 MHz, DMSO-d6): δ = 7.92 (s, 
1H), 6.82 (t, J = 7.9 Hz, 1H), 6.68 (t, J = 1.9 Hz, 1H), 6.52-6.50 (m, 1H), 
6.22 (d, J = 1.8 Hz, 1H), 6.13-6.11 (m, 1H), 4.91 (s, 2H), 2.52-2.48 (m, 
1H), 0.63-0.59 (m, 2H), 0.38-0.35 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 165.2, 
147.6, 135.7, 133.5, 129.9, 125.7, 121.7, 23.1, 5.6; IR (film): ῦ = 3332, 1607, 1548, 1495, 
1218, 1022, 760 cm-1; MS (ESI): m/z: calcd for C10H13N3NaO+: 214.2, found: 214.0. 
1-(3-Aminophenyl)-3-(3-(trifluoromethyl)phenyl)urea (3l) 
White solid; Yield: 92 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.89 (s, 
1H), 8.45 (s, 1H), 8.03 (s, 1H), 7.53-7.48 (m, 2H), 7.28 (d, J = 6.9 Hz, 
1H), 6.90 (t, J = 7.9 Hz, 1H), 6.81 (t, J = 2.0 Hz, 1H), 6.54 (dd, J = 
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7.9, 2.0 Hz, 1H), 6.21 (dd, J = 7.9, 2.0 Hz, 1H), 5.03 (s, 2H); 13C NMR (125 MHz, DMSO-
d6): δ = 152.2, 149.1, 140.6, 139.8, 129.8, 129.4 (q, J = 31.3 Hz), 128.9, 124.1 (q, J = 272.3 
Hz), 121.5, 117.7 (q, J = 3.8 Hz), 113.8 (q, J = 4.1 Hz), 108.3, 106.2, 103.9; IR (film): ῦ = 
3306, 1633, 1557, 1333, 1110, 769 cm-1; MS (ESI): m/z: calcd for C14H12F3N3NaO+: 318.3, 
found: 318.1. 
1-(4-Aminophenyl)-3-(3-(trifluoromethyl)phenyl)urea (3m)119 
Brown solid; Yield: 69 %; 1H NMR (400 MHz, DMSO-d6): δ = 
9.41 (s, 2H), 8.00 (s, 2H), 7.61-7.57 (m, 3H), 7.54-7.50 (m, 2H), 
7.33-7.28 (m, 3H); 13C NMR (125 MHz, DMSO): δ = 152.7, 152.6, 140.8, 140.3, 133.1, 
129.9, 129.9, 129.6 (q, J =  24.9 Hz), 124.2 (q, J = 272.3 Hz), 122.1, 121.6, 120.3, 118.4 (q, 
J = 3.8 Hz), 114.3 (q, J = 4.0 Hz); 19F NMR (282 MHz, DMSO-d6): δ = -61.30; IR (neat): 
ῦ = 3304, 2873, 1599, 1656, 1615, 1556, 1515, 1493, 1448, 1424, 1329, 1311, 1230, 1215, 
1164, 1119, 1096, 1068, 884, 794, 741, 699, 655, 512 cm-1; MS (ESI), m/z: calcd for 
C14H13F3N3O+: 296.26, found: 296.0. 
IV. Cyclization of 2-(3-chloroquinoxalin-2-yl)malononitrile 
 
General procedure A for the cyclization of 2-(3-chloroquinoxalin-2-
yl)malononitrile 
To a solution of 2-(3-chloroquinoxalin-2-yl)malononitrile (1 eq) in 1 : 1 EtOH – 
toluene solution (0.09 M) the primary amine (4 eq for 4a-i, 5a, 5f, 5k and 5l, 2 eq for 5b-
d, 5g-i and 5m and 1 eq for 5n) was added. The reaction mixture was heated to 130-160 
°C for 4-12 h and cooled down. The formed solid was filtered off and washed with Et2O 
and EtOH to obtain the desired compounds 4a, 4d-i, 5a, 5d, 5i, 5f, 5k and 5l in pure 
form. Compounds 5c and 5i were purified by preparative thin layer chromatography and 
4b, 4c and 5n by flash column chromatography (hex/EtOAc, 1:1).  
General procedure B for the cyclization of 2-(3-chloroquinoxalin-2-
yl)malononitrile  
To a solution of 2-(3-chloroquinoxalin-2-yl)malononitrile (1.0 eq) in DMF (0.10 M) the 
primary amine (1.0 eq for 5e, 5j and 1.2 eq for 5m) was added. The reaction mixture was 
heated to 80 °C for 12 h, concentrated and purified by flash column chromatography 
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(hexane/EtOAc 1:1 to EtOAc/MeOH/Et3N, 90:9:1 for 5m and EtOAc/MeOH, 9:1 for 5e, 
5j).  
2-Amino-1-(o-tolyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile (4a) 
Yellow solid; Yield: 73 %; 1H NMR (400 MHz, DMSO-d6): δ = 8.27 (s, 
2H), 7.94 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.60-7.44 (m, 
6H), 2.02 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 159.7, 143.6, 
142.4, 140.3, 137.3, 137.3, 131.4, 130.9, 130.2, 129.9, 127.5, 127.5, 127.1, 
126.8, 125.6, 115.2, 60.3, 17.1; IR (film): ῦ = 3356, 3299, 3065, 2205, 1638, 1551, 1482, 
1432, 1398, 753, 730, 597 cm-1; HRMS (ESI): m/z: calcd for C18H14N5+: 300.1244, found: 
300.1241. 
2-Amino-1-(2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile 
(4b) 
Orange solid; 1H NMR (500 MHz, DMSO-d6): δ = 8.34 (s, 2H), 7.95 (dd, 
J = 8.3, 1.3 Hz, 1H), 7.76 (dd, J = 8.3, 1.3 Hz, 1H), 7.59 (ddd, J = 8.3, 
7.0, 1.3 Hz, 1H), 7.48 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.45-7.42 (m, 1H), 
7.33 (d, J = 7.6 Hz, 2H), 1.95 (s, 6H); 13C NMR (125 MHz, DMSO-d6): δ = 159.2, 143.5, 
141.5, 140.4, 137.5, 137.4, 130.0, 129.8, 128.8, 127.6, 127.1, 126.9, 125.7, 115.0, 60.2, 17.3; 
IR (film): ῦ = 3306, 3059, 2986, 2204, 1665, 1606, 1566, 763, 754, 595 cm-1; HRMS (ESI): 
m/z: calcd for C19H16N5+: 314.1400, found: 314.1400. 
2-Amino-1-(2-chloro-6-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carbonitrile (4c) 
Orange solid; 1H NMR (500 MHz, DMSO-d6): δ = 8.47 (s, 2H), 7.94 (d, J 
= 8.2 Hz, 1H), 7.76 (d, J = 8.3 Hz, 1H), 7.61-7.55 (m, 3H), 7.51-7.47 (m, 
2H), 2.08 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 159.3, 143.6, 
141.5, 140.7, 140.5, 137.2, 133.5, 131.5, 130.0, 128.5, 127.9, 127.5, 127.0, 
126.9, 125.7, 115.0, 60.4, 17.6; IR (film): ῦ = 3332, 3154, 2923, 2208, 1656, 1559, 1462, 
1209, 1025, 762 cm-1; HRMS (ESI): m/z: calcd for C18ClH13N5+: 334.0854, found: 334.0853.  
2-Amino-1-(5-methoxy-2-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carbonitrile (4d) 
Yellow solid; Yield: 53 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.30 (s, 
2H), 7.94 (dd, J = 8.3, 1.3 Hz, 1H), 7.77 (dd, J = 8.3, 1.3 Hz, 1H), 
7.58 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.48 (ddd, J = 8.3, 6.9 Hz, 1.3 Hz, 
1H), 7.41 (d, J = 8.5 Hz, 1H), 7.13-7.09 (m, 2H), 3.77 (s, 3H), 1.91 (s, 3H); 13C NMR (125 
MHz, DMSO-d6): δ = 159.6, 158.3, 143.6, 142.2, 140.3, 137.3, 131.9, 131.4, 128.7, 127.5, 
127.0, 126.8, 125.6, 116.2, 115.2, 115.1, 60.2, 55.4, 16.2; IR (film): ῦ = 3315, 3144, 3061, 
2208, 1636, 1546, 1506, 1447, 1313, 1209, 1030, 820, 760, 735 cm-1; HRMS (ESI): m/z: calcd 
for C19H16N5O+: 330.1349, found: 330.1348. 
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2-Amino-1-(5-(hydroxymethyl)-2-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-
3-carbonitrile (4e) 
Yellow solid; Yield: 74 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.28 (s, 
2H), 7.94 (d, J = 8.0 Hz, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.58 (ddd, J 
= 8.0, 7.1, 1.0 Hz, 1H), 7.49-7.47 (m, 3H), 7.34 (s, 1H), 5.33 (t, J = 
5.5 Hz, 1H), 4.56 (d, J = 5.5 Hz, 2H), 1.98 (s, 3H); 13C NMR (125 
MHz, DMSO-d6): δ = 159.7, 143.6, 142.3, 142.1, 140.3, 137.2, 135.3, 131.1, 130.5, 128.1, 
127.5, 127.4, 127.1, 126.8, 125.7, 115.1, 62.0, 60.3, 16.8; IR (film): ῦ = 3343, 3309, 3124, 
2208, 1637, 1550, 1446, 766, 599 cm-1; HRMS (ESI): m/z: calcd for C19H16N5O+: 330.1349, 
found: 330.1346.  
2-Amino-1-(2-chlorophenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile (4f) 
Orange solid; Yield: 37 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.45 (s, 
2H), 7.95 (dd, J = 8.3, 1.0 Hz, 1H), 7.79 (dd, J = 8.1, 1.3 Hz, 1H), 7.77-
7.74 (m, 2H), 7.68 (td, J = 7.6, 1.7 Hz, 1H), 7.64-7.58 (m, 2H), 7.49 
(ddd, J = 8.3, 7.1, 1.3 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 
159.6, 143.5, 142.3, 140.4, 137.1, 133.1, 132.2, 132.0, 130.5, 129.5, 128.8, 127.5, 127.0, 126.9, 
125.7, 114.9, 60.4; IR (film): ῦ = 3347, 3301, 2210, 1641, 1551, 1477, 1432, 1399, 743 cm-1; 
MS (ESI): m/z: calcd for C17H10ClN5Na+: 342.7, found: 342.1. 
2-Amino-1-(2-fluorophenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile (4g) 
Yellow solid; Yield: 79 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.43 (s, 
2H), 7.95 (dd, J = 8.3, 1.1 Hz, 1H), 7.76 (dd, J = 8.3, 1.2 Hz, 1H), 7.72-
7-67 (m, 2H), 7.62-7.54 (m, 2H), 7.51-7.46 (m, 2H); 13C NMR (125 MHz, 
DMSO-d6): δ = 159.7, 158.4 (d, J = 250.4 Hz), 143.5, 142.4, 140.4, 137.1, 
132.3 (d, J = 8.0 Hz), 131.7, 127.5, 127.1, 127.0, 125.8, 125.7 (d, J = 3.6 Hz), 119.3 (d, J = 
13.2 Hz), 117.1 (d, J = 19.1 Hz), 114.8, 60.7; IR (film): ῦ = 3308, 3109, 2206, 1639, 1555, 
1436, 1213, 760 cm-1; MS (ESI): m/z: calcd for C17H10FN5Na+: 326.3, found: 326.2. 
2-Amino-1-(3-hydroxyphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile (4h) 
Yellow solid; Yield: 73 %; 1H NMR (500 MHz, DMSO-d6): δ = 9.93 (s, 
1H), 8.26 (s, 2H), 7.93 (dd, J = 8.3, 1.3 Hz, 1H), 7.77 (dd, J = 8.3, 1.3 
Hz, 1H), 7.58 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.49 (ddd, J = 8.3, 7.0, 
1.3 Hz, 1H), 7.42 (t, J = 8.0 Hz, 1H), 6.99 (ddd, J = 8.0, 2.1, 0.8 Hz, 
1H), 6.95 (ddd, J = 8.0, 2.1, 0.8 Hz, 1H), 6.90 (t, J = 2.1 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 159.6, 158.3, 143.5, 142.6, 140.3, 137.2, 132.6, 130.5, 127.5, 127.0, 126.7, 
125.6, 119.1, 116.6, 115.6, 115.1, 60.4; IR (film): ῦ = 3437, 3349, 2952, 1654, 1554, 1433, 
1282, 824, 767 cm-1; MS (ESI): m/z: calcd for C17H11N5NaO+: 324.3, found: 324.2. 
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2-Amino-1-(3-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carbonitrile (4i) 
Orange solid; Yield: 44 %; 1H NMR (500 MHz, DMSO-d6): δ = 
13.77 (s, 1H), 8.37 (s, 2H), 8.19 (d, J = 7.9 Hz, 1H), 8.08 (s, 1H), 
7.94 (d, J = 8.3 Hz, 1H), 7.76-7.71 (m, 2H), 7.60-7.57 (m, 2H), 7.48 
(t, J = 7.5 Hz, 1H), 2.41 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ 
= 159.8, 153.7, 143.6, 142.8, 140.3, 137.1, 133.2, 132.3, 130.3, 129.1, 127.5, 127.0, 126.7, 
126.5, 126.0, 125.6, 115.1, 60.7, 11.6, 1C is missing due to overlapping; IR (film): ῦ = 3452, 
3312, 3173, 2219, 1659, 1561, 1466, 1410, 1045, 740 cm-1; HRMS (ESI): m/z: calcd for 
C20H16N8+: 367.1414, found: 367.1417.  
N-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-
yl)phenyl)cyclopropanecarboxamide (5a)  
Yellow solid; Yield: 65 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.56 
(s, 1H), 8.48 (s, 2H), 7.94 (d, J = 8.1 Hz, 1H), 7.82-7.78 (m, 3H), 
7.62-7.49 (m, 3H), 7.21 (d, J = 7.6 Hz, 1H), 1.83 (quint, J = 6.1 Hz, 
1H), 0.82-0.81 (m, 4H); 13C NMR (125 MHz, DMSO-d6): δ = 171.9, 
159.9, 143.2, 142.7, 140.6, 138.8, 136.9, 131.8, 130.1, 127.6, 127.1, 126.0, 125.8, 123.1, 119.8, 
118.8, 114.7, 60.8, 14.5, 7.2; IR (film): ῦ = 3239, 2208, 1653, 1551, 1450, 1201, 954, 756 cm-
1; HRMS (ESI): m/z: calcd for C21H17N6O+: 369.1458, found: 369.1459. 
N-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)phenyl)-3-
(trifluoromethyl)benzamide (5b) 
Yellow solid; Yield: 78 %; 1H NMR (500 MHz, DMSO-d6): δ = 
10.76 (s, 1H), 8.36-8.28 (m, 4H), 8.05 (d, J = 8.4 Hz, 1H), 8.00-
7.94 (m, 3H), 7.83-7-77 (m, 2H), 6.66 (t, J = 8.1 Hz, 1H), 7.60-
7.57 (m, 1H), 7.51-7.48 (m, 1H), 7.34 (d, J = 7.9 Hz, 1H); 13C 
NMR (125 MHz, DMSO-d6): δ = 164.1, 159.6, 143.5, 142.7, 
140.3, 140.1, 137.1, 135.4, 132.0, 131.8, 130.1, 129.8, 129.1 (q, J = 
32.1 Hz), 128.3 (q, J = 3.5 Hz), 127.5, 127.0, 126.8, 125.6, 124.3, 124.1 (q, J = 3.8 Hz), 
123.8 (q, J = 272.5Hz), 121.2, 120.2, 115.0, 60.6; IR (film): ῦ = 3326, 3155, 2210, 1663, 
1561, 1426, 1115, 660 cm-1; HRMS (ESI): m/z: calcd for C25H15F3N6NaO+: 495.1152, found: 
495.1146. 
N-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-4-methyl phenyl)-3- 
(trifluoromethyl)benzamide (5c) 
Yellow solid; Yield: 30 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.67 (s, 
1H), 8.36 (br, 2H), 8.31(s, 1H), 8.27 (d, J = 7.9 Hz, 1H), 8.03-7.91 (m, 
3H), 7.86 (d, J = 1.8 Hz, 1H), 7.83-7.74 (m, 2H), 7.59 (t, J = 7.1 Hz, 
1H), 7.55-7.45 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 164.0, 
CHAPTER 2: EPH TYROSINE KINASE INHIBITORS 
56 
 
159.6, 143.6, 142.3, 140.4, 138.1, 137.3, 135.5, 132.7, 131.9, 131.6, 130.8, 129.8, 129.2 (q, J 
= 32.1 Hz), 128.3 (q, J = 3.1 Hz), 127.6, 127.2, 126.9, 125.8, 124.17 (q, J = 3.8 Hz), 123.95 
(q, J = 272.5 Hz), 122.1, 121.2, 115.1, 60.43, 16.68; 19F NMR (282 MHz, DMSO-d6): δ = -
61.07; IR (neat): ῦ  = 3326, 3166, 2212, 1656, 1596, 1565, 1508, 1485, 1445, 1391, 1326, 
1309, 1256, 1203, 1166, 1124, 1092, 1073, 1037, 817, 755, 693, 650, 599, 477, 411 cm-1; 
HRMS (ESI), m/z: calcd for C26H18F3N6O+: 487.1489, found: 487.1492. 
N-(3-(2-Amino-3-cyano-1H-pyrrolo [2,3-b] quinoxalin-1-yl)-4-fluorophenyl)-3-
(trifluoromethyl)benzamide (5d) 
Yellow solid; Yield: 57 %;1H NMR (500 MHz, DMSO-d6): δ = 10.87 (s, 
1H), 8.77 (br, 2H), 8.33 (s, 1H), 8.31 (d, J = 7.7 Hz, 1H), 8.12 (dd, J = 
6.5, 2.7 Hz, 1H), 8.11-8.06 (m, 1H), 8.00-7.96 (m, 2H), 7.82-7.79 (m, 2H), 
7.65-7.58 (m, 2H), 7.53 (dd, J = 8.2, 6.9 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 164.1, 160.0, 155.6, 153.7, 143.0, 142.6, 136.9, 136.2, 
135.3, 131.9, 129.8, 129.3, 129.1, 128.4, 128.2, 127.7, 127.5, 126.2, 125.0, 
124.2, 122.9, 118.8, 117.3, 117.2, 114.4, 61.3; 19F NMR (282 MHz, DMSO-d6): δ = -61.07, -
125.90 – -126.02 (m); IR (neat): ῦ = 3338, 3076, 2230, 1649, 1624, 1552, 1511, 1471, 1390, 
1329, 1253, 1223, 1120, 1073, 917, 834, 809, 755, 693, 658, 596, 510, 419 cm-1; HRMS (ESI), 
m/z: calcd for C25H15F4N6O+: 491.1238, found: 491.1240. 
N-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-4-methylphenyl)-3-
((4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide) (5e) 
Brown solid; Yield: 24 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.70 
(s, 1H), 8.44-8.38 (m, 5H), 8.25 (s, 1H), 8.18 (s, 1H), 7.97 (dd, J = 
13.0, 9.2 Hz, 1H), 7.83 (s, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.69 (s, 1H), 
7.60 (t, J = 7.1 Hz, 1H), 7.55 (d, J = 8.5 Hz, 1H), 7.49 (t, J = 7.5 Hz, 
1H), 2.18 (s, 3H), 2.01 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ = 
163.2, 159.6, 143.6, 142.3, 140.4, 139.0, 137.8, 137.3, 137.3, 135.3, 
133.0, 131.7, 130.9, 127.6, 127.2, 126.9, 125.8, 122.6, 122.2, 121.8, 
121.4, 115.1, 114.2, 60.4, 16.7, 13.6; 19F NMR (282 MHz, DMSO-d6): δ = -61.07; IR (neat): 
ῦ = 3299, 3066, 2925, 2204, 1651, 1603, 1565, 1538, 1498, 1463, 1393, 1378, 1317, 1281, 
1251, 1176, 1125, 1080, 1011, 880, 817, 755, 691, 664, 598, 446 cm-1; HRMS (ESI), m/z: 
calcd for C30H22F3N8O+: 567.1863, found: 567.1862.  
3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-N-cyclopropylbenzamide 
(5f) 
Yellow solid; Yield: 55 %; 1H NMR (500 MHz, DMSO-d6): δ = 8.52 
(d, J = 4.0 Hz, 1H), 8.36 (s, 2H), 8.07-8.05 (m, 1H), 7.99 (s, 1H), 
7.94 (dd, J = 8.3, 1.1 Hz, 1H), 7.76-7.71 (m, 3H), 7.59 (ddd, J = 8.3, 
7.0, 1.1 Hz, 1H), 7.49 (ddd, J = 8.3, 7.0, 1.1 Hz, 1H), 2.91-2.86 (m, 
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1H), 0.73-0.69 (m, 2H), 0.59-0.56 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 166.1, 
159.7, 143.5, 142.7, 140.3, 137.1, 135.8, 131.9, 131.7, 129.9, 128.3, 127.5, 127.0, 126.8, 125.7, 
115.0, 60.6, 23.0, 5.6, 1C is missing due to overlapping; IR (film): ῦ = 3285, 3116, 2210, 
1644, 1563, 1444, 1295, 1143, 747 cm-1; HRMS (ESI), m/z: calcd for C21H17N6O+: 369.1458, 
found: 369.1456.   
3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-N-(3-
(trifluoromethyl)phenyl)benzamide (5g) 
Yellow solid; Yield: 31 %; 1H NMR (500 MHz, DMSO-d6): δ = 
10.61 (s, 1H), 8.43 (s, 2H), 8.24-8.20 (m, 3H), 8.08 (d, J = 8.3 
Hz, 1H), 7.96 (dd, J = 8.3, 1.0 Hz, 1H), 7.87-7.82 (m, 2H), 7.77 
(dd, J = 8.3, 1.0 Hz, 1H), 7.64-7-58 (m, 2H), 7.51-7.47 (m, 2H); 
13C NMR (125 MHz, DMSO-d6): δ = 164.6, 159.7, 143.5, 142.7, 
140.4, 139.6, 137.1, 135.8, 132.6, 132.1, 130.1, 129.9, 129.3 (q, J = 
31.6 Hz), 128.9, 128.0, 127.5, 127.1, 126.9, 125.7, 124.0 (q, J = 272.3 Hz), 123.7, 120.1 (q, J 
= 3.8 Hz), 116.3 (q, J = 4.0 Hz), 115.0, 60.7; IR (film): ῦ = 3346, 3184, 2211, 1660, 1561, 
1443, 1331, 1121, 596 cm-1; HRMS (ESI): m/z: calcd for C25H16F3N6O+: 473.1332, found: 
473.1334. 
3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-4-methyl-N-(3-
(trifluoromethyl)phenyl)benzamide (5h) 
Yellow solid; Yield: 33 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.53 (s, 
1H), 8.43 (br, 2H), 8.21 (s, 1H), 8.19 (dd, J = 8.2, 1.6 Hz, 1H), 8.13 (s, 
1H), 8.08 (d, J = 8.4 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 7.6 
Hz, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.62-7.59 (m, 2H), 7.51-7.45 (m, 2H), 
2.12 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 164.5, 159.9, 143.8, 
142.5, 142.2, 140.6, 139.9, 137.4, 133.6, 131.9, 131.3, 130.1, 129.9, 129.8, 
129.6, 129.5, 129.2, 127.8, 127.4, 127.2, 126.0, 125.4, 124.0, 123.2, 120.3, 116.7, 115.3, 60.8, 
17.5; 19F NMR (282 MHz, DMSO-d6): δ = -61.27; IR (neat): ῦ = 3323, 3130, 2922, 2360, 
2205, 1651, 1555, 1443, 1332, 1260, 1165, 1121, 1069, 796, 759, 696, 667, 659, 598, 418 cm-1; 
HRMS (ESI), m/z: calcd for C26H18F3N6O+: 487.1489, found: 487.1493. 
3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-4-fluoro-N-(3-
(trifluoromethyl)phenyl)benzamide (5i)  
Yellow solid; Yield: 65 %; 1H NMR (400 MHz, DMSO-d6): δ = 10.71 (s, 
1H), 8.74 (br, 2H), 8.39-8.35 (m, 2H), 8.23 (s, 1H), 8.09 (d, J = 9.0 Hz, 
1H), 7.97 (d, J = 8.4 Hz, 1H), 7.81-7.76 (m, 2H), 7.65-7.60 (m, 2H), 7.54-
7.47 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 163.8, 161.8, 160.0, 
159.6, 143.1, 139.7, 137.0, 132.4, 131.9, 131.8, 130.0, 129.5, 129.3, 127.7, 
127.5, 126.2, 125.2, 123.9, 123.0, 120.3, 117.6, 117.4, 116.5, 116.5, 114.7, 
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61.3; 19F NMR (282 MHz, DMSO-d6): δ = -61.27, -115.32 – -115.52 (m); IR (neat): ῦ = 
3258, 3121, 2226, 1884, 1686, 1652, 1618, 1581, 1563, 1515, 1493, 1471, 1389, 1330, 1277, 
1212, 1172, 1120, 1095, 1073, 887, 844, 796, 761, 748, 694, 594, 517, 510, 479, 443 cm-1; 
HRMS (ESI), m/z: calcd for C25H15F4N6O+: 491.1238, found: 491.1244. 
3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)-4-methyl-N-(4-methyl-
1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide) (5j) 
Orange solid; Yield: 21 %; 1H-NMR (400 MHz, DMSO-d6): δ = 10.65 
(s, 1H), 8.43 (s, 2H), 8.27 (s, 1H), 8.19-8.21 (m, 2H), 8.14 (s, 2H), 7.97 
(d, J = 8.5 Hz, 1H), 7.78-7.73 (m, 3H), 7.60 (t, J = 7.1 Hz, 1H), 7.51-
7.47 (m, 2H), 2.17 (s, 3H), 2.13 (s, 3H); 13C NMR (100 MHz, DMSO-
d6): δ = 164.5, 159.7, 143.6, 142.3, 142.3, 141.1, 140.5, 138.9, 137.9, 
137.3, 134.9, 133.0, 131.8, 131.2, 131.0, 130.7, 130.5, 129.7, 129.3, 
127.6, 127.2, 127.0, 125.9, 124.7, 115.0, 115.0, 114.2, 60.6, 17.4, 13.5; 
19F NMR (282 MHz, DMSO-d6): δ = -61.34; IR (neat): ῦ = 3303, 2924, 2855, 2202, 1683, 
1653, 1614, 1565, 1499, 1479, 1444, 1407, 1325, 1309, 1269, 1241, 1227, 1193, 1170, 1123, 
1103, 1082, 1021, 1008, 930, 863, 808, 758, 750, 694, 671, 627, 597, 523, 473, 446, 413, 402 
cm-1; HRMS (ESI), m/z: calcd for C30H22F3N8O+: 567.1863, found: 567.1861.  
1-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)phenyl)-3-
cyclopropylurea (5k) 
Yellow solid; 1H NMR (500 MHz, DMSO-d6): δ = 8.60 (s, 1H), 8.28 
(s, 2H), 7.93 (d, J = 8.3 Hz, 1H), 7.77 (d, J = 8.2 Hz, 1H), 7.61-7.57 
(m, 3H), 7.50-7.46 (m, 2H), 7.07 (d, J = 7.9 Hz, 1H), 6.50 (s, 1H), 
2.56-2.52 (m, 1H), 0.65-0.61 (m, 2H), 0.42-0.39 (m, 2H); 13C NMR 
(125 MHz, DMSO-d6): δ = 159.6, 155.8, 143.5, 142.6, 141.7, 140.3, 
137.2, 132.0, 129.9, 127.5, 127.0, 126.7, 125.6, 121.2, 118.7, 117.7, 115.1, 60.4, 22.3, 6.3; IR 
(film): ῦ = 3321, 3160, 2923, 2207, 1695, 1537, 1449, 1244, 1031, 754 cm-1; HRMS (ESI), 
m/z: calcd for C21H18N7O+: 384.1567, found: 384.1567. 
1-(3-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)phenyl)-3-(3-
(trifluoromethyl)phenyl)urea (5l) 
Yellow solid; Yield: 54 %; 1H NMR (500 MHz, DMSO-d6): δ = 
9.19 (s, 1H), 9.14 (s, 1H), 8.33 (s, 2H), 8.02 (s, 1H), 7.94 (d, J 
= 8.1 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.70-7.67 (m, 2H), 
7.60-7.47 (m, 5H), 7.32 (d, J = 7.5 Hz, 1H), 7.18 (d, J = 7.3 
Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 159.6, 152.4, 
143.5, 142.7, 140.7, 140.3, 137.2, 132.2, 130.1, 129.8, 129.4 (q, J 
= 31.4 Hz), 127.5, 127.0, 126.7, 125.6, 124.1 (q, J = 272.4 Hz), 122.3, 121.8, 119.3, 118.3, 
118.2 (q, J = 3.4 Hz), 115.1, 114.1 (q, J = 4.4 Hz), 60.5, 1C is missing due to overlapping; 
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IR (film): ῦ = 3322, 3157, 2208, 1663, 1560, 1446, 1320, 1163, 1117, 754 cm-1; HRMS 
(ESI): m/z: calcd for C25H17F3N7O+: 488.1441, found: 488.1442.  
1-(4-(2-Amino-3-cyano-1H-pyrrolo[2,3-b]quinoxalin-1-yl)phenyl)-3-(3-
(trifluoromethyl)phenyl)urea (5m) 
Yellow solid; Yield: 61 %; 1H NMR (500 MHz, DMSO-d6): δ = 
9.18 (s, 1H), 9.15 (s, 1H), 8.28 (br, 2H), 7.93 (dd, J = 8.4, 1.0 
Hz, 1H), 7.76 (dd, J = 8.3, 1.2 Hz, 1H), 7.72 (d, J = 8.8 Hz, 
2H), 7.63 (d, J = 7.5 Hz, 1H), 7.60 – 7.51 (m, 3H), 7.47 (d, J = 
8.8 Hz, 2H), 7.34 (d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, 
DMSO-d6): δ = 213.8, 160.0, 152.5, 143.7, 143.0, 140.6, 140.4, 
140.4, 137.3, 130.0, 129.7, 129.5, 129.4, 127.6, 127.1, 126.7, 125.6, 125.5, 125.5, 122.8, 122.0, 
119.4, 118.3 (q, J = 4.5 Hz), 115.2, 114.2 (q, J = 3.2 Hz), 60.4; 19F NMR (282 MHz, 
DMSO-d6): δ = -61.27; IR (neat): ῦ = 3282, 3066, 2597, 2225, 1655, 1622, 1602, 1551, 
1514, 1493, 1446, 1336, 1313, 1232, 1201, 1174, 1166, 1120, 1069, 834, 793, 757, 696, 668, 
659, 596, 510, 483,474, 420 cm-1; HRMS (ESI), m/z: calcd for C25H17F3N7O+: 488.1441, 
found: 488.1441. 
2-Amino-1-(N-Boc-p-phenylamine)-1H-pyrrolo[2,3-b]quinoxaline-3-carbonitrile 
(5n) 
Yellow solid; 46 %; 1H NMR (400 MHz, DMSO-d6): δ = 9.66 (s, 1H), 
8.24 (br, 2H), 7.92 (dd, J = 8.5, 1.3 Hz, 1H), 7.74 (dd, J = 8.5, 1.3 Hz, 
1H), 7.68 (d, J = 8.7 Hz, 2H), 7.59-7.55 (m, 1H), 7.48 (ddd, J = 8.3, 
7.1, 1.6 Hz, 1H), 7.42 (d, J = 8.8 Hz, 2H), 1.52 (s, 9H); 13C NMR (125 
MHz, DMSO-d6): δ = 160.0, 152.8, 143.7, 143.0, 140.7, 140.4, 137.3, 129.4, 127.6, 127.1, 
126.8, 125.7, 125.4, 119.1, 115.2, 79.5, 60.4, 28.1; IR (neat): ῦ = 3349, 3256, 3160, 2214, 
1700, 1671, 1592, 1565, 1502, 1482, 1443, 1413, 1394, 1369, 1314, 1238, 1214, 1166, 1058, 
1028, 1020, 840, 752, 624, 599, 528, 418 cm-1; HRMS (ESI), m/z: calcd for C22H21N6O2+: 
401.1721, found: 401.1720. 
V. Synthesis of quinoxaline carboxamides 
 
General procedure for the hydrolysis of carbonitriles 
A solution of the carbonitrile (1.0 eq) in sulfuric acid (0.15 M) was stirred for 30 min 
at 25 °C. The reaction was poured into ice cold water and basified with a solution of 
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ammonium hydroxide (25%) to pH 7. The resulting solid was filtered off and washed with 
cold water obtaining the final products. The crude product of 6e was then heated in 
acetone (5.0 mL) at 160 °C for 1 h. After cooling to room temperature, the solid was 
filtered off and washed with hexane to afford the desired product in pure form. 
In the case of 6a-d, 6f-i and 7a, 7f, 7k the residue was redissolved in EtOAc and 
extracted with a saturated solution of NaHCO3 affording the corresponding product in pure 
form. 7l and 7f were further recrystallized in acetone and 7k by column chromatography 
(EtOAc). 
2-Amino-1-(o-tolyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide (6a) 
Yellow solid; Yield: 74 %; mp 152-155 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 8.05 (s, 2H), 7.95 (dd, J = 8.3, 1.3 Hz, 1H), 7.77-7.75 (m, 2H), 
7.59-7.53 (m, 3H), 7.48-7.44 (m, 3H), 7.39 (d, J = 2.2 Hz, 1H), 2.04 (s, 
3H); 13C NMR (125 MHz, DMSO-d6): δ = 166.6, 159.0, 143.2, 141.5, 
139.7, 137.3, 136.8, 131.3, 131.0, 130.0, 129.8, 127.6, 127.4, 126.8, 126.6, 
125.1, 82.5, 17.2; IR (film): ῦ = 3366, 3157, 1651, 1627, 1526, 1464, 1026, 746, 644, 595 cm-
1; HRMS (ESI): m/z: calcd for C18H16N5O+: 318.1349, found: 318.1346. 
2-Amino-1-(2,6-dimethylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide 
(6b) 
Orange solid; Yield: 4.5 % over two steps; mp 157-159 °C; Purity: 90 %; 
1H NMR (500 MHz, DMSO-d6): δ = 8.07 (s, 2H), 7.95 (d, J = 8.3 Hz, 
1H), 7.78-7.76 (m, 2H), 7.58 (ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 7.48-7.41 (m, 
3H), 7.35-7.34 (m, 2H), 1.96 (s, 6H); 13C NMR (125 MHz, DMSO-d6): δ 
= 166.6, 158.6, 142.3, 141.4, 139.7, 137.6, 136.9, 130.0, 129.9, 128.7, 127.6, 126.8, 126.7, 
125.2, 82.5, 17.3; IR (film): ῦ = 3443, 3395, 3309, 1632, 1568, 1523, 1463, 758, 596 cm-1; 
HRMS (ESI): m/z: calcd for C19H19N5O+: 332.1506, found: 332.1503. 
2-Amino-1-(2-chloro-6-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (6c) 
Red solid; Yield: 1 % over two steps; mp 241-243 °C; Purity: 91 %; 1H 
NMR (400 MHz, DMSO-d6): δ = 8.22 (s, 2H), 7.95 (dd, J = 8.3, 1.1 Hz, 
1H), 7.79-7.75 (m, 2H), 7.62-7.56 (m, 3H), 7.52 (dd, J = 7.4 Hz, J = 1.2 
Hz, 1H), 7.47 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.39 (s, 1H), 2.08 (s, 3H); 13C NMR (125 
MHz, DMSO-d6): δ = 166.5, 158.5, 142.3, 141.5, 140.7, 139.8, 136.8, 133.7, 131.4, 130.0, 
128.7, 127.9, 127.6, 126.8, 125.3, 82.7, 17.7, one C is missing due to overlapping; IR (film): 
ῦ = 3359, 3293, 3167, 1649, 1609, 1523, 1455, 1256, 1036, 757, 597 cm-1; HRMS (ESI): m/z: 
calcd for C18H15ClN5O+: 352.0960, found: 352.0959. 
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2-Amino-1-(5-methoxy-2-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (6d) 
Yellow solid; Yield: 72 %; mp 215-217 °C; 1H NMR (300 MHz, DMSO-
d6): δ = 7.94 (d, J = 7.7 Hz, 1H), 7.79-7.76 (m, 2H), 7.57 (ddd, J = 
8.2, 6.9, 1.3 Hz, 1H), 7.49-7.37 (m, 3H), 7.15-7.09 (m, 2H), 3.78 (s, 
3H), 1.94 (s, 3H), NH2-not observed; 13C NMR (125 MHz, DMSO-d6): δ 
= 166.6, 158.9, 158.2, 143.1, 141.5, 139.6, 136.8, 131.8, 131.6, 128.7, 127.6, 126.8, 126.6, 
125.1, 115.9, 115.0, 82.5, 55.4, 16.3; IR (film): ῦ = 3482, 3405, 3295, 3067, 2998, 2930, 
1630, 1612, 1507, 1465, 1308, 1227, 1119, 1027, 817, 745, 596 cm-1; HRMS (ESI): m/z: calcd 
for C19H18N5O2+: 348.1455, found: 348.1454. 
2-Amino-1-(5-(hydroxymethyl)-2-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-
3-carboxamide (6e) 
Yellow solid; Yield: 72 %; Purity: 88%; 1H NMR (500 MHz, DMSO-
d6): δ = 8.03 (s, 2H), 7.94 (dd, J = 8.3, 1.3 Hz, 1H), 7.77-7.75 (m, 
2H), 7.57 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.49-7.48 (m, 2H), 7.46 
(ddd, J = 8.3, 7.0,  1.3 Hz, 1H), 7.39-7.36 (m, 2H), 5.34 (t, J = 5.6 
Hz, 1H), 4.57 (d, J = 5.6 Hz, 2H), 2.00 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 166.6, 
159.0, 143.1, 142.0, 141.4, 139.6, 136.8, 135.3, 131.0, 130.7, 127.9, 127.6, 127.4, 126.8, 126.6, 
125.1, 82.5, 62.0, 16.9; IR (film): ῦ = 3339, 3247, 3162, 1661, 1603, 1148, 1036 ,876, 762, 
702 cm-1; HRMS (ESI): m/z: calcd for C19H18N5O2+: 348.1455, found: 348.1458.  
2-Amino-1-(2-chlorophenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide (6f) 
Yellow solid; Yield: 69 %; mp 207-209 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 8.20 (s, 2H), 7.95 (dd, J = 8.3, 1.3 Hz, 1H), 7.80 (dd, J = 8.3, 
1.3 Hz, 1H), 7.77-7.75 (m, 3H), 7.69 (td, J = 7.6, 1.7 Hz, 1H), 7.63 (td, J 
= 7.6, 1.4 Hz, 1H), 7.58 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.46 (ddd, J = 
8.3, 7.0, 1.3 Hz, 1H), 7.37 (s, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 166.5, 158.9, 143.1, 
141.5, 139.7, 136.7, 133.2, 132.2, 131.8, 130.5, 129.7, 128.7, 127.5, 126.8, 126.7, 125.2, 82.6; 
IR (film): ῦ = 3370, 3270, 3173, 1650, 1607, 1522, 1024, 748 cm-1; HRMS (ESI): m/z: calcd 
for C17H12ClN5NaO+: 360.0623, found: 360.0622.  
2-Amino-1-(2-fluorophenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide (6g) 
Yellow solid; Yield: 55 %; mp 272-275 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 8.26 (s, 2H), 7.96 (dd, J = 8.3, 1.0 Hz, 1H), 7.78-7.68 (m, 4H), 
7.61-7.56 (m, 2H), 7.50-7-46 (m, 2H), 7.39 (s, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 166.4, 158.9, 158.4 (d, J = 250.2 Hz), 143.2, 141.5, 139.8, 
136.6, 132.0 (d, J = 8.0 Hz), 131.6, 127.5, 126.8, 125.6 (d, J = 3.6 Hz), 125.2, 119.5 (d, J = 
13.2 Hz), 117.0 (d, J = 19.2 Hz), 82.8, 1C is missing due to overlapping; IR (film): ῦ = 
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3474, 3394, 3153, 1659, 1507, 1215, 1024, 745 cm-1; HRMS (ESI): m/z: calcd for 
C17H12FN5NaO+: 344.0918, found: 344.0919. 
2-Amino-1-(3-hydroxyphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide (6h) 
Yellow solid; Yield: 7 %; mp 326-327 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 9.95 (s, 1H), 8.06 (s, 2H), 7.94 (d, J = 8.2 Hz, 1H), 7.80-7.77 
(m, 2H), 7.57 (ddd, J = 8.3, 7.0, 1.2 Hz, 1H), 7.49-7.43 (m, 2H), 7.35 (s, 
1H), 7.00-6.97 (m, 2H), 6.94 (t, J = 2.1 Hz, 1H); 13C NMR (125 MHz, 
DMSO-d6): δ = 166.6, 158.8, 158.3, 143.3, 141.4, 139.6, 136.7, 132.7, 
130.5, 127.6, 126.7, 126.6, 125.1, 118.8, 116.3, 115.3, 82.5; IR (film): ῦ = 3396, 3312, 1635, 
1505, 1283, 754 cm-1; HRMS (ESI): m/z: calcd for C17H13N5NaO2+: 342.0962, found: 
342.0960. 
2-Amino-1-(3-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (6i) 
Yellow solid; Yield: 13 %; mp 320-322 °C; Purity: 94 %; 1H NMR 
(500 MHz, DMSO-d6): δ =13.83 (s, 1H), 8.20-8.11 (m, 4H), 7.95 
(dd, J = 8.3, 1.2 Hz, 1H), 7.79-7.73 (m, 3H), 7.62 (d, J = 7.6 Hz, 
1H), 7.58 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.46 (ddd, J = 8.3, 6.9, 
1.2 Hz, 1H), 7.37 (s, 1H), 2.41 (s, 3H); 13C NMR (125 MHz, DMSO-
d6): δ = 166.6, 160.0, 158.9, 153.7, 143.5, 141.5, 139.7, 136.7, 133.2, 132.4, 130.2, 128.7, 
127.6, 126.8, 126.6, 126.2, 125.6, 125.1, 82.7, 11.5; IR (film): ῦ = 3370, 3302, 1592, 1524, 
1129, 754 cm-1; HRMS (ESI): m/z: calcd for C20H17N8O+: 385.1520, found: 385.1522. 
2-Amino-1-(3-(cyclopropanecarboxamido)phenyl)-1H-pyrrolo[2,3-b]quinoxaline-
3-carboxamide (7a)  
Yellow solid; Yield: 51 %; mp 319-320 °C; Purity: 93 %; 1H NMR 
(500 MHz, DMSO-d6): δ = 10.51 (s, 1H), 8.09 (s, 2H), 7.94 (dd, J = 
8.3, 1.1 Hz, 1H), 7.81-7.77 (m, 4H), 7.59-7-56 (m, 2H), 7.47 (ddd, J 
= 8.3, 7.1, 1.3 Hz, 1H), 7.36 (s, 1H), 7.25-7.23 (m, 1H), 1.82 (quint, J 
= 6.2 Hz, 1H), 0.82-0.81 (m, 4H); 13C NMR (125 MHz, DMSO-d6): δ 
= 171.9, 166.6, 158.8, 143.3, 141.4, 140.6, 139.7, 136.7, 132.2, 130.0, 127.6, 126.8, 126.6, 
125.1, 122.8, 119.4, 118.5, 82.5, 14.5, 7.2; IR (film): ῦ = 3442, 3361, 3136, 1654, 1459, 1240, 
1036, 762 cm-1; HRMS (ESI): m/z: calcd for C21H19N6O2+: 387.1564, found: 387.1563. 
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2-Amino-1-(3-(3-(trifluoromethyl)benzamido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7b) 
Yellow solid; Yield: 33 %; mp 302-304 °C; 1H NMR (500 MHz, 
DMSO-d6): δ = 10.77 (s, 1H), 8.32 (s, 1H), 8.29 (d, J = 7.9 Hz, 
1H), 8.15-8.05 (m, 3H), 8.00-7.95 (m, 3H), 7.83-7.79 (m, 3H), 7.67 
(t, J = 8.1 Hz, 1H), 7.60-7.57 (m, 1H), 7.49-7.46 (m, 1H), 7.37-7-
36 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 166.6, 164.1, 
158.8, 143.4, 141.4, 140.1, 139.7, 136.7, 135.4, 132.2, 131.8, 130.1, 
129.7, 129.1 (q, J = 32.1 Hz), 128.3 (q, J = 3.6 Hz), 127.6, 126.8, 126.6, 125.1, 124.1 (q, J 
= 3.8 Hz), 124.0, 123.8 (q, J = 272.5 Hz), 120.9, 120.0, 82.6; IR (film): ῦ = 3452, 3362, 
3275, 1639, 1490, 1330, 1171, 757 cm-1; HRMS (ESI): m/z: calcd for C25H18F3N6O2+: 
491.1438, found: 491.1443. 
2-Amino-1-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7c) 
Yellow solid; Yield: 70 %; mp 220-225 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 10.69 (s, 1H), 8.31 (s, 1H), 8.27 (d, J = 7.9 Hz, 1H), 7.99-7.95 
(m, 3H), 7.87 (s, 1H), 7.81-7.77 (m, 3H), 7.58 (t, J = 7.5 Hz, 1H), 7.54 
(d, J = 8.4 Hz, 1H), 7.47 (t, J = 7.8 Hz, 1H), 7.39 (s, 1H), 2.01 (s, 3H); 
13C NMR (125 MHz, DMSO-d6): δ = 166.6, 164.0, 158.9, 143.1, 141.5, 
139.8, 138.0, 136.9, 135.5, 132.7, 131.9, 131.5, 131.0, 129.8, 129.2 (q, J = 
32.1 Hz), 128.3 (q, J = 3.5 Hz), 127.7, 126.9, 126.7, 125.2, 124.2 (q, J = 
3.7 Hz), 124.0 (q, J = 272.5 Hz), 121.9, 121.2, 82.61, 16.75; 19F NMR (282 MHz, DMSO-
d6): δ = -61.07; IR (neat): ῦ =3301, 3220, 3063, 1637, 1592, 1570, 1509, 1440, 1417, 1332, 
1251, 1169, 1121, 1091, 1072, 822, 799, 757, 694, 616, 597, 471, 439, 429 cm-1; HRMS (ESI), 
m/z: calcd for C26H20F3N6O+: 505.1598, found: 505.1594. 
2-Amino-1-(2-fluoro-5-(3-(trifluoromethyl)benzamido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7d) 
Yellow solid; Yield: 68 %; mp 205-209 °C; Purity: 90 %; 1H NMR (500 
MHz, DMSO-d6): δ = 10.80 (s, 1H), 8.33-8.28 (m, 4H), 8.08-8.07 (m, 2H), 
7.99 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 8.3 Hz, 1H),  7.83-7.77 (m, 3H), 
7.63 -7.58  (m, 2H), 7.49 (t, J = 7.5 Hz, 1H), 7.42 (s, 1H); 13C NMR (125 
MHz, DMSO-d6): δ = 166.5, 164.2, 159.0, 153.8, 143.2, 141.6, 139.9, 
136.7, 136.1, 135.3, 131.9, 129.9, 129.4, 127.7, 127.0, 125.4, 124.2, 122.8, 
119.4, 117.3, 83.0; 19F NMR (282 MHz, DMSO-d6): δ = -61.07, -125.82 
(ddd, J = 9.6, 6.4, 4.7 Hz); IR (neat): ῦ = 3293, 3201, 3073, 1638, 1571, 1462, 1417, 1401, 
1332, 1250, 1168, 1122, 1071, 1031, 808, 758, 695, 597, 474, 454, 433 cm-1; HRMS (ESI), 
m/z: calcd for C25H17F4N6O2+: 509.1344, found: 509.1343. 
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2-Amino-1-(2-methyl-5-((4-methyl-1H-imidazol-1-yl)-5-
(trifluoromethyl)benzamido)phenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (7e) 
Brown solid; Yield: 90 %; mp 230-235 °C;  Purity: 88 %; 1H NMR 
(500 MHz, DMSO-d6): δ = 10.71 (s, 1H), 8.45 (s, 1H), 8.39 (br, 1H), 
8.25 (s, 1H), 8.18 (s, 1H), 8.13 (br, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.96 
(d, J = 8.1 Hz, 1H), 7.84 (s, 1H), 7.79 – 7.77 (m, 2H), 7.69 (s, 1H), 
7.60 – 7.56 (m, 2H), 7.47 (t, J = 7.7 Hz, 1H), 7.38 (s, 1H), 2.18 (s, 
3H), 2.03 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 166.6, 163.2, 
158.9, 143.1, 141.5, 139.8, 139.0, 137.8, 137.3, 136.9, 135.2, 133.0, 
131.6, 131.1, 131.0, 130.7, 127.6, 126.9, 126.7, 125.2, 124.5, 122.6, 
122.3, 122.0, 121.8, 121.3, 114.2, 82.6, 16.7, 13.5; 19F NMR (282 MHz, DMSO-d6): δ = -
61.06; IR (neat): ῦ = 3048, 1643, 1571, 1509, 1450, 1376, 1303, 1250, 1174, 1090, 884, 837, 
756, 691, 614, 598, 460 cm-1; HRMS (ESI), m/z: calcd for C30H24F3N8O2+: 585.1969, found: 
585.1964.  
2-Amino-1-(3-(cyclopropylcarbamoyl)phenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (7f) 
Yellow solid; Yield: 46 %; mp 294-296 °C; Purity: 93 %; 1H NMR 
(500 MHz, DMSO-d6): δ = 8.54 (d, J = 4.1 Hz, 1H), 8.16 (s, 2H), 
8.06 (dt, J = 7.0, 1.9 Hz, 1H), 8.02 (s, 1H), 7.95 (dd, J = 8.3, 1.1 
Hz, 1H), 7.78-7.72 (m, 4H), 7.58 (ddd, J = 8.3, 6.9, 1.1 Hz, 1H), 7.47 
(ddd, J = 8.3, 6.9, 1.1 Hz, 1H), 7.37 (s, 1H), 2.91-2.86 (m, 1H), 0.73-
0.69 (m, 2H), 0.59-0.56 (m, 2H); 13C NMR (125 MHz, DMSO-d6): δ = 166.5, 166.1, 158.9, 
143.4, 141.5, 139.7, 136.7, 135.8, 132.0, 131.5, 129.8, 128.0, 127.6, 127.2, 126.8, 126.7, 125.1, 
82.6, 23.0, 5.6; IR (film): ῦ = 3468, 3298, 3117, 1637, 1526, 1457, 1304, 760 cm-1; HRMS 
(ESI): m/z: calcd for C21H19N6O2+: 387.1564, found: 387.1564. 
2-Amino-1-(3-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7g) 
Yellow solid; Yield: 61 %; mp 312-314 °C; 1H NMR (500 MHz, 
DMSO-d6):  = 10.62 (s, 1H), 8.24-8.22 (m, 5H), 8.08 (d, J = 8.4 
Hz, 1H), 7.96 (dd, J = 8.3, 1.0 Hz, 1H), 7.89-7.84 (m, 2H), 7.80-
7.78 (m, 2H), 7.64-7.57 (m, 2H), 7.49-7.46 (m, 2H), 7.39 (s, 1H); 
13C NMR (125 MHz, DMSO-d6):  = 166.5, 164.6, 158.8, 143.4, 
141.5, 139.8, 139.6, 136.7, 135.7, 132.3, 132.2, 130.1, 129.9, 129.3 
(q, J = 31.6 Hz), 128.6, 127.7, 127.6, 126.8, 126.7, 125.2, 124.0 (q, J = 272.3 Hz), 123.7, 
120.1 (q, J = 3.8 Hz), 116.3 (q, J = 4.0 Hz), 82.7; IR (film): ῦ = 3436, 3272, 1607, 1511, 
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1334, 1112, 751 cm-1; HRMS (ESI): m/z: calcd for C25H18F3N6O2+: 491.1438, found: 
491.1440. 
2-Amino-1-(2-methyl-(5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-
pyrrolo[2,3-b]quinoxaline-3-carboxamide (7h) 
Yellow solid; Yield: 75 %; 1H NMR (500 MHz, DMSO-d6): δ = 10.53 (s, 
1H), 8.21-8.15 (m, 5H), 8.08 (d, J = 8.0 Hz, 1H), 7.96 (d, J = 7.4 Hz, 
1H), 7.78-7.77 (m, 2H), 7.73 (d, J = 8.1 Hz, 1H), 7.62-7.57 (m, 2H), 7.49-
7.45 (m, 2H), 7.40 (s, 1H), 2.13 (s, 3H); 13C NMR (125 MHz, DMSO-d6): 
δ = 166.6, 164.4, 159.0, 143.1, 142.0, 141.6, 139.8, 139.8, 136.8, 133.3, 
131.7, 131.3, 129.9, 129.5, 129.2, 129.2, 127.7, 126.9, 126.8, 125.3, 123.9, 
120.1, 116.5, 82.8, 17.4; 19F NMR (282 MHz, DMSO-d6): δ = -61.27; IR (neat): ῦ = 3289, 
3213, 2926, 2158, 1638, 1570, 1525, 1492, 1443, 1332, 1167, 1121, 1070, 796, 755, 697, 595, 
473, 459, 446, 432 cm-1; HRMS (ESI), m/z: calcd for C26H20F3N6O+: 505.1594, found: 
505.1594. 
2-Amino-1-(2-fluoro-(5-((3-(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-
pyrrolo[2,3-b]quinoxaline-3-carboxamide (7i) 
Yellow solid; Yield: 99 %; Purity: 91 %; 1H NMR (500 MHz, DMSO-d6): 
δ = 10.64 (s, 1H), 8.39-8.34 (m, 3H), 8.21 (s, 2H), 8.07 (d, J = 7.8 Hz, 
1H), 7.97 (d, J = 8.1 Hz, 1H), 7.80-7.74 (m, 3H), 7.64-7.59 (m, 2H), 7.50-
7.47 (m, 2H), 7.43 (s, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 166.4, 
163.8, 161.8, 159.8, 158.9, 143.2, 141.6, 139.9, 139.7, 136.7, 132.1, 131.7, 
131.5, 130.0, 129.5, 129.3, 127.7, 127.1, 127.0, 125.5, 125.2, 123.9, 123.1, 
120.3, 119.8, 119.7, 117.6, 117.4, 116.5, 83.1; 19F NMR (282 MHz, DMSO-
d6): δ = -61.28, -115.24 – -115.33 (m); IR (neat): ῦ =3292, 3207, 3070, 1641, 1571, 1514, 
1491, 1444, 1332, 1275, 1167, 1116, 1094, 1070, 797, 754, 697, 614, 597, 481, 419 cm-1. 
HRMS (ESI), m/z: calcd for C25H17F4N6O2+: 509.1344, found: 509.1343. 
2-Amino-1-(2-methyl-5-((3-(4-methyl-1H-imidazol-1-yl)-(5-
(trifluoromethyl)phenyl)carbamoyl)phenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (7j)  
Orange solid; Yield: 85 %; mp 233-238 °C; Purity: 91 %  1H NMR (500 
MHz, DMSO-d6): δ = 10.66 (s, 1H), 8.27 (s, 1H), 8.22 – 8.15 (m, 5H), 
7.97 (d, J = 8.4 Hz, 1H), 7.78 – 7.73 (m, 4H), 7.59 (t, J = 7.6 Hz, 1H), 
7.49 – 7.46 (m, 2H), 7.40 (s, 1H), 7.09 (br, 2H), 2.16 (s, 3H), 2.15 (s, 
3H); 13C-NMR (125 MHz, DMSO-d6): δ = 166.6, 164.5, 159.0, 143.2, 
142.4, 141.6, 141.1, 139.8, 138.9, 138.0, 136.8, 135.0, 133.0, 131.8, 131.4, 
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129.6, 129.2, 127.7, 126.9, 126.9, 125.3, 124.7, 115.0, 114.3, 111.9, 109.5, 109.5, 82.8, 17.5, 
13.6; 19F NMR (282 MHz, DMSO-d6): δ = -61.34; IR (neat): ῦ = 3303, 2923, 2202, 1683, 
1653, 1614, 1565, 1499, 1478, 1444, 1325, 1309, 1268, 1241, 1226, 1193, 1170, 1123, 1103, 
1082, 1021, 1008, 929, 863, 807, 758, 750, 694, 670, 627, 597, 579, 523, 470, 452, 439, 411 
cm-1; HRMS (ESI), m/z: calcd for C30H24F3N8O2+: 585.1969, found: 585.1970. 
2-Amino-1-(3-(3-cyclopropylureido)phenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (7k) 
Yellow solid; Yield: 0.6 % over 2 steps; 1H NMR (500 MHz, DMSO-
d6): δ = 8.64 (s, 1H), 8.06 (s, 2H), 7.94 (dd, J = 8.3, 1.2 Hz, 1H), 
7.79-7.77 (m, 2H), 7.63-7.62 (m, 2H), 7.58 (ddd, J = 8.3, 6.9, 1.3 Hz, 
1H), 7.51-7.45 (m, 2H), 7.35 (s, 1H), 7.09 (d, J = 8.1 Hz, 1H), 6.53 
(s, 1H), 2.56-2.52 (m, 1H), 0.65-0.61 (m, 2H), 0.42-0.39 (m, 2H); 13C 
NMR (125 MHz, DMSO-d6): δ = 166.6, 158.8, 155.8, 143.4, 141.7, 
141.4, 139.7, 136.7, 132.1, 129.9, 127.6, 126.8, 126.6, 125.1, 120.9, 118.4, 117.4, 82.5, 22.3, 
6.3; IR (film): ῦ = 3411, 3289, 1639, 1514, 1292, 1024, 761 cm-1; HRMS (ESI): m/z: calcd 
for C21H19N7NaO2+: 424.1492, found: 424.1494. 
2-Amino-1-(3-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7l) 
Yellow solid; Yield: 15 %; mp 303-305 °C; Purity: 91 %; 1H 
NMR (400 MHz, DMSO-d6): δ = 9.45 (s, 1H), 9.40 (s, 1H), 
8.12 (s, 2H), 8.02 (s, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.80-7.78 
(m, 2H), 7.72-7.68 (m, 2H), 7.60-7.45 (m, 5H), 7.36 (s, 1H), 
7.31 (d, J = 7.6 Hz, 1H), 7.20 (d, J = 8.4 Hz, 1H); 13C NMR 
(125 MHz, DMSO-d6): δ = 166.6, 158.8, 152.4, 143.4, 141.4, 
140.7, 140.3, 139.7, 136.7, 132.3, 130.1, 129.8, 129.4 (q, J = 
31.4 Hz), 127.6, 126.8, 126.6, 125.1, 124.1 (q, J = 31.4 Hz), 121.9, 121.8, 118.9, 118.1 (q, J 
= 31.4 Hz), 118.0, 114.0 (q, J = 31.4 Hz), 82.6; IR (film): ῦ = 3504, 3405, 3292, 1637, 
1601, 1566, 1331, 1108, 754 cm-1; HRMS (ESI): m/z: calcd for C25H19F3N7O2+: 506.1547, 
found: 506.1547.  
2-Amino-1-(4-(3-(3-(trifluoromethyl)phenyl)ureido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (7m) 
Yellow solid; Yield: 99 %; mp 205-210 °C; 1H NMR (400 MHz, 
DMSO-d6): δ = 9.61 (br, 1H), 8.07 (s, 1H), 7.92 (d, J = 7.8 Hz, 
1H), 7.78-7.74 (m, 4H),  7.68 (d, J = 7.5 Hz, 1H), 7.57-7.51 (m, 
2H), 7.49-7.44 (m, 3H), 7.32 (s, 1H), 7.30 (s, 1H); 13C NMR (100 
MHz, DMSO-d6): δ = 166.7, 159.1, 152.7, 143.6, 141.4, 140.8, 
140.6, 139.7, 136.8, 129.8, 129.7, 129.3, 129.1, 127.5, 126.8, 126.5, 
2.3 EXPERIMENTAL SECTION 
67 
 
125.6, 125.5, 125.0, 122.9, 121.9, 119.3, 118.0, 114.2, 82.6; 19F NMR (282 MHz, DMSO-d6): 
δ = -61.24; IR (neat): ῦ = 3305, 1637, 1567, 1515, 1493, 1446, 1336, 1314, 1232, 1174, 
1120, 1096, 1069, 794, 756, 698, 662, 614, 597, 528, 516, 473, 457, 421, 413 cm-1; HRMS 
(ESI), m/z: calcd for C25H19F3N7O2+: 506.1547, found: 506.1549.  
2-Amino-1-(N-Boc-p-phenylamine)-1H-pyrrolo[2,3-b]quinoxaline-3-carboxamide 
(7n) 
Yellow solid; Yield: 86 %; 1H NMR (400 MHz, DMSO-d6): δ = 7.92 (d, J 
= 7.8 Hz, 1H), 7.77-7.70 (m, 2H), 7.56 (t, J = 7.5 Hz, 1H), 7.46 (t, J = 
7.3 Hz, 1H), 7.30 (br, 1H), 7.19 (d, J = 8.6 Hz, 2H), 6.81 (d, J = 8.5 Hz, 
2H); 13C NMR (125 MHz, DMSO-d6): δ = 166.7, 159.6, 144.0, 141.4, 
139.6, 136.9, 129.4, 127.6, 126.7, 126.5, 125.1, 115.0, 82.4, 2C are missing due to 
overlapping; IR (neat): ῦ = 3337, 3186, 2957, 1635, 1567, 1519, 1444, 1414, 1365, 1315, 
1297, 1265, 1237, 1193, 1167, 1058, 1030, 832, 797, 753, 707, 612, 596, 518, 474, 461, 447, 
433, 421 cm-1; HRMS (ESI), m/z: calcd for C17H15N6O+: 319.1302, found: 319.1306. 
2-Amino-1-(5-hydroxy-2-methylphenyl)-1H-pyrrolo[2,3-b]quinoxaline-3-
carboxamide (11d) 
To a solution of 2-amino-1-(5-methoxy-2-methylphenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (6d, 135 mg, 0.389 mmol) in anhydrous 
CH2Cl2 (5.00 mL) at -78 °C BBr3 (1 M in CH2Cl2, 972 µL, 0.972 mmol) 
was added. The reaction was allowed to warm to room temperature and 
was then heated for 4 h at 130 °C. The formed solid was filtered off and 
purified by flash chromatography on silica gel (gradient EtOAc:MeOH 99:1 to 98:2) to 
afford the desired product in pure form (88.2 mg, 68 % yield). mp 272-274 °C; Purity: 94 
%; 1H NMR (500 MHz, DMSO-d6): δ = 9.73 (s, 1H), 8.02 (s, 2H), 7.94 (dd, J = 8.3, 1.3 
Hz, 1H), 7.78 (dd, J = 8.2, 1.3 Hz, 1H), 7.75 (s, 1H), 7.57 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 
7.46 (ddd, J = 8.2, 6.9, 1.3 Hz, 1H), 7.37 (s, 1H), 7.30 (d, J = 8.4 Hz, 1H), 6.94 (dd, J = 
8.4, 2.5 Hz, 1H), 6.81 (d, J = 2.5 Hz, 1H), 1.88 (s, 3H); 13C NMR (125 MHz, DMSO-d6): δ 
= 166.6, 158.8, 156.3, 143.0, 141.4, 139.6, 136.8, 131.9, 131.3, 127.6, 126.8, 126.6, 125.1, 
117.2, 116.2, 82.4, 16.2, one C is missing due to overlapping; IR (film): ῦ = 3455, 3380, 
3292, 3200, 1633, 1511, 1461, 1021, 753, 595 cm-1; HRMS (ESI): m/z: calcd for C18H16N5O2+: 
334.1299, found: 334.1296. 
2-Amino-1-(4-(3-(3-(trifluoromethyl)phenyl)thioureido)phenyl)-1H-pyrrolo[2,3-
b]quinoxaline-3-carboxamide (12n) 
To a solution of 2-amino-1-(N-Boc-p-phenylamine)-1H-
pyrrolo[2,3-b]quinoxaline-3-carboxamide (7n, 10 mg, 0.031 
mmol) in DMF (0.10 mL) 3-(trifluoromethyl)phenyl 
isothiocyanate (3.7 µL, 0.024 mmol) was added. The reaction 
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mixture was stirred at 25 °C for 12 hours. The resulting precipitate was filtered off and 
washed with DCM and hexane, affording the desired thiourea as a yellow solid in pure 
form (8.63 mg, 69 % yield). 1H NMR (400 MHz, DMSO-d6): δ = 10.22 (br, 2H), 8.08 (br, 
2H), 8.02 (s, 1H), 7.95 (dd, J = 8.2, 1.3 Hz, 1H), 7.86-7.73 (m, 5H), 7.64-7.53 (m, 4H), 
7.52-7.43 (m, 2H), 7.35 (s, 1H); 13C NMR (125 MHz, DMSO-d6): δ = 166.7, 159.1, 143.6, 
141.5, 140.4, 140.0, 139.8, 136.8, 129.6, 129.2, 129.0, 128.8, 127.9, 127.7, 127.3, 126.9, 126.7, 
125.2, 124.2 123.0, 120.8, 119.7, 82.7; 19F NMR (282 MHz, DMSO-d6): δ = -61.16; IR 
(neat): ῦ = 3302, 3193, 2917, 2848, 1639, 1602, 1515, 1448, 1330, 1164, 1120, 1095, 1069, 
797, 758, 696, 667, 596, 521, 475, 464, 449, 439 cm-1; HRMS (ESI), m/z: calcd for 
C25H19F3N7OS+: 522.1318, found: 522.132. 
2.3.2 Differential Scanning Fluorimetry  
To a  2 µM solution of EphA3 in 10 mM Tris HCl buffer (pH 8.0) containing 100 mM 
NaCl, 5X SPYRO Orange fluorescent dye together with the test compounds prediluted in 
DMSO at a concentration of 20 µM (1.4 % final DMSO concentration) were added. A final 
volume of 40 µL was added per well in a 96 well plate and incubated at room temperature 
for 1h. The plates were centrifuged for 3 min at 450 rcf. The temperature gradient was 
performed in the range of 25-75 °C (50 acquisitions per degree at a ramp rate of 4.4 °C/s) 
using a LightCycler 480 Real-Time PCR System. The detection of protein unfolding was 
performed with an excitation wavelength of 488 nm and an emission of 580 nm. All 
measurements were performed in triplicate.  
2.3.3 FRET based enzymatic assay 
Selected compounds were tested in the Z’-LYTETM Kinase Assay Kit–Tyr 1 Peptide 
(Invitrogen, USA) in a Corning 384 well microtiter plate. Fluorescence progress curves 
were measured upon excitation at 400 nm and emission at 445 and 520 nm. The assay 
contained a final concentration of EphB4 and ATP of 25 ng/µL and 125 µM (which is near 
its Km), respectively, and was run at room temperature for 2 h. IC50 values (inhibitor 
concentration at which enzyme activity is reduced by 50%) are determined after carrying 
out assays at ten different concentrations between 20 µM and 10 pM. 
2.3.4 Surface Plasmon Resonance Measurements 
The affinity of 7m and 11d towards EphA3 was determined using Surface Plasmon 
Resonance measurements on a ProteOn XPR36 (Bio-Rad Laboratories, AG). EphA3 was 
immobilized on a GLH chip (Bio-Rad Laboratories AG) by standard amine coupling 
procedures achieving a RU of 4000-6000 and equilibrated with steriled-filtered buffer 
(10mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005 % Tween 20 pH 8.0) with a flow rate 
of 60 µL/min. Association of 7m and 11d  was performed at 25 °C using serial dilutions of 
2.3 EXPERIMENTAL SECTION 
69 
 
the inhibitors in duplicates for 400 s, whereas dissociation of the inhibitors from the chip 
was monitored for 36,000 seconds. Data were normalized using interspot referencing and 
subtraction of a separate analyte channel run with buffer and BSA. All sensograms were 
fitted using a 1:1 Langmuir model provided by the ProteOn Manager Software (Bio-Rad 
Laboratories AG), and the association (kon) and dissociation (koff) rate constants were used 
to determine the equilibrium dissociation constants (KD).  
2.3.5 X-Ray Diffraction Analysis 
I. Protein expression and purification 
A clone of the EphA3 kinase domain (residues: 606-947) was obtained from Prof. 
Sirano Dhe-Paganon’s group120 and expressed in Escherichia coli strain BL21 (DE3). Cells 
expressing EphA3 were induced with a 1 mM solution of isopropyl-β-D-
thiogalactopyranoside (IPTG) for 12 h at 15 °C. Cell pellets were resuspended in buffer A 
(50 mM Tris, pH 8.0, and 100 mM NaCl, supplemented with protease inhibitors) and lysed 
by sonication. After centrifugation at 15,000 rpm for 1 h, the soluble fraction of EphA3 
was purified using HisTrap FF crude and HiTrap Q HP columns (GE Healthcare), 
followed by gel filtration chromatography (Superdex75; GE Healthcare). The appropriate 
fractions were combined and concentrated to ~10 mg/mL using Amicon filter devices (10 
kDa as cutoff) in a storage solution (100 mM sodium chloride and 10 mM Tris-HCl pH 8.0, 
5% glycerol). The resulting solution was aliquoted and stored at -80 °C for further usage. 
II. Crystallization, Data Collection, and Structure Determination 
Apo crystals of the EphA3 kinase domain were grown at 20 °C using the hanging drop 
vapor diffusion method. Equal volumes of protein and reservoir solutions (0.1 M sodium 
cacodylate pH 6.5, 0.15 M ammonium sulfate, 22.5 % PEG 3350) were mixed and crystals 
appeared after 1 to 2 days. A 5 mM solution of inhibitor (in 100 % DMSO) was added into 
the hanging drop to reach a final DMSO concentration of 10 % (v/v). The crystals were 
soaked with compounds A or B for 1 to 24 h and flash-frozen in liquid nitrogen without 
extra cryoprotectant. Cocrystallization trials were performed for compound 7m. EphA3 
was first mixed with a 5 mM compound 7m solution (in 100 % DMSO) to a final 10 % 
DMSO concentration and then incubated on ice for 30 minutes. EphA3-7m crystals were 
grown under the same conditions as described above for the EphA3 apo crystals.  Data sets 
were collected on a Pilatus 6M detector at the Swiss Light Source beamline X06SA of the 
Paul Scherrer Institute (Villigen, Switzerland) and indexed, integrated and scaled with the 
XDS121 and CCP4 programs.122 The structures were solved by molecular replacement with 
PHASER123 using the apo EphA3 kinase domain structure (PDB entry 2GSF) as a search 
model and refined with PHENIX.124 The atomic coordinates and structure factors of EphA3 
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in complex with the inhibitors A, B, 7m have been deposited with the Protein Data Bank 
as entries 4P4C, 4P5Q and 4P5Z respectively. 
 Compound  A Compound B Compound 7m 
Space group 
Unit cell   
a (Å) 
b (Å) 
c (Å) 
Resolution range (Å) 
Unique reflections  
<I/σ(I)> 
R merge        
Completeness (%) 
Multiplicity 
Refinement 
     Resolution range (Å) 
     R factor/R free 
     Mean B factors (A2) 
     RMS bonds (Å) 
     RMS angles (°)  
P 1 21 1
 
53.91 
38.16 
75.53 
38.16-1.6 
39425(5697) 
13.9(3.7) 
0.052 (0.317) 
98.2 (97.6) 
3.5(3.5) 
 
33.64-1.60 
17.78/20.14 
18.90 
0.0087 
1.343 
P 1 21 1
 
53.37                         
38.2 
75.77 
47.48-1.35 
64017(2998) 
15.9(2.1) 
0.049(0.705) 
97.1(93.2) 
4.1(4.0) 
 
39.19-1.35 
15.70/18.19 
24.40 
0.0055 
1.258 
 
P 1 21 1 
 
52.81 
38.24 
75.46 
47.02-2.0 
20066(2819) 
15.6(3.0) 
0.069(0.586) 
99.1(96.2) 
6.5(6.5) 
 
47.02-2.00 
17.96/21.86 
43.90 
0.0151 
1.724 
 
2.3.6 Selectivity profile 
The selectivity profiling was performed at DiscoveRx in a library of 456 kinases at a 
concentration of 1 µM. Briefly, kinases were mostly expressed as fusion proteins to T7 
phase and grown in 24-well blocks in E. Coli (derived from the BL21 strain). The rest of 
the kinases were expressed in HEK-293 cells and tagged with DNA for qPCR detection. 
Affinity resins were generated by mixing streptavidin-coated magnetic beads with 
biotinylated small molecule ligands for 30 minutes at 25 °C, followed by biotin and 
blocking buffer addition (SeaBlock (Pierce), 1 % BSA, 0.05 % Tween 20, 1 mM DTT). 
Inhibitors were kept at 40x stocks in 100 % DMSO and added to the corresponding 384-
well plates (40 µL). After 1 hour of incubation at 25 °C while shacking, affinity beads were 
washed with 0.05% Tween 20 in PBS. The beads were re-suspended in PBS buffer 
containing 0.05 % Tween 20 and 0.5 µM non-biotinylated affinity ligand, to then be 
incubated at 25 °C for 30 minutes while shacking. The kinase concentration present in the 
eluate was determined by qPCR.  
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2.3.7 Cellular phosphorylation assays 
Cellular phosphorylation experiments were performed at ProQinase GmbH. Mouse 
embryonic fibroblast cells, stably transfected to overexpress full-length human EphB4, were 
plated at 4×104 cells/well in DMEM (Dulbelcco’s modified Eagle’s medium) supplemented 
with 10 % FCS in 48-well culture dishes. Medium was replaced by DMEM without FCS 
before test compounds prediluted in 100 % DMSO were added (final DMSO concentration 
of 1 %). After incubation for 90 min at 37 °C, cells were stimulated for 2 h at 4 °C using 
murine ephrinB2-Fc at a final concentration of 2 µg/ml. Quantification of EphB4 
phosphorylation was assessed in a 96-well plate via sandwich ELISA using a myc capture 
antibody and an antiphosphotyrosine detection antibody. 
2.3.8 In house cell culture and GI50 determination 
MDA-MB-231 cells obtained from the UZH Cancer Institute and A498 cells obtained 
from Prof. Krek (Institute of Cell Biology, ETH) were cultured in DMEM supplemented 
with 10 % (v/v) fetal bovine serum. K562 cells obtained from Dr. Silvio Hemmi (Institute 
of Molecular Life Sciences, UZH), KM12 (UZH Cancer Institute) and HOP-92 (purchased 
from the NCI) were cultured using RPMI medium supplemented with 10 % (v/v) fetal 
bovine serum. All the media were additionally supplemented with 100 units/mL of 
penicillin, 100 μg/mL of streptomycin, 4.5 g/L glucose, 0.11g/L sodium pyruvate and 2mM 
glutamine and the cells were grown at 37 ºC in 5  % CO2 atmosphere with 80 % relative 
humidity.  
MDA-MB-231, A498, KM12 and HOP-92 cells were plated at 10,000 cells per well 
(100 μL per well) in 96-well culture dishes and allowed to incubate for 24 h. In the case of 
HT29, 20,000 cells per well were seeded and incubated for 24 h. The old media was 
removed, cells were washed with PBS (phosphate-buffered saline) and fresh media was 
added. A 5 mM solution of inhibitor (in 100% DMSO) was serially diluted in the culture 
media (12 different concentrations were used) and allowed to incubate for 72 h (MDA-MB-
231) or 48h (A498, KM12, HT29 and HOP-92). Control cells were treated with the same 
DMSO concentrations. After the incubation period the media was once more removed and 
the cells were washed with PBS to then be incubated with fresh media containing 86 nM 
resazurin. After 4 hours, the fluorescence was quantified using a fluorescence microplate 
reader (Biotek, FLx800TM) at the respective excitation and emission wavelength of 560 and 
590 nm. Resazurin becomes fluorescent under mitochondrial reduction and its emission 
directly correlates with the metabolic viability of the cells.  The measured fluorescence 
values were corrected from the control samples containing DMSO and IC50 values were 
determined by plotting the fraction of metabolically active cells against the log of the drug 
concentration. All measurements were performed at least in triplicate.   
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In the case of K-562 leukemia cells, they were seeded at a density of 20,000 cells per 
well in 100μL of RMPI media in a 96 well microtiter plates. After 24 hours, 12.5 μL of a 
10 fold concentrated drug or DMSO solution in RMPI media was added in every well. 
After 48 hour incubation, cell viability was studied by measuring the ability of the cells to 
process resazurin. Resazurin was added to every well to obtain a final concentration of 86 
nM, and after 3 hours, the fluorescence was quantified using a fluorescence microplate 
reader (Biotek, FLx800TM) at the respective excitation and emission wavelength of 560 and 
590 nm as described above. All measurements were performed at least in triplicate.   
2.3.9 Antiproliferative activity against patient derived tumor 
cell lines 
The assessment of antiproliferative activity against patient derived tumor cell lines 
was performed in Oncotest. Cell lines were routinely passaged once or twice weekly and 
maintained in culture for up to 20 passages. All cells were cultured in RPMI 1640 medium 
supplemented with 10 % (v/v) fetal calf serum and 0.1 mg/mL gentamicin (medium and 
all components from PAA, Cölbe, Germany) at 37 °C in a humidified atmosphere with 5 % 
CO2. A modified propidium iodide (PI) assay was used to assess the anticancer activity of 
the compounds. Briefly, cells were harvested from exponential phase cultures, counted, and 
plated in 96-well flat-bottom microtiter plates at a cell density of 4000−20 000 cells per 
well. After a 24 h recovery period, allowing the cells to resume exponential growth, 10 μL 
of culture medium (four control wells/plate) and culture medium with the test compound 
were added by the liquid handling robotic system and treatment was continued for four 
days. The compounds were applied in half log increments at 10 concentrations in duplicate. 
Next, cells were washed with 200 μL of PBS to remove dead cells. Subsequently, 200 μL of 
a solution containing 7 μg/mL propidium iodide (PI) and 0.1% (v/v) Triton X-100 was 
added. After an incubation period of 1−2 h at room temperature, fluorescence (FU) was 
measured using the Cytofluor 4000 microplate reader (excitation λ = 530 nm, emission λ 
= 620 nm) to quantify the amount of attached viable cells. For calculations, the mean 
value of duplicate/quadruplicate (untreated control) data was used. Quality criteria for a 
successful assay included fluorescence intensity signal of >500 units from the untreated 
control wells. 
2.3.10 Spheroid-based cellular angiogenesis assay 
The experiments were performed in ProQinase Gmbh and pursued in modification of 
the originally published protocol.125 In brief, spheroids were prepared as described126 by 
pipetting 500 HUVEC in a hanging drop on plastic dishes to allow overnight spheroid 
aggregation. 50 HUVEC spheroids were then seeded in 0.9 ml of a collagen gel and 
pipetted into individual wells of a 24 well plate to allow polymerization. The test 
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compounds in combination with the respective growth were added after 30 min by 
pipetting 100 μl of a 10-fold concentrated working solution on top of the polymerized gel. 
Plates were incubated at 37 °C for 24 hours and fixed by adding 4 % Roti-Histofix (Roth, 
Karlsruhe, Germany). 
Sprouting intensity of HUVEC spheroids treated with the growth factors and 
inhibitors were quantitated by an image analysis system determining the cumulative sprout 
length per spheroid (CSL) using an inverted microscope and the digital imaging software 
Analysis 3.2 (Soft imaging system, Münster, Germany). The mean of the cumulative 
sprout length of 10 randomly selected spheroids was analyzed as an individual data point. 
The reduction of sprouting below negative control levels could be due to neutralization of 
basal concentrations of the respective target or the induction of cell death. With regard to 
the visual characterization cell death can neither be confirmed nor excluded. 
 
Figure 19. HUVEC spheroids were embedded in a 3D collagen gel, stimulated 
with VEGF-A (25 ng/ml) and treated for 24 h with different concentrations of 11d 
(in M, as indicated). The cumulative sprout length of 10 randomly selected 
spheroids per data point was analyzed and the relative inhibition by the test 
compound determined. Fitting of inhibition curves and calculation of IC50 values 
was performed with GraphPad Prism 5. 
2.3.11 In Vivo evaluation 
I. Pharmacokinetic Evaluation in Mice  
Compounds in Table 4 were administered via oral (PO) and intravenous (IV, tail 
vein) routes at doses of, 5 mg/kg and 1 mg/kg, respectively, in formulations consisting of, 
for IV dosing, each compound within a clear solution of DMSO/Solutol® HS 
15/phosphate-buffered saline, pH 7.4 (PBS) (5/5/90, v/v/v), and of, for PO dosing, each 
compound as a heterogeneous suspension in DMSO/1% methylcellulose (5/95, v/v). Blood 
samples collected over an 8-hour time period (at 3, 10, 30, 60, 120, 240, 360 and 1440 
minutes, and 10, 30, 60, 120, 240, 360, 480 and 1440 minutes, for IV and PO 
administrations, respectively) following administration were centrifuged at 2500 G for 15 
minutes at 4 °C within one hour of collection and stored at -20 °C until analysis. 
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Compound concentration in plasma at each time point was then determined following 
acetonitrile precipitation of each sample followed by HPLC-MS analysis performed in 
triplicates, i.e., based on the mean of the compound concentration at that time point in 
blood samples of three mice. Pharmacokinetic data was generated by non-compartmental 
analysis (NCA) of the plasma data using WinNonLin. Bioavailability (F) was calculated as 
a ratio of areas under the curve (AUClast) of the plot of compound concentration versus 
time up to the time point of the last observation that was greater than the limit of 
quantification. Animal studies of pharmacokinetics were performed in compliance with the 
recommendations of the Guide for Care and Use of Laboratory Animals with respect to 
restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care in 
a facility that was monitored and inspected by Cerep Institutional Animal Care and Use 
Committee. 
II. Xenograft mouse model efficacy evaluation 
Xenograft experiments were conducted on 9 week old 18-27 g female athymic NCr 
Nu/Nu mice (Charles River Laboratories, Inc.), injected at the flank with 5x106 MDA-MB-
231 cells. Tumor size was measured by digital caliper. Once tumor volume reached 108-126 
mm3, mice were sorted into a treatment and vehicle-control cohort consisting of 9 animals 
each such that the group mean tumor volumes were of 112 mm3. The treatment cohort 
received oral doses corresponding to 50 mg/kg of compound 11d twice daily for 21 days 
(with the exception of a single dose on the first day), formulated as per the PO 
formulation of the pharmacokinetic study. The control group received the same 
formulation but excluding compound 11d, according to the same protocol. Following 
treatment initiation, body weight and tumor volume of all mice in both groups was 
evaluated bi-weekly up to day 19. The %TGI was calculated according to the formula: [1-
(MTVcompound treated/MTVcontrol)] x 100, where MTV corresponds to the Median Tumor 
Volume for the group. Animal studies of efficacy were performed in compliance with the 
recommendations of the Guide for Care and Use of Laboratory Animals with respect to 
restraint, husbandry, surgical procedures, feed and fluid regulation, and veterinary care by 
CRL-DRS-NC in an AAALAC accredited facility.…………………………………………………………………….
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3 
BROMODOMAIN LIGANDS 
 
3.1 Introduction 
Bromodomain proteins constitute an emerging topic in the field of drug discovery due, in a 
large extent, to their involvement in the regulation of many genes.1 In the next sections, 
epigenetic targets are introduced, with a special focus on bromodomains and their ligands.  
3.1.1 Epigenetics 
The central dogma of molecular biology, enunciated by Francis Crick in 1956 and re-stated 
in 1970, describes the flow of genetic information in living organisms: how genes in DNA direct 
the synthesis of RNA and proteins, as well as how DNA is replicated (Figure 1).2 Transcription 
is the first step of gene expression, where a DNA segment is converted into mRNA by RNA 
polymerases. The mRNA is then translated in the ribosomes into proteins, and as a 
consequence, the information changes from being stored as nucleotide base pair sequences to 
aminoacid sequences.  
 
Figure 1. Schematic representation of the dogma of molecular biology. 
Epigenetics, from the greek Epi, which means above, are mechanisms that regulate gene 
transcription that are not encoded by the DNA sequence, and has been defined as ‘‘regulation 
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beyond our genes’’.3 Not only our genetic predispositions play a key role on the development of 
certain diseases, but so do the more dynamic epigenetic processes during DNA transcription. 
Modifying our genome remains a highly challenging endeavor, but there is an emerging 
possibility to control and modify epigenetic motifs that might be key for the development of 
certain diseases. More importantly, it has been shown that cancer initiation and progression 
occurs not only because of genetic modifications, but also due to epigenetic alterations.4-5 
The genetic material is compactly stored within the nucleus of the cell in chromosomes, 
which are condensed in chromatin fibers. Within chromatin, the double helix DNA is wrapped 
around nucleosomes (Figure 2). Nucleosomes are octamer proteins composed of four histone 
proteins, whose flexible N-terminus is called ‘‘histone tail’’. The surface of histones is mainly 
occupied by aminoacids containing basic side chains, such as lysines and asparagines, which are 
positively charged at physiological pH. As DNA is negatively charged, it can easily bind to the 
positively charged histone surface establishing salt bridges, hydrogen bonds and hydrophobic 
interactions. As a consequence, DNA-based processes such as replication, transcription and 
repair are highly dependent on chromatin’s structure (referred to as chromatin remodeling). 
 ‘‘Histone tails’’ are subjected to a wide range of post transcriptional modifications 
(PTMs), which affect chromatin architecture (by altering histone-histone and histone-DNA 
interactions), gene expression, cell fate determination, differentiation and disease onset and/or 
maintenance.6-7 Acetylation, mono/multi methylation and phosphorylation of aminoacid 
residues in the ‘‘histone tails’’ are post-translational modifications that are likely to occur and 
are enclosed in the so called epigenetic ‘‘histone code’’ (defined as the ensemble of PTMs 
occurring in histone proteins).1, 8-9 Such modifications are a result of a concerted, sequence and 
context dependent action of different protein interaction modules that are classified in three 
major groups (Figure 2): ‘‘writers’’, ‘‘erasers’’ and ‘‘readers’’.   
 
Figure 2. Chromatin is a complex composed of DNA, RNA and proteins that is 
located in the nucleus of the cell. It compacts DNA into a smaller volume to fit in the 
cell, allows cell mitosis, prevents DNA damage and controls gene expression and DNA 
replication. In chromatin the DNA is wrapped around histones, whose tails are 
subjected to multiple PTMs by ‘‘writers’’, ‘‘erasers’’ and ‘‘readers’’. The PTMs  include 
lysine acetylation, which will be explained in detail in the next sub-section.10  
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The message that is brought by epigenetic ‘‘writers’’ such as HATs (histone acetyltransferases), 
HMTs (histone mehtyltransferases), kinases (see chapter 2 for more information) and 
ubiquitinases is deciphered by epigenetic ‘‘readers’’ such as bromodomains, chromodomains or 
tudors among others.11-12 The opposite effect, the removal of the message, is carried out by the 
“erasers” (e.g. HDACs, histone deacetylases). In this chapter special attention is given to 
epigenetic ‘‘readers’’, specifically to bromodomains.  
I. Protein lysine acetylation 
Protein lysine acetylation (KAc) is an important PTM within the ‘‘histone code’’1, 8-9 that 
takes place on over 1750 proteins.13 It occurs when an acetyl group of acetyl-CoA is transferred 
to the ɛ amino group of a lysine residue by a histone acetyltransferase (HAT) (Figure 3). 
Acetylation causes a neutralization of the charge in lysine residues that leads to a change in the 
electrostatic interaction between them and the negatively charged DNA.3 By neutralizing the 
charge of the ‘‘histone tails’’, chromatin becomes more flexible, making DNA more accessible 
for transcription (Figure 1). Deregulation in the acetylation levels can result in changes in gene 
expression such as the inactivation of tumor suppressor functions and the activation of 
oncogenes, leading to cancer, among other diseases. As a result, lysine acetylation is nowadays 
considered an important PTM that is able to modulate several cellular proteins and its 
importance has been compared to protein phosphorylation performed by tyrosine kinases (see 
Chapter 2 for more information).  
 
Figure 3. Histone acetyltransferase (HAT) enzymes (“writers”) introduce acetyl groups 
in lysines (left), which are “read” by bromodomains (middle). The acetylated residues 
are removed by histone deacetylases (HDACs), that act as “erasers” (right).14 
The FDA (U. S. Food and Drug Administration) approved two drugs for the treatment of 
T-cell lymphoma called vorinostat15 and romidepsin,16 which are histone deacetylase (HDAC) 
inhibitors, thus demonstrating the potential to treat diseases by modifying acetylation 
pathways. As a consequence, there has been an increased interest in the search of small 
molecules that are able to interact with acetyl lysine ‘‘erasers’’, ‘‘writers’’ and recently also 
with ‘‘readers’’ (including bromodomains).3 
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Bromodomains are potential therapeutic targets due to their ability to modify cellular 
lysine acetylation17-22 and have been associated with several diseases such as diabetes, obesity, 
oncology, inflammation, viral infection and metabolic and cardiovascular disorders.23-26 The 
interest in bromodomain biology and the efforts towards the development of bromodomain 
ligands has dramatically increased over the last 3-4 years.14, 27-28 However, bromodomain related 
research has just started, and the underlying biological processes and exact therapeutic 
pathways related to these proteins remain unknown.  
3.1.2 Bromodomains: structure and function 
Bromodomains are named after the Drosophila gene brahma, where they were first 
identified.29 They are protein interaction modules that are part of large protein architectures 
and function as epigenetic ‘‘readers’’ (Figures 2, 3). Bromodomains specifically recognize the ɛ-
N-acetylated lysine residues (KAc group) present in proteins (especially in histones)30-31  
through a conserved interaction mode, altering the process of chromatin remodelling.32 
However, bromodomains are only able to bind to acetylated lysines with moderate affinity 
presenting Kd values in the range of tens to hundreds of micromolar.33-34 There are 61 different 
bromodomains recognized within the human genome spread across 46 multidomain proteins 
(with up to six bromodomains per protein)35-36 and they are phylogenetically divided into eight 
distinct families as shown in Figure 4.37 
 
Figure 4. Phylogenetic tree of the human bromodomain family.38 Bromodomains are 
phylogenetically divided into eight families (I-VIII). CREBBP and EP300, proteins of 
interest in this work, are highlighted in red. Family II, also known as BET family, is 
the most studied bromodomain family up to date.  
Bromodomains are part of multidomain proteins that present specific functions. According 
to the function of the multidomain protein, bromodomains can be further classified into 
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different subgroups: histone acetyltransferases (known as HATs, such as CREBBP, GCN5 and 
PCAF, which function as transcription coactivators), histone methyltransferases (ASH1L, 
MLL), ATP-dependent chromatin-remodeling complexes (Swi2/Snf2) and transcriptional 
regulators carrying tandem bromodomains and an extra terminal domain (the BET family of 
bromodomains, family II, Figure 4).  
Bromodomains consist of approximately 110 amino acids and despite their large sequence 
diversity, they share a common tertiary structure that is described as a left-handed bundle of 
four helices (αZ, αA, αB and αC), which are linked by two loops (ZA and BC loops).39 The 
hydrophobic KAc binding site is conserved in all bromodomains and is formed by the ZA and 
BC loops at one end of the helical bundle (Figure 5, A, B).31 It anchores the carbonyl oxygen of 
the acetyl group of the KAc by forming two hydrogen bonds; one to the NH2 of the conserved 
asparagine (Asn1168 in the CREBBP bromodomain, Figure 5, C, hydrogen bonds shown as 
dashed lines) and a second one to the side chain of a conserved tyrosine residue (Tyr1125, 
Figure 5, C, hydrogen bonds shown as dashed lines)31, 40 through one structured water molecule 
(Figure 5, B and C, shown as a spheres and ellipses respectively ).  
The so called ZA channel, as well as the LPF shelf (indicated in Figure 5, B, C) have 
proven to be of high importance during the design of bromodomain ligands.41-42 Both regions 
are located within the ZA loop, and the LPF shelf, in particular, is composed of three 
aminoacids, leucine (L), proline (P) and phenylalanine (F), which vary among different 
bromodomains (e.g. it corresponds to the WPF shelf, tryptophan, proline and phenylalanine, in 
the case of the BET bromodomain family).   
 
Figure 5. A) Ribbon representation of the CREBBP bromodomain composed of the 
four canonical helices (αZ, αA, αB and αC) and two loop regions (ZA and BC loops) in 
complex with KAc (PDB code 3P1C). B) Typical binding mode of KAc to 
bromodomains forming interactions, in the case of CREBBP, with Asn1168 (in light 
blue) and Tyr1125 (in magenta, via a structure water molecule, shown as spheres). The 
residues belonging to the ZA channel and LPF shelf, two important regions of the 
binding site, are indicated. C) 2D representation of the binding mode of the acetylated 
lysine KAc (in green). Water molecules are shown as ellipses and the hydrogen bonds 
are indicated as dashed lines. The residues belonging to the ZA channel and LPF shelf, 
two important regions of the binding site, are indicated. 
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The acetyl group of KAc interacts with a water molecule network composed of four to six 
water molecules located at the bottom of the binding site that provides stability to the KAc 
binding site (shown as spheres and ellipses, Figure 5, B and C respectively). The asparagine 
(Asn1168) and tyrosine residue (Tyr1125) that are essential for the function of the 
bromodomain also take part in the hydrogen-bonding network with the crystallographically 
ordered water molecules. 
According to Molecular Dynamic simulations (MD) performed on several      
bromodomains17, 43 the four protein helices are rather rigid, whereas the ZA and BC loop regions 
that contribute to KAc binding present high conformational flexibility. However, the flexibility 
of the loops might substantially decrease in the presence of inhibitors.17 Surprisingly, MD 
simulations performed by Caflisch and coworkers revealed that the conserved asparagine 
residue located in the binding site (e.g., Asn1168 in CREBBP, Figure 5) is able to reversibly 
rotate its side chain orienting it towards the solvent, especially on those bromodomains 
belonging to family VII in the phylogenetic tree (Figure 4).43 Moreover, the conserved tyrosine 
residue (Tyr1125 in Figure 5) is also flexible and can point towards the outside of the 
bromodomain, especially in BRDT(1), CREBBP, BAZ2B, SMARCA4, and BRD1, which is in 
agreement with experimental data (PDB codes 2RFJ and 2DKW).43 Importantly, the 
mentioned tyrosine movement creates a rearrangement of the protein resulting in a smaller and 
occluded binding site.  
The large amount of structural information available for bromodomains has enabled a 
careful study of their aminoacid sequence and the main differences among them have been 
identified, enabling the rational design of bromodomain ligands. An overview of the sequence 
diversity of several bromodomains is given in Table 1.  
The selectivity towards different bromodomains is thought to arise from length and 
sequence diversity within the ZA and BC loop regions that interact with residues located in 
close proximity to the KAc binding site.36, 39, 44 Whereas the differences in these loop regions 
within the same bromodomain family are relatively small, they are significant when comparing 
bromodomains belonging to different families such as CREBBP and ATAD2 (Table 1). The so 
called hydrophobic WPF shelf in the BET family (Table 1, in red) is in fact LPF shelf in the 
case of CREBBP or RVF in ATAD2. The gatekeeper residue located at the bottom of the shelf 
also varies between isoleucine (BD1 domains of the BET family and ATAD2), valine (BD2 
domains of the BET family and CREBBP, Figure 5, B) or tyrosine (GCN5, KAT2A) residues 
(Table 1, in blue). These differences cause changes in the size and electronics of the binding 
sites within different bromodomain families that could be addressed in order to design selective 
bromodomain ligands.  
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Table 1. Multiple sequence alignment of human BET bromodomains, BRD2, BRD3, 
BRD4, and BRDT, with GCN5, CREBBP and ATAD2. Highlighted in blue is the I/V 
to Y sequence diference in the gatekeeper residue at the bottom of the LPF shelf 
(Figure 5, B, C). The WPF motif (tryptophan, proline and phenylalanine shelf) is 
highlighted in red, and the conserved tyrosine and asparagine residues that are key for 
the recognition of acetylated lysines are highlighted in yellow and green respectively.45 
                   —————— αZ———— ———        —————–————  ZA loop  —————————————    —αA 
BRD2(1) KPGRVTNQLQ YLHKVVMKAL WK- - -HQFAW PFRQPVDAVK LGLPDYHKII KQPMDMGTIK 
BRD3(1) KPGRKTNQLQ YMQNVVVKTL WK- - -HQFAW PFYQPVDAIK LNLPDYHKII KNPMDMGTIK 
BRD4(1) KPKRQTNQLQ YLLRVVLKTL WK- - -HQFAW PFQQPVDAVK LNLPDYYKII KTPMDMGTIK 
BRDT(1) KNGRLTNQLQ YLQKVVLKDL WK- - - HSFSW PFQRPVDAVK LKLPDYYTII KNPMDLNTIK 
BRD2(2) SKKGKLSEQL KHCNGILKEL LSKKHAAYAW PFYKPVDASA LGLHDYHDII KHPMDLSTVK 
BRD3(2) GKKGKLSEHL RYCDSILREM LSKKHAAYAW PFYKPVDAEA LELHDYHDII KHPMDLSTVK 
BRD4(2) EKSSKVSEQL KCCSGILKEM FAKKHAAYAW PFYKPVDVEA LGLHDYCDII KHPMDMSTIK 
BRDT(2) VKTVKVTEQL RHCSEILKEM LAKKHFSYAW PFYNPVDVNA LGLHNYYDVV KNPMDLGTIK 
CREBBP - - IFKPEELR QALMPTLEAL YR- - QDPESL PFRQPVDPQL LGIPDYFDIV KNPMDLSTIK 
GCN5/KAT2A - - - - DPDQLY TTLKNLLAQI KS- - - HPSAW PFMEPVKKS- -EAPDYYEVI RFPIDLKTMT 
ATAD2 QEEDTFRELR LFLRNVTHRL AI- - -DKRFR VFTKPVDPD- -EVPDYVTVI KQPMDLSSVI 
 
 -αA  —– ———– αB—– —————– BC  loop————    —————––––––– αC –––—————– 
BRD2(1) RRLENNYYWA ASECMQDFNT MFTNCYIYNK P- - - -TDDIV LMAQTLEKIF LQKVASMPQE 
BRD3(1) KRLENNYYWS ASECMQDFNT MFTNCYIYNK P- - - -TDDIV LMAQALEKIF LQKVAQMPQE
BRD4(1) KRLENNYYWN AQECIQDFNT MFTNCYIYNK P- - - -GDDIV LMAEALEKLF LQKINELPTE 
BRDT(1) KRLENKYYAK ASECIEDFNT MFSNCYLYNK P- - - -GDDIV LMAQALEKLF MQKLSQMPQE
BRD2(2) RKMENRDYRD AQEFAADVRL MFSNCYKYMP P- - - -DHDVV AMARKLQDVF EFRYAKMPDE 
BRD3(2) RKMDGREYPD AQGFAADVRL MFSNCYKYMP P- - - -DHEVV AMARKLQDVF EMRFAKMPDE
BRD4(2) SKLEAREYRD AQEFGADVRL MFSNCYKYNP P- - - -DHEVV AMARKLQDVF EMRFAKMPDE
BRDT(2) EKMDNQEYKD AYKFAADVRL MFMNCYKYNP P- - - -DHEVV TMARMLQDVF ETHFSKIPIE 
CREBBP RKLDTGQYQE PWQYVDDVWL MFNNAWLYNR K- - - -TSRVY KFCSKLAEVF EQEIDPVMQS 
GCN5/KAT2A ERLRSRYYVT RKLFVADLQR VIANCREYNP P- - - -DSEYC RCASALEKFF YFKLKEGGLI 
ATAD2 SKIDLHKYLT VKDYLRDIDL ICSNALEYNP DRDPGDRLIR HRACALRDTA YAIIKEELDE 
 
In the next section, an overview of known bromodomain ligands linked to their 
corresponding therapeutic potential is given. Special attention is given to the BET family of 
bromodomains, since it has been widely explored, as well as to CREBBP and EP300, proteins 
of interest in this work.  
3.1.3 Bromodomain ligands 
Zhou and coworkers were the first to obtain structural information (in solution) on 
bromodomains in 2002, showing that PCAF bromodomain (family I, Figure 4) was able to 
specifically bind to HIV-1 Tat peptide upon lsyine acetylation, and that such interaction was 
important for HIV transcription.30 Bromodomains were then considered as a potential 
therapeutic strategy against HIV.30, 46 Zhou et al. carried out a PCAF bromodomain inhibitor 
discovery campaign using NMR screening techniques that resulted in compounds with affinities 
in the micromolar range. An example is given in Figure 6, where compound 1 is able to bind in 
the HIV-1 Tat peptide binding pocket with an IC50 of 1.6 µM. 
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Figure 6. Structure of the PCAF inhibitor developed by Zhou et al.46 
Since this breakthrough on the first non-peptidic small molecule acting as bromodomain 
inhibitor, the bromodomain field has gained increased attention and several bromodomain 
inhibitors have been reported in peer reviewed journals.41-42, 47  
From the reported bromodomain inhibitors, three key interaction areas can be 
distinguished in the bromodomain binding site: the KAc binding pocket, the LPF/WPF shelf 
and the ZA channel (Figure 7). The KAc mimic has been usually achieved by methyl-
substituted five-membered ring heterocycles that form hydrogen bonds with the conserved 
asparagine and tyrosine residues. The methyl group of the KAc, located in a small hydrophobic 
pocket formed by a valine and phenylalanine residues, has proven to be important for binding 
affinity. As all bromodomains present a highly conserved KAc binding pocket, these 
interactions are unlikely to be responsible for bromodomain selectivity, but more likely orient 
the ligand and play a role in bromodomain recognition. 
 
Figure 7. 3D (A) and 2D (B) representation of the bromodomain binding site divided 
into three regions: KAc binding site (in blue), WPF shelf (in yellow) and ZA channel 
(in green). The conserved asparagine Asn140 and tyrosine Tyr97 residues responsible 
for ligand binding are shown in light blue and pink respectively, together with the 
aminoacid residues belonging to the ZA channel and WPF shelf. The conserved 
crystallographic water molecules are also indicated as red spheres (A) or ellipses (B) in 
red. Figure recreated from PDB code 3MXF.   
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The LPF or WPF shelf (composed of different aminoacids according to the bromodomain, 
Table 1) is mainly hydrophobic and interacts with lipophilic and aromatic substituents of the 
ligand contributing to bromodomain selectivity and potency (Figure 7, in yellow).  
The third region that can be distinguished within the binding site is the ZA channel 
(Figure 7, in green), which has been explored to gain potency and selectivity of small molecule 
ligands. There is usually one conserved water molecule within the ZA channel that forms 
interactions with the backbone residues of the protein and the rest of the conserved water 
molecules (Figure 7B, in red ellipses). All of the conserved water molecules define the shape 
and size of the binding site and need to be taken into account during the design of 
bromodomain inhibitors.  
I. BET family ligands 
The BET family of bromodomains is composed of four members in mammals: BRD2, 
BRD3, BRD4 and BRDT (Figure 4, family II), each containing two conserved N-terminal 
bromodomains. Among the studied bromodomain targets, the BET bromodomain family has 
received preminent attention as they are known to control the transcription of virus replication 
(HIV48 and EBV49 replication in the case of BRD4)50-51 and inflammatory responses.52 Indeed, 
NF-κB, a transcription factor that regulates the immune response of the cell, can be acetylated 
in its Lys30 residue, causing BRD4 binding and resulting in the transcription of NF-κB   
genes.52-53 
Special attention has been drawn towards BRD4 bromodomain due to its key role in 
several cellular processes including mitosis.54-55 BRD4 is a key player in the regulation of 
transcriptional elongation by being able to recruit P-TEFb (positive transcription elongation 
factor).54, 56-57 As a consequence, BRD4 has been described as an attractive target related to 
cancers such as acute myeloid leukaemia,58, 17 Burkitt's lymphoma,49 NUT midline carcinoma,59 
breast60 and colon cancer,61 as well as to inflamatory diseases.52 In fact, several bromodomain 
ligands from the BET family of bromodomains (family II, Figure 4) are currently in clinical 
trials (see subsection F).47, 62  
Most of the potent and selective bromodomain inhibitors discovered up to date target the 
BET bromodomain family, namely BRD2, BRD3, BRD4 and BRDT. However, the chemical 
diversity of BET inhibitors is quite limited and they can only be classified into a few different 
chemical scaffolds: methyl-triazolodiazepines and related chemotypes (2-6),17, 20, 45, 63-67 3,5-
dimethylisoxazoles (7-11)21, 68-73 and other chemotypes, including  3-methyldihydroquina- 
zolinones (12),74-75 1-acyltetrahydroquinolines (13),76-77 pyrazolopyridazines (14),78 pyrrolopyri-
dinones (15),79-80 benzimidazoles (16),81 and 2-thiazolidinones (17),82 (Figure 8). 
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Figure 8. Reported chemotypes of BET bromodomain ligands. The structural motifs 
acting as KAc mimic are shown in blue. 
In the next sections, two of the most studied scaffolds, triazolodiazepines (2, 3, 5, 6) and 
dimethylisoxazoles (7-11) will be presented in detail, and other chemotypes able to mimic KAc 
will also be introduced (12-20). 
 
A) 1, 2, 4-Triazolodiazepines 
The first BET potent and selective ligands, methyl triazolodiazepines 2 and 3, were 
discovered in 2010 by Filippakopolus et al.17 and Nicodeme et al. respectively.20 These 
molecules present a previleged diazepine structural core that is present in central nervous 
system drugs such as alprazolan and triazolam. Whereas Filippakopoulos and coworkers based 
their drug discovery campaign in high throughput techniques and docking studies from 
knowledge stemming from a patent from Mitsubishi Pharmaceuticals,83 Nicodeme et al. 
performed a phenotypic screening to discover up-regulators of apolipoprotein A1 (ApoA1), 
which is involved in protection from atherosclerosis and anti-inflammation.84  
(+)-JQ1 (2) is a potent BRD4(1) inhibitor (Kd = 49 nM determined by ITC, Isothermal 
Titration Calorimetry, and IC50 = 77 nM determined by AlphaScreen) and is selective against 
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the BET family of bromodomains (family II, Figure 4) according to differential scanning 
fluorimetry (DSF).17 (+)-JQ1 (2) is able to displace BRD4 from chromatin in cell based assays 
using fluorescence recovery after photobleaching (FRAP). Furthermore, it inhibits the 
proliferation of various cancer cells and its in vivo efficacy has been demonstrated on a NUT 
midline carcinoma (NMC) mice xenograft. Further studies have also shown efficacy in 
metabolic disease85 and acute myeloid leukemia mice models86 and non-small cell lung cancer 
cells.87 
I-BET762 (3) shows similar potency as (+)-JQ1 (2) with a Kd of 55 nM (measured by 
ITC) and an IC50 of 36 nM according to a FRET assay against BRD4(1).45 Compound 3 is able 
to suppress the expression of pro-inflammatory genes in vivo and inhibits the proliferation of 
several cancer cells.45 Its efficacy has also been demonstrated in several tumor and immune-
inflammatory models, and is currently undergoing clinical phase I/II studies (see sub-section 
F).61, 71, 88 
From the structure activity relationship (SAR) studies performed by both research groups 
the importance of the absolute configuration at the molecule’s stereocenter can be highlighted, 
as the opposite enantiomers were inactive due to steric clashes with residues of the ZA loop 
region. The crystal structures of 2 and 3 have been solved with a variety of BET 
bromodomains showing excellent shape complementarity with the KAc binding site thanks to 
the curvature of the triazolodiazepine core. Both ligands present almost identical binding poses 
and occupy the totality of the binding site. The key interactions of (+)-JQ1 (2) and I-BET762 
(3) in BRD4(1) are shown in Figure 9.  
The triazole ring of (+)-JQ1 (1) and I-BET762 (3) is deeply inserted into the binding site 
acting as a KAc mimic, with the methyl group pointing into the small hydrophobic pocket that 
recognizes the methyl group of KAc (Figure 9). SAR studies performed by Filippakopoulos et 
al. proved the methyl group to be essential for binding affinity, as its replacement by other 
groups (H, Et, Ph, NH2 or carbonyl) was detrimental for binding.17 One of the nitrogen atoms 
of the triazole ring accepts a water mediated hydrogen bond from the evolutionary conserved 
tyrosine (Tyr97) and the second nitrogen atom accepts a hydrogen bond from the conserved 
asparagine Asn140 (Figure 9 B, D, hydrogen bonds are shown as dashed lines).20, 45 
The 4-chlorophenyl (2-4, 6) and phenyl ring (5) moieties, common for several analogues,45 
protrude out of the binding pocket and interact in the hydrophobic WPF shelf, which is 
composed of residues Trp81, Pro82 and Phe83 located in the ZA loop (Figure 9). The fused 
aromatic ring of the triazolodiazepine core (the dimethylthiophene in compound 2 and 
methoxybenzo moiety in compound 3) are located in the lipophilic ZA channel and mainly 
establish van der Waals interactions (Figure 9).      
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Figure 9. A, C) Molecular interactions of (+)-JQ1 (2) (A, PDB code 3MXF) and I-
BET762 (3) (C, PDB code 3P5O) with BRD4(1). B, D) The acetyl-lysine binding 
pocket of BRD4(1) is shown as a 2D representation in complex with ligands 2 and 3. 
The inhibitors are shown in green. The conserved residues tyrosine Tyr97 and 
asparagine Asn140 responsible for binding and the residues belonging to the WPF shelf 
and ZA channel are indicated. The hydrogen bonds between the protein and the 
inhibitors are indicated as dashed lines. 
B) 3,5-Dimethylisoxazoles 
3,5-Dimethylisoxazoles have been independently identified as BRD4(1) inhibitors by 
Dawson et al.,21 Hewings et al.68 and Bamborough et al.69  
Hewings and coworkers discovered that the solvent N-methyl pyrrolidinone (NMP) binds 
weakly within the KAc binding pocket, and a subsequent screening of methyl-bearing 
heterocycles resulted in dimethylisoxazole 21 as a hit.68 Starting from the dimethylisoxazole hit 
21, Hewings et al. developed lower molecular weight fragments resulting in compounds 22 and 
the most potent compound 9 (IC50 = 382 nM according to AlphaScreen), as illustrated in 
Figure 10.68 The dimethylisoxazole ring binds within the KAc-binding pocket as a KAc isostere: 
the oxygen atom of the five membered ring (mimic of the carbonyl oxygen of KAc) accepts a 
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hydrogen bond from the conserved asparagine Asn140 (Figure 11B, hydrogen bonds shown as 
dashed lines), the nitrogen acts as a hydrogen bond acceptor from tyrosine Tyr97 (Figure 11B, 
hydrogen bonds shown as dashed lines) and one of the methyl groups occupies a small 
hydrophobic pocket analogous to the terminal methyl in KAc. 
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Figure 10. Starting hit (21) and optimized dimethylisoxazole derivatives (22 and 9) 
as BET inhibitors reported by Hewings et al.68, 89 The structural motifs acting as KAc 
mimic are shown in blue. 
The hydroxyl group in the phenol moiety is involved in hydrogen bonds with the 
conserved crystallographic water molecules within the ZA channel, whereas the hydroxy group 
attached to the stereogenic center in 9 interacts with the solvent, making its configuration not 
relevant for binding (Figure 11). Finally, the phenyl substituent lies within the WPF shelf, in a 
similar region as the chlorophenyl in tetrazolodiazepines 2 and 3 (Figure 9).17, 20 This compound 
series presents higher ligand efficiency values than the triazolodiazepine inhibitors (Figure 8, 
top) due to their low molecular weights, making them promising leads for the development of 
more potent BET inhibitors. Moreover, sub-microlar GI50 values were obtained for compound 9 
against an acute myeloid leukemia cell line.68, 89  
 
Figure 11. A) Molecular interactions of 9 (PDB code 4J0S) with BRD4(1). B) The 
acetyl-lysine binding pocket of BRD4(1) is shown as a 2D representation in complex 
with ligand 9. The inhibitor is shown in green. The conserved residues tyrosine Tyr97 
and asparagine Asn140 responsible for binding and the residues belonging to the WPF 
shelf and ZA channel are indicated. The hydrogen bonds between the protein and the 
inhibitor are indicated as dashed lines. 
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Independently, Bamborough and coworkers screened potential fragments as KAc mimics 
towards BET bromodomains and found low molecular weight 3,5-dimethylisoxazoles as good 
candidates.69 Compounds bearing a sulfonamide group on the phenyl ring in meta relative 
position to the isoxazole presented higher binding affinities, as the sulfonamide introduces a 
bent in the shape of the molecule directing the cycloalkyl substituents into the WPF shelf. 
Introduction of polar and solubilizing groups in the molecule resulted in isoxazole 8, a molecule 
that shows high selectivity for the BET bromodomains and low micromolar IC50 values on a cell 
based cytokine IL-6 assay.69 
Another example of 3,5-dimethylisoxazoles was discovered by a phenotypic screening 
campaign in search for ApoA1 up-regulators by Dowson and coworkers.21 A medicinal 
chemistry campaign yielded I-BET151 (11), which presents high affinity towards BRD3 in 
vitro and nanomolar IC50 values towards MLL fusion leukemia cell lines. Its therapeutic 
potential has also been established in a MLL leukemia in vivo model.21  
Aside from the above-mentioned ligands, dimethylisoxazoles have also been greatly 
explored by other groups leading to the development substituents with different chemotypes as 
illustrated in Figure 8 (7,10).70, 73  
C) Other chemotypes  
Even though triazolodiazepines and dimethylisoxazoles have been two of the most studied 
scaffolds within the bromodomain inhibitor pool, a few additional chemotypes have been 
identified as bromodomain ligands (Figure 8, 12-13). Their binding interactions within the 
KAc binding pocket are illustrated in Figure 12. 
 
Figure 12. Schematic representation of the binding modes of the KAc mimics of 
compounds 12 and 13 in the binding site.90 The arrows indicate the connection vectors 
with the rest of the molecule. The hydrogen bonds between the protein and the 
inhibitors are indicated as dashed lines. 
The dihydroquinazoline-3,5-dimethylisoxazole 21 (Figure 10)68 presents two distinct 
binding modes. In both, the 3,5-dimethylisoxazole or the dihydroquinazoline can act as KAc 
mimic. Taking the dual binding mode of compound 21 into account, Knapp and coworkers 
explored the utility of the dihydroquinazoline core as BET bromodomain inhibitor.74 The study 
led to the discovery of benzenesulfonamide-quinazolin-2-ones, being PFI-1 (12) one of the most 
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potent derivatives found in this campaign. The cyclic urea of the dihydroquinazoline ring is 
buried in the binding pocket mimicking the KAc ligand (Figure 12, A). In an analogous 
approach to the work of Bamborough and coworkers in the design of isoxazole 8,69 sulfonamide 
linkers were incorporated to direct its aromatic substituents towards the WPF shelf.  
PFI-1 (12) shows high specificity towards the BET bromodomain family, even though a 
certain binding towards CREBBP and EP300 is also observed by differential scanning 
fluorimetry (DSF).74 Its cellular activity was confirmed in an IL-6 assay (a cytokine that is 
produced by NF-κB) and antiproliferative activities with GI50 values in the low micromolar 
level were observed in leukemia cell lines. Moreover, PFI-1 (12) shows a promising 
pharmacokinetic profile in vivo for oral administration.74-75, 91   
A number of 1-acyltetrahydroquinoline derivatives have been patented by 
GlaxoSmithKline, including I-BET762 (13), as KAc mimics (see Figure 12, B for an schematic 
representation of its binding mode).76 Compound 13 is able to inhibit the growth of several 
cancer cell lines and its efficacy in vivo for treating neuroblastoma and endotoxemia has been 
confirmed.76, 92 
Further examples of BET bromodomain ligands have been published as patents, including 
pyrazolopyridazines (14) by Costellation Pharmaceuticals78 and pyrrolopyridinones and 
pyrrolopyridazinones (15) by GlaxoSmithKline, Constellation Pharmaceuticals, Pfizer, Dana-
Farver Cancer Institute and Abbott Laboratories.79-80  
D) Virtual screening as a tool for the discovery of novel chemotypes 
Virtual screening has been a very efficient tool in the discovery of novel KAc mimetics as 
bromodomain ligands (Figure 13).81-82, 93-95  
 
Figure 13. Schematic representation of the binding modes of the KAc mimics of 
compounds 17-20 in the binding site.90 The arrows indicate the connection vectors with 
the rest of the molecule. The hydrogen bonds between the protein and the inhibitors are 
indicated as dashed lines. 
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The first in silico guided design of bromodomain inhibitors was conducted by Ito and 
coworkers in 2011. An initial high throughput docking campaign on BRD2(1), followed by the 
screening of 192 compounds experimentally afforded benzimidazole 16 (Figure 8), which was 
able to inhibit BRD2(1) with a Kd value of 28 µM.81 Unexpectedly, the benzene ring occupies 
the KAc binding site without forming any interactions with the conserved asparagine Asn140 
and tyrosine residue Tyr97, which also explains the low affinity of the ligand (see PDB code 
3AQA for further details). 
Another virtual screening campaign performed in 2013 by Shen and coworkers resulted in 
the identification of new chemotypes (e.g. thiazolidinones) as potential BET inhibitors.82 After 
docking a subset of the ZINC library with Glide on BRD4(1), 41 fragments were selected, and 
X-ray crystallography was used to further identify hits. The 2-thiazolidinone moiety was found 
to act as a KAc mimic (Figure 13, A). Based on the crystal structure (PDB code 4HXN), the 
initial 2-thiazolidinone fragment was further optimized, including, once more, sulfonamide 
substituents that resulted in an increase of potency, being thiazolidinone 17  (Figure 8) the 
most active analogue with an IC50 value of 0.23 µM in BRD4(1).82  
 In the same year, Hoelder and coworkers were able to identify new scaffolds as KAc 
mimetics by a virtual screening approach against BRD4(1).93  Commercially available 
compounds that matched the hydrogen-bond pattern and steric constraints of the KAc binding 
site were selected and docked with the software Glide, resulting in unprecedented KAc 
mimetics with IC50 values in the µM range: chloropyridones (being compound 18 the most 
active from the series, Figure 13, B), triazolopyrimidines, quinolones, pyrrolopyridones and 
pyrrolopyrimidones.93 
 Few months later, a new in silico screening campaign against BRD4(1) was carried out 
by Günther and coworkers.94 A library composed of 7 million molecules was screened and 22 
compounds were selected and purchased, leading to seven compounds with significant binding 
affinity (six of which were unkown scaffolds). The 4-acyl pyrrole 19 (Figure 7, PDB code 
3UVW), with a Kd of 237 nM and a GI50 value of 17 µM in a leukemia cell line, constitutes an 
interesting new scaffold for the design of potent BET inhibitors.94 The pyrrole ring binds within 
the KAc binding pocket showing high surface complementarity, while the acyl substituent 
interacts with the conserved asparagine and tyrosine residues (Figure 13, C).  
Our collaborators, the group of Prof. Caflisch in the Biochemistry Institute (UZH) have 
greatly contributed to the bromodomain research in the last year.43, 95 In fact, they implemented 
an in house developed fragment based in silico ALTA procedure96 for the discovery of new 
BRD4(1) ligands, resulting in the low micromolar active cyclohexanone 20 (Figure 8) among 
other active chemotypes.95 The binding mode of the KAc mimetic of compound 20 is shown in 
Figure 13, D (PDB code 4PCE).  
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E) Kinase inhibitors with bromodomain activity 
Interestingly, two similar studies published almost simultaneously identified kinase 
inhibitors (some of them clinically approved) as BRD4(1) nanomolar ligands.97-98  
Ember et al. assessed the binding of more than 500 known kinase inhibitors by robotic co-
crystallization on BRD4(1) and BRDT(1) obtaining X-ray structures of 14 kinase inhibitors in 
complex with bromodomains.98 Independently, the Structural Genomics Consortium (SGC), in 
collaboration with DiscoveRx, screened 628 kinase inhibitors against BRD4(1) using an 
AlphaScreen assay.97 Surprisingly, both studies led to kinase inhibitors BI-2536 (23) and TG-
101348 (24) as two of the most potent compounds against BRD4(1), with Kd values of 37 and 
164 nM respectively and a high selectivity towards BET bromodomains (Figure 14).97-98 Both 
compounds were able to displace BRD4 from chromatin in cells, as well as to suppress c-Myc 
oncogene expression (a marker of BET inhibition).97  
These results suggest that kinases and bromodomains share a high degree of 
pharmacophore similarity.  However, the chemical moieties of the kinase inhibitors that 
interact as KAc mimic do not always represent the groups interacting with the ATP-binding 
site of the kinase. The fact that BET bromodomains might be off-targets of kinase inhibitors 
constitutes a very important piece of information that will very likely impact bromodomain 
and kinase research (see chapter 2 for more information on kinase inhibitors).  
 
Figure 14. Two kinase inhibitors, 23 and 24 show potent BRD4(1) activity. The 
atoms highlighted in blue in 23 correspond to the KAc mimic for bromodomain binding 
and those in red interact with the hinge region of the kinase (see chapter 2 for further 
details). In TG-101348 (24), the same moiety is responsible for both, bromodomain and 
kinase binding (indicated in pink).  
F) Clinical studies with BET bromodomain ligands41, 47 
Based on all the BET bromodomain ligands available in the literature, we can conclude 
that numerous efforts have been invested in the last 3-4 years in the development of BET 
family bromodomain ligands, both in industry and academia. The high number of X-ray crystal 
structures has allowed a thorough study of the potency and selectivity of protein-ligand 
interactions. However, the usefulness of bromodomain ligands for therapeutical applications 
remains an open question.47 The five BET bromodomains that are currently undergoing clinical 
trials might shed some light into the validation of bromodomains as therapeutical targets.62 
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The clinical candidates for which their chemical structure has been disclosed are shown in 
Figure 15. I-BET762 (3) is being pursued against NUT midline carcinoma (NMC), solid tumors 
and haematological malignancies, RVX-208 (25) towards the treatment of atherosclerosis and 
type II diabetes and OTX015 (26) against acute leukemia and hematological malignancies. 
Other clinical candidates include CPI-0610 (for the treatment of progressive lymphoma) and 
TEN-010, which is a derivative of (+)JQ1 (2) and is being evaluated against NMC. 
 
Figure 15. Bromodomain ligands currently in clinical trials.62 The structural motifs 
acting as KAc mimic are shown in blue. 
II. CREBBP and EP300 ligands 
The bromodomain containing protein CREBBP is gaining more attention as a target for 
the development of small organic inhibitors. EP300 and CREBBP belong to the same 
bromodomain family (family III, Figure 4) and share 96 % sequence similarity.99 They are part 
of a multidomain protein that contains HAT (histone acetyltransferase) catalytic activity, 
meaning that they are able to acetylate conserved lysine amino acids on histone or non-histone 
proteins, as well as having an acetylated lysine binding domain (bromodomain).100-101 Due to 
the acetyltransferase and bromodomain activities, CREBBP and EP300 have at least 400 
interacting protein partners (such as transcription factors and co-activators and acetylated 
histones),102 which highlights their importance within the protein-protein interactome.103 
CREBBP and EP300 play important roles in DNA replication and repair, cell growth and 
cell cycle regulation and genomic stability.104-105 As an example, EP300 and CREBBP are able 
to acetylate p53 in its K382 residue upon extracellular stress or DNA damage through their 
HAT domain and they are also known to specifically bind to acetylated p53 via their 
bromodomain.106 As a consequence, changes in the p53-dependent activation of target genes 
take place, resulting in cell cycle arrest, senescence or apoptosis. 107-109 p53 is a tumor suppressor 
gene, and as such, its mutations are known to occur in about 50 % of human cancers.107, 110-111 In 
addition, p53 is implicated in a wide variety of malignancies such as Alzheimer’s disease, 
Parkinson’s disease, spinal cord diseases, ischemic brain injury, infectious and auto-immune 
related disorders (including multiple sclerosis) and myocardial ischemia.99, 112-117 
Interestingly, CREBBP and EP300 have been described to have opposite effects in 
oncology, being either oncogenes or tumor supressors.102, 118 On the one hand, chromosome 
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translocations resulting in gene fusions containing CREBBP or EP300 have been linked to 
leukemias and lymphomas.102, 119 On the other hand, CREBBP and EP300 are mutated in solid 
tumors and B cell lymphoma, suggesting they possess a tumor suppressing role.105, 120 
CREBBP and EP300 were first targeted to inhibit their acetyltransferase activity.102, 121-122 
The inhibitors suppressed lysine acetylation and cell proliferation, and their efficacy was also 
demonstrated in in vivo cancer xenograft models.102, 121-122 Nowadays, there is an emerging 
strategy to target the CREBBP and EP300 bromodomains, which has resulted in the 
development of a few CREBBP and EP300 ligands in the last year.  
The main structural difference between the BET family and CREBBP bromodomain lies 
within the hydrophobic LPF shelf (Figure 16). The residue Trp81 of the WPF shelf in 
BRD4(1) (Figure 16, A) is substituted by Leu1109 in CREBBP (Figure 16, B). As Leu1109 is 
located further away from the binding site compared to Trp81, a larger space arises in 
CREBBP (Figure 16, indicated as pink spheres). More importantly, the presence of the 
arginine residue Arg1173 (also missing in the BET bromodomain family) provides a basic 
environment in the entrance of the binding site in CREBBP. Those two main differences are 
thought to contribute towards CREBBP selectivity and have been addressed in the 
development of CREBBP inhibitors.68, 99, 123-125  
 
Figure 16. 3D representation of a BET bromodomain (A, PDB code 3MXF) and 
CREBBP bromodomain (B, PDB code 4NR7) binding site divided into three regions: 
KAc binding site (in blue), WPF or LPF shelf (in yellow) and ZA channel (in green). 
The main differences between both bromodomains are highlighted by a red circle.  
The first CREBBP ligands were developed by Zhou and coworkers in 2006 via NMR 
screening of 200 compounds that contained a KAc mimic.123 As the entrance to the CREBBP 
bromodomain is positively charged due to the arginine residue Arg1173, the compound library 
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was composed of electron-rich molecules. The study resulted in fourteen ligands including 
compounds 27 and 28, which were able to block the interaction between p53 KAc382 and 
CREBBP (Figure 17).  
Following a similar approach, the same group disclosed azobenzenes as potential 
bromodomain inhibitors.124 An optimization campaign yielded ischemin 29, which has a Kd 
value of 19 µM and an IC50 value of 5 µM in a cell based p21 luciferase assay (a p53 target 
gene).124 The NMR structure of compound 29 shows that the ligand does not bind deep within 
the binding site (Figure 18) and it only forms one hydrogen bond with the conserved 
asparagine Asn1168 via the phenol. On the other end of the molecule, the sulfonate substituent 
forms an electrostatic interaction with arginine Arg1173, located at the entrance of the binding 
site. The same arginine residue also interacts with the aniline through hydrogen bonding 
(Figure 18, B, hydrogen bonds shown as dashed lines). Ischemin has moderate selectivity: it is 
5-fold more selective for CREBBP over PCAF, BRD4(1) and BAZ2B based on a fluorescence 
assay.  
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Figure 17. First CREBBP ligands developed by Zhou et al.123-124 
 
Figure 18. A) Molecular interactions of 29 (PDB code UL84) with CREBBP. B) The 
acetyl-lysine binding pocket of CREBBP is shown as 2D representation in complex with 
ligand 29. The inhibitor is shown in green. The conserved residues tyrosine Tyr1125 
and asparagine Asn1168 responsible for binding and the residues belonging to the LPF 
shelf and ZA channel are indicated, together with Arg1173, a characteristic residue of 
CREBBP that is located in the BC loop. The hydrogen bonds between the protein and 
the inhibitors are indicated as dashed lines. 
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A few medicinal chemistry campaigns in the course of developing BET bromodomain 
ligands (see sub-section I) have also yielded CREBBP ligands with moderate to low selectivity. 
Two examples are shown in Figure 19.  
Out of the numerous 3,5-dimethylisoxazol derivatives developed by Hewings et al.63 (see 
sub-section I), compound 30 has an IC50 value of 32 µM and 28 µM against CREBBP and 
BRD2(1) respectively.63 Interestingly, the carboxylate group mimics the sulfonate in the 
azobenzene 29 (Figure 17) by interacting with arginine Arg1173, an interaction that might be 
responsible for CREBBP activity (for further details see PDB code 3SVH).  
Another example of non-selective CREBBP ligands is 1,2,4-triazolo[4,3-a]phthalazine 31, 
which was discovered by Brennan et al. in 2013.126 The phthalazine derivatives maintained the 
3-methyl-1,2,4-triazolo core of potent BET inhibitors such as (+)-JQ1 (2) and I-BET762 (3) 
and varied the fused ring and substituents present in the ZA channel and WPF shelf in order 
to change the selectivity towards bromodomains outside the BET family. After the addition of 
solubilizing groups, the chloro substituted sulfonamide 31 (Figure 19) was found to be potent 
towards CREBBP (IC50 = 0.20 µM), although showing, at the same time, a higher potency 
against BRD4(1) with an IC50 of 0.16 µM.126  
 
Figure 19. CREBBP inhibitors steaming from BET inhibitor optimization     
campaigns.68, 126 The structural motifs acting as KAc mimic are shown in blue. 
The first CREBBP potent and selective ligands were recently and almost simultaneously 
reported by the group of Conway125 and the Structural Genomics Consortium (SGC)99, 127-128 
(32-34, Figure 20). Both studies originated from KAc mimics already known for BET 
inhibitors (Figure 8).  
 
Figure 20. First potent and selective CREBBP inhibitors.99, 125, 127-128 The structural 
motifs acting as KAc mimic are shown in blue. 
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Conway and co-workers initiated their study inspired by the dihydroquinazoline KAc 
mimic already explored as BET ligands (compound 12, Figure 8).125 Since the 
dihydroquinazoline motif was found to be susceptible to oxidation,68, 89 more stable KAc mimics 
were investigated, including benzoxazinones and dihydroquinoxalinones, the latter resulting in 
more potent ligands. The amide of the dihydroquinoxalinone forms two hydrogen bonds with 
Asn1168, while the methyl group occupies the same small hydrophobic pocket as the acetyl 
gorup in KAc (Figure 21, A, B). The intramolecular hydrogen bond formed between the 
secondary amine and the carbonyl of the amide provides the right orientation for the 
tetrahydroquinoline substituent to reach an induced fit pocket below the Arg1173 residue 
establishing a cation-π interaction (Figure 21, A, B).125 An optimization of the mentioned 
interaction with Arg1173 by introducing electron rich substituents in the aromatic ring, lead to 
the most potent ligand in the series, 32, which shows high CREBBP potency (an IC50 value of 
323 nM by Alphascreening and a Kd of 390 nM  determined by ITC) and a 3.5 fold selectivity 
over BRD4(1) (with a Kd of 1.4 µM).125 Compound 32 was also able to displace the CREBBP 
bromodomain from chromatin in cells, as demostrated in a FRAP assay.125  
Hay et al. developed slightly more potent and selective CREBBP ligands starting from the 
BET ligand isoxazole 7 (Figure 8).99 Analogues were designed based on X-ray structures of an 
intermediate compound on both, BRD4(1) and CREBBP, with the aim to gain selectivity 
towards CREBBP. SAR studies yielded compound SGC-CBP30 (31), which shows an 
unprecedented selectivity of 40 fold for the CREBBP bromodomain against BRD4(1) (with a 
Kd of 21 nM and 850 nM in CREBBP and BRD4(1) respectively). Due to the high similarity 
between CREBBP and EP300, isoxazole 33 is also able to strongly bind to EP300 (Kd = 32 
nM).99  
The X-ray structure of compound 33 is shown in Figure 21, where the isoxazole acts as a 
KAc mimic as explained in the previous sub-section. The aryl ring bearing electron rich 
substituents establishes a cation-π interaction with the guanidino group of Arg1173, in analogy 
to compound 32. The chiral methyl group is located below the aryl ring locking its position 
and providing the right orientation for the cation-π interaction to take place. Finally, the 
morpholino group points towards the solvent resulting in an improved water solubility, an 
important property when aiming for compounds that could reach the drug market. The cellular 
activity of isoxazole 33 was evaluated using a fluorescence recovery after photo-bleaching 
(FRAP) assay, concluding that the CREBBP bromodomain could succesfully be displaced from 
chromatin at low concentrations of the compound. Moreover, it could inhibit p53 activity in a 
dose dependent manner and displayed a GI50 value of 8.1 µM against U2OS osteosarcoma   
cells.99  
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Figure 21. A, C) Molecular interactions of 32 (A, PDB code 4NYW) and 33 (C, PDB 
code 4NR7) with CREBBP. B, D) The acetyl-lysine binding pocket of CREBBP is 
shown as 2D representation in complex with ligands 32 and 33. The inhibitor is shown 
in green. The conserved residues tyrosine Tyr1125 and asparagine Asn1168 responsible 
for binding together with Arg1173, a characteristic residue of CREBBP and residues 
belonging to the LPF shelf and ZA channel are indicated. The hydrogen bonds between 
the protein and the inhibitors are indicated as dashed lines. 
The last known CREBBP selective inhibitor, I-CBP112 (34), has also been developed in 
the SGC.128 It presents an IC50 value of 170 nM by AlphaScreen and its selectivity has been 
confirmed against several other bromodomains by surface plasmon resonance. 
Due to the scarce number of selective CREBBP ligands available, all of them, 32-34, 
reported during the course of this work, we decided to initiate an in silico driven screening 
campaign, the aim being the development of novel, potent and selective CREBBP ligands. 
Such molecules could contribute to unravel the biological processes behind this bromodomain 
and find its direct therapeutical application. The results are presented in section 3.2.  
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III. Other bromodomain ligands 
There has been very little work done outside the BET and CREBBP/EP300 
bromodomains. In fact, only three bromodomains have been addressed by potent inhibitors 
(Figure 22, 35-38): BAZ2B, BRPF1 and SMARCA4, which have been characterized as non-
druggable bromodomains in a study conducted by Vidler et al.129 The biological function of the 
mentioned bromodomains remains elusive, but the existence of potent inhibitors might help 
unravel their therapeutical applications.  
Importantly, bromosporine (39)130 is a special tool within the bromodomain inhibitors pool 
that is able to bind to a diverse set of bromodomains (including BRD2, BRD3, BRD4, BRDT, 
PB1, CECR2, TAF1, BAZ2A, TAF1, BRD9 and CREBBP). It was developed at the SGC and 
could be very useful for studying the biological role of a diverse set of bromodomains as well as 
for validating functional assays.  
Figure 22. Potent inhibitors that target bromodomains outside the BET family or 
CREBBP/EP300 bromodomains.131-134 The structural motifs acting as KAc mimic are 
shown in blue. 
3.2 Fragment-based Design of Potent and Selective 
CREBBP Bromodomain Ligands: Polar Interactions 
with Arg1173 as a Tool Towards Selectivity 
The quest for bromodomain inhibitors as potential therapeutic tools has bloomed in recent 
years based on the growing understanding of epigenetic processes. Earlier this year, Rooney et. 
al reported the first nM potent CREBBP inhibitors based on dihydroquinoxalinone scaffolds.125 
Absolute stereocontrol was required to attain the desired potency and still only moderate 
selectivity against BRD4(1), the most promiscuous bromodomain, was found. Recently, Hay et. 
al reported a medicinal chemistry optimization campaign for selective CREBBP bromodomain 
inhibitors starting from a non-selective 3,5-dimethylisoxazole ligand.99 
We decided to take a different approach specifically focussing on the target95, 135 and 
started our CREBBP ligand-identification campaign by fragment-based high-throughput 
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docking into the structure of the CREBBP bromodomain. Herein we present the result of a 
computer-aided, structure-based approach which has enabled the discovery of several nM 
ligands of the CREBBP bromodomain upon optimization of binding by modulation of the 
electrostatic interaction with Arg1173 (numbering from PDB structure 3SVH), a residue 
located at the entrance of the binding site that is considered to be key for attaining selectivity 
towards CREBBP.68, 123-124 The anchor-based library tailoring procedure (ALTA)136-138 was used 
for high-throughput docking (further details can be found in the experimental section). 
Initially, the nearly two million compounds in the ZINC leads-now library (version of Oct. 
2012) were decomposed into fragments by the program DAIM.139 Upon filtering out fragments 
without rings and hydrogen bond donor/acceptor groups, a total of 106,534 fragments were 
docked by the program SEED140-141 which takes into account electrostatic solvation by 
numerical solution of the generalized Born equation.142 The top (about 4,000) fragments were 
used to retrieve nearly 800,000 molecules in the ZINC library which they originated from. 
Docking of these molecules was carried out by AutoDock Vina143 and the poses were ranked by 
the SEED energy140-141 followed by clustering. Finally, 17 compounds (cluster representatives) 
were chosen for in vitro validation. The acyl benzene A showed activity and was selected for 
further investigations based on its amenability to potential chemical editing. Three additional 
acyl-benzene derivatives (compounds B, C and D) were also purchased and tested (Figure 23). 
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Figure 23. Left: Commercially available compound A identified in the high-
throughput docking campaign and its available analogues B-D. Equilibrium dissociation 
constant (Kd) values and/or the percentage of residual binding to a known ligand with 
respect to the DMSO control determined in the competition binding assay 
(BROMOScan at DiscoveRx)144-145 are shown. The common structural features of A-D 
are shown in blue. Right: Docked poses of A (carbon atoms in magenta) and B (carbon 
atoms in yellow) into the CREBBP bromodomain (gray). The side chains of the 
conserved Tyr1125 and Asn1168 residues, together with Arg1173 are shown as sticks.  
The good affinity of compound B for CREBBP (Kd of 5 µM determined by a competition 
binding assay148, 149) highlighted the importance of the salt bridge formed between the 
molecule’s carboxylic acid and the Arg1173 residue (Figure 23, right). Due to its potency, 
ligand efficiency (0.36 kcal/mol per heavy atom) and chemically novel blueprint within the 
CREBBP bromodomain inhibitors’ pool131 we decided to focus our optimization campaign on 
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compound B. Our strategy was to preserve its acylbenzene moiety (“head group”) since the 
carbonyl group is involved in a hydrogen bond with the conserved Asn1168 in the docked pose. 
Several modifications were designed in order to generate both potent and selective 
CREBBP inhibitors. First, we decided to keep the fumaric acid moiety and modulate the 
interactions of the substituents in ortho- position relative to the amide group with the 
hydrophobic residues located on top of the binding site, Ile1122 and Leu1120. Replacement of 
the ethoxy group originally present in B with OMe, Me or F substituents did not have a strong 
effect on affinity (Table 2, compounds 40-43). We then turned our attention towards the side 
chain of the molecule while preserving the carboxylic acid moiety that interacts with Arg1173. 
Remarkably, the substitution of the fumaric acid by an isophthalic group in 45 (which might 
also provide a higher metabolic stability) resulted in a 6-fold improvement in binding affinity 
representing the first nanomolar CREBBP inhibitor of our derivatization campaign. We 
hypothesized that such improvement in affinity could be due to a more favorable interaction 
with the Arg1173 residue and the so-called LPF shelf together with a less unfavorable entropic 
penalty compared to the slightly more flexible fumaric acid derivative. The methyl isophthalate 
derivative 46 showed similar potency as 45 indicating that its ester is involved in favorable 
polar interactions with Arg1173. 
Table 2. First approach towards the optimization of compound B. 
 
Cmpd R1 R2 ΔTm(°C)[a] Kd (μM)[b] IC50 (μM)[c] 
B Fumaric acid OEt 1.8 5.00 – 
40 Fumaric acid OMe 1.1 – 60 
41 Fumaric acid Me 0.2 – >100 
42 Fumaric acid F -0.1 – >100 
43 Fumaric acid H 0.1 – 30 
44 1,2-Cyclopropyl carboxylic acid OEt 1.1 – >100 
45  OEt 3.8 0.77 8.7 
46  OEt 2.8 0.59 5.0 
47  OEt 1.9 – 64 
[a] Median value of the shift in the melting temperature (number of measurements > 
10). SEM values did not exceed 0.2 °C a part from the SEM value for compound 7 
(0.5°C). [b] Kd values were determined by a competition binding assay148, 149 in 
duplicates. [c] IC50 values were determined at BPS Bioscience by means of a TR-FRET 
assay in duplicates.  
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The crystal structure of compound 45 in complex with the CREBBP bromodomain 
(solved at a 1.7 Å resolution, Figure 24) revealed an overall binding mode similar to the docked 
pose of the fumaric acid derivative B obtained in silico (Figure 23, right). Compound 45 binds 
in the acetyl-lysine pocket,36 with its acyl substituent involved in a hydrogen bond with the 
side chain of the conserved Asn1168 and a water-bridged hydrogen bond with the Tyr1125 side 
chain hydroxyl. The acetyl benzene head, together with its ethoxy substituent, presents high 
shape complementarity with the binding site. The NH group of the amide linker forms a 
hydrogen bond with a water molecule whose oxygen atom is located at a distance of 3.0 Å from 
the carbonyl oxygen of Pro1110 (in the LPF shelf): the geometry for a water-bridged hydrogen 
bond, however, is not ideal as the water oxygen is not in the plane of the Pro110 carbonyl. In 
contrast, the carbonyl group of the amide linker is involved in a favorable water-bridged 
hydrogen bond with the guanidinium of the Arg1173 side chain. Crucially, the aromaticity of 
the benzoic acid provides the optimal orientation for the carboxylic acid of compound 45 to 
form a very favorable polar interaction with the Arg1173 guanidinium of the CREBBP 
bromodomain. Previously, electrostatic interactions between the sulfonate group of ischemin 
and this arginine residue were observed.124 Moreover, Conway and coworkers already reported a 
relatively weak ligand of CREBBP and BET bromodomains bearing a carboxylic acid that, 
even if not in direct contact with Arg1173, could form weak electrostatic  interactions with this 
positively charged residue, resulting in a preferential binding towards CREBBP.68 
 
Figure 24. Crystal structure of CREBBP (gray) in complex with compound 45 (green) 
(PDB code 4TQN). The conserved Tyr1125 and Asn1168 residues, together with 
Arg1173 are shown as sticks. 
Finite-difference Poisson calculations were performed with CHARMM146-147 using the 
crystal structure of the CREBBP bromodomain in complex with compound 45 (PDB code 
4TQN) to evaluate the electrostatic contribution of the polar interaction to the free energy of 
binding of compounds 45 and 46. The finite-difference Poisson calculation takes into account 
solvent screening effects which are significant because the Arg1173 side chain is partially 
exposed to the solvent (Figure 24). Despite the partial solvent accessibility, the electrostatic 
interaction between the carboxyl group of compound 45 and the guanidinium group of Arg1173 
contributes -13.6 kcal/mol, which is about half of the total electrostatic interaction energy      
(-26.9 kcal/mol) between compound 45 and the CREBBP bromodomain.148  Analysis of the 
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individual contributions to the binding free energy of compounds 45 and its methyl ester 
derivative 46 shows that the former has a slightly more favorable electrostatic contribution     
(ΔG45electr – ΔG46electr = -0.8 kcal/mol) whereas the latter has a more favorable van der Waals 
contribution (ΔG45vdW – ΔG46vdW = 1.4 kcal/mol) so that the difference in the calculated total 
binding free energy is close to zero in line with the very similar dissociation constants of 
compounds 45 and 46 measured experimentally (Table 3). 
With the high resolution crystal structure of the first nM ligand 45 in hand we further 
explored the chemical space around this scaffold by introducing modifications at three different 
positions as illustrated in Table 3. Thermal shift values similar to the one of compound 45 
were observed for ligands bearing larger hydrophobic substituents within the acyl benzene head 
(48-51). More importantly, the replacement of the carboxylic acid by a tetrazole as isoster 
(54) maintained the affinity, whereas sulfonamides (55, 56) could not improve the large 
affinity gain achieved by the salt bridge formed in the presence of carboxylic acid in compound 
45. We then decided to enlarge our inhibitors towards the ZA channel by introducing both 
heteroaromatic (57, 58) as well as linear substituents (59-61) bearing hydrogen bond acceptors 
or donors in R3 that could interact with the amino acid residues located in the ZA loop. These 
modifications led to the most potent inhibitors of our optimization campaign, compounds 58, 
60 and 61, with Kd values of 170 nM, 540 nM and 400 nM, respectively (Table 4). The similar 
thermal shift values measured with the CREBBP bromodomain and its paralogue, EP300 
(Table 3), are consistent with the fact that identical residues are present in the acetyl-lysine 
binding site of both proteins.  
Compounds 62 and 63 were synthesized (Figure 25, top) to explore the effect of the amide 
direction (62) and the presence of an N-methyl carboxamide as a surrogate of the acetyl 
moiety (63).131 In both cases a decrease in affinity for CREBBP was observed, confirming the 
excellent shape complementarity between the acyl benzene moiety and the acetyl-lysine binding 
site of the CREBBP bromodomain and its paralogue EP300. 
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Table 3. Optimization of compound 45. 
 
 
Cmpd R1 R2 R3 
ΔTm (°C)[a] IC50 
(μM) [b] CBP EP300
48 OPr CO2H H 3.8 3.4 7.4 
49 OiBu CO2H H 3.5 3.0 NA 
50 OCH2Cyc CO2H H 3.4 3.6 NA 
51 OBn CO2H H 3.3 2.6 NA 
52 Morph CO2H H 1.4 1.3 NA 
53 Cyc CO2H H 3.1 3.1 15 
54 OEt 1-Tetrazole H 3.3 2.6 7.5 
55 OEt PhNHSO2 H 0.0 0.0 >10 
56 OEt PhSO2NH H 0.5 0.4 NA 
57 OEt CO2H 4-pyridyl 4.1 3.9 3 
58 OEt CO2H 3-furyl 5.2 5.9 1[c] 
59 OEt CO2H CH2OH 3.8 3.7 3 
60 OEt CO2H CH2OMe 5.1 4.6 2[c] 
61 OEt CO2H CH2OTHP 6.0 5.9 1[c] 
[a] Median value of the shift in the melting temperature (number of measurements > 
4). SEM values did not exceed 0.5 °C. [b] IC50 values for the CREBBP bromodomain 
were determined by means of a TR-FRET assay in duplicates (“NA”: an IC50 value 
could not be obtained). [c] Kd values for 58, 59 and 60 were determined by a 
competition binding assay148, 149 in duplicates with values of 0.17, 0.54 and 0.40 µM, 
respectively. Cyc: cyclopropyl; Morph: N-morpholyl; Bn: benzyl; THP: 
tetrahydropyrane.  
 
Figure 25. Top: Compounds 62 and 63. Bottom: Potent ligands of the CREBBP 
bromodomain previously reported.99, 125-126 
Remarkable target selectivity for CREBBP and EP300 over the other five human 
bromodomains (each belonging to a different subfamily) was found for the nanomolar ligands 
45, 58, 60, and 61 according to thermal shift (see experimental section, Figures 28-30). 
Interestingly, the most potent inhibitor 58, showed only 1.7 °C thermal shift against BRD4(1), 
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which is the most promiscuous bromodomain.99, 125 The selectivity was further investigated by 
isothermal titration calorimetry (ITC)149 and a competition binding assay (Table 4).148, 149 The 
BRD4(1)-Kd/CREBBP-Kd ratio determined by competition binding yields selectivity factors of 
>65, 59, and 48 for compounds 45, 58, and 60, respectively. Such selectivity towards the 
CREBBP bromodomain confirms the importance of the salt bridge with the positively charged 
Arg1173 for the design of selective CREBBP ligands. Importantly, the high ligand efficiency 
(LE)150-151 was preserved throughout the optimization campaign. Moreover, the LE values (0.28 
to 0.35 kcal/mol per heavy atom) and the ligand-lipophilic efficiency (LLE) values (close to 
4.0) of our nM ligands 45, 58, 60, and 61, compare positively with those of previously 
disclosed ligands of the CREBBP bromodomain 31-33 (Figure 25, bottom).99, 125-126  
Table 4. Activity and selectivity of the most potent acyl benzene derivatives.  
Cmpd LE[a] LLE 
 Kd
(µM) 
ITC 
 
Kd (µM) competition binding assay148, 149  ΔTm (°C)[b] 
 CBP  CBP BRD4(1) BRD4(2) BRD2(1,2) S[c]  CBP EP300 BRD4(1)
45 0.35 3.7  2.0  0.77 >50 >50 >50 >65  3.8 3.4 0.4 
58 0.32 3.2  0.3  0.17 10 36 36 59  5.2 5.9 1.5 
60 0.32 4.0  0.8  0.54 26 >50 >50 48  5.1 4.6 1.3 
61 0.28 3.8  –  0.40 - - - -  6.0 5.9 1.7 
[a] LE = ligand efficiency, calculated as (ΔG/number of heavy atoms), is reported in 
kcal/mol per heavy atom; LLE = lipophilic ligand efficiency (calculated as             
pKd-clogP),150-151 clogP was calculated using ChemDraw. [b] Median value of the shift in 
the melting temperature (number of measurements > 9). SEM values did not exceed 0.3 
°C. [c] Selectivity (S) between the CREBBP and BRD4(1) bromodomains determined 
by the ratio of Kd values obtained via the competition binding assay.148, 149  
 Screening of our most potent CREBBP inhibitors against a panel of ten cancer cell lines 
showed lack of overall toxicity and significant growth inhibition for the leukaemia cell lines 
MOLM-13, ML2 and HL-60 specifically for compounds 45, 48, 61 and 62 (see experimental 
section, Tables 9 and 10). The methyl esters derived from compounds 45, 48-50, 58 and 59-62 
were also tested showing an equivalent or higher cell growth inhibitory activity compared to 
the corresponding acid counterparts, probably due to their better cell permeability. In fact, the 
methyl ester of 61 presented toxicity values in the low micromolar range, with GI50 values of 
14.4 and 5.3 µM for ML2 and MOLM-13, respectively, which could be linked to the 
involvement of CREBBP in some subtypes of acute myeloid leukaemia.152-154  
In an effort to expand the chemical diversity of the thus far limited portfolio of selective 
CREBBP/EP300 ligands,68, 99, 123-125 we decided to replace the acetyl benzene head by different 
chemical motifs while keeping the benzoic acid substitution that proved to be crucial in our 
optimization campaign. To achieve this goal, a library of about 400 heteroaromatics was 
docked with SEED140-141 to the crystal structure of CREBBP (PDB code 3P1C) and BRD4(1) 
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(PDB code 3MXF). The top fragments sorted according to predicted binding energy to 
CREBBP were visually inspected while overlaying their docked pose to the X-ray crystal 
structure of compound 45. Six fragments were selected based on their binding energy to 
CREBBP and selectivity against BRD4(1) as predicted by SEED140-141 (Table 6 in the 
experimental section), their orientation relative to the benzoic acid moiety of compound 45, 
their novelty within the bromodomain ligand pool, and their synthetic accessibility. 
Hybridization of these fragments with benzoic acid yielded compounds 64-66, which proved to 
be low micromolar ligands of the CREBBP bromodomain in the competition binding assay 
(Table 5). Moreover, the selectivity values of the new CREBBP ligands are consistent with the 
predicted binding energies calculated in silico.155 
Table 5. Benzoic acid-templated ligands containing novel acetylated lysine mimics. 
 
 
Cmpd 
LE 
CBP 
Kd (µM)[a] ΔTm(°C)[b] ΔEcalculated[c] 
CBP BRD4(1) CBP BRD4(1) CBP BRD4(1) 
64 0.30 17.0 6.9 1.2 2.6 -19.9 -18.3 
65 0.37 4.1 33 1.9 1.0 -19.4 -14.5 
66 0.36 1.1 41 4.4 1.5 -19.9 -16.5 
[a] Kd values were determined by a competition binding assay148, 149  in duplicates. A Kd 
value of 1.6 µM for compound 30 was measured by ITC (Figure 31 in the experimental 
section). [b] Median value of the shift in the melting temperature (number of 
measurements > 12). SEM values did not exceed 0.3 °C. [c] SEED total energy140-141 in 
kcal/mol for the compounds without amide linker. The compounds are involved in a 
hydrogen bond with the conserved Asn1168 in the binding modes obtained by docking 
with SEED.140-141 
In summary, we have discovered in silico, validated by X-ray crystallography, and 
optimized by chemical synthesis a series of nM potent and selective acyl benzene ligands of the 
CREBBP bromodomain. Fragment-based, high-throughput docking was employed for the 
identification of novel scaffolds whose affinity was enhanced in a straightforward manner by 
incorporating interactions within the ZA channel. The direct polar interaction between the 
benzoic acid moiety of these ligands (e.g. compound 45, Figure 24, PDB code 4TQN) and the 
Arg1173 guanidinium is unprecedented and can be exploited for the design of selective ligands 
of the CREBBP bromodomain. In a second step of our in silico design campaign, we hybridized 
the benzoic acid moiety with fragments docked close to the conserved Asn1168 and prioritized 
according to predicted energy of binding to the CREBBP bromodomain, obtaining three novel 
acetylated lysine mimics. The specificity and easy synthetic availability of our compounds will 
be useful to unravel the role of CREBBP in several types of solid tumours and haematological 
malignancies. 
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3.3 Experimental section 
3.3.1 Fragment-based high-throughput docking 
The ALTA (anchor-based library tailoring) procedure was used for fragment-based high-
throughput docking (Figure 26). First the program DAIM139 was employed to decompose the 
nearly two million compounds in the ZINC leads-now library (version of Oct. 2012). The 
conserved Asn1168 of the CREBBP bromodomain (numbering from PDB structure 3SVH) is 
involved in binding the natural ligand acetyl-lysine. To target Asn1168 fragments with at least 
one hydrogen bond donor or acceptor were kept. Further removal of fragments without a ring 
resulted in a library of 106,534 fragments. 
The crystal structures of the CREBBP bromodomain in complex with the natural ligand 
acetyl-lysine (PDB code 3P1C) and the complex with the synthetic inhibitor 3,5-
dimethylisoxazole (3SVH) show different orientation of the side chain of Val1174, the so-called 
gatekeeper residue.156  In addition, the side chain of Arg1173 points towards the solvent and 
seems very mobile. In the 3P1C structure, Arg1173 is located just above the Leu-Pro-Phe 
segment (usually called WPF-shelf as Trp is the first residue in this triad in most 
bromodomains) and acts as a potential hydrogen donor around that region.129 However, in 
3SVH the Arg1173 side chain points in a direction away from the Leu-Pro-Phe segment. Given 
these differences, it was decided to use both structures for docking.     
The library of 106,534 fragments was docked by the program SEED,141 which calculates 
the electrostatic energy in a continuum approximation using an efficient numerical evaluation 
of the Born radii.  The Born radii are a measure of the amount of solute (i.e., low-dielectric 
volume) around each atom of the protein or fragment. They are employed in the generalized 
Born formula for the calculation of the electrostatic contribution to the intermolecular 
interaction and desolvation of the ligand.142, 157  
After fragment docking by the program SEED two additional filters were applied to reduce 
the number of fragments to less than 5,000 for each of the two CREBBP inhibitors: SEED 
total energy efficiency more favorable than -0.125 kcal mol-1 g-1 and hydrogen bonding penalty 
less or equal 1.158  With these filters, 91% (docked to 3SVH) and 82% (docked to 3P1C) of the 
fragments were involved in hydrogen bond(s) with Asn1168 while these percentages were 33% 
(3SVH) and 41% (3P1C) for the entire dataset. 
The top (about 4,000) fragments were used to retrieve the molecules in the ZINC library 
which they originated from (called parent compounds hereafter). There were 808,588 (docking 
in 3SVH) and 754,411 (3P1C) parent compounds in total and for each of them at most 15 
poses were generated by AutoDock Vina.143 All the poses of the parent compounds were then 
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minimized, filtered and rescored. In the end, the 1,000 top-ranked poses according to the SEED 
total energy were clustered based on the functional groups interacting with the conserved 
Asn1168. This clustering yielded only 20 different functional groups. Finally, explicit solvent 
molecular dynamics simulations (started from the docked poses) were used to further reduce 
the number of compounds to 17 representative molecules which were purchased for validation 
in vitro. 
 
Figure 26. Application of the ALTA (anchor-based library tailoring) procedure136, 138 to 
the CREBBP bromodomain. The program DAIM automatically decomposes molecules 
into fragments by cutting at rotatable bonds.139 CHARMM atom types and non-
bonding parameters used in SEED141-142, 157 were generated by MATCH.159 The program 
for fragment docking (called SEED141-142, 157) requires about 5 seconds per fragment on a 
single core of an i7 CPU at 2.8 GHz. CHARMM minimization of the fragment with 
rigid CREBBP took about 2 seconds per fragment.  
3.3.2 Finite-difference Poisson calculations 
The electrostatic contribution to the binding free energy was evaluated by numerical 
solution of the Poisson equation using the finite-difference method as implemented in the 
PBEQ module147 of the program CHARMM.146 The solute/solvent dielectric discontinuity 
surface was delimited by the molecular surface spanned by the surface of a rolling probe of 1.4 
Å. The dielectric constant of the solute and the solvent were set to 2.0 and 78.5, respectively. 
The ionic strength was set to zero, and the temperature was set to 300 K. The size of the 
initial grid was determined by considering a layer of at least 20 Å around the solute.  The 
partial charges of the solute were distributed on the grid points by the trilinear interpolation 
algorithm. First the linearized Poisson equation was solved on a grid of 1.0 Å spacing, which 
was followed by a focused calculation with a grid encompassing all of the solute and a grid 
spacing of 0.3 Å. For both calculations an iterative procedure (successive over-relaxation) was 
used.  All calculations were carried out independently on the crystal structure (PDB code 
4TQN) and the minimized crystal structure.  The latter was obtained by conjugate gradient 
minimization with the CHARMM program (version 38b1), and the CHARMM param36 force 
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field for CREBBP and the CHARMM general force field (which is compatible with CHARMM 
param36) for compound 45.  
3.3.3 Fragment docking  
Fragment docking to the CREBBP and BRD4(1) bromodomain was carried out with 
the in-house developed program SEED. 
 
Table 6. Selected fragments to be coupled to the benzoic acid side chain and their 
binding energy values calculated by SEED.140-141  
  CREBBP   BRD4(1)  
Fragment 
van der 
Waals 
electrostatic total 
 van der 
Waals 
electrostatic total 
I -14.0 -2.3 -16.3  -14.6  0.5 -14.0 
II -18.5 -1.4 -19.9  -17.5 -0.8 -18.3 
III -17.5 -1.9 -19.4  -16.6   2.1 -14.5 
IV -15.3 -4.6 -19.9  -17.7   1.1 -16.5 
V -16.7 -1.4 -18.1  -15.9 1.6 -14.4 
VI -15.3 -3.1 -18.4  -15.8 1.8 -14.1 
VII -15.6 -4.0 -19.6  -15.4 -0.6 -16.1 
The CHARMM36160 and CGenFF161 force fields were used for the protein and 
fragments, respectively. The electrostatic energy is the sum of bromodomain 
desolvation, fragment desolvation, and intermolecular interaction screened by the 
solvent which is treated implicitly by the generalized Born approximation.162. All values 
are in kcal/mol.  
3.3.4 Synthetic methods 
All reactions, unless otherwise stated, were carried out under inert gas atmosphere using 
standard Schlenk-techniques. All reagents were used as received unless otherwise noted. 
Solvents were purchased in the best quality available, degassed by purging thoroughly with 
nitrogen and dried over activated molecular sieves of appropriate size. Alternatively, they were 
purged with argon and passed through alumina columns in a solvent purification system 
(Innovative Technology). Reactions were monitored by thin layer chromatography (TLC) using 
Merck TLC silica gel 60 F254. Flash column chromatography was performed over silica gel (230-
400 mesh). NMR spectra were recorded on AV 300, AV2 400 or AV2 500 MHz Bruker 
spectrometers. Chemical shifts are given in ppm. The spectra are calibrated to the residual 1H 
and 13C signals of the solvents. Multiplicities are abbreviated as follows: singlet (s), doublet (d), 
triplet (t), quartet (q), doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and 
broad (br). Melting points were determined on a Mettler Toledo MP70 melting point 
instrument. High-resolution electrospray ionization mass spectrometry was performed on a 
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Finnigan MAT 900 (Thermo Finnigan, San Jose, CA, USA) double-focusing magnetic sector 
mass spectrometer. Ten spectra were acquired. A mass accuracy ≤2 ppm was obtained in the 
peak matching acquisition mode by using a solution containing 2 µL PEG200, 2 µL PPG450, 
and 1.5 mg NaOAc (all obtained from Sigma-Aldrich, Buchs, Switzerland) dissolved in 100 mL 
MeOH (HPLC Supra grade, Scharlau, E-Barcelona) as internal standard.  
The following compounds were prepared according to previously reported procedures: 
72,163 73,164 75,165 80,166 81,167 82,167 84,168 86,169 88,170 92171 and 93.172   
I. Synthesis of non-commercially available carboxylic acids (37-57)  
 
Dimethyl cyclopropane-1,2-dicarboxylate (72)163  
Colourless oil; Yield: 29 %; 1H NMR (400 MHz, CDCl3): δ = 3.70 (s, 6H), 
2.22 – 2.12 (m, 2H), 1.48 – 1.40 (m, 2H); 13C NMR (100 MHz, CDCl3): δ = 
172.2, 52.1, 22.2, 15.3; IR (neat): ῦ = 2955, 1724, 1437, 1399, 1332, 1270, 1197, 1169, 1026, 
904, 839, 753, 661, 444, 419, 407 cm-1; MS (ESI), m/z: calcd for C7H10NaO4+, 181.1; found, 
180.9. 
 
2-(Methoxycarbonyl)cyclopropane-1-carboxylic acid (73)164  
Colourless oil; Yield: 40 %; 1H NMR (400 MHz, CDCl3): δ = 3.72 (s, 3H), 2.27 
– 2.22 (m, 1H), 2.21 – 2.16 (m, 1H), 1.50 (tdd, J = 9.9, 6.0, 4.0 Hz, 2H); 13C 
NMR (100 MHz, CDCl3): δ = 177.5, 171.8, 52.3, 22.7, 22.0, 15.8; IR (neat): ῦ = 2958, 1704, 
1438, 1309, 1176, 913, 743, 415 cm-1; MS (ESI), m/z: calcd for C6H7O4-, [M-H]-, 143.0; found, 
142.9. 
 
 
3-(1H-Tetrazol-1-yl)benzoic acid (75)165 
White solid;  Yield: 95 %; mp 174-176 °C; 1H NMR (300 MHz, DMSO-d6): δ 
= 13.48 (br, 1H), 10.21 (s, 1H), 8.42 (s, 1H), 8.18 (d, J = 8.0 Hz, 1H), 8.10 (d, 
J = 7.8 Hz, 1H), 7.78 (t, J = 7.9 Hz, 1H); 13C NMR (75 MHz, DMSO-d6): δ = 
166.1, 142.4, 134.0, 132.7, 130.6, 130.2, 125.2, 121.6; IR (neat): ῦ = 3454, 3397, 3137, 2898, 
2788, 2621, 2518, 1704, 1636, 1592, 1500, 1479, 1453, 1289, 1277, 1217, 1195, 1103, 1063, 900, 
816, 758, 707 cm-1; MS (ESI), m/z: calcd for C8H5N4O2-, [M-H]-, 189.0; found, 188.8.  
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3-(N-Phenylsulfamoyl)benzoic acid (80)166 
White solid;  Yield: 93 %; mp 193-195 °C; 1H NMR (400 MHz, DMSO-d6): 
δ = 10.36 (s, 1H), 8.29 (t, J = 1.7 Hz, 1H), 8.12 (d, J = 7.8 Hz, 1H), 7.94 
(d, J = 7.9 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.23 (t, J = 7.9 Hz, 2H), 7.11 
– 7.01 (m, 3H); 13C NMR (101 MHz, DMSO-d6): δ = 165.9, 140.0, 137.3, 133.3, 131.8, 130.6, 
129.9, 129.2, 127.3, 124.5, 120.5; IR (neat): ῦ = 3246, 2980, 2868, 1686, 1598, 1493, 1444, 1408, 
1339, 1294, 1218, 1207, 1173, 1159, 1135, 1075, 1025, 928, 899, 854, 823, 749, 735 cm-1; MS 
(ESI), m/z: calcd for C13H10NO4S-, [M-H]-, 276.0; found, 275.9.  
 
Methyl 3-(phenylsulfonamido)benzoate (81)167  
White solid; Yield: 86 %; mp 161-163 °C; 1H NMR (400 MHz, DMSO-d6): δ 
= 10.55 (s, 1H), 7.76 (d, J = 7.4 Hz, 2H), 7.70 (s, 1H), 7.61 (d, J = 7.0 Hz, 
2H), 7.57 – 7.54 (m, 2H), 7.42 – 7.34 (m, 2H), 3.81 (s, 3H); 13C NMR (126 
MHz, DMSO-d6): δ = 165.6, 139.2, 138.2, 133.1, 130.5, 129.8, 129.4, 126.6, 
124.7, 124.4, 120.3, 52.3; IR (neat): ῦ = 3412, 3227, 3070, 1701, 1605, 1591, 1474, 1446, 1438, 
1401, 1337, 1296, 1216, 1175, 1156, 1122, 1114, 1088, 1000, 984, 948, 901, 853, 752, 714 cm-1; 
MS (ESI), m/z: calcd for C14H13NNaO4S+, 314.1; found, 314.0.  
 
3-(Phenylsulfonamido)benzoic acid (82)167 
Acid 82 was prepared using the reported procedure and used without further 
purification. The presence of the acid was confirmed by IR and MS. IR (neat): 
ῦ = 3250, 3064, 2963, 2825, 1682, 1587, 1447, 1424, 1405, 1333, 1297, 1263, 
1158, 1089, 948, 906, 882, 823, 762, 749, 722 cm-1; MS (ESI), m/z: calcd for 
C13H10NO4S-, [M-H]-, 276.0; found, 276.0.  
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3-Bromo-5-(methoxycarbonyl)benzoic acid (84)168 
Acid 84 was prepared using the reported procedure and used without further 
purification. The presence of the acid was confirmed by IR and MS. IR 
(neat): ῦ = 3079, 2859, 2647, 2522, 1684, 1600, 1574, 1540, 1448, 1391, 1267, 
1199, 1147, 905, 797, 754, 727, 712 cm-1; MS (ESI), m/z: calcd for C9H6BrO4-, [M-H]-, 256.9; 
found, 256.8.  
 
 
Dimethyl 5-(hydroxymethyl)isophthalate (86)169 
White solid; Yield: 47 %; mp 106-108 °C; 1H NMR (400 MHz, CDCl3): δ 
= 8.60 (s, 1H), 8.31 – 8.15 (m, 2H), 4.81 (s, 2H), 3.95 (s, 6H); 13C NMR (101 
MHz, CDCl3): δ = 166.2, 141.9, 132.0, 130.9, 129.8, 64.2, 52.4; IR (neat): ῦ 
= 3490, 2954, 1719, 1603, 1437, 1247, 1183, 1107, 1002, 969, 921, 888, 788, 749, 719 cm-1; MS 
(ESI), m/z: calcd for C11H12NaO5+, 247.1; found, 246.9.  
 
Dimethyl 5-(methoxymethyl)isophthalate (87) 
To a solution of dimethyl 5-(hydroxymethyl)isophthalate (86, 150 mg, 0.669 
mmol) in DMF (1.50 mL) NaH (53.5 mg, 1.34 mmol) was added and stirred 
at 25 °C for 30 minutes. Methyl iodide (83.3 µL, 1.34 mmol) was added and 
the reaction mixture was stirred for 3 hours at 25 °C. The reaction was 
quenched by addition of 1 M HCl solution and extracted with EtOAc three times. The 
combined organic phases were dried over MgSO4 and concentrated under reduced pressure. The 
residue was then purified by flash column chromatography (hexane: EtOAc, 3:1) affording the 
desired product in pure form as a white solid (133 mg, 0.558 mmol,  83 % yield). mp 83-85 °C; 
1H NMR (500 MHz, CDCl3): δ = 8.60 (s, 1H), 8.28 – 8.13 (m, 2H), 4.54 (s, 2H), 3.95 (s, 6H), 
3.42 (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 166.2, 139.4, 132.8 130.8, 130.0, 73.6, 58.5, 52.4; 
IR (neat): ῦ = 3490, 2954, 1719, 1603, 1437, 1247, 1183, 1107, 1002, 969, 921, 888, 788, 749, 
719 cm-1; MS (ESI), m/z: calcd for C12H14NaO5+, 261.1; found, 261.0.  
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Dimethyl 5-((tetrahydro-2H-pyran-2-yl)methyl)isophthalate (88)170  
White solid; Yield: 87 %; mp 45-48 °C; 1H NMR (400 MHz, CDCl3): δ = 
8.59 (t, J = 1.6 Hz, 1H), 8.25 – 8.19 (m, 2H), 4.85 (dd, J = 12.4, 0.4 Hz, 
1H), 4.73 (t, J = 3.5 Hz, 1H), 4.57 (d, J = 12.4 Hz, 1H), 3.94 (s, 6H), 3.93 – 
3.85 (m, 1H), 3.60 – 3.51 (m, 1H), 1.93 – 1.81 (m, 1H), 1.81 – 1.51 (m, 5H); 13C NMR (101 
MHz, CDCl3): δ = 166.2, 139.5, 132.9, 130.7, 129.8, 98.2, 67.9, 62.2, 52.3, 30.4, 25.4, 19.2; IR 
(neat): ῦ = 2952, 2927, 2882, 2846, 1719, 1603, 1453, 1434, 1331, 1318, 1242, 1214, 1203, 1108, 
1055, 1015, 965, 911, 869, 811, 751, 720, 712 cm-1; MS (ESI), m/z: calcd for C16H20NaO6+, 331.1; 
found, 331.1.  
 
3-(Methoxycarbonyl)-5-(methoxymethyl)benzoic acid (89)173  
Acid 89 was prepared using the reported procedure and used without further 
purification. The presence of the acid was confirmed by IR and MS. IR 
(neat): ῦ = 2918, 2861, 2824, 2626, 1694, 1605, 1458, 1440, 1417, 1314, 1263, 
1209, 1115, 1103, 1003, 968, 922, 751, 704 cm-1; MS (ESI), m/z: calcd for 
C11H11O5-, [M-H]-, 223.1; found, 222.9. 
 
3-(Methoxycarbonyl)-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)benzoic acid (90)  
To a solution of dimethyl 5-((tetrahydro-2H-pyran-2-yl)methyl)isophthalate 
(88, 150 mg, 0.486 mmol) 1M NaOH solution (0.486 mL, 0.486 mmol) was 
added and stirred at 25 °C for 12 hours. The pH of the reaction mixture was 
then adjusted to 3-4 by adding 10 % citric acid solution and extracted with EtOAc three times 
and brine. The combined organic phases were dried over MgSO4 and concentrated under 
reduced pressure. The residue was then purified by flash column chromatography (5 % MeOH 
in DCM) affording the desired product in pure form as a white solid (102 mg, 0.347 mmol, 72 
%). mp 87-93 °C; 1H NMR (400 MHz, CDCl3): δ = 10.92 (br, 1H), 10.92 (s, 1H), 8.30 (s, 1H), 
8.28 (s, 1H), 4.88 (d, J = 12.5 Hz, 1H), 4.76 (t, J = 3.3 Hz, 1H), 4.60 (d, J = 12.5 Hz, 1H), 
3.95 (s, 3H), 3.94 – 3.87 (m, 1H), 3.63 – 3.53 (m, 1H), 1.88 (dt, J = 13.0, 4.3 Hz, 1H), 1.83 – 
1.49 (m, 5H); 13C NMR (101 MHz, CDCl3): δ = 170.7, 166.1, 139.7, 133.7, 133.4, 130.9, 130.5, 
130.0, 98.2, 67.9, 62.2, 52.4, 30.4, 25.3, 19.2; IR (neat): ῦ = 2943, 2873, 1727, 1687, 1606, 1458, 
1436, 1421, 1354, 1310, 1252, 1202, 1121, 1072, 1034, 1017, 975, 942, 912, 869, 814, 752, 703 cm-
1; HRMS (ESI), m/z: calcd for C15H18NaO6+, 317.0996; found, 317.0994.  
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Methyl 5-acetyl-2ethoxybenzoate (92)171 
White solid; Yield: 88 %; mp 50-53 °C;  1H NMR (400 MHz, CDCl3): δ = 8.38 (t, 
J = 2.2 Hz, 1H), 8.08 (dd, J = 8.8, 2.4 Hz, 1H), 7.00 (d, J = 8.8 Hz, 1H), 4.20 (q, 
J = 7.0 Hz, 2H), 3.91 (s, 3H), 2.57 (d, J = 2.0 Hz, 3H), 1.49 (t, J = 7.0 Hz, 3H); 
13C NMR (101 MHz, CDCl3): δ = 196.1, 166.0, 162.0, 133.6, 132.6, 129.4, 120.1, 
112.6, 64.9, 52.1, 26.3, 14.5; IR (neat): ῦ = 2986, 2947, 1697, 1676, 1597, 1496, 1468, 1439, 
1352, 1266, 1249, 1233, 1164, 1110, 1101, 1074, 1036, 958, 929, 859, 841, 816, 786, 718 cm-1; MS 
(ESI), m/z: calcd for C12H14NaO4+, 245.1; found, 244.9.  
 
5-Acetyl-2-ethoxybenzoic acid (93)172 
Pale yellow solid; Yield: 77 %; mp 118-121 °C;  1H NMR (400 MHz, MeOD): δ = 
8.39 (d, J = 2.4 Hz, 1H), 8.13 (dd, J = 8.8, 2.4 Hz, 1H), 7.18 (d, J = 8.8 Hz, 1H), 
4.24 (q, J = 7.0 Hz, 2H), 2.57 (s, 3H), 1.46 (t, J = 7.0 Hz, 3H); 13C NMR (101 
MHz, CDCl3): δ = 198.5, 169.0, 163.3, 135.1, 133.4, 130.6, 121.9, 114.0, 66.2, 26.4, 
14.8; IR (neat): ῦ = 2989, 2938, 2810, 2615, 1681, 1666, 1598, 1497, 1403, 1354, 1293, 1263, 
1224, 1167, 1110, 1076, 1027, 968, 928, 806 cm-1; MS (ESI), m/z: calcd for C11H11NaO4+, 230.1; 
found, 230.9.  
II. Synthesis of non-commercially available anilines (102-108) 
 
General procedure for ether synthesis (95-98) 
To a solution of 1-(4-hydroxy-3-nitrophenyl)ethan-1-one (94, 1.0 eq) in DMF (0.30 M), the 
alkyl iodide (1.2 eq) and K2CO3 (4.0 eq) were added. The reaction mixture was stirred at 80 ºC 
for 12 h. A saturated solution of NH4Cl was added and it was extracted with Et2O three times. 
The combined organic phases were dried over MgSO4 and concentrated under reduced pressure. 
The obtained residue was purified by flash column chromatography (2:1, hexane:EtOAc) 
affording the desired products in pure form.  In the case of alkyl chlorides (products 96 and 
97), the alkyl chloride (2.0 eq) was first stirred in DMF (0.30 M) in the presence of NaI (2.0 
eq) for 30 min. The phenol (1.0 eq) and K2CO3 (4.0 eq) were then added and the same 
procedure as the one described above was followed.  
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1-(3-Nitro-4-propoxyphenyl)ethan-1-one (95) 
White solid; Yield: 84 %; mp 57-60 °C; 1H NMR (400 MHz, CDCl3): δ = 8.40 (d, J 
= 2.1 Hz, 1H), 8.13 (dd, J = 8.8, 2.2 Hz, 1H), 7.12 (d, J = 8.8 Hz, 1H), 4.15 (t, J = 
6.4 Hz, 2H), 2.59 (s, 3H), 2.17 – 1.53 (m, 2H), 1.08 (t, J = 7.4 Hz, 3H); 13C NMR 
(101 MHz, CDCl3): δ = 194.8, 155.8, 139.5, 133.8, 129.3, 126.1, 114.0, 71.6, 26.3, 
22.2, 10.3; IR (neat): ῦ = 2981, 2972, 2927, 2884, 1666, 1608, 1524, 1499, 1462, 
1399, 1356, 1282, 1258, 1156, 1077, 1056, 965, 907, 899, 828, 774 cm-1; HRMS (ESI), m/z: calcd 
for C11H14NO4+, 224.0917; found, 224.0918.  
 
1-(4-Isobutoxy-3-nitrophenyl)ethan-1-one (96) 
Pale yellow solid; Yield: 90 %; mp 61-63 °C; 1H NMR (500 MHz, CDCl3): δ = 
8.41 (d, J = 2.2 Hz, 1H), 8.13 (dd, J = 8.8, 2.2 Hz, 1H), 7.11 (d, J = 8.8 Hz, 
1H), 3.94 (d, J = 6.4 Hz, 2H), 2.59 (s, 3H), 2.17 (dp, J = 13.3, 6.6 Hz, 1H), 1.07 
(s, 3H), 1.06 (s, 3H); 13C NMR (125 MHz, CDCl3): δ = 194.8, 155.9, 139.3, 133.8, 
129.2, 126.2, 113.9, 76.1, 28.2, 26.3, 19.0; IR (neat): ῦ = 2966, 2876, 1677, 1609, 1568, 1531, 
1470, 1419, 1355, 1273, 1235, 1166, 1066, 1004, 988, 976, 957, 910, 824, 815, 762, 739 cm-1; 
HRMS (ESI), m/z: calcd for C12H16NO4+, 238.1074; found, 238.1077.  
 
1-(4-(Cyclopropylmethoxy)-3-nitrophenyl)ethan-1-one (97) 
Yellow solid; Yield: 73 %; mp 74-77 °C;  1H NMR (400 MHz, CDCl3): δ = 8.40 
(d, J = 2.2 Hz, 1H), 8.12 (dd, J = 8.8, 2.2 Hz, 1H), 7.11 (d, J = 8.8 Hz, 1H), 
4.06 (d, J = 6.8 Hz, 2H), 2.59 (s, 3H), 1.39 – 1.25 (m, 1H), 0.73 – 0.66 (m, 2H), 
0.45 – 0.39 (m, 2H); 13C NMR (101 MHz, CDCl3): δ = 194.8, 155.7, 139.6, 133.7, 
129.4, 126.1, 114.3, 74.6, 26.3, 9.8, 3.4; IR (neat): ῦ = 3275, 3092, 3011, 1673, 1607, 1566, 1527, 
1497, 1412, 1360, 1271, 1171, 1066, 1024, 977, 911, 886, 835, 826, 809 cm-1; HRMS (ESI), m/z: 
calcd for C12H14NO4+, 236.0917; found, 236.0918.  
 
1-(4-(Benzyloxy)-3-nitrophenyl)ethan-1-one (98)  
Pale yellow solid; Yield: 90 %; mp 132-135 °C; 1H NMR (400 MHz, CDCl3): δ 
= 8.42 (d, J = 2.2 Hz, 1H), 8.11 (dd, J = 8.8, 2.2 Hz, 1H), 7.45-7.32 (m, 5H), 
7.18 (d, J = 8.8 Hz, 1H), 5.31 (s, 2H), 2.58 (s, 3H); 13C NMR (101 MHz, 
CDCl3): δ = 194.7, 155.1, 139.7, 134.7, 133.7, 129.8, 128.8, 128.5, 126.9, 126.1, 
114.6, 71.4, 26.3; IR (neat): ῦ = 2923, 1679, 1611, 1569, 1531, 1493, 1417, 1346, 1267, 1237, 
1178, 1066, 1018, 979, 911, 890, 828, 732 cm-1; HRMS (ESI), m/z: calcd for C15H14NO4+, 
272.0917; found, 272.0917.  
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General procedure for the reduction of nitro phenyls (102-108) 
To a mixture of nitrophenyl (1 eq) in EtOH (0.3 M) SnCl2. 2H2O (4 eq) was added. The 
reaction mixture was heated to 80 °C for 2-5 h, cooled, and concentrated under reduced 
pressure. The pH was basified to pH 5 by the addition of a 5 M NaOH solution. The resulting 
precipitate was filtered off and washed with EtOAc. The organic layer was washed with brine, 
dried over MgSO4, filtered, and concentrated under reduced pressure. The obtained residue was 
purified by flash column chromatography (hex: EtOAc, 3:1-1:1) affording the desired anilines in 
pure form.  
 
1-(3-Amino-4-propoxyphenyl)ethan-1-one (102) 
Brown solid;  Yield: 40%; mp 53-55 °C; 1H NMR (400 MHz, CDCl3): δ = 7.40 – 
7.37 (m, 2H), 6.79 (d, J = 8.1 Hz, 1H), 4.03 (t, J = 6.5 Hz, 2H), 2.52 (s, 3H), 1.98 
– 1.78 (m, 2H), 1.07 (t, J = 7.4 Hz, 3H); 13C NMR (101 MHz, CDCl3): δ = 197.2, 
150.9, 135.8, 130.5, 120.8, 114.3, 110.1, 70.0, 26.3, 22.5, 10.5; IR (neat): ῦ = 3485, 
3369, 2961, 2934, 2877, 1671, 1615, 1580, 1513, 1474, 1439, 1350, 1295, 1253, 1219, 
1148, 1063, 1039, 1013, 977, 916, 886, 787, 770 cm-1; HRMS (ESI), m/z: calcd for C11H16NO2+, 
194.1176; found, 194.1179.  
 
1-(3-Amino-4-isobutoxyphenyl)ethan-1-one (103)  
Brown-red oil;  Yield: 53 %; 1H NMR (400 MHz, CDCl3): δ = 7.37 – 7.34 (m, 
3H), 6.77 (d, J = 8.3 Hz, 1H), 3.90 (br, 2H), 3.82 (d, J = 6.5 Hz, 1H), 2.52 (s, 
3H), 2.15 (dp, J = 13.3, 6.7 Hz, 1H), 1.06 (s, 3H), 1.05 (s, 3H); 13C NMR (101 
MHz, CDCl3): δ = 197.3, 150.7, 136.2, 130.5, 120.4, 113.9, 110.0, 74.7, 28.2, 26.2, 
19.2; IR (neat): ῦ = 3472, 3363, 2959, 2928, 2873, 1667, 1613, 1583, 1513, 1470, 1440, 1359, 
1296, 1210, 1153, 1064, 1022, 880, 795 cm-1; HRMS (ESI), m/z: calcd for C12H18NO2+, 208.1332; 
found, 208.1334.  
 
1-(3-Amino-4-(cyclopropylmethoxy)phenyl)ethan-1-one (104)  
Brown solid;  Yield: 61 %; mp 44-46 °C; 1H NMR (400 MHz, CDCl3): δ = 7.36 – 
7.34 (m, 2H), 6.74 (d, J = 8.9 Hz, 1H), 3.94 (br, 2H), 3.90 (d, J = 6.9 Hz, 2H), 
2.52 (s, 3H), 1.34 – 1.25 (m, 1H), 0.72 – 0.56 (m, 2H), 0.40 – 0.32 (m, 2H); 13C 
NMR (101 MHz, CDCl3): δ = 197.3, 150.7, 136.3, 130.6, 120.4, 114.0, 110.2, 
73.2, 26.3, 10.2, 3.2; IR (neat): ῦ = 3471, 3359, 3082, 2995, 2925, 1659, 1614, 1582, 1512, 1444, 
1409, 1351, 1299, 1250, 1216, 1153, 1058, 1020, 1002, 979, 941, 877, 837, 794 cm-1; HRMS 
(ESI), m/z: calcd for C12H16NO2+, 206.1176; found, 206.1175.  
 
 
 
CHAPTER 3: BROMODOMAIN LIGANDS 
126 
 
1-(3-Amino-4-(benzyloxy)phenyl)ethan-1-one (105)  
Yellow solid;  Yield: 53 %; mp 119-122 °C; 1H NMR (400 MHz, CDCl3): δ = 
7.44 – 7.34 (m, 7H), 6.87 (d, J = 9.0 Hz, 1H), 5.16 (s, 2H), 3.93 (br, 2H), 2.52 
(s, 3H); 13C NMR (101 MHz, CDCl3): δ = 197.2, 150.3, 136.4, 136.3, 130.9, 
128.7, 128.3, 127.5, 120.3, 114.1, 110.7, 70.5, 26.3; IR (neat): ῦ = 3457, 3355, 
2997, 2921, 1659, 1614, 1580, 1510, 1444, 1386, 1358, 1301, 1248, 1211, 1160, 1065, 1023, 997, 
981, 927, 891, 857, 792, 749, 705 cm-1; HRMS (ESI), m/z: calcd for C15H16NO2+, 242.1176; 
found, 242.1176.  
 
1-(3-Amino-4-methyoxyphenyl)ethan-1-one (106)  
Light yellow solid;  Yield: 48 %; mp 96-99 °C; 1H NMR (400 MHz, CDCl3): δ = 7.40 
(dd, J = 8.4, 2.2 Hz, 1H), 7.36 (d, J = 2.1 Hz, 1H), 6.81 (d, J = 8.3 Hz, 1H), 3.92 
(s, 3H), 2.53 (s, 3H); 13C NMR (75 MHz, CDCl3): δ = 197.3, 151.3, 136.1, 130.7, 
120.5, 114.0, 109.2, 55.6, 26.2; IR (neat): ῦ = 3454, 3370, 2935, 1667, 1584, 1514, 
1440, 1298, 1219, 905, 729, 648, 406 cm-1; MS (ESI), m/z: calcd for C9H11NNaO2+, 188.1; found, 
187.9.  
 
1-(3-Amino-4-methylphenyl)ethan-1-one (107)  
Light brown solid;  Yield: 79 %; mp 77-78 °C; 1H NMR (400 MHz, CDCl3): δ = 7.30 
(d, J = 1.6 Hz, 1H), 7.28 (s, 1H), 7.12 (d, J = 7.5 Hz, 1H), 3.77 (br, 2H), 2.54 (s, 
3H), 2.22 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 198.2, 144.8, 136.3 130.4, 128.0, 
119.0, 113.8, 26.5, 17.5; IR (neat): ῦ = 3433, 3347, 3229, 1664, 1633, 1602, 1567, 1417, 1357, 
1303, 1287, 1237, 1199, 1141, 955, 856, 834 cm-1; MS (ESI), m/z: calcd for C9H12NO+, 150.1; 
found, 149.9.  
 
1-(3-Amino-4-fluorophenyl)ethan-1-one (108)  
White solid; Yield: 69 %; mp 65-68 °C; 1H NMR (300 MHz, CDCl3): δ= 7.41 (dd, 
J = 8.7, 2.2 Hz, 1H) 7.31 (ddd, J = 8.4, 4.6, 2.2 Hz, 1H), 7.03 (dd, J = 10.6, 8.4 
Hz, 1H), 3.68 (br, 2H), 2.54 (s, 3H). 13C NMR (126 MHz, CDCl3): δ = 191.0, 154.5 
(d, J = 247.7 Hz), 134.8 (d, J = 13.1 Hz), 134.0 (d, J = 3.1 Hz), 119.7 (d, J = 7.9 
Hz), 116.5 (d, J = 5.3 Hz), 115.1 (d, J = 19.7 Hz), 26.4; 19F NMR (376 MHz, CDCl3): δ =  -
127.87; IR (neat): ῦ = 3396, 3325, 3217, 1665, 1607, 1589, 1510, 1422, 1309, 1282, 1244, 1196, 
1137, 1099, 1060, 964, 878, 802, 713 cm-1; MS (ESI), m/z: calcd for C8H8FNNaO+, 176.2; found, 
178.8.  
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1-(3-Amino-4-morpholinophenyl)ethan-1-one (110) 
A solution of 1-(4-Bromo-3-nitrophenyl)ethanone (109, 500 mg, 2.05 mmol) in 
isopropanol (5.00 mL) was heated at 110 ºC for 3 h. SnCl2.2H2O (1.80 g, 7.98 mmol) 
was then added and heated at 110 ºC for 5 h.  The reaction mixture was 
concentrated under reduced pressure and the pH was basified to pH 5 by the 
addition of a 5 M NaOH solution. The resulting precipitate was filtered off and 
washed with EtOAc. The organic layer was washed with brine, dried over MgSO4, filtered, and 
concentrated under reduced pressure. The obtained residue was purified by flash column 
chromatography (hex: EtOAc, 1:1) affording the desired aniline in pure form as a brown solid 
(145 mg, 0.579 mmol, 32 % yield over two steps). mp 141-144 °C; 1H NMR (500 MHz, CDCl3): 
δ = 7.37 (dd, J = 8.2, 1.7 Hz, 1H), 7.34 (d, J = 1.6 Hz, 1H), 6.99 (d, J = 8.1 Hz, 1H), 4.05 
(br, 2H), 3.88 – 3.84 (m, 4H), 3.01 – 2.96 (m, 4H), 2.53 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
= 197.7, 143.4, 141.0, 133.4, 120.0, 118.7, 114.5, 67.3, 50.7, 26.5; IR (neat): ῦ = 3380, 3311, 
2962, 2924, 2824, 1671, 1627, 1591, 1566, 1505, 1445, 1424, 1370, 1363, 1301, 1288, 1255, 1213, 
1205, 1106, 1065, 1041, 966, 941, 920, 902, 861, 845, 821, 728 cm-1; HRMS (ESI), m/z: calcd for 
C12H17N2O2+, 221.1285; found, 221.1283.  
 
3-Amino-4-ethoxy-N-methylbenzamide (112)  
To a solution of 3-amino-4-ethoxybenzoic acid (111, 100 mg, 0.552 mmol) in DMF 
(1.80 mL), methylamine hydrochloride (150 mg, 2.22 mmol), HOBt (89.4 mg, 0.662 
mmol), EDC.HCl (1.104 mmol, 212 mg) and DIPEA (385 µL, 2.21 mmol) were 
added. The solution was stirred at 55 °C for 12 h, it was concentrated and purified 
by flash column chromatography (5 % MeOH in DCM) affording the desired amide 
as a white solid in pure form (75.0 mg, 0.384 mmol, 70 % yield). mp 142-145 °C; 1H NMR (400 
MHz, CDCl3): δ = 7.18 (d, J = 2.2 Hz, 1H), 7.06 (dd, J = 8.3, 2.2 Hz, 1H), 6.75 (d, J = 8.3 
Hz, 1H), 5.98 (br, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.90 (br, 2H), 2.98 (d, J = 4.9 Hz, 3H), 1.45 
(t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 168.2, 149.0, 136.3, 127.3, 117.0, 113.6, 
110.4, 63.9, 26.7, 14.8; R (neat): ῦ = 3461, 3361, 3282, 2985, 2930, 1610, 1593, 1577, 1550, 
1508, 1473, 1390, 1314, 1282, 1223, 1146, 1112, 1040, 886, 823, 777 cm-1; HRMS (ESI), m/z: 
calcd for C10H15N2O2+, 195.1128; found, 195.1129.  
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III. Amide coupling reactions 
General procedure A for amide formation  
The desired aniline (1.0 eq) and carboxylic acid (1.2 or 1.3 eq) were dissolved in DMF 
(0.10 M) and EDC.HCl (1.5-2.0 eq), DIPEA (1.5 eq) and HOBt (1.5-2 eq) were added at 25 
ºC. In the case of 46, 55, 115, 116, 120, 132 and 133, EDC (1.5-2.0 eq) and no DIPEA was 
used. The reaction mixture was stirred for 12-48 h at 25 ºC, it was concentrated and 
redissolved in EtOAc. The organic phase was extracted with saturated NaHCO3 solution, 1M 
HCl and brine. The combined organic phases were dried over MgSO4 and concentrated under 
reduced pressure. The obtained residue was purified by flash column chromatography (using 
1:1 hex: EtOAc, EtOAc or 2:1 EtOAc:hex as eluent), affording the desired amides in pure form. 
This method was used to obtain 46, 54-56, 115, 116, 118, 120, 129 and 131-134. 
 
General procedure B for amide formation  
To a solution of the carboxylic acid (1.0 eq) in toluene (1.0 M) thionyl chloride (2.0 eq) 
and one drop of DMF were added. The solution was refluxed for 3 h, concentrated and 
dissolved in DCM (0.50 M). The corresponding aniline (1.2 eq) was added and the reaction 
mixture was stirred at 25 °C for 12h. The reaction mixture was concentrated and purified by 
flash column chromatography (hex:EtOAc, 2:1) obtaining the desired amides in pure form. 
This method was used to obtain intermediates 123-128 and 133. 
Synthesis of fumaric acid derivatives 
 
Methyl (E)-4-((5-acetyl-2-methoxyphenyl)amino)-4-oxobut-2-enoate (115)  
White solid;  Yield: 35 %; mp 191-194 °C; 1H NMR (300 MHz, CDCl3): δ 
= 9.11 (d, J = 1.8 Hz, 1H), 8.05 (s, 1H), 7.81 (dd, J = 8.6, 2.2 Hz, 1H), 
7.14 – 6.91 (m, 3H), 3.99 (s, 3H), 3.84 (s, 3H), 2.60 (s, 3H); 13C NMR (126 
MHz, CDCl3): δ = 197.0, 165.8, 161.4, 151.5, 136.6, 131.2, 130.6, 126.8, 
125.4, 120.7, 109.7, 56.2, 52.3, 26.5; IR (neat): ῦ = 3379, 2959, 1718, 1686, 1676, 1645, 1591, 
1537, 1493, 1423, 1366, 1312, 1298, 1271, 1257, 1159, 1130, 1021, 976, 885, 824, 801, 763 cm-1; 
HRMS (ESI), m/z: calcd for C14H16NO5+, 278.1023; found, 278.1022.   
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Methyl (E)-4-((5-acetyl-2-methylphenyl)amino)-4-oxobut-2-enoate (116)  
White solid;  Yield: 57%; mp 130-133 °C; 1H NMR (300 MHz, CDCl3): δ = 
8.64 (s, 1H), 8.45 (s, 1H), 8.01 (d, J = 7.7 Hz, 1H), 7.63 – 7.49 (m, 2H), 
7.35 – 7.15 (m, 1H), 4.14 (s, 3H), 2.88 (s, 3H), 2.88 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ = 197.1, 165.4, 161.7, 137.6, 137.0, 135.9, 135.1, 130.8, 
129.3, 125.4, 123.8, 52.1, 26.6, 18.0; IR (neat): ῦ = 3353, 2954, 1715, 1685, 1670, 1652, 1605, 
1529, 1499, 1439, 1355, 1316, 1274, 1226, 1201, 1161, 1139, 1016, 1003, 985, 822, 795, 768 cm-1; 
HRMS (ESI), m/z: calcd for C14H16NO4+, 262.1074; found, 262.1072.  
 
Methyl (E)-4-((5-acetyl-2-fluorophenyl)amino)-4-oxobut-2-enoate (117) 
To a solution of mono methyl fumarate (113, 127 mg, 0.980 mmol) at 0 °C 
in DCM (1.00 mL) oxalyl chloride (84.1 µL, 0.980 mmol) and one drop of  
DMF were added. The solution was stirred at 0 ºC for 20 min and at 25 °C 
for 30 min. The aniline, 1-(3-amino-4-fluorophenyl)ethan-1-one (72, 50.0 
mg, 0.327 mmol),  was slowly added at 0 ºC, followed by Et3N (209 µL, 1.50 mmol) and 
DMAP (12.0 mg, 0.0980 mmol). The reaction mixture was stirred at 25 ºC for 12 h, it was 
quenched with a saturated solution of NH4Cl and extracted with EtOAc three times. The 
combined organic layers were dried over MgSO4 and concentrated under reduced pressure. The 
obtained residue was purified by flash column chromatography (1:1 hex: EtOAc) affording the 
desired amide in pure form as a white solid (37.0 mg, 0.140 mmol, 43 % yield). mp 176-179 °C; 
1H NMR (400 MHz, CDCl3): δ = 9.06 (d, J = 6.7 Hz, 1H), 7.79 (ddd, J = 8.5, 5.1, 2.2 Hz, 2H), 
7.21 (dd, J = 10.3, 8.7 Hz, 1H), 7.13 (d, J = 15.3 Hz, 1H), 7.00 (d, J = 15.3 Hz, 1H), 3.85 (s, 
3H), 2.62 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 196.5, 165.6, 161.6, 135.7, 134.1 (d, J = 
3.2 Hz), 132.1,  126.0 (d, J = 10.8 Hz), 125.6 (d, J = 8.2 Hz), 122.6, 115.4, 115.2, 52.42, 26.63; 
IR (neat): ῦ = 3354, 2963, 2924, 1715, 1686, 1650, 1614, 1600, 1540, 1487, 1441, 1418, 1357, 
1320, 1293, 1261, 1215, 1183, 1153, 1113, 974, 877, 818, 766 cm-1; HRMS (ESI), m/z: calcd for 
C13H13FNO4+, 266.0823; found, 266.0823.  
 
Methyl (E)-4-((3-acetylphenyl)amino)-4-oxobut-2-enoate (118)  
White solid;  Yield: 50 %; mp 177-178 °C; 1H NMR (400 MHz, CDCl3): δ = 
8.64 (s, 1H), 8.21 (d, J = 7.5 Hz, 1H), 8.14 (s, 1H), 7.75 (d, J = 7.7 Hz, 
1H), 7.49 (t, J = 7.9 Hz, 1H), 7.28 (d, J = 14.3 Hz, 1H), 7.01 (d, J = 15.3 
Hz, 1H), 3.87 (s, 3H), 2.67 (s, 3H); 13C NMR (125 MHz, CDCl3): δ = 198.4, 
166.2, 161.8, 138.4, 137.6, 136.9, 131.2, 129.6, 125.0, 124.7, 119.2, 52.5, 26.7; IR (neat): ῦ = 
3332, 1723, 1687, 1673, 1607, 1551, 1485, 1440, 1360, 1334, 1299, 1275, 1223, 1204, 1154, 1003, 
973, 898, 878, 811, 711 cm-1; HRMS (ESI), m/z: calcd for C13H14NO4+, 248.0917; found, 
248.09144.  
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Methyl 2-((5-acetyl-2-ethoxyphenyl)carbamoyl)cyclopropane-1-carboxylate (120)  
White solid;  Yield: 55 %; mp 166-168 °C; 1H NMR (400 MHz, CDCl3): δ = 
8.99 (s, 1H), 8.05 (s, 1H), 7.74 (dd, J = 8.6, 2.1 Hz, 1H), 6.92 (d, J = 8.7 Hz, 
1H), 4.21 (q, J = 7.0 Hz, 2H), 3.74 (s, 3H), 2.56 (s, 3H), 2.35 – 2.26 (m, 1H), 
2.20 – 2.11 (m, 1H), 1.63 – 1.57 (m, 1H), 1.52 (t, J = 7.0 Hz, 3H), 1.49 – 1.44 
(m, 1H); 13C NMR (100 MHz, CDCl3): δ = 197.0, 173.0, 168.4, 150.5, 130.4, 
127.2, 124.6, 120.4, 110.4, 64.7, 52.2, 26.5, 25.5, 22.0, 15.5, 14.7; IR (neat): ῦ = 3289, 2986, 
2951, 2925, 1723, 1682, 1653, 1601, 1586, 1544, 1500, 1423, 1362, 1344, 1277, 1231, 1203, 1172, 
1131, 1039, 956, 925, 875, 815,   cm-1; HRMS (ESI), m/z: calcd for C16H19NNaO5+, 328.1155; 
found, 328.1152.  
Synthesis of benzoic acid derivatives. Scope on the acyl benzene 
 
Methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)benzoate (46)  
White solid;  Yield: 80%; mp 137-140 °C; 1H NMR (400 MHz, DMSO-
d6): δ = 9.14 (d, J = 2.2 Hz, 1H), 8.65 (s, 1H), 8.53 (t, J = 1.5 Hz, 1H), 
8.28 – 8.18 (m, 1H), 8.12 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.77 (dd, J = 
8.6, 2.2 Hz, 1H), 7.60 (td, J = 7.8, 0.5 Hz, 1H), 6.96 (d, J = 8.6 Hz, 1H) 
4.24 (q, J = 7.0 Hz, 2H), 3.96 (s, 3H), 2.60 (s, 3H), 1.54 (t, J = 7.0 Hz, 3H);13C NMR (100 
MHz, CDCl3): δ = 197.0, 166.1, 164.1, 151.1, 135.1, 132.8, 131.5, 130.8, 130.4, 129.2, 127.7, 
127.2, 124.9, 120.5, 110.4, 64.8, 52.4, 26.5, 14.7; IR (neat): ῦ = 3430, 2979, 2954, 1720, 1678, 
1590, 1537, 1468, 1433, 1294, 1261, 1228, 1205, 1145, 1033, 988, 907, 797, 728 cm-1; HRMS 
(ESI), m/z: calcd for C19H20NO5+, 342.1336; found, 342.1331.  
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Methyl 3-((5-acetyl-2-bromophenyl)carbamoyl)benzoate (123) 
White solid;  Yield: 60 %; mp 133-135 °C; 1H NMR (400 MHz, CDCl3): δ 
= 9.14 (d, J = 1.9 Hz, 1H), 8.61 (s, 1H), 8.54 (br, 1H), 8.28 (dd, J = 7.8, 
1.3 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 7.75 – 7.60 (m, 3H), 3.98 (s, 3H), 
3.98 (s, 3H); 13C NMR (100 MHz, CDCl3): δ = 197.1, 166.0, 164.5, 137.4, 
135.9, 134.5, 133.3, 132.7, 131.6, 131.1, 129.4, 128.0, 124.7, 123.0, 119.0, 52.5, 26.7; IR (neat): ῦ 
= 3242, 2923, 2853, 1726, 1691, 1649, 1572, 1524, 1436, 1414, 1315, 1295, 1245, 1213, 1092, 
1083, 1027, 932, 817, 732, 724, 706 cm-1; HRMS (ESI), m/z: calcd for C17H14BrNNaO4+, 
397.9998; found, 397.9996.  
 
Methyl 3-((5-acetyl-2-propoxyphenyl)carbamoyl)benzoate (124)  
White solid; Yield: 40 %; mp 132-135 °C; 1H NMR (400 MHz, CDCl3): 
δ = 9.18 (d, J = 2.1 Hz, 1H), 8.69 (s, 1H), 8.54 (t, J = 1.5 Hz, 1H), 
8.28 – 8.21 (m, 1H), 8.15 (ddd, J = 7.8, 1.9, 1.2 Hz, 1H), 7.80 (dd, J = 
8.6, 2.2 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 
4.15 (t, J = 6.5 Hz, 2H), 3.97 (s, 3H), 2.63 (s, 3H), 2.03 – 1.87 (m, 2H), 
1.14 (t, J = 7.4 Hz, 3H); 13C NMR (126 MHz, CDCl3): 197.2, 166.1, 164.1, 151.2, 135.1, 132.9, 
131.7, 130.9, 130.5, 129.3, 127.6, 127.3, 124.9, 120.5, 110.5, 70.6, 52.4, 26.6, 22.5, 10.5; IR 
(neat): ῦ = 3321, 2970, 2923, 1726, 1681, 1655, 1602, 1585, 1537, 1498, 1461, 1422, 1361, 1331, 
1300, 1272, 1202, 1137, 1096, 1074, 975, 887, 805, 728, 719 cm-1;HRMS (ESI), m/z: calcd for 
C20H22NO5+, 356.1493; found, 356.1493.  
 
Methyl 3-((5-acetyl-2-isobutoxyphenyl)carbamoyl)benzoate (125)  
Beige solid;  Yield: 89 %; mp 116-119 °C; 1H NMR (400 MHz, CDCl3): 
δ = 9.19 (d, J = 2.1 Hz, 1H), 8.71 (s, 1H), 8.54 (d, J = 1.6 Hz, 1H), 
8.29 – 8.21 (m, 1H), 8.19 – 8.12 (m, 1H), 7.79 (dd, J = 8.6, 2.2 Hz, 
1H), 7.62 (t, J = 7.8 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 3.94 – 3.96 (m, 
5H), 2.62 (s, 3H), 2.24 (dp, J = 13.3, 6.7 Hz, 1H), 1.13 (d, J = 6.7 Hz, 
6H); 13C NMR (100 MHz, CDCl3): δ = 197.1, 166.0, 164.0, 151.2, 135.1, 132.9, 131.7, 130.9, 
130.5, 129.3, 127.4, 127.3, 124.9, 120.3, 110.5, 75.2, 52.4, 28.3, 26.6, 19.2; IR (neat): ῦ = 3317, 
2959, 1725, 1678, 1652, 1601, 1583, 1535, 1497, 1468, 1422, 1360, 1331, 1301, 1277, 1258, 1201, 
1140, 1094, 1075, 1018, 885, 809, 727 cm-1; HRMS (ESI), m/z: calcd for C21H24NO5+, 370.1649; 
found, 370.1649.  
 
Methyl 3-((5-acetyl-2-(cyclopropylmethoxy)phenyl)carbamoyl)benzoate (126)  
Pale yellow solid;  Yield: 91 %; mp 141-142 °C; 1H NMR (400 MHz, 
CDCl3): δ = 9.17 (d, J = 2.1 Hz, 1H), 8.78 (s, 1H), 8.56 (t, J = 1.5 
Hz, 1H), 8.27 – 8.21 (m, 1H), 8.21 – 8.13 (m, 1H), 7.77 (dd, J = 8.6, 
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2.2 Hz, 1H), 7.62 (t, J = 7.8 Hz, 1H), 6.94 (d, J = 8.6 Hz, 1H), 4.02 (d, J = 7.1 Hz, 2H), 3.96 
(s, 3H), 2.61 (s, 3H), 1.44 – 1.30 (m, 1H), 0.78 – 0.66 (m, 2H), 0.46 – 0.42 (m, 2H); 13C NMR 
(100 MHz, CDCl3): δ = 197.0, 166.0, 164.0, 151.2, 135.1, 132.8, 131.7, 130.8, 130.5, 129.2, 
127.6, 127.5, 124.8, 120.4, 110.8, 74.0, 52.4, 26.5, 10.1, 3.2; IR (neat): ῦ = 3426, 2923, 2853, 
1722, 1672, 1587, 1531, 1473, 1462, 1432, 1340, 1305, 1295, 1267, 1254, 1228, 1204, 1146, 1098, 
1077, 1026, 990, 921, 905, 804, 729, 720 cm-1; HRMS (ESI), m/z: calcd for C21H22NO5+, 
368.1493; found, 368.1495.  
 
Methyl 3-((5-acetyl-2-(benzyloxy)phenyl)carbamoyl)benzoate (127)  
White solid; Yield: 74 %; mp 149-152 °C; 1H NMR (400 MHz, 
CDCl3): δ = 9.20 (d, J = 2.1 Hz, 1H), 8.67 (s, 1H), 8.51 (d, J = 1.6 
Hz, 1H), 8.26 – 8.18 (m, 1H), 8.07 (ddd, J = 7.7, 1.8, 1.2 Hz, 1H), 
7.80 (dd, J = 8.6, 2.2 Hz, 1H), 7.57 (t, J = 7.7 Hz, 1H), 7.48 – 7.37 
(m, 5H), 7.08 (d, J = 8.6 Hz, 1H), 5.27 (s, 2H), 3.94 (s, 3H), 2.63 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ = 197.0, 166.0, 164.1, 150.9, 135.5, 135.0, 132.8, 131.5, 130.9, 130.8, 129.1, 128.9, 
128.6, 127.7, 127.6, 127.3, 124.8, 120.6, 111.3, 71.2, 52.4, 26.5; IR (neat): ῦ = 3303, 3064, 2954, 
2921, 1732, 1717, 1681, 1651, 1602, 1585, 1536, 1498, 1425, 1332, 1282, 1202, 1146, 1078, 1024, 
973, 885, 832, 797, 728, 719 cm-1; HRMS (ESI), m/z: calcd for C24H21NNaO5+, 426.1312; found, 
426.1307.  
 
Methyl 3-((5-acetyl-2-morpholinophenyl)carbamoyl)benzoate (128)  
Pale yellow solid; Yield: 95 %; mp 152-155 °C; 1H NMR (500 MHz, 
CDCl3): δ = 9.51 (s, 1H), 9.17 (s, 1H), 8.58 (d, J = 1.1 Hz, 1H), 8.26 (t, 
J = 8.7 Hz, 2H), 7.81 (d, J = 8.3 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 7.31 
(d, J = 8.3 Hz, 1H), 4.00 (s, 3H), 3.99-3.97 (m, 4H), 3.01 (s, 4H), 2.65 (s, 
3H); 13C NMR (126 MHz, CDCl3): δ = 197.5, 166.0, 163.7, 145.3, 134.8, 
134.6, 133.2, 133.0, 132.0, 130.8, 129.5, 127.1, 124.3, 120.6, 120.1, 67.5, 52.5, 52.3, 26.7; IR 
(neat): ῦ = 3327, 2958, 2582, 1731, 1673, 1579, 1525, 1427, 1356, 1292, 1258, 1234, 1217, 1109, 
932, 918, 814, 801, 719 cm-1; HRMS (ESI), m/z: calcd for C21H23N2O5+, 383.1602; found, 
383.1602.  
 
Methyl 3-((2-ethoxy-5-(methylcarbamoyl)phenyl)carbamoyl)benzoate (129)  
White solid;  Yield: 66 %; mp 161-163 °C; 1H NMR (400 MHz, CDCl3): δ 
= 8.81 (d, J = 2.1 Hz, 1H), 8.65 (s, 1H), 8.49 (s, 1H), 8.20 (d, J = 7.8 
Hz, 1H), 8.12 – 8.01 (m, 1H), 7.70 (dd, J = 8.5, 2.1 Hz, 1H), 7.57 (t, J = 
7.8 Hz, 1H), 7.57 (t, J = 7.8 Hz, 1H), 6.45 (d, J = 4.2 Hz, 1H), 4.17 (q, J 
= 7.0 Hz, 2H), 3.94 (s, 3H), 2.97 (d, J = 4.8 Hz, 3H), 1.50 (t, J = 7.0 
Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 167.5, 166.0, 164.1, 149.7, 135.0, 132.7, 131.4, 130.8, 
129.1, 127.7, 127.1, 126.9, 124.7, 117.1, 110.7, 64.6, 52.4, 26.7, 14.6; IR (neat): ῦ = 3432, 3305, 
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2935, 1723, 1683, 1655, 1590, 1537, 1490, 1467, 1437, 1316, 1302, 1260, 1235, 1216, 1143, 1113, 
1040, 1023, 974, 902, 815, 802, 718 cm-1; HRMS (ESI), m/z: calcd for C19H20N2NaO5+, 379.1264; 
found, 379.1262.  
 
Synthesis of benzoic acid derivatives. Scope on the side chain 
 
Methyl 2-((5-acetyl-2-ethoxyphenyl)carbamoyl)benzoate (131)  
Pale brown solid;  Yield: 40 %; mp 130-134 °C; 1H NMR (400 MHz, CDCl3): 
δ = 9.16 (s, 1H), 8.09 (s, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.78 (dd, J = 8.6, 
1.8 Hz, 1H), 7.63 – 7.54 (m, 3H), 6.94 (d, J = 8.6 Hz, 1H), 4.19 (q, J = 7.0 
Hz, 2H), 3.87 (s, 3H), 2.62 (s, 3H), 1.44 (t, J = 7.0 Hz, 3H); 13C NMR (100 
MHz, CDCl3): δ = 197.2, 167.1, 167.0, 150.9, 138.2, 132.2, 130.5, 130.3, 130.1, 129.3, 127.5, 
127.5, 124.8, 120.7, 110.5, 64.7, 52.7, 26.6, 14.6; IR (neat): ῦ = 3274, 2954, 2926, 1727, 1670, 
1651, 1600, 1584, 1537, 1497, 1473, 1427, 1357, 1335, 1265, 1202, 1141, 1115, 1071, 1035, 959, 
805, 767, 709 cm-1; HRMS (ESI), m/z: calcd for C19H19NNaO5+, 364.1155; found, 364.1155. 
 
N-(5-Acetyl-2-ethoxyphenyl)-3-(1H-tetrazol-1-yl)benzamide (54)  
Brown solid;  Yield: 98 %; mp 168-169 °C; 1H NMR (400 MHz, DMSO-
d6): δ = 10.19 (s, 1H), 9.85 (s, 1H), 8.49 – 8.48 (m, 1H), 8.31 (d, J = 2.2 
Hz, 1H), 8.17 – 8.11 (m, 2H), 7.87 (dd, J = 8.6, 2.2 Hz, 1H), 7.84 (t, J = 
8.0 Hz, 1H), 7.22 (d, J = 8.7 Hz, 1H), 4.22 (q, J = 7.0 Hz, 2H), 2.55 (s, 
3H), 1.38 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 196.2, 164.0, 155.2, 142.5, 
136.2, 133.9, 130.5, 129.3, 128.5, 127.6, 126.5, 124.9, 124.1, 120.4, 111.9, 64.4, 26.4, 14.4; IR 
(neat): ῦ = 3439, 3086, 2970, 2923, 1666, 1591, 1535, 1489, 1430, 1363, 1336, 1260, 1242, 1203, 
1133, 1090, 1078, 1032, 1006, 963, 893, 808, 742, 732 cm-1; HRMS (ESI), m/z: calcd for 
C18H18N5O3+, 352.1404; found, 352.1404.  
 
N-(5-Acetyl-2-ethoxyphenyl)-3-(N-phenylsulfamoyl)benzamide (55)  
White solid;  Yield: 63 %; mp 186-189 °C;  1H NMR (500 MHz, 
DMSO-d6): δ = 10.41 (s, 1H), 9.85 (s, 1H), 8.34 (s, 1H), 8.26 (d, J 
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= 1.9 Hz, 1H), 8.17 (d, J = 7.7 Hz, 1H), 7.93 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.6, 2.1 Hz, 
1H), 7.71 (t, J = 7.8 Hz, 1H), 7.31 – 7.16 (m, 3H), 7.12 (s, 1H), 7.11 (s, 1H), 7.03 (t, J = 7.4 
Hz, 1H), 4.19 (q, J = 6.9 Hz, 2H), 2.53 (s, 3H), 1.35 (t, J = 6.9 Hz, 3H);  13C NMR (125 MHz, 
DMSO-d6): δ = 196.2, 163.9, 155.3, 140.1, 137.4, 135.3, 131.5, 129.7, 129.5, 129.3, 129.2, 127.6, 
126.5, 126.2, 124.9, 124.3, 120.2, 111.9, 64.4, 26.4, 14.4; IR (neat): ῦ = 3423, 3235, 2986, 1682, 
1667, 1600, 1589, 1536, 1482, 1469, 1433, 1345, 1258, 1228, 1211, 1159, 1111, 1029, 915, 890, 
814, 764, 754, 740 cm-1; HRMS (ESI), m/z: calcd for C23H23N2O5S+, 439.1322; found, 439.1316.  
 
N-(5-Acetyl-2-ethoxyphenyl)-3-(phenylsulfonamido)benzamide (56)  
Pale yellow solid;  Yield: 52 % over two steps; mp 217-220 °C; 1H 
NMR (500 MHz, CDCl3): δ = 10.56 (br, 1H), 9.44 (s, 1H), 8.37 (d, 
J = 2.0 Hz, 1H), 7.83 (dd, J = 8.7, 2.1 Hz, 1H), 7.79 (d, J = 7.4 
Hz, 2H), 7.68 (s, 1H), 7.63 – 7.60 (m, 2H), 7.58-7.55 (m, 2H), 7.40 
(t, J = 7.8 Hz, 1H), 7.34 – 7.28 (m, 1H), 7.19 (d, J = 8.7 Hz, 1H), 4.19 (q, J = 7.0 Hz, 2H), 
2.53 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ = 196.2, 164.5, 154.5, 
139.3, 138.1, 135.4, 133.1, 129.5, 129.4, 127.1, 126.8, 126.6, 123.6, 122.9, 122.7, 119.1, 111.7, 
64.4, 26.4, 14.4, 1 C is missing due to overlapping; IR (neat): ῦ = 3393, 3168, 2973, 2908, 1667, 
1598, 1584, 1530, 1472, 1423, 1366, 1332, 1273, 1156, 1139, 1089, 1044, 971, 899, 881, 808, 743, 
720 cm-1; HRMS (ESI), m/z: calcd for C23H23N2O5S+, 439.1322; found, 439.1324.  
 
Methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)-5-bromobenzoate (132)  
Pale yellow solid;  Yield: 44 % over two steps; mp 159-161 °C; 1H NMR 
(400 MHz, CDCl3): δ = 9.09 (d, J = 2.2 Hz, 1H), 8.58 (br, 1H), 8.43 (t, 
J = 1.5 Hz, 1H), 8.38 – 8.33 (m, 1H), 8.27 (t, J = 1.8 Hz, 1H), 7.80 (dd, 
J = 8.6, 2.2 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 4.26 (q, J = 7.0 Hz, 2H), 
3.98 (s, 3H), 2.62 (s, 3H), 1.55 (t, J = 7.0 Hz, 3H);13C NMR (100 MHz, 
CDCl3): δ = 197.0, 164.8, 162.7, 151.2, 136.9, 135.7, 134.8, 132.5, 130.5, 126.9, 126.1, 125.3, 
123.3, 120.6, 110.5, 64.9, 52.7, 26.5, 14.7; IR (neat): ῦ = 3414, 2960, 2922, 1739, 1689, 1673, 
1588, 1531, 1485, 1437, 1340, 1290, 1259, 1227, 1205, 1150, 1111, 1070, 1029, 981, 931, 889, 800, 
750, 733, 723 cm-1; HRMS (ESI), m/z: calcd for C19H18BrNNaO5+, 442.0261; found, 442.0264.  
 
Methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)-5-(methoxymethyl)benzoate (133)  
White solid;  Yield: 17 % over two steps; mp 123-125 °C; 1H NMR (400 
MHz, CDCl3): δ = 9.16 (d, J = 2.1 Hz, 1H), 8.67 (s, 1H), 8.47 (s, 1H), 
8.21 (s, 1H), 8.13 (s, 1H), 8.13 (s, 1H), 6.98 (d, J = 8.7 Hz, 1H), 4.59 (s, 
2H), 4.26 (q, J = 7.0 Hz, 2H), 3.97 (s, 3H), 3.46 (s, 3H), 2.63 (s, 3H), 
1.56 (t, J = 6.9 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 197.1, 166.1, 
164.1, 151.2, 140.2, 135.4, 131.7, 131.1, 130.5, 127.2, 126.9, 124.9, 120.6, 110.5, 73.6, 64.8, 58.6, 
52.5, 26.6, 14.7, 1 C is missing due to overlapping; IR (neat): ῦ = 3422, 2922, 2851, 1724, 1686, 
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1669, 1601, 1588, 1531, 1485, 1431, 1262, 1223, 1206, 1146, 1112, 1031, 999, 885, 794, 746, 727 
cm-1; HRMS (ESI), m/z: calcd for C21H24NO6+, 386.1598; found, 386.1596.  
 
Methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)-5-(((tetrahydro-2H-pyran-2-
yl)oxy)methyl)benzoate (134)   
White solid;  Yield: 44 %; mp 133-135 °C; 1H NMR (400 MHz, CDCl3): δ 
= 9.16 (d, J = 2.1 Hz, 1H), 8.65 (s, 1H), 8.46 (s, 1H), 8.22 (s, 1H), 8.15 
(s, 1H), 7.79 (dd, J = 8.6, 2.2 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 4.91 (d, 
J = 12.6 Hz, 1H), 4.76 (t, J = 3.5 Hz, 1H), 4.62 (d, J = 12.6 Hz, 1H), 
4.25 (q, J = 7.0 Hz, 2H), 3.97 (s, 3H), 3.95 – 3.87 (m, 1H), 3.62 – 3.53 
(m, 1H), 2.62 (s, 3H), 1.92 – 1.84 (m, 1H), 1.83 – 1.57 (m, 5H), 1.55 (t, J = 7.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ = 197.1, 166.1, 164.2, 151.1, 140.2, 135.3, 131.8, 131.0, 130.6, 130.5, 
127.2, 126.8, 124.9, 120.6, 110.5, 98.3, 68.0, 64.8, 62.2, 52.4, 30.5, 26.5, 25.4, 19.3, 14.7; IR 
(neat): ῦ = 3437, 2935, 2864, 1721, 1685, 1669, 1593, 1552, 1489, 1441, 1343, 1313, 1256, 1214, 
1200, 1182, 1136, 1115, 1022, 974, 906, 871, 802, 740, 716 cm-1; HRMS (ESI), m/z: calcd for 
C25H29NNaO7+, 478.1836; found, 478.1835.  
Procedure B
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Methyl 3-(5-acetyl-2-ethoxybenzamido)benzoate (136)  
Pale yellow solid; Yield: 34 %; mp 128-130 °C; 1H NMR (400 MHz, 
CDCl3): δ = 10.04 (s, 1H), 8.87 (d, J = 2.4 Hz, 1H), 8.22 (t, J = 1.8 Hz, 
1H), 8.14 (dd, J = 8.7, 2.4 Hz, 1H), 7.98 (ddd, J = 8.1, 2.2, 1.0 Hz, 1H), 
7.81 (ddd, J = 7.7, 1.6, 1.1 Hz, 1H), 7.45 (t, J = 7.9 Hz, 1H), 7.09 (d, J 
= 8.8 Hz, 1H), 4.38 (q, J = 7.0 Hz, 2H), 3.93 (s, 3H), 2.63 (s, 3H), 1.69 (t, J = 7.0 Hz, 3H); 13C 
NMR (100 MHz, CDCl3): δ = 196.4, 166.7, 162.4, 160.0, 138.5, 133.8, 133.3, 131.0, 130.9, 129.2, 
125.4, 124.4, 120.9, 120.9, 112.6, 65.7, 52.2, 26.5, 14.8; IR (neat): ῦ = 3319, 2951, 2925, 1722, 
1671, 1599, 1560, 1489, 1435, 1363, 1335, 1291, 1268, 1239, 1213, 1162, 1109, 1071, 1025, 969, 
884, 814, 795, 751 cm-1; HRMS (ESI), m/z: calcd for C19H20NO5+, 342.1336; found, 342.1336.  
IV. Suzuki cross-coupling reactions 
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Methyl 3-((5-acetyl-2-cyclopropylphenyl)carbamoyl)benzoate (137)  
To a solution of methyl 3-((5-acetyl-2-bromophenyl)carbamoyl)benzoate 
(123, 33 mg, 0.088 mmol) in THF:H2O (3:1, 0.22 M) Pd(OAc)2 (2.0 mg, 
0.0089 mmol), S-Phos (4.0 mg, 0.0097 mmol) and K3PO4 (68 mg, 0.312 
mmol) were added. The solution was purged with N2 and heated to 90 ºC 
for 12 hours. The reaction mixture was diluted with water and extracted with EtOAc three 
times. The combined organic phases were dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography (1:1 hex:EtOAc) affording 
the final product in pure form as a pale brown solid (15 mg, 0.044 mmol, 51 % yield). mp 125-
130 °C; 1H NMR (400 MHz, CDCl3): δ = 8.92 (d, J = 1.7 Hz, 1H), 8.66 (br, 1H), 8.59 (t, J = 
1.6 Hz, 1H), 8.28 – 8.23 (m, 1H), 8.22 – 8.16 (m, 1H), 7.72 (dd, J = 8.1, 1.8 Hz, 1H), 7.63 (t, J 
= 7.8 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 3.97 (s, 3H), 2.63 (s, 3H), 1.93 (tdd, J = 10.9, 7.3, 3.6 
Hz, 1H), 1.20 – 1.09 (m, 2H), 0.86 – 0.76 (m, 2H); 13C NMR (101 MHz, CDCl3): δ = 197.7, 
166.1, 164.2, 137.7, 136.8, 136.3, 135.0, 132.9, 131.8, 130.9, 129.4, 128.6, 127.5, 124.1, 121.0, 
52.5, 26.7, 11.7, 6.2; IR (neat): ῦ = 3267, 2954, 2924, 1725, 1677, 1643, 1606, 1569, 1525, 1413, 
1357, 1319, 1282, 1251, 1221, 1201, 1136, 1098, 1045, 1015, 987, 898, 880, 813, 797, 727 cm-1; 
HRMS (ESI), m/z: calcd for C20H19NNaO4+, 360.1206; found, 360.1203. 
 
 
General procedure for Suzuki cross-couplings 
To a solution of methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)-5-bromobenzoate (132) in 
dioxane (0.24 M) and water (1 drop), the corresponding boronic acid (1.1 eq), K2CO3 (3.0 eq) 
and Pd(PPh3)4 (0.25 eq) were added. The reaction was stirred for 12 h at 90 °C. It was diluted 
with water and extracted with EtOAc three times. The combined organic phases were dried 
over MgSO4 and concentrated under reduced pressure. The obtained residue was purified by 
flash column chromatography (hex: EtOAc, 2:1 to pure EtOAc) affording the coupled products. 
This procedure was used to obtain intermediates 138 and 139.  138 was extracted and used in 
the next step without further purification.  
 
Methyl 3-((5-acetyl-2-ethoxyphenyl)carbamoyl)-5-(furan-3-yl)benzoate (139)  
Yellow solid;  Yield: 42 %; mp 156-163 °C; 1H NMR (400 MHz, CDCl3): 
δ = 9.16 (d, J = 2.2 Hz, 1H), 8.70 (s, 1H), 8.37 (t, J = 1.6 Hz, 1H), 8.32 
(t, J = 1.6 Hz, 1H), 8.27 (t, J = 1.8 Hz, 1H), 7.88 (dd, J = 1.4, 0.9 Hz, 
3.3 EXPERIMENTAL SECTION 
137 
 
1H), 7.80 (dd, J = 8.6, 2.2 Hz, 1H), 7.54 (t, J = 1.6 Hz, 1H), 6.98 (d, J = 8.6 Hz, 1H), 6.81 
(dd, J = 1.9, 0.9 Hz, 1H), 4.26 (q, J = 7.0 Hz, 2H), 3.98 (s, 3H), 2.62 (s, 3H), 1.57 (t, J = 7.0 
Hz, 3H); 13C NMR (100 MHz, CDCl3): δ = 197.0, 166.0, 164.0, 151.2, 144.3, 139.5, 135.7, 134.1, 
131.4, 130.5, 129.9, 129.1, 127.2, 125.5, 125.0, 124.9, 120.6, 110.5, 108.6, 64.8, 52.5, 26.5, 14.7; 
IR (neat): ῦ = 2927, 2851, 1724, 1682, 1592, 1535, 1434, 1261, 1024, 803, 794, 765, 748 cm-1; 
HRMS (ESI), m/z: calcd for C23H21NNaO6+, 430.1261; found, 430.1260.  
V. Methyl ester hydrolysis of the amide coupling products 
General procedure for ester hydrolysis 
To a solution of the methyl ester (1 eq) in THF (0.1 M) a 1M LiOH solution (5 eq) was 
added. The reaction mixture was stirred at 25 °C for 2-6 h. It was then concentrated under 
reduced pressure and 1M HCl was added. The obtained precipitate was washed with hexanes, 
Et2O and cold DCM, affording the desired carboxylic acids in pure form.  For the synthesis of 
57, the reaction mixture was diluted with water and extracted with DCM and Et2O three 
times. The pH of the water phase was then brought to pH 3-4 by addition of 1M HCl and the 
resulting precipitate was filtered off and washed with DCM.  
For the synthesis of 59, the pH of the reaction mixture was brought to 1 by the addition 
of 1M HCl solution. It was then concentrated, redissolved in EtOH (0.1 M) and PTSA (0.1 eq) 
was added. The solution was stirred at 25 °C for 5 h and concentrated. Upon the addition of 
1M HCl solution, the final product precipitated. It was filtered out and washed with 1M HCl 
solution and Et2O affording the desired alcohol in pure form.   
In the case of 61, the reaction mixture was diluted with water and extracted with hexane. 
The aqueous phase was then brought to pH 3-4 by addition of a 10% citric acid solution. It was 
extracted with EtOAc three times, the combined organic phases were dried over MgSO4 and 
evaporated under reduced pressure obtaining the final product 61 in pure form.  
 
 
(E)-4-((5-Acetyl-2-methoxyphenyl)amino)-4-oxobut-2-enoic acid (40)  
Yellow solid; Yield: 53 %; mp 172-174 °C; 1H NMR (500 MHz, MeOD): δ = 
8.82 (s, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.37 (d, J = 15.4 Hz, 1H), 7.16 (d, J 
= 8.6 Hz, 1H), 6.83 (d, J = 15.6 Hz, 1H), 4.00 (s, 3H), 2.57 (s, 3H); 13C 
NMR (125 MHz, MeOD): δ = 199.2, 168.4, 164.6, 155.6, 138.0, 132.6, 
131.0, 128.1, 127.8, 123.7, 111.5, 56.8, 26.5; IR (neat): ῦ = 3306, 3068, 2949, 2840, 1702, 1665, 
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1589, 1542, 1516, 1445, 1422, 1359, 1302, 1269, 1213, 1174, 1134, 1023, 973, 886, 813 cm-1; 
HRMS (ESI), m/z: calcd for C13H14NO5+, 264.0867; found, 264.0869.  
 
(E)-4-((5-Acetyl-2-methylphenyl)amino)-4-oxobut-2-enoic acid (41)  
White solid;  Yield: 60 %; mp 203-204 °C; 1H NMR (400 MHz, MeOD): δ 
= 8.14 (s, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.41 (d, J = 7.9 Hz, 1H), 7.28 (d, 
J = 15.3 Hz, 1H), 6.84 (d, J = 15.4 Hz, 1H), 6.76 (s, 1H),  2.58 (s, 3H), 
2.35 (s, 3H). 13C NMR (125 MHz, DMSO-d6): δ = 207.2, 176.3, 172.1, 
147.1, 146.9, 146.0, 145.1, 140.9, 140.8, 135.4, 133.9, 36.6, 28.1; IR (neat): ῦ = 3266, 2925, 
2604, 1714, 1659, 1607, 1573, 1536, 1417, 1288, 1259, 1231, 1177, 977, 912, 905, 822, 811, 706 
cm-1; HRMS (ESI), m/z: calcd for C13H13NO4+, 248.0917; found, 248.0916.  
 
(E)-4-((5-Acetyl-2-fluorophenyl)amino)-4-oxobut-2-enoic acid (42)  
White solid;  Yield: 60 %; mp 218-220 °C; 1H NMR (400 MHz, MeOD): δ = 
8.76 (dd, J = 7.5, 2.0 Hz, 1H), 7.86 (ddd, J = 8.5, 4.7, 2.2 Hz, 1H), 7.32 (t, 
J = 9.5 Hz, 1H), 7.30 (d, J = 13.9 Hz, 1H), 6.86 (d, J = 15.4 Hz, 1H), 2.60 
(s, 3H); 13C NMR (125 MHz, MeOD): δ = 198.5, 168.2, 164.8, 164.6, 159.2, 
157.2, 155.9, 154.0, 140.8, 137.5, 137.2, 135.0, 133.2, 132.8, 127.9 (d, J = 9.0 Hz), 127.3 (d, J = 
12.3 Hz), 126.3 (d, J = 11.6 Hz), 125.6 (d, J = 2.2 Hz), 125.5 (d, J = 7.8 Hz), 123.8, 116.8 (d, 
J = 20.8 Hz), 116.0 (d, J = 20.0 Hz), 102.4, 26.7, presence of rotamers; IR (neat): ῦ = 3446, 
3297, 3084, 1707, 1666, 1611, 1601, 1546, 1487, 1417, 1362, 1335, 1293, 1267, 1192, 1112, 990, 
925, 887, 825, 758, 721 cm-1; HRMS (ESI), m/z: calcd for C12H11FNO4+, 252.0667; found, 
252.0669.  
 
(E)-4-((3-Acetylphenyl)amino)-4-oxobut-2-enoic acid (43)  
Off white solid;  Yield: 90 %; mp 237-239 °C; 1H NMR (400 MHz, DMSO-
d6): δ = 13.03 (s, 1H), 10.72 (s, 1H), 8.26 (s, 1H), 7.92 (d, J = 7.9 Hz, 1H), 
7.72 (d, J = 7.7 Hz, 1H), 7.51 (t, J = 7.9 Hz, 1H), 7.14 (d, J = 15.3 Hz, 
1H), 6.69 (d, J = 15.4 Hz, 1H), 2.57 (s, 3H); 13C NMR (125 MHz, DMSO-
d6): δ = 197.6, 166.3, 161.9, 139.0, 137.4, 136.9, 131.1, 129.4, 124.1, 123.9, 118.6, 26.8; IR 
(neat): ῦ = 3349, 2835, 2682, 2570, 1703, 1661, 1609, 1552, 1490, 1421, 1363, 1341, 1307, 1281, 
1166, 974, 879, 794 cm-1; HRMS (ESI), m/z: calcd for C12H12NO4+, 234.0761; found, 234.0760.  
 
2-((5-Acetyl-2-ethoxyphenyl)carbamoyl)cyclopropane-1-carboxylic acid (44)   
White solid;  Yield: 84 %; mp 234-235 °C; 1H NMR (500 MHz, DMSO-d6): 
δ = 12.50 (br, 1H), 9.65 (s, 1H), 8.53 (s, 1H), 7.73 (dd, J = 8.5, 1.7 Hz, 
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1H), 7.13 (d, J = 8.6 Hz, 1H), 4.21 (q, J = 6.9 Hz, 2H), 2.71 – 2.62 (m, 1H), 2.48 (s, 3H), 1.94 
– 1.87 (m, 1H), 1.41 (t, J = 7.0 Hz, 3H), 1.34 – 1.22 (m, 2H); 13C NMR (125 MHz, DMSO-d6): 
δ = 196.2, 173.1, 169.1, 152.7, 129.2, 127.1, 125.9, 121.9, 111.4, 64.3, 26.3, 23.3, 21.5, 14.4, 14.2; 
IR (neat): ῦ = 3408, 2992, 2414, 1716, 1642, 1598, 1575, 1517, 1425, 1366, 1320, 1271, 1191, 
1130, 1082, 1037, 969, 930, 892, 879, 810 cm-1; HRMS (ESI), m/z: calcd for C15H17NNaO5+, 
314.0999; found, 314.0996.  
 
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)benzoic acid (45)  
White solid;  Yield: 60 %; mp 224-226 °C; 1H NMR (400 MHz, MeOD): δ 
= 8.65 (d, J = 2.2 Hz, 1H), 8.61 – 8.59 (m, 1H), 8.25 (ddd, J = 7.8, 1.6, 
1.2 Hz, 1H), 8.17 (ddd, J = 7.8, 1.8, 1.2 Hz, 1H), 7.90 (dd, J = 8.7, 2.2 
Hz, 1H), 7.67 (dd, J = 8.0, 7.5 Hz, 1H), 7.17 (d, J = 8.7 Hz, 1H), 4.27 (q, 
J = 7.0 Hz, 2H), 2.59 (s, 3H), 1.50 (t, J = 7.0 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 
196.2, 166.8, 164.6, 155.2, 134.8, 132.3, 131.7, 131.2, 129.3, 129.0, 128.5, 127.4, 126.7, 124.7, 
111.9, 64.4, 26.4, 14.4; IR (neat): ῦ = 3437, 3412, 2988, 1710, 1684, 1672, 1603, 1585, 1533, 
1429, 1301, 1269, 1229, 1205, 1147, 1126, 1077, 1032, 904, 801, 732 cm-1; HRMS (ESI), m/z: 
calcd for C18H18NO5+, 328.1180; found, 328.1176.  
 
3-((5-Acetyl-2-propoxyphenyl)carbamoyl)benzoic acid (48)  
Beige solid;  Yield: 77 %; mp 208-211 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 8.63 (dd, J = 15.5, 7.4 Hz, 2H), 8.25 (d, J = 7.7 Hz, 1H), 8.17 
(d, J = 7.7 Hz, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.66 (t, J = 7.7 Hz, 1H), 
7.17 (d, J = 8.6 Hz, 1H), 4.16 (t, J = 6.3 Hz, 2H), 2.59 (s, 3H), 1.96 – 
1.84 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H); 13C NMR (125 MHz, DMSO-d6): 
δ = 189.7, 159.2, 157.9, 146.7, 126.8, 124.6, 123.3, 121.6, 120.7, 120.1, 119.0, 118.6, 115.3, 
103.0, 62.3, 17.0, 14.0, 1.3, 1 C is missing due to overlapping; IR (neat): ῦ = 3427, 2965, 2940, 
1719, 1665, 1639, 1590, 1507, 1434, 1404, 1389, 1333, 1262, 1206, 1158, 1070, 1035, 1009, 910, 
810, 727 cm-1; HRMS (ESI), m/z: calcd for C19H20NO5+, 342.1336; found, 342.1341.  
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3-((5-Acetyl-2-isobutoxyphenyl)carbamoyl)benzoic acid (49)  
White solid;  Yield: 94 %; mp 221-223 °C; 1H NMR (400 MHz, DMSO-
d6): δ = 13.21 (s, 1H), 9.79 (s, 1H), 8.52 (t, J = 1.5 Hz, 1H), 8.26 (d, J 
= 2.2 Hz, 1H), 8.20 – 8.16 (m, 1H), 8.16 – 8.12 (m, 1H), 7.86 (dd, J = 
8.6, 2.2 Hz, 1H), 7.68 (t, J = 7.7 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 3.92 
(d, J = 6.4 Hz, 2H), 2.54 (s, 3H), 2.06 (dt, J = 13.2, 4.8 Hz, 1H), 0.99 
(s, 3H), 0.97 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ = 196.2, 166.7, 164.5, 155.7, 134.8, 
132.2, 131.6, 131.2, 129.3, 129.0, 128.3, 127.6, 126.7, 124.9, 111.8, 74.5, 27.7, 26.4, 18.9; IR 
(neat): ῦ = 3375, 2963, 2933, 2877, 2469, 1682, 1644, 1596, 1581, 1510, 1426, 1411, 1356, 1316, 
1297, 1270, 1214, 1128, 1107, 1017, 956, 885, 810, 724, 724 cm-1; HRMS (ESI), m/z: calcd for 
C20H21NNaO4+, 378.1312; found, 378.1309. 
 
3-((5-Acetyl-2-(cyclopropylmethoxy)phenyl)carbamoyl)benzoic acid (50)   
Beige solid; Yield: 54 %; mp 221-223 °C; 1H NMR (400 MHz, DMSO-
d6): δ = 13.23 (s, 1H), 9.76 (s, 1H), 8.53 (s, 1H), 8.32 (d, J = 2.2 Hz, 
1H), 8.21 – 8.17 (m, 1H), 8.17 – 8.13 (m, 1H), 7.84 (dd, J = 8.6, 2.3 
Hz, 1H), 7.69 (t, J = 7.8 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 4.03 (d, J 
= 6.8 Hz, 2H), 2.54 (s, 3H), 1.33 – 1.20 (m, 1H), 0.60 – 0.51 (m, 2H), 0.42 – 0.34 (m, 2H); 13C 
NMR (125 MHz, DMSO-d6): δ = 196.2, 166.7, 164.4, 155.2, 134.8, 132.3, 131.7, 131.2, 129.4, 
129.1, 128.3, 127.4, 126.8, 124.4, 112.3, 72.9, 26.4, 9.9, 3.0; IR (neat): ῦ = 3075, 2957, 2927, 
1716, 1670, 1597, 1582, 1510, 1432, 1412, 1396, 1291, 1276, 1262, 1217, 1160, 1111, 1069, 1023, 
991, 906, 796, 728 cm-1; HRMS (ESI), m/z: calcd for C20H19NNaO5+, 376.1155; found, 376.1151. 
 
3-((5-Acetyl-2-(benzyloxy)phenyl)carbamoyl)benzoic acid (51)   
White solid;  Yield: 79 %; mp 210-215 °C; 1H NMR (400 MHz, 
DMSO-d6): δ = 9.88 (s, 1H), 8.54 (s, 1H), 8.30 (d, J = 1.9 Hz, 1H), 
8.12 (t, J = 8.1 Hz, 2H), 7.85 (dd, J = 8.6, 2.1 Hz, 1H), 7.61 (t, J = 
7.7 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.37 (t, J = 7.4 Hz, 2H), 7.30 
(d, J = 7.4 Hz, 1H), 7.26 (d, J = 8.7 Hz, 1H), 5.32 (s, 2H), 2.54 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ = 196.2, 167.1, 165.0, 155.0, 136.5, 134.5, 132.2, 130.7, 129.7, 128.4, 128.3, 127.8, 
127.3, 127.1, 125.1, 112.5, 69.9, 26.4, three carbons are missing due to overlapping; IR (neat): ῦ 
= 3414, 3085, 1713, 1660, 1637, 1593, 1584, 1510, 1434, 1400, 1390, 1323, 1296, 1274, 1221, 
1165, 1021, 995, 896, 803, 724, 702 cm-1; HRMS (ESI), m/z: calcd for C23H20NO5+, 390.1336; 
found, 390.1335.  
 
3-((5-Acetyl-2-morpholinophenyl)carbamoyl)benzoic acid (52)   
White solid;  Yield: 76 %; mp 249-252 °C; 1H NMR (500 MHz, DMSO-d6): 
δ = 13.32 (s, 1H), 9.93 (s, 1H), 8.53 (s, 1H), 8.43 (d, J = 1.7 Hz, 1H), 
8.21 (d, J = 7.7 Hz, 1H), 8.16 (d, J = 7.7 Hz, 1H), 7.82 (dd, J = 8.4, 1.4 
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Hz, 1H), 7.71 (t, J = 7.7 Hz, 1H), 7.29 (d, J = 8.4 Hz, 1H), 3.78 (t, J = 3.9 Hz, 4H), 2.99 (t, J 
= 4.1 Hz, 4H), 2.55 (s, 3H); 13C NMR (126 MHz, DMSO-d6): δ = 196.7, 166.8, 164.2, 149.3, 
134.7, 132.5, 131.9, 131.8, 131.3, 131.2, 129.3, 128.2, 126.5, 124.2, 119.7, 66.4, 51.0, 26.6; IR 
(neat): ῦ = 3346, 2981, 2831, 1723, 1676, 1644, 1598, 1577, 1529, 1457, 1432, 1283, 1234, 1215, 
1112, 1069, 935, 918, 894, 848, 824, 726 cm-1; HRMS (ESI), m/z: calcd for C20H21N2O5+, 
369.1445; found, 369.1444.  
 
3-((5-Acetyl-2-cyclopropylphenyl)carbamoyl)benzoic acid (53)   
Pale yellow solid;  Yield: 57 %; mp 95-100 °C; 1H NMR (400 MHz, 
DMSO-d6): δ = 10.29 (s, 1H), 8.58 (s, 1H), 8.21 – 8.09 (m, 3H), 7.94 (s, 
1H), 7.77 (d, J = 8.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 8.6 
Hz, 1H), 2.55 (s, 3H), 2.18 – 2.04 (m, 1H), 1.06 – 0.93 (m, 2H), 0.76 – 
0.69 (m, 2H);13C NMR (100 MHz, DMSO-d6): δ = 197.0, 167.1, 165.4, 145.0, 137.1, 134.5, 
134.4, 132.2, 130.9, 128.5, 128.5, 126.3, 126.2, 124.9, 26.6, 11.5, 9.0, one C is missing due to 
overlapping; IR (neat): ῦ = 3282, 2920, 1683, 1638, 1608, 1571, 1532, 1416, 1358, 1294, 1260, 
1231, 1101, 1077, 1046, 1022, 882, 819, 797, 728 cm-1; HRMS (ESI), m/z: calcd for 
C19H17NNaO4+, 346.1050; found, 346.1047. 
 
3-((2-Ethoxy-5-(methylcarbamoyl)phenyl)carbamoyl)benzoic acid (63)   
Pale brown solid;  Yield: 62 %; mp 226-229 °C; 1H NMR (400 MHz, 
MeOD): δ = 8.60 (t, J = 1.5 Hz, 1H), 8.42 (d, J = 2.2 Hz, 1H), 8.27 – 
8.22 (m, 1H), 8.19 – 8.15 (m, 1H), 7.73 – 7.60 (m, 2H), 7.14 (d, J = 8.7 
Hz, 1H), 4.23 (q, J = 6.9 Hz, 2H), 2.92 (s, 3H), 1.48 (t, J = 7.0 Hz, 3H); 
13C NMR (100 MHz, MeOD): δ = 170.3, 168.8, 167.4, 154.6, 136.3, 134.0, 
132.9, 132.8, 132.7, 130.2, 130.1, 130.0, 129.6, 127.8, 127.7, 126.7, 123.7, 112.6, 65.8, 27.0, 15.0, 
presence of rotamers; IR (neat): ῦ = 3398, 3081, 2981, 2525, 1689, 1661, 1601, 1573, 1467, 
1429, 1395, 1336, 1267, 1234, 1195, 1167, 1123, 1029, 913, 782, 760, 735 cm-1; HRMS (ESI), 
m/z: calcd for C18H18N2O5+, 343.1289; found, 343.1283.  
 
2-((5-Acetyl-2-ethoxyphenyl)carbamoyl)benzoic acid (47)   
White solid;  Yield: 57 %; mp 143-146 °C; 1H NMR (400 MHz, MeOD): δ = 
8.75 (s, 1H), 8.02 (d, J = 7.6 Hz, 1H), 7.86 (d, J = 8.9 Hz, 1H), 7.71 – 7.62 
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(m, 1H), 7.63 – 7.55 (m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 4.22 (q, J = 6.9 Hz, 2H), 2.59 (s, 3H), 
2.59 (s, 3H); 13C NMR (126 MHz, MeOD): δ = 198.7, 197.9, 169.8, 169.1, 168.0, 154.3, 151.3, 
138.4, 136.6, 132.7, 131.8, 130.9, 130.6, 130.0, 129.5, 129.5, 128.8, 128.1, 127.4, 126.6, 123.4, 
120.4, 114.1, 110.9, 109.8, 64.5, 63.8, 48.2, 48.1, 48.1, 47.9, 47.9, 47.8, 47.7, 47.7, 47.7, 47.7, 
47.6, 47.4, 47.3, 47.3, 47.1, 25.1, 24.9, 13.7, 13.4, presence of rotamers; IR (neat): ῦ = 3272, 
2970, 2936, 1713, 1662, 1603, 1583, 1540, 1498, 1436, 1275, 1254, 1220, 1159, 1128, 1043, 933, 
884, 809, 786, 730, 710, 704 cm-1; HRMS (ESI), m/z: calcd for C18H18NO5+, 328.1180; found, 
328.1181.  
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)-5-(pyridin-4-yl)benzoic acid (57)  
White solid;  Yield: 40 % over two steps; mp 270-276 °C; 1H NMR (500 
MHz, DMSO-d6): δ = 9.91 (s, 1H), 8.70 (d, J = 5.7 Hz, 2H), 8.55 (s, 1H), 
8.45 (s, 1H), 8.42 (s, 1H), 8.30 (s, 1H), 7.87 (dd, J = 8.5, 2.0 Hz, 1H), 
7.83 (d, J = 4.9 Hz, 2H), 7.22 (d, J = 8.7 Hz, 1H), 4.21 (q, J = 6.9 Hz, 
2H), 2.55 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, DMSO-
d6): δ= 196.2, 166.3, 164.1, 155.6, 145.4, 136.3, 136.0, 132.5, 131.0, 130.8, 
130.4, 129.4, 127.8, 126.4, 125.5, 123.6, 112.0, 64.4, 26.4, 14.4, 1 C is missing due to 
overlapping; IR (neat): ῦ = 3441, 2969, 1682, 1591, 1540, 1432, 1357, 1331, 1260, 1225, 1203, 
1066, 1027, 797, 748, 732, 707 cm-1; HRMS (ESI), m/z: calcd for C23H21N2O5+, 405.1445; found, 
405.1440.  
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)-5-(furan-3-yl)benzoic acid (58)    
Beige solid;  Yield: 55 %; mp 210-214 °C; 1H NMR (500 MHz, DMSO-d6): 
δ = 13.37 (s, 1H), 9.90 (s, 1H), 8.42 (s, 1H), 8.37 (s, 1H), 8.33 (s, 1H), 
8.29 (s, 1H), 7.87 (dd, J = 8.5, 1.9 Hz, 1H), 7.83 (s, 1H), 7.22 (d, J = 8.4 
Hz, 1H), 7.13 (s, 1H), 4.21 (q, J = 6.6 Hz, 2H), 2.55 (s, 3H), 1.38 (t, J = 
6.8 Hz, 3H); 13C NMR (126 MHz, DMSO-d6): δ = 196.3, 166.8, 164.5, 
155.4, 144.8, 140.6, 135.5, 132.9, 131.9, 129.3, 128.9, 128.6, 127.6, 127.0, 126.6, 125.2, 124.7, 
111.9, 108.7, 64.4, 26.5, 14.5; IR (neat): ῦ = 3424, 3147, 2988, 2935, 1719, 1678, 1658, 1588, 
1540, 1492, 1432, 1361, 1336, 1266, 1202, 1183, 1141, 1070, 1024, 907, 890, 873, 808, 795, 741 
cm-1; HRMS (ESI), m/z: calcd for C22H19NO6+, 394.1285; found, 394.1279.  
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)-5-(methoxymethyl)benzoic acid (60)   
White solid;  Yield: 50 %; mp 185-187 °C; 1H NMR (500 MHz, DMSO-d6): 
δ = 13.29 (br, 1H), 9.86 (s, 1H), 8.44 (s, 1H), 8.26 (s, 1H), 8.13 (s, 1H), 
8.09 (s, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.21 (d, J = 8.6 Hz, 1H), 4.57 (s, 
2H), 4.20 (q, J = 6.7 Hz, 2H), 3.36 (s, 3H), 2.54 (s, 3H), 1.37 (t, J = 6.8 
Hz, 3H); 13C NMR (125 MHz, DMSO-d6): δ = 196.3, 166.8, 164.6, 155.4, 
139.6, 134.9, 131.2, 131.0, 130.6, 129.4, 127.6, 126.7, 125.0, 111.9, 72.7, 64.4, 57.9, 26.5, 14.5; 
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one C is missing due to overlapping; IR (neat): ῦ = 3443, 2986, 2922, 1683, 1592, 1539, 1432, 
1361, 1263, 1243, 1190, 1135, 1113, 1035, 893, 809, 742, 708 cm-1; HRMS (ESI), m/z: calcd for 
C20H21NNaO6+, 394.1261; found, 394.1263. 
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)-5-(((tetrahydro-2H-pyran-2-
yl)oxy)methyl)benzoic acid (61)   
White solid;  Yield: 78 %; mp 165-170 °C; 1H NMR (500 MHz, DMSO-
d6): δ = 13.23 (br, 1H), 9.80 (s, 1H), 8.44 (s, 1H), 8.31 (d, J = 1.9 Hz, 
1H), 8.14 (s, 1H), 8.11 (s, 1H), 7.85 (dd, J = 8.6, 2.1 Hz, 1H), 7.20 (d, J 
= 8.7 Hz, 1H), 4.82 (d, J = 12.6 Hz, 1H), 4.75 (t, J = 3.3 Hz, 1H), 4.62 
(d, J = 12.6 Hz, 1H), 4.21 (q, J = 6.9 Hz, 2H), 3.81 (ddd, J = 11.1, 8.3, 
2.9 Hz, 1H), 3.53 – 3.49 (m, 1H), 2.54 (s, 3H), 1.84 – 1.65 (m, 2H), 1.62 – 1.44 (m, 4H), 1.37 (t, 
J = 6.9 Hz, 3H); 13C NMR (126 MHz, DMSO-d6): δ = 196.4, 166.8, 164.7, 155.3, 139.8, 135.1, 
131.4, 131.2, 130.8, 129.5, 127.6, 127.5, 126.9, 124.8, 112.0, 97.8, 67.6, 64.5, 61.6, 30.3, 26.5, 
25.1, 19.2, 14.5; IR (neat): ῦ = 3427, 2938, 2873, 1718, 1679, 1647, 1590, 1536, 1436, 1343, 
1296, 1260, 12001, 1185, 1121, 1073, 1027, 976, 957, 899, 809, 743 cm-1; HRMS (ESI), m/z: 
calcd for C24H27NNaO7+, 464.1680; found, 464.1678. 
 
 
 
3-((5-Acetyl-2-ethoxyphenyl)carbamoyl)-5-(hydroxymethyl)benzoic acid (59)   
White solid; Yield: 27 % over two steps; mp 225-228 °C; 1H NMR (500 
MHz, DMSO-d6): δ = 13.24 (s, 1H), 9.83 (s, 1H), 8.39 (s, 1H), 8.27 (s, 
1H), 8.12 (d, J = 4.9 Hz, 2H), 7.86 (d, J = 8.5 Hz, 1H), 7.21 (d, J = 8.6 
Hz, 1H), 5.49 (t, J = 5.6 Hz, 1H), 4.65 (d, J = 5.5 Hz, 2H), 4.20 (q, J = 
6.9 Hz, 2H), 2.54 (s, 3H), 1.37 (t, J = 6.9 Hz, 3H); 13C NMR (126 MHz, 
DMSO-d6): δ = 196.3, 167.0, 164.7, 155.3, 143.8, 134.7, 131.0, 130.1, 129.8, 129.4, 127.5, 126.9, 
126.8, 124.9, 111.9, 64.4, 62.2, 26.5, 14.5; IR (neat): ῦ = 3391, 3262, 2975, 2933, 1719, 1646, 
1604, 1581, 1541, 1498, 1477, 1437, 1361, 1336, 1298, 1274, 1232, 1206, 1183, 1147, 1054, 1037, 
987, 904, 893, 821, 796, 753, 710 cm-1; HRMS (ESI), m/z: calcd for C19H20NO6+, 358.1285; 
found, 358.1285.  
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3-(5-Acetyl-2-ethoxybenzamido)benzoic acid (62)   
Pale yellow solid;  Yield: 69 %; mp 209-212 °C; 1H NMR (500 MHz, 
DMSO-d6): δ = 12.96 (br, 1H), 10.34 (s, 1H), 8.39 (s, 1H), 8.20 (d, J = 
1.9 Hz, 1H), 8.09 (dd, J = 8.7, 2.0 Hz, 1H), 7.91 (d, J = 7.8 Hz, 1H), 7.68 
(d, J = 7.7 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H), 7.28 (d, J = 8.7 Hz, 1H), 
4.26 (q, J = 6.9 Hz, 2H), 2.57 (s, 3H), 1.40 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, DMSO-
d6): δ = 196.0, 167.1, 164.0, 159.5, 139.1, 132.4, 131.4, 130.2, 129.4, 129.0, 124.9, 124.4, 123.7, 
120.3, 112.7, 64.7, 26.5, 14.4; IR (neat): ῦ = 3343, 2981, 1719, 1670, 1596, 1552, 1488, 1409, 
1362, 1299, 1265, 1203, 1149, 1110, 1080, 1025, 921, 890, 811, 756 cm-1; HRMS (ESI), m/z: 
calcd for C18H17NNaO5+, 350.0999; found, 350.0995.  
VI. Synthesis of novel bromodomain ligands based on docking studies 
(64-66) 
Due to an on-going patent application, the synthesis of compounds 64-66 will not be 
disclosed.  
3.3.5 Bromodomain expression and purification 
Proteins were purified as described previously.31  Briefly, His-tagged bromodomains were 
expressed in Escherichia coli BL21(DE3) cells upon induction with isopropyl thio-beta-D-
galactoside (IPTG, final concentration 0.1 mM) for 16 h at 18 °C.  Bacteria were lysated and 
(when required) the resulting extract was treated to remove DNA, either passing it through a 
DEAE column or adding 0.15% polyethylenimine (PEI).  The His-tagged proteins were purified 
on HisTrap columns (GE Healthcare) and eluted using a step gradient of imidazole. The poly-
Histidine tags were removed by overnight incubation with His-tagged tobacco etch virus (TEV) 
protease purified in-house (if required by the purification protocol, in the meantime the sample 
was exchanged via dialysis). A size-exclusion chromatography step (HiLoad 16/600 Superdex75 
column) and a Ni-affinity chromatography step were subsequently performed to finally purify 
the cleaved bromodomains.  Samples were then concentrated, flash frozen and stored at –80 
°C.  
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3.3.6 X-ray crystallography 
I. Crystallization, Data Collection, and Structure Determination 
Crystals of the CREBBP bromodomain were grown at 4°C using the hanging drop vapor 
diffusion method. A 50 mM solution of compound 45 (in 100 % DMSO) was added into the 
CREBBP protein to reach a final DMSO concentration of 1 % (v/v) and the mixture was 
incubated on ice for 1 hour before crystallization. Then equal volumes of protein 
(with compound 45) and reservoir solutions (0.1 M MES pH 6.5, 0.10 MgCl2, 20 % 
PEG 6000, 10 % ethylene glycol) were mixed and crystals appeared after 1 to 2 days. The 
crystals were flash-frozen in liquid nitrogen with extra 10% ethylene glycol as cryoprotectant 
for measurements. Data sets were collected on a PILATUS 6MF detector at the Swiss Light 
Source beamline X06SA of the Paul Scherrer Institute (Villigen, Switzerland) and indexed, 
integrated and scaled with the XDS174 and CCP4 programs.175 The structures were solved by 
molecular replacement with PHASER176 using the CREBBP structure (PDB entry 4NR5) as a 
search model and refined with PHENIX.177 The atomic coordinates and structure factors of 
CREBBP in complex with inhibitor 45 have been deposited with the Protein Data Bank as 
entry 4TQN. 
Table 7 
Compound 45 
Space group P1 21 1
Unit cell  
a (Å) 24.94
b (Å) 42.94
c (Å) 51.98
alpha 90.00
beta 97.24
gamma 90.00
Resolution range (Å) 42.94 -1.70
Unique reflections 12119(1768)
<I/σ(I)> 15.6(5.3)
R merge 0.068(0.380)
Completeness (%) 99.9(99.2)
Multiplicity 6.5(6.2)
Refinement
Resolution range (Å) 33.00-1.70
R factor/R free 0.1813/0.1990
Mean B factors (A2) 23.24
RMS bonds (Å) 0.006
RMS angles (°) 1.155
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II. Composite Omit Map of Ligand 45 
 
Figure 27. 2mFo – DFc electron density maps contoured at 1σ (grey mesh) were 
generated in a region within 1.6 Å for compound 45 using PHENIX and Pymol.  
3.3.7 Thermal shift measurements 
Thermal shift measurements were carried out as previously described17 with a final volume 
of 20 µl, ligand and protein concentrations 100 µM (50 µM for compound 57) and 2 µM, 
respectively.  The reported values (ΔTm) are calculated as the difference between the 
transition midpoints of an individual sample and the average of the reference wells (containing 
the protein and the DMSO only) in the same plate. DMSO concentration was kept at 0.2% 
(v/v). 
I. Phylogenetic tree  
The bromodomain sequence aligment previously reported by Filippakopoulos et al. was 
used excluding the residues from the plasmid.31 The evolutionary history was inferred using the 
Neighbor-Joining method.178 The optimal tree with the sum of branch length = 21.33784094 is 
shown. The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were 
computed using the Poisson correction method179 and are in the units of the number of amino 
acid substitutions per site. The analysis involved 61 amino acid sequences. All positions 
containing gaps and missing data were eliminated. There were a total of 57 positions in the 
final dataset. Evolutionary analyses were conducted in MEGA6.180 
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II. Selectivity profiles 
 
Figure 28.  Bromodomain phylogenetic tree showing the selectivity evaluation of 45 as 
determined by thermal shift measurements (ΔTm) against a panel of different 
bromodomains. Sphere size and color indicate relative ΔTm values according to the 
legend. 
 
Figure 29.  Bromodomain phylogenetic tree showing the selectivity evaluation of 
compounds 58, 60, and 61 as determined by thermal shift measurements (ΔTm) 
against a panel of different bromodomains. Sphere size and color indicate relative ΔTm 
values according to the legend, which is different from the one of the previous figure.  
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Figure 30.  Selectivity evaluation of compounds 40, 45, 46, 48, 53, 54, 58-62, 64-66 
as determined by thermal shift measurements (ΔTm) against a panel of seven 
bromodomains. Independent measurements are shown as dots and the median is shown 
as a circle. The dashed line at 1°C is an arbitrary threshold based on the scatter plot in 
Figure 31.  
3.3.8 TR-FRET assays 
TR-FRET assays were carried out in duplicate at BPS Bioscience using a recombinant 
CBP bromodomain (BPS catalogue #31128) and the BET Ligand (BPS catalogue #33000) as 
provided in the CREBBP TR-FRET Assay Kit (BPS catalogue #32619). A 10 mM solution of 
the compound under investigation in DMSO was prepared and shipped to BPS Bioscience, 
where it was tested at 10 concentrations over the range of 0.001-10 µM (compounds 45, 46, 
48-52, 54-58, 60-62) or 0.01-100 µM (compounds 40-44, 47, 53, 59, 63) . Each compound 
solution was then diluted in water to obtain a 10% DMSO solution. 2 µL of this dilution were 
added to a 20 µL reaction mixture (12.5 nM CBP, 125 nM BET Ligand, including FRET dyes 
and the amount of compound needed to reach the indicated concentration in the Table below). 
The resulting mixture was incubated for 2 hours at room temperature prior to reading the TR 
40 45 46 48 53
54 58 59 60 61
62 64 65 66 
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(time resolved)-FRET signal using a Tecan Infinite M1000 plate reader. The negative control 
consisted of the aforementioned mixture in which the buffer was added in place of compound.  
TR-FRET were recorded as the ratio of the fluorescence of the acceptor and the donor dyes 
(acceptor/donor). 
The TR-FRET data was analyzed using Graphpad Prism software. The percent activity in 
the presence of each compound was calculated according to the following equation: % activity 
= [(F- Fb)/(Ft – Fb)]×100, where Ft is the TR-FRET signal in the absence of any compound 
(100 % activity), Fb the TR-FRET signal in the absence of the bromodomain (0 % activity) 
and F the TR-FRET signal in the presence of the compound. The percent inhibition was 
calculated according to the following equation: % inhibition = 100 - % activity. The values of 
% activity versus a series of compound concentrations were then plotted using non-linear 
regression analysis of Sigmoidal dose-response curve generated with the equation Y=B+(T-
B)/1+10((LogIC50-X)×Hill Slope), where Y=percent activity, B=minimum percent activity, 
T=maximum percent activity, X= logarithm of compound and Hill Slope=slope factor or Hill 
coefficient. The IC50 value corresponds to the concentration causing a half-maximal percent 
activity. 
3.3.9 BROMOscan assays 
Kd determinations by means of BROMOscan technology was carried out at DiscoveRx. E. 
coli derived from BL21 strain was used as host to grow T7 phage strains displaying the 
bromodomains. E. coli, grown to log-phase, were infected with T7 phage (from a frozen stock, 
being the multiplicity of infection 0.4) and incubated while shaking at 32 °C for 90-150 
minutes, until lysis. In order to remove cell debris, lysates were centrifuged at 5,000 x g and 
filtered (0.2 μm). Affinity resins were obtained by treating streptavidin-coated magnetic beads 
with biotinylated acetylated peptide ligands for 30 minutes at 25°C. Those beads were then 
blocked with excess of biotin and washed with blocking buffer (SeaBlock (Pierce), 1 % bovine 
serum albumin, BSA, 0.05 % Tween20, 1 mM dithiothreitol, (DTT) removing the unbound 
ligand and reducing non-specific phage binding.  
During the experiment, the bromodomain, ligand-bound affinity beads and test compounds 
were combined in a buffer composed of 17% SeaBlock, 0.33x phosphate-buffered solution, PBS, 
0.04% Tween20, 0.02% BSA, 0.004% sodium azide and 7.4 mM DTT. Test compounds were 
prepared as 50 mM in pure DMSO and diluted to 5 mM with monoethylene gycol, MEG (100× 
concentrated in respect to the top screening concentration, 50 µM). During the assay a DMSO 
and MEG final concentration of 0.1% and 0.9% respectively was used. The assays were carried 
out in polystyrene 96-well plates in a final volume of 0.135 mL.  The assay plates were 
incubated at 25 °C with shaking for 1 hour and the affinity beads were washed with a buffer 
composed of 0.05% Tween 20 in PBS. The beads were then re-suspended in the elution buffer 
(1x PBS, 0.05% Tween 20, 2 μM non-biotinylated affinity ligand) and incubated at 25°C with 
shaking for 30 minutes. The bromodomain concentration in the eluates was measured by 
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qPCR. Binding constants (Kd) were calculated with a standard dose-response curve using the 
Hill equation and curves were fitted using a non-linear least square fit with the Levenberg-
Marquardt algorithm. 
3.3.10 ITC Experiments  
Isothermal Titration Calorimetry experiments were performed on a VP-ITC instrument 
(MicroCal, Inc., Northampton, MA). Protein samples thoroughly dialyzed against the same 
batch of buffer in order to minimize artifacts due to minor differences in buffer composition 
and the protein concentration was determined after a filtering through a 0.22 μm pore-size 
filter.  
Bromodomains (300-500 μM) were injected into the 1.4-mL sample cell containing the 
compound (50 μM) dissolved into the ITC buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 1% 
DMSO). The titration experiments were carried out at 15°C while stirring at 300 rpm: after a 
control injection of 2 µL, 29 10-μL injections (10 s duration, with a 4 min interval between) 
were performed. The raw data were integrated, normalized for concentration, and analyzed 
using a single binding site model, supplied with the MicroCal Origin software package to obtain 
the apparent Kd values (Kdapp). The actual Kd values were calculated assuming that DMSO 
acted as a competing ligand131 according to the equation:181 
ܭௗ ൌ ܭௗ
௔௣௣
1 ൅ ሾܦܯܱܵሿܭௗ஽ெௌை
 
where [DMSO] and KdDMSO indicate the DMSO concentration in the ITC buffer and the 
dissociation constant of the DMSO for the bromodomain under investigation, respectively 
(Figure S9).  
The KdDMSO value for CREBBP was calculated titrating the histone H3K56ac peptide (ac-
IRRYQ(Kac)STELLY-am, where ac-, -am and Kac, indicate acetylation, amidation and 
acetylated lysine side chain, respectively, purchased at GenScript) into a CREBBP 
bromodomain solution in the presence and absence of 0.75% DMSO with protein and peptide 
concentrations of 688 or 740 µM and 85 µM, respectively (Figure 35).  
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Figure 31. ITC titration curves for the binding of the CREBBP and BRD4(1) 
bromodomains (upper and lower panels, respectively) to compounds 45, 58, 60 and 66.  
 
Figure 32. The N-terminally acetylated, C-terminaly amidated IRRYQ(Kac)STELLY 
peptide was titrated into a CREBBP bromodomain solution in the absence of DMSO 
(experiment 1) and in the presence of 0.75% DMSO (experiment 2). The Kd for DMSO 
was calculated as shown in the right panel.  
  
45 58 60 66
45 58 60 66
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Table 8. Thermodynamic parameters measured by ITC for the CREBBP bromodomain. 
ΔG and ΔH values are given in kcal/mol, ΔS values are given in cal/mol/T.  
Cmpd N Kdapp (μM) ΔG ΔH ΔS
45 0.99 ± 0.01 8.13 ± 0.43 –6.7 –10.9 ± 0.1 –14.5
58 0.70 ± 0.00 1.11 ± 0.08 –7.9 –13.7 ± 0.1 –20.1
60 0.79 ± 0.00 3.25 ± 0.10 –7.2 –11.9 ± 0.0 –16.2
66 0.75 ± 0.00 5.69 ± 0.16 –6.9 –10.8 ± 0.0 –13.6
 
3.3.11 Cell culture and cytotoxicity measurements 
MDA-MB-231, HT-29 cells (obtained from the UZH Cancer Institute) and HeLa cells 
(obtained from Dr. Nathan Luedtke, Chemistry Department, UZH) were cultured in DMEM 
supplemented with 10 % (v/v) fetal bovine serum. K562 cells (obtained from Dr. Silvio Hemmi, 
Institute of Molecular Life Sciences, UZH), HL-60, ML2 (obtained from Dr. Nathan Luedtke, 
Chemistry Department, UZH) and HOP-92 (purchased from the NCI) were cultured using 
RPMI medium supplemented with 10 % (v/v) fetal bovine serum. Finally, AML3, PL-21 and 
MOLM-13 (obtained from Dr. Nathan Luedtke, Chemistry Department, UZH) were cultured 
using RPMI medium supplemented with 20 % (v/v) fetal bovine serum. All the media were 
additionally supplemented with 100 units/mL of penicillin, 100 μg/mL of streptomycin, 4.5 g/L 
glucose, 0.11g/L sodium pyruvate and 2mM glutamine and the cells were grown at 37 ºC in 5  
% CO2 atmosphere with 80 % relative humidity.  
MDA-MB-231, HT-29, HeLa, HOP-92 and PC-3 cells were plated at 10,000 cells per 
well (100 μL per well) in 96-well culture dishes and allowed to incubate for 24 h. The old media 
was removed, cells were washed with PBS (phosphate-buffered saline) and fresh medium was 
added. A 5 mM solution of inhibitor (in 100% DMSO) was serially diluted in the culture media 
(8 different concentrations were used) and allowed to incubate for 72 h (MDA-MD-231, HT-29, 
HOP-92, HL-60, ML2, AML3, PL-21, MOLM-13 and PC-3) or 48h (HeLa and K562). Control 
cells were treated with the same DMSO concentrations. After the incubation period the 
medium was removed, cells were washed with PBS to be then incubated with fresh medium 
containing 86 nM resazurin. Resazurin is reduced to the fluorescent resorufin in the 
mitochondria: the fluorescence intensity upon incubation in the presence of a living cell culture 
thus directly correlates with the metabolic viability of the cells.  Fluorescence was quantified 
after 4 hours using a fluorescence microplate reader (Biotek, FLx800TM, excitation and emission 
wavelengths 560 and 590 nm, respectively). The measured fluorescence values were corrected 
from the control samples containing DMSO.  
Leukemia cell lines (K562, HL-60, ML2, AML3, PL-21 and MOLM-13) were seeded at a 
density of 20,000 cells per well in 100 μL of RMPI media in 96 well microtiter plates. After 24 
hours, 12.5 μL of a 10 fold concentrated drug (or DMSO solution for the control) in RMPI 
media was added in every well. After 48 hour incubation, resazurin was added to every well to 
obtain a final concentration of 86 μM and, after 3 hours,  cell viability was assessed by 
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measuring the ability of the cells to process resazurin by quantifying the fluorescence using a 
fluorescence microplate reader (Biotek, FLx800TM) as described above.   
Table 9. Resazurin reduction (percentage of the control) upon incubation of 
compounds 45, 48, 49, 54, 58-62 for 48 or 72 h at a concentration of 50 µM in eleven 
different cancer cell lines. This preliminary screening of toxicity was done as a single 
experiment.  NM indicates no metabolic activity change in comparison to the DMSO-
tre ated cells. 
Cmpd MDA-MD-231 HT-29 HeLa HOP-92 K562 HL-60 ML2 AML3 PL-21 MOLM-13 PC-3
45 NM NM NM 80.3 98.3 77.1 98.3 86.8 90.2 65.2 87.7
48 90.7 NM 94.8 91.0 NM 62.8 NM 87.3 74.7 15.1 84.3
49 NM NM 97.6 71.9 NM 87.8 97.3 90.0 86.0 NM 89.1
54 86.7 NM 93.2 97.8 81.3 43.2 64.1 63.0 59.4 50.2 94.1
58 NM NM 84.5 65.3 84.8 42.1 53.2 68.9 69.2 49.4 65.0
59 84.3 NM 94.2 72.8 NM 90.3 NM 98.7 NM 76.3 99.9
60 94.4 NM 90.4 77.3 NM 84.7 NM 96.9 94.3 73.2 81.8
61 88.2 NM 89.3 78.3 90.8 45.7 26.5 69.9 70.5 43.0 64.1
62 NM NM NM NM 99.2 68.6 NM 84.2 86.3 74.8 69.5
 
Table 10. Metabolic activity values (%) on three different leukemia cell lines at 50 µM 
compound concentration.[a]  
Cmpd 
HL-60 ML2 MOLM-13 
Acid Ester Acid Ester Acid Ester 
45 80 78 93 75 71 46 (46 µM)[b] 
48 78 89 66 97 19 (33 µM)[b] 82 
49 89 89 100 86 89 88 
50 77 85 88 99 73 76 
54 59 - 107 - 57 - 
58 59 96 91 85 60 90 
59 89 - 102 - 91 - 
60 81 74 104 73 85 66 
61 65 73 93 36 (14.4 µM)[b] 61 11 (5.3 µM)[b] 
62 82 88 66 60 60 26 (37 µM)[b] 
[a] Metabolic activity values were determined using resazurin reduction after 72 h 
incubation with the corresponding compound in comparison to DMSO treated cells at 
eight different concentrations (100-0.8 µM). The % of metabolic activity at 50 µM 
compound concentration is shown. The % of metabolic activity is given as the mean of 
at least three independent experiments. Variability around the mean value was < 26 % 
in all cases. [b] Values in parentheses are GI50 values as determined by triplicate 
experiments with less than 30 % standard error. 
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3.3.12 Comparison table to known CREBBP ligands  
Table 11. Activity and selectivity of acyl benzene derivatives and comparison with previously 
reported CREBBP bromodomain ligands.  
Cmpd LE[a] LLE 
 Kd (µM) ITC  Kd (µM) competition binding assay144-145  ΔTm (°C)[b] 
 CBP  CBP BRD4(1) BRD4(2) BRD2(1,2) S[c]  CBP EP300 BRD4(1) 
This study      
45 0.35 3.7  2.0  0.77 >50 >50 >50 >65  3.6 3.4 0.5 
58 0.32 3.2  0.3  0.17 10 36 36 59  4.9 5.9 1.7 
60 0.32 4.0  0.8  0.54 26 >50 >50 48  5.0 4.6 1.3 
61 0.28 3.8  –  0.40 - - - -  6.0 5.9 1.6 
Reported by others      
31126 0.25 2.4    0.20[d] 0.16[d] - - 0.8  7.6 - 4.4 
32125 0.29 4.3 
 
0.3 
 
 1.38[e] - - 4  5.4 - – 
3399 0.27 2.0  0.021  0.080[d]  0.85 5.2 - 40  9.7 9.7 1.8 
[a] LE = ligand efficiency calculated as (ΔG/number of heavy atoms) is reported in 
kcal/mol per heavy atom; LLE = lipophilic ligand efficiency (calculated as             
pKd-clogP),150-151 clogP was calculated using ChemDraw. [b] Median value of the shift in 
the melting temperature (number of measurements between 9 and 38 per 
compound/protein pair). The largest SEM was 0.5 °C and most SEM values were 
below 0.2 °C. [c] Selectivity (S) between the CREBBP and BRD4(1) bromodomains 
determined by the ratio of Kd values obtained via the competition binding assay. It was 
not possible to calculate the selectivity using the Kd values obtained via ITC due to the 
impossibility to reliably fit the titration curves for the BRD4(1) bromodomain. [d] 
Potency determined by AlphaScreen. [e] Potency determined by Isothermal Titration 
Calorimetry (ITC).………………………….…………………………………………………………………………………………….
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4 
TOWARDS THE DISCOVERY OF SMALL 
MOLECULE ACTIN BINDERS 
 
Actin is the most abundant eukaryotic protein and participates in many important 
cellular functions such as muscle contraction, cell motility, cell division, vesicle and 
organelle movement, cell signaling and establishment and maintenance of cell junctions and 
cell shape. The importance of the actin cytoskeleton in pathogenic processes such as 
angiogenesis and metastasis has made it an attractive target for the development of new 
anticancer drugs. However, up to date no small organic molecules have been developed 
that could validate the therapeutical potential of actin. Instead, there are a variety of 
complex natural products that interact with this protein, whose therapeutical applications 
have not been studied due to the scarce amounts in which these molecules can be isolated 
from their natural sources. 
The project presented in this chapter aims, in collaboration with the group of Prof. 
Amedeo Caflisch (Biochemistry Department, UZH), to apply and develop new methods for 
the in silico discovery of novel actin binding molecules inspired by natural product “small 
molecules” (NPs).  
In the next section, a general overview of the actin cytoskeleton and the known actin 
binding natural products is given.  To the introduction section, the results and discussion 
follow, and the chapter finishes with a conclusion section. 
4.1 Introduction 
4.1.1 Cytoskeleton fibers 
The cytoskeleton is a dynamic three dimensional structure that fills the cytoplasm in 
eukaryotic cells and acts as both, motor and framework.1 The cytoskeleton is mostly 
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composed of long fibers (polymers) stemming from the repetitive assembly and disassembly 
of certain proteins.  
Three different types of fibers can be distinguished within the cell cytoskeleton 
according to their composition and size (Figure 1). The smallest fibers (3-6 nm in 
diameter) are referred to as microfilaments and are composed of actin (Figure 1, left), the 
protein of interest in this work. The biggest fibers (20-25 nm in diameter) are called 
microtubules, they adopt the shape of hollow cylindrical tubes and are composed of the 
cytoskeletal protein tubulin (Figure 1, middle). The size of intermediate filaments lies 
between microfilaments and microtubules, as they are 10 nm in diameter (Figure 1, right). 
Intermediate filaments are heterogeneous structures composed of a variety of fibrous 
proteins that provide the tensile strength to the cell and can only be found in organisms 
with multicellular organization such as vertebrates, nematodes and mollusks.  
 
Figure 1. Components of the cytoskeleton in the epithelial cells of the intestine: 
actin filaments (red), mictrotubules (yellow) and intermediate filaments (blue). 
Microfilaments give the shape to the cell surface, while microtubules grow out of 
the centrosome to the cell periphery and intermediate filaments connect adjacent 
cells.2 
Out of the three above-mentioned types of cytoskeletal fibers, tubulin has been the 
most studied by far. Tubulin is a 50 kDa in size globular protein that represents 3-4 % of 
the total protein content in all eukaryotic cells. It can be found in different forms (α-, β-, 
γ-, δ-, ε-, and ζ-tubulin) depending on its cellular location and function. α- and β-Tubulin 
subunits form heterodimers, which assemble into protofilaments that build up microtubules 
of variable length (200 nm – 25 µm) as depicted in Figure 2. For heterodimers to associate 
between each other forming protofilaments, both, α- and β-tubulin subunits must have a 
GTP (guanosine triphosphate) molecule bound. As the heterodimers associate, the GTP 
bound to β-tubulin hydrolyses into GDP (guanosine diphosphate), which remains bound to 
the α-tubulin subunit (close-up in Figure 2). Finally, the protofilaments associate laterally 
to form sheets, and eventually microtubules are assembled. During this process, accessory 
proteins are able to influence the stability and dynamics of mictrotubule assembly.  
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Figure 2. Structure of microtubules. Microtubules are formed by the 
macroassembly of protofilaments into hollow cylinders. The protofilaments are 
composed of repeating units of α- and β-tubulin heterodimers. A tubulin 
heterodimer in complex with the tubulin stabilizer taxol (shown as a surface 
representation in magenta) is given as a close-up on the right hand side. PDB code 
1JFF.2 
Mircrotubules are responsible for a wide variety of key cellular functions. They provide 
the structural framework that maintains the cell shape and influences the organization of 
various organelles and components of the cytoskeleton, as well as the formation of an 
internal transport network for vesicles and organelles (including mitochondria and 
lysosomes). Moreover, the rigid internal core provided by microtubules is employed by 
microtubule associated motor proteins to generate force and movement in motile structures 
such as cilia and flagella, that are tail like protusions of certain prokaryotic and eukaryotic 
cells that play an important role in cell locomotion and as sense organs. More importantly, 
microtubules form the spindle apparatus during cell division (Figure 3) ensuring the proper 
segregation of duplicated chromosomes into daughter cells during cytokinesis, the process 
in which the cytoplasm of a cell is divided into two. The spindle apparatus also regulates 
the assembly and location of an actin-rich contractile ring that pinches and separates the 
two daughter cells (see section 4.1.2 for further details).  
 
 
Figure 3. Spindle apparatus formed during cell division. 
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Due to its key biological functions, tubulin has been widely studied and several 
compounds able to interfere with tubulin assembly have been reported and applied for 
cancer treatment, such as paclitaxel, also known as taxol (Figure 2).3 In contrast, actin has 
recently been recognized as a potential therapeutic target and its key role in numerous 
diseases is starting to be unraveled. A general introduction to actin focusing on actin 
binding proteins and natural products is given in the next sections.  
4.1.2 Actin structure: G actin vs. F actin 
Actin is the most abundant protein in eukaryotic cells representing 5-10 % of the total 
protein content in cells, increasing up to 20 % in muscle.4 Actin is also one of the most 
highly-conserved proteins in nature, sharing more than 80 % of its structural constituents 
in species as remotely related as humans and algae.5 
Actin exists in monomeric form (referred to as globular or G-actin) or as a polymer 
(known as filamentous or F-actin). G-actin is 43 kDa in size and can be divided into four 
subdomains (Figure 4, right).6, 7 The so called cleft region is located in the middle of the 
four subdomains and is usually occupied by an ATP (adenosine triphosphate) or ADP 
(adenosine diphosphate) molecule, together with a divalent cation, Ca2+ or Mg2+, (Figure 4, 
right).8 G-actin can reversibly self-assemble through non-covalent interactions into long 
and double-stranded helical polymers known as filamentous or F-actin (Figure 4, left and 
middle). Unfortunately, no high-resolution X-ray structure of F-actin is yet available, and 
thus, several models of the filament have been proposed.9, 10              
 
Figure 4. Left: Representation of F-actin derived from Holme’s model.9 Middle: 
Close-up of a model of three actin monomers forming an F-actin filament.10 Right: 
X-ray structure of G-actin in complex with ATP (shown as sticks) and a Mg2+ ion 
(PDB code 1WUA). The four subdomains are indicated in different colors and the 
ATP-binding cleft is specified.  
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I. Mechanism of actin polymerization 
The ATP-dependent polymerization mechanism in which G-actin assembles into F-
actin can be divided into four reversible steps:  activation, nucleation, elongation and 
annealing (Figure 5).11  
As a first step of the actin polymerization process, salts induce a conformational 
change in G-actin, causing ATP-bound monomers (three or more) to associate with each 
other forming oligomers (referred to as the nucleation step). This step constitutes the rate 
determining step of actin polymerization, which generates a lag time.5  
After the nucleation sites are formed, the elongation step starts: F-actin polymers 
grow at both ends of the filament, ‘‘pointed end’’ (-) and ‘‘barbed end’’ (+), generating 
filament polarity. The “barbed end” or “plus end” (which elongates five to ten times 
faster) is comprised of subdomains 2 and 4, whereas the “pointed end” or “minus end” 
consists of subdomains 1 and 3 (Figure 5, close-up).12, 13 During polymerization, ATP 
hydrolyses into inorganic phosphate and ADP, resulting in a conformational change in 
subdomain 2 of actin (Figure 5, close-up).8, 14 Elongation continues until the monomer 
concentration reaches the critical concentration (see Figure 6 for further information).  
Dissociation of actin monomers from the filament takes place mainly at the “pointed 
end”).11 At the end of the polymerization, the actin filament assembly reaches a steady 
state where dissociation and association are equal and the actin filaments appear to 
“treadmill”, maintaining the filament length almost constant.15 As a final step, actin 
filaments can also associate with each other in a process called annealing.16 
 
Figure 5. ATP-dependent polymerization of G-actin into F-actin. As a close-up a 
schematic representation of F-actin is given, where the four different subdomains 
and the two filament ends, the ‘‘barbed end’’ (or + end) and the ‘‘pointed end’’ (or 
– end), are indicated.  
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In order for polymerization to take place, several factors such as pH and salt 
concentration need to fall under a controlled range. Furthermore, even at optimal pH and 
salt concentration, a minimum concentration of G-actin monomers is required, referred to 
as the critical concentration (Cc). The critical concentration (Figure 6) is defined as the 
monomer concentration at which the association rate (rate of G-actin addition onto the 
filament, k+) equals the dissociation rate (rate of G-actin dissociation from the filament,   
k-). Dissociation is dominant below the critical concentration, whereas above the critical 
concentration the association process is favored. An estimation of actin association and 
dissociation rates on actin is given in Figure 6, right.  
 
 
 Cc k+ k- 
(-) end 0.6 µM 1.3 µM -1 s -1 0.8 s -1 
(+) end 0.12 µM 12 µM -1 s -1 1.4 s -1 
 
 
 
 Figure 6. Left: Schematic representation of the effect of the critical concentration 
(Cc) during the actin filament assembly process. Actin filaments start polymerizing 
only at concentrations above the Cc.2 Right: Actin association and dissociation 
rates on actin filaments. Relative actin association (k+) and dissociation rates (k-) 
depend on the monomer concentration and the critical concentration (Cc).17 
The value of the critical concentration depends on several conditions such as ionic 
strength of the solution, presence of divalent cations, pH and temperature. At low salt 
concentrations, for instance, the critical concentration is high and actin will not polymerize 
even at high monomer concentrations. Alternatively, the addition of salt, 20-100 mM KC1 
and/or 0.5-5 mM MgCl2, to a solution of monomers induces polymerization.18 The effect 
that the pH, ionic strength, nucleotide type, ions and temperature have on actin 
polymerization has been summarized in Table 1.  
Table 1. Effect of solution conditions on actin polymerization.19 
 Favours F-actin Favours G-actin 
pH Low (5-6) High (8-9) 
Ionic strength Moderate (0.1M NaCl) Low (zero) 
Nucleotide ATP ADP 
Divalent cation Mg2+ Ca2+ 
Temperature High (37 °C) Low (4 °C) 
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II. Biological function of actin 
The actin cytoskeleton is responsible for a wide range of key cellular functions. Due to 
its strong and dynamic character, it guarantees cell durability, maintains the cell shape 
and anchors cytoskeletal proteins; whereas thanks to its flexibility it can accommodate the 
multiple and varied demands of the cell.20-23  
Actin microfilaments interact with other cytoskeleton fibers (see section 4.1.1). On the 
one hand, they cooperate with microtubules via microtubule-associated proteins during the 
transport of vesicles and organelles.24 On the other hand, they enable extracellular stimuli 
to be transmitted to key targets like ribosomes and chromosomes in cooperation with 
intermediate filaments.25 
The distribution of actin filaments is highly dependent on the specific function of the 
cell or tissue. In polarized cells such as those of the epithelium, actin filaments play a key 
role in tissue organization and establishment of cell polarity and cohesion (Figure 7). As an 
example, a dense bundle of cross-linked actin filaments form the structural core of 
microvilli, which are microscopic membrane protrusions that increase the surface area of 
cells (Figure 7, left). Furthermore, the integrity of epithelial cell layers is maintained by a 
belt of actin (adhesion belt, Figure 7, middle), which links the cytoskeleton between 
adjacent cells, and by a cell cortex (Figure 7, right), which determines the shape, stiffness 
and movement of the cell surface.  
 
Figure 7. Actin filament distribution in epithelial cells. 
Actin filaments are the primary cytoskeleton components that drive cell motility 
(Figure 8), and as such, they are highly abundant in membrane protrusions that are used 
by cells to migrate (called filopodia and lamellipodia). Cell movement is essential for the 
formation of tissue during embryonic development, wound healing and immune responses, 
and errors during this process could have serious consequences, including mental 
retardation, vascular disease, tumor formation and metastasis.  
Two main theories have been developed to explain the movement of a cell’s front edge: 
the cytoskeletal and the membrane flow model. According to the cytoskeletal model 
(Figure 8, A) the cell cortex (Figure 7, right) in moving cells is concentrated towards the 
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leading edge, where rapid actin polymerization occurs.26 The formation of actin filaments 
pushes the leading front forward and, as a consequence, the cell migrates.27, 28 On the other 
hand, the membrane flow model states that the extension of the leading edge is the result 
of membrane addition through exocytosis (Figure 8, B).29  
 
Figure 8. Two main models of cell migration. A) Cytoskeletal model: actin 
polymerization drives cell movement. B) Membrane flow model: membrane is 
brought towards the leading edge of the cell through exocytosis.  
In muscle cells, actin-associated myosin motor proteins use ATP hydrolysis that takes 
place upon actin polymerization to apply forces against stress fibers during muscle 
contraction.30 The energy liberated during ATP hydrolysis can also be converted to tensile 
force that retracts the edge of motile cells. Alternatively, in non-muscle cells, actin 
filaments function as “track” for cargo transport myosins (non-conventional myosins), 
which use ATP hydrolysis to transport vesicles and organelles.  
The actin-based structures previously described are disassembled before cell division, 
which causes the cell to stop moving and become rounded. During cell division, actin 
bundles play the key role of orienting the microtubule network. Moreover, the proper 
assembly, orientation, and contraction of the actin filament ring (contractile ring) pinches 
and separates the daughter cells during cytokinesis in cell division (Figure 9). 
 
Figure 9. Actin filament distribution during cytokinesis in cell division. 
4.1.3 Actin binding molecules 
I. Actin binding proteins  
 As seen in the last section, the actin cytoskeleton is of upmost importance for a 
wide variety of cellular processes that demand an accurate control of the interchange 
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between monomeric G-actin and polymeric F-actin filaments. Proteins that bind to G-actin 
monomers or F-actin filaments are able to influence the actin filament assembly and 
disassembly process in different ways that are classified as follows: monomer 
‘‘sequestering’’ proteins, nucleating proteins, ‘‘capping’’ and ‘‘severing’’ proteins, stabilizing 
and crosslinking proteins (Figure 10).31, 32 
 
Figure 10. Overview of actin binding proteins classified according to their mode of 
action in ‘‘sequestering’’, nucleating, ‘‘capping’’, ‘‘severing’’, stabilizing (not shown) 
and crosslinking proteins.32 
G-actin monomer binding proteins (also called “sequestering” proteins) are able to 
bind to G-actin monomers. Profilin is a representative example, as it facilitates the 
exchange of ADP by ATP in G-actin, thus enabling actin polymerization (Figure 10, A).33  
Actin nucleating proteins ease oligomer formation during nucleation, which is the rate 
determining step of the actin polymerization process. The ARP2/3 complex is a nucleating 
protein that binds to two G-actin monomers and the side of an F-actin filament 
simultaneously, resulting in the formation of a new F-actin filament (Figure 10, B).28 
Another example of nucleating proteins are formins, which in cooperation with profiling (a 
“sequestering” protein) nucleate new filaments.34 Spire has also been recently recognized as 
an actin nucleator that is able to recruit four actin monomers forming a nucleation seed for 
actin polymerization to begin.35  
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The so called “capping” proteins cover one of the F-actin filament ends, inhibiting as a 
consequence, the addition and loss of G-actin monomers. “Severing” proteins, on the other 
hand, promote the disassembly of actin filaments. CapZ, for instance, prevents 
polymerization by “capping” the “barbed end” of the filament, whereas cofilin is able to 
“sever” actin filaments inducing “pointed end” depolymerization.36 Interestingly, proteins 
like gelsolin are able to perform both processes, “cap” and “sever” F-actin filaments.37  
Another type of actin binding proteins are classified as crosslinking proteins, which 
influence the packing and organization of actin filaments into secondary structures, 
including unordered networks (filamin), tight (fimbrin) and loose (α-actinin) bundles.38 
The last type of actin binding proteins, the so called stabilizers, such as tropomyosin, 
stabilize F-actin filaments inhibiting their depolymerization.   
Alternatively, actin filament assembly can be modulated by external processes 
(referred to as upstream regulation), such as controlled nucleotide hydrolysis (e.g. ATP on 
actin) and reversible modifications (e.g. phosphorylation) on components that control the 
actin assembly process. As an example, cofilins are inhibited as soon as they are 
phosphorylated by kinases.36 As their phosphate group is removed by dephosphatases, 
cofilins are reactivated and are able to regulate the actin polymerization process by 
“severing” F-actin filaments. 
II. Actin binding natural products 
In addition to the extensive research and the wide variety of proteins known to 
interact with actin, actin binding natural products have also greatly contributed to the 
study of actin dynamics. Most of these secondary metabolites are of marine origin and play 
a role in the chemical defense of the organisms where they originate. Interestingly, they are 
able to mimic the mode of action of proteins by “sequestering” monomers, “capping” 
and/or “severing” filaments and promoting polymerization by nucleation or by 
stabilization of the filaments. Actin binding natural products are classified into two main 
groups: destabilizers (which inhibit F-actin filament assembly or destabilize filaments) and 
stabilizers.  
a) Actin destabilizers 
There are two different binding pockets in G-actin where actin destabilizers are known 
to bind: the ATP binding site (only targeted by latrunculins) and the “barbed end” 
(Figure 5).  
Most actin destabilizers interact in a hydrophobic region of the “barbed end” (such as 
swinholide A,39 misakinolide,40 reidispongiolide,41 sphinxolide B,42 mycalolides,43 
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kabiramides,43 aplyronine,44 bistramide45, 46 and cytochalasins47). These molecules possess a 
large macrocycle and display a long and stereochemically complex side chain usually 
terminated in a highly polar functional group (e.g. formamide, Figure 11). 
Their macrocyclic moiety binds in a hydrophobic cleft between subdomains 1 and 3 of 
the “barbed end”, followed by the intercalation of the molecule’s tail into the cleft 
separating the two subdomains.38, 48 Three examples of natural products that bind within 
subdomains 1 and 3 and their binding mode are given in Figure 12.  
 
Figure 11. Structural diversity in actin destabilizing natural products of marine 
origin.  
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Figure 12. Structures of aplyronine A (PDB code 1WUA), bistramide A (PDB 
code 2FXU) and swinholide A (PDB code 1YXQ) in their respective complexes 
with actin. Actin is shown as a ribbon representation and toxins are shown as 
sticks in light blue. The toxins interact with the ‘‘barbed end’’ of the filament, 
between subdomains 1 and 3.  
Taking their mode of action into account, actin destabilizing toxins targeting the 
“barbed end” can be divided into those that “sequester” actin monomers (either in a 1:1 or 
in a 1:2 ratio), “severe” F-actin filaments by disrupting interactions between adjacent 
monomers (such as mycalolides,43 aplyronine A44 and bistramide A45, 46) and/or “cap” the 
end of the filament inhibiting monomer association or dissociation (such as cytochalasins47 
and misakinolide40). Interestingly, several natural products are able to do both, “cap” and 
“sever” actin filaments (such as swinholide A,39 reidispongiolide,41 sphinxolide42 and 
kabiramides43). An schematic description of the above-mentioned mode of actions is 
provided in Figure 13, and further details can be found in Table 2.  
 
Figure 13. Possible mode of action of actin destabilizers. Actin destabilizers can 
“sequester” monomers and “cap” or “sever” the F-actin filaments.  
Bistramide A and cytochalasin are two structurally different actin destabilizers that 
bind within the “barbed end” (Figure 12) that are worth mentioning.45-47 The interaction of 
Bistramide A with actin takes place through the entire length of the hydrophobic cleft and 
it involves more polar contacts than other natural products (Figure 12, middle).45, 46 
Bistramide A does not only “sequester” actin in a 1:1 ratio, but it is the only actin 
destabilizer able to covalently modify actin.45, 46 Cytochalsin, on the other hand, promotes 
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nucleation and “caps” the “barbed end” of the filament (Table 2), a unique mode of action 
among actin destablizers.47  
Table 2. Binding site, mode of action and main structural features of actin 
destabilizers.  
Binding type 
Natural 
product 
Mode of action
Structural 
features 
Sequestering 
ratio 
Severing
Capping
barbed 
end 
Other 
Bind at the 
nucleotide cleft 
Latrunculins49, 50 1:1 - - - 
Medium ring size.
Thiazolidinone ring, 
no side chain 
Bind between 
subdomains 1-3 
Swinholide A39 2:1 √ √ - > 40 membered 
ring macrolides, 
symmetric 
structures,  2 
lateral chains 
Misakinolide40 2:1 - √ - 
Reidispongiolide41 1:1 √ √ - 
25-30 membered 
ring macrolides, one 
polar lateral chain 
Sphinxolide B42 1:1 √ √ - 
Mycalolide43 
(trisoxazole) 
1:1 √ - - 
Kabiramide43 
(trisoxazole) 
1:1 √ √ - 
Aplyronine44 1:1 √ - - 
Bistramide45, 46 1:1 √ - 
Covalent 
modification 
of actin 
Polyether 
Cytochalasins47 1:1 - √ Promotes 
nucleation 
Rigid bicycic 
isoindolone core 
fused to a 
macrocycle 
 
Latrunculins, which are the focus of this work, are the only actin binding natural 
products able to bind within the ATP binding cleft that is located at the “pointed end” of 
the actin filament. Latrunculin cytotoxins are isolated from the Red Sea sponge Negombata 
Magnifica49, 50 and are very efficient actin polymerization inhibitors by “sequestering” G-
actin in a 1:1 complex.51 They possess a biologically rare thiazolidinone ring that is buried 
in the binding site and a hydrophobic macrocyclic ring. The thiazolidinone ring is involved 
in five intramolecular hydrogen bonds with the protein (one of which is water mediated) as 
illustrated in Figure 14.   
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Figure 14. Crystal structure of actin-latrunculin complex, PDB code 1ESV.49 As a 
close-up, the hydrogen bonds that latrunculin forms with G-actin are shown as 
dashed lines, in a 3D representation. On the right, a 2D representation of 
latrunculin’s binding mode is given. Latrunculin is shown in blue and the hydrogen 
bonds are shown as dashed lines  
 b) Actin stabilizers 
Actin stabilizers constitute another class of actin binding natural products. No X-ray 
structure of actin stabilizers with F-actin has yet been solved in complex with actin. 
However, information about the binding mode of actin stabilizers has been been studied 
based on X-ray fiber diffraction data, electron microscopy and biochemical analysis.52-55 
Actin stabilizers present a cyclic depsipeptide as common structural feature (Figure 
15). As well as stabilizing F-actin filaments, some actin stabilizers are able to promote 
nucleation and/or induce actin polymerization in non-polymerizing conditions (Table 1), 
referred to as nucleators (such as jasplakinolide,56 chondramides57 and dolastatin58). A more 
detailed explanation of actin stabilizers’ mode of action is given in Table 3.  
  
Figure 15. Chemical structure of some actin stabilizing natural products. 
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Table 3. Mode of action and main structural features of actin stabilizers.  
Natural product 
Mode of action
Structural features F-actin 
stabilizer 
Polym. 
inducera 
Nucleation
promoterb 
Competition
with phalloidin 
binding site 
Other 
Phalloidin59 √ - - - - Bicyclic heptapeptide
Jasplakinolide56 √ √ √ √ - 
16-19 membered 
cyclic depsipeptide 
Chondramide57 √ √ n.r. √ - 
Doliculide60 √ √ n.r. √ - 
Dolastatin58 √ √ n.r. - - 30 membered cyclic 
depsipeptide 
Amphidinolide H55, 61 √ - - - 
Covalent 
modification 
of actin 
26 membered 
macrolide. Allyl 
epoxide 
Hectochlorin62 √ √ √ - - 19 membered 
macrolyde 
aInduces actin polymerization under non polymerizing conditions. bHelps the 
nucleation (rate determining step), thereby decreasing the lag-time. n.r. not 
reported 
Phalloidin is one of the best known actin filament stabilizing compounds.59 Its binding 
mode has been characterized by microscopic and X-ray fiber diffraction methods, which 
showed that it interacts with three actin monomers simultaneously via three different 
binding sites enhancing filament stability (Figure 16).53 Moreover, phalloidin has been 
labelled with different fluorophores, which have been successfully applied to visualize F-
actin in cell based studies. 
 
Figure 16. Binding sites of actin-stabilizing macrolides. Phalloidin interacts with 
three monomers simultaneously,53 whereas dolastatin binds between subdomain 4 
and subdomain 1 of the diagonal subunit.63 Amphidinolide H (not shown) is known 
to form a covalent bond with Tyr198 in yeast or Tyr200 in mammalian actin (blue 
sticks).55 
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Amphidinolide H, presents a unique chemical structure among actin stabilizers with 
the presence of an epoxide ring.55, 61 A tyrosine residue located in subdomain 4 of actin 
(Tyr198 in yeast, Tyr200 in mammalian actin) is able to nucleophilically attack the 
epoxide moiety forming a covalent bond.……………………………………………………………………………………  
4.2 In Silico design of actin inhibitors 
4.2.1 Challenges and overview of the project 
The discovery of new, versatile actin binding small molecules is highly valuable. First 
of all, actin binding molecules present a different and unique mode of action when 
interfering with the highly complex dynamics of the actin cytoskeleton, and they are thus 
valuable tools to study cellular pathways that are dependent on the actin cytoskeleton. 
Second, they are promising leads for anticancer drug development due to the direct 
implication of actin in cell motility (including cell invasion, division and metastasis)12 and 
the high cytotoxicity displayed by some actin binding natural products.21, 23, 64  
Cancer cells, which are defined as cells that have lost their regulatory mechanism to 
control their growth and proliferation, present an altered molecular composition, 
organization and polymeric state of the actin cytoeskeleton.65, 66 As actin is present in all 
cells, the main limitation of the above-mentioned actin binding molecules is the potential 
inespecificity of clinical candidates to distinguish between healthy and malignant cells. 
However, this caveat is also present in tubulin targeting molecules such as taxol, which is 
used as an anti-cancer drug.67 Nevertheless, as the rate of actin polymerization is enhanced 
in highly proliferative cells, the effect of actin binding molecules in cancer cells might be 
intensified, resulting in a cytostatic rather than in a cytotoxic effect.  
The first goal of this project was to develop an in silico fragment-based docking 
approach inspired by natural product small molecules (NPs) for the discovery of inhibitors 
targeting the nucleotide cleft of G-actin. The structural information available from X-Ray 
structures of natural products interacting with G-actin has revealed two distinct binding 
sites: a hydrophobic cleft between subdomains 1 and 3 where molecules bind to monomeric 
or dimeric G-actin (e.g. swinholide39, mycalolide43, etc…) and a nucleotide cleft located 
between subdomains 2 and 4 (targeted by latrunculins).51 We have chosen the nucleotide 
cleft as our working model due to the presence of polar interactions, especially buried 
hydrogen bonds that make the discovery of high affinity inhibitors more probable. The 
cleft located between subdomains 1 and 3, on the other hand, represents a shallower 
environment, and thus, the main contribution of inhibitor binding will take place via weak 
hydrophobic interactions.   
4.2 IN SILICO DESIGN OF ACTIN INHIBITORS 
183 
 
An overview of the work-flow of the project is given in Figure 17. First, we aim to 
design a focused library based on natural products and ATP binding drugs that can offer a 
high specificity towards finding actin binders. The library will then be fragmented in a 
retrosynthetic manner and the obtained fragments will be docked, ranked and evaluated 
according to their binding free energy. Finally, in order to select the most promising 
fragments, molecular dynamic (MD) simulations will be performed. The selected fragments 
will then be synthesized and their affinity towards actin will be evaluated using in vitro 
and cell based techniques.   
 
Figure 17. Work-flow of the project. Starting from a library of NP molecules, 
different fragments will be obtained and docked into the ATP binding site. The 
fragments will be ranked according to their predicted binding energy and selected 
for further studies, including chemical synthesis and biological evaluation.  
4.2.2 In silico design  
A general overview of the performed computer based design is given in this section. 
For further details, please refer to Sandra Rennebaum’s PhD thesis in the group of Prof. 
Amedeo Caflisch (‘‘Actin: computational design of novel inhibitors and study of the 
influence of the natural product latrunculin on conformational dynamics’’, Biochemistry 
Institute, UZH, 2012).  
First, a natural product based library composed of 140 000 compounds was 
constructed. Natural products are a major source of drugs, as more than 50% of 
antibacterials and 60% of anticancer compounds are based on nature’s secondary 
metabolites.68 Moreover, natural products are biologically pre-validated, relevant to nature 
and they can be considered as selected fractions of the chemical space during the course of 
evolution.69 Furthermore, they offer a structural diversity that cannot be found in 
synthetically prepared chemical compounds, which enables the study of a new part of the 
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chemical space not provided by currently available libraries such as ZINC,70 a commonly 
used library in in silico screening campaigns that is composed of commercially available 
molecules.  
The natural product based library was compiled by combining natural product subsets 
from a variety of sources: natural product subset of the August 2009 version of the ZINC 
library, the Human Metabolome Database, Mircrosource Discovery and the Traditional 
Chinese Medicine Database. After the removal of compounds containing metals, a library 
composed of 140 000 molecules was obtained (Figure 18).  
 
 
Figure 18. Work-flow of the in silico design of actin inhibitors. 
The NP library was then decomposed in a retrosynthetic fashion according to specific 
organic chemical reactions using the software ReCore and CoLibri71, 72 (Figure 19), so that 
all possible fragment combinations were taken into account in the next steps of the in silco 
design. As a result, a total of 1 200 000 fragments were obtained, which are chemically 
more feasible to synthesize. 
Only fragments with a molecular weight between 50-400 g/mol and up to ten 
rotatable bonds were kept, resulting in 150 000 fragments. A 400 g/mol cut-off was applied 
in order to retrieve small fragments for a later lead optimization, which generally results in 
an increased molecular weight and worse drug-like properties. Those fragments were 
docked using AutoDock73 and several poses per fragment (an average of 17) were obtained. 
An energy minimization of the poses in the rigid protein was then conducted using 
CHARMM.79, 80 
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Figure 19. Cleavage rules designed according to organic chemical reactions. 
In the next step of the in silico campaign an approach called consensus scoring was 
implemented. Consensus scoring combines several scoring functions that rank a set of 
docked poses according to their interaction energies, and has been shown to increase 
performance hit rates in virtual screening.74, 75 Five consensus scorings involving different 
force fields and parameters were evaluated in order to select the most promising fragments 
(Figure 20).  
Figure 20. Overview of the implemented consensus scorings. 
Different force fields were used in order to evaluate the interaction energies, including 
SEED (Solvation Energy for Exhaustive Docking),77, 78 CHARMM79, 80 (Chemistry at 
HARvard Molecular Mechanics) and TAFF (Tripos Atomic Force Field).76 Both the SEED 
total interaction energy77, 78 and the CHARMM total interaction energy79, 80 account for 
electrostatic and van der Waals interactions. Moreover, the SEED total energy77, 78 takes 
the desolvation of both the ligand and the receptor into account. TAFF, on the other 
hand, does not include electrostatic interactions, but only van der Waals and bonded 
interactions.76  The CHARMM van der Waals efficiency is the CHARMM van der Waals 
interaction energy divided by the molecular weight. It is important to take the molecular 
CHAPTER 4: TOWARDS THE DISCOVERY OF SMALL MOLECULE ACTIN BINDERS 
186 
 
weight into account, as the largest molecules tend to give the most favorable energies due 
to a greater number of intermolecular interactions that they are able to form.  
Together with the mentioned scoring functions, the number of rotatable bonds and 
ligand strain were considered (Figure 20, consensus scorings 4 and 5). The former is a 
simple approximation to incorporate the entropic penalty of the ligand upon binding, as 
ligands with many rotatable bonds present a higher entropic penalty due to the loss of 
rotational degrees of freedom upon binding. Ligand strain, on the other hand, allows 
discarding those molecules that adopt a high energy conformation upon binding.  
The molecules were sorted according to the median rank of the interaction energies in 
order to discard outliers.81 The top 100 fragments from consensus scorings 1 and 4, the 300 
top ranking fragments from consensus scoring 5 and the 17 fragments appearing in the top 
100 in the five consensus scorings were visually inspected using the software Witnotp and 
Pymol. The selection of the fragments was based on several parameters such as hydrogen 
bond analysis to the key residues involved in hydrogen bonds in the actin-latrunculin 
complex (Tyr69, Asp157, Thr186 and Arg210, Figure 14), hydrophobic interactions, 
structural diversity of the fragments and drug-like properties (by fulfilling Lipinsky’s rule 
of five).82 After visual inspection, fifteen fragments were selected to be further studied in 
molecular dynamics (MD) simulations (Figure 21).  
 Figure 21. Selected fragments for MD simulations. 
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For each selected ligand 10-20 independent explicit water MD runs were performed 
starting from the docked pose obtained with AutoDock.83 The potential affinity of the 
ligands was examined by taking the number of unbinding events into account (Table 4). 
An unbinding event was defined to take place if the separation of the center of mass of the 
ligand and the center of mass of the binding site was larger than 10 Å. Thus, a ligand that 
presents a low number of unbinding events is more likely to have a higher affinity for the 
protein.Time series of the distances between the ligands and the binding site indicated that 
most ligands present multiple binding modes and dissociation pathways.  
Table 4. Overview of the MD simulations performed with compounds A1-O1.  
Compound Number of runs
Number of 
unbinding 
events 
A1 15 1 
B1 20 0 
C1 15 0 
D1 20 6 
E1 10 9 
F1 20 12 
G1 20 14 
H1 20 9 
I1 20 6 
J1 20 6 
K1 16 7 
L1 20 5 
M1 15 3 
enantiomer 1 M2 10 1 
enantiomer 2 M2 10 0 
N1 20 6 
O1 20 7 
 
This approach resulted in the selection of six scaffolds for synthesis. Compounds A1-
E1, were automatically discarded for bad parametrization of the phosphate group (B1, 
C1), bad performance on the MD simulations (E1) or sugar character of the molecules 
(A1, D1). On the other hand, compounds J1-O1 were selected due to their synthetic 
feasibility and performance on MD simulations (Table 4).  Due to the high similarity of 
compound M1 with the commercially available racemic mixture M2, MD simulations were 
run with both enantiomers (Table 4). Surprisingly, better results were obtained for 
compound M2, with 1 and 0 unbinding events in 10 independent runs. Thus, the biological 
evaluation was performed with the commercially available hit M2.  
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Figure 21. Comparison between compound M1 and the commercially available 
compound M2 
4.3 Chemical synthesis of selected molecules 
4.3.1 Synthesis of compound J1 
  The synthesis of compound J1 started from commercially available resorcinol, which 
was mono-etherified with ethylbromoacetate affording phenol 1 and subsequently 
hydrolyzed in the presence of NaOH into 3-hydroxyphenoxy acetic acid (2). Acid 2 was 
then coupled to L-valine tert-butyl ester (3) with DCC affording the desired amide 4 in 
moderate yield. A final hydrolysis of tert-butyl ester 4 provided the final product N-(3-
hydroxyphenoxy)acetyl-L-valine J1 in 52% yield (Scheme 1).  
Scheme 1a 
 
aReagents and conditions: a) BrCH2CO2Et, K2CO3, DMF, 25 °C, 12 h, 30%; b) 
NaOH, EtOH, reflux, 12 h, 88% c) tBuOAc, HClO4, 25 °C, 12 h, 63%; d) DCC, 
HOBt, Et3N, THF, 25 °C, 24 h, 64%; e) TFA, DCM, 25 °C, 4 h, 52%.  
4.3.2 Synthesis of compounds K1 and K2                        
Triethyl phosphonoacetate was heated to reflux with phosphorus (V) pentachloride to 
afford 5, which was reacted with 2,2,2-trifluoroethanol to obtain the bis(trifluoroethyl) 
phosphonester 6. A Horner–Wadsworth–Emmons reaction under Still and Genari 
conditions was performed in the presence of p-anysaldehyde in order to obtain ethyl cis-4-
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methoxycinnamate (7), which was subsequently hydrolyzed to cis-4-methoxycinnamic acid 
(8). As a final step, acid 8) was coupled to D-alanine in the presence of DCC and           
N-hydroxysuccinimide affording N-(cis-p-methoxycinnamoyl)-D-alanine K1 (Scheme 2).  
  Scheme 2a 
 
aReagents and conditions: a) PCl5, reflux, 12 h; b) F3CCH2OH, iPr2NEt, benzene, 25 
°C, 2 h, 49% over two steps; c) (i) K[N(Si(Me3)2], 18-crown-6, toluene, -20 °C; (ii) 
p-anysaldehyde, 25 °C, 4 h, 47%; d) 1M NaOH, EtOH, reflux, 3 h, 92%; e) D-
alanine, DCC, N-hydroxysuccinimide, dioxane, 25 °C, 12 h, 60%; f) D-alanine, 
DCC, N-hydroxysuccinimide, dioxane, 25 °C, 12 h, 63%.  
The synthesis of K2 was carried out in an analogous manner by coupling the 
commercially available trans-p-methoxy cinnamic acid and D-alanine in the presence of 
DCC and N-hydroxisuccinimide (Scheme 2).  
4.3.3 Synthesis of compound L1’ 
Instead of synthesizing molecule L1 (Figure 21) with a cis relative configuration 
between the substituents in the cyclohexane ring, the trans stereoisomer was prepared due 
to the commercial availability of trans-4-(aminomethyl)cyclohexanecarboxylic acid. As the 
carboxylic acid is pointing towards the solvent in the predicted binding mode, the trans or 
cis disposition of the substituents will likely not have an influence on the molecule’s 
activity. For simplicity, we will refer to this molecule as L1’.  
The synthesis started by the Fmoc protection of L-alanine to give N-Fmoc-L-alanine 
(9). Upon treatment of 9 with SOCl2, N-Fmoc-L-alanine acid chloride (10) was obtained, 
which was coupled to trans-4-(aminomethyl)cyclohexanecarboxylic acid under basic 
conditions to give 11. As a final step, the free amine in 11 was reacted with acetic acid in 
the presence of acetic anhydride obtaining the corresponding formamide L1’.  
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Scheme 3a 
 
aReagents and conditions: a) Fmoc-Cl, H2O, dioxane, 25 °C, 12 h, 81%; b) SOCl2, 
DCM, 25 °C, 12 h, 71%; c) trans-4-(aminomethyl)cyclohexanecarboxylic acid, 10% 
NaOH, H2O, 25 °C, 12 h, 77%; d) HCO2H, Ac2O, 25 °C, 12 h, 62%. 
4.3.4 Synthesis of compound N1 and derivatives thereof           
The stereocenter present in compound N1 was introduced by the commercially 
available D-tyrosine, which was protected to afford Boc-D-tyrosine (12) and coupled to 
glycine methyl ester in the presence of NMM and CDMT obtaining dipeptide Boc-D-Tyr-
D-Gly-OMe (13, Scheme 4). Dipeptide 13 was hydrolyzed under basic conditions to obtain 
Boc-D-Tyr-Gly (14), followed by a coupling reaction with ethanolamine in the presence of 
DCC as a coupling agent, which provided Boc-D-Tyr-Gly-aminoethanol (15). Dipeptide 15 
was deprotected to give D-Tyr-Gly-aminoethanol (16) and then reacted with acetic acid 
and acetic anhydride affording the desired formamide 17, whose acetyl group was removed  
in the presence of K2CO3 in methanol delivering alcohol N2. 
Unfortunately, alcohol N2 could not be successfully oxidized into the final product 
N1. Thus, a more convergent synthesis was designed (Scheme 5) that comprised the 
presence of the aldehyde motif masked as an acetal protecting group. However, the 
synthesized aldehyde N1 decomposed upon storage at -20 °C, and thus, no biological 
evaluation was performed.  
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Scheme 4a 
 
aReagents and conditions: a) (Boc)2O, Et3N, H2O, dioxane, 25 °C, 12 h, 97%; b) 
Glycine methyl ester hydrochloride, NMM, CDMT, EtOAc, 25 °C, 3 h, 78%; c) 2M 
NaOH, MeOH, 25 °C, 2 h, 98 %; d) Ethanolamine, DCC, HOBt, DMF, 25 °C, 12 h, 
69%; e) 33% HCl, EtOH, H2O, 25 °C, 12 h, 98%; f) HCO2H, Ac2O, 25 °C, 12 h,    
41 % ; g) K2CO3, MeOH, quantitative.  
Scheme 5a 
 
aReagents and conditions: a) (i) Ac2O, HCO2H, 2 h, 86%, (ii) Glycine methyl ester, 
DCC, HOBt, Et3N, DMF, 25 °C, 12 h, 71%, (iii) 2M NaOH, MeOH, rt, 2 h, 100%; 
b) Aminoacetaldehyde dimethyl acetal, DCC, HOBt, DMF, 25 °C, 12 h, 49%; c) 
15% HCl, H2O, 25 °C, 3h, 35%.   
The corresponding enantiomers of N1-N3, referred to as N4-N6, were prepared in an 
analogous manner to that described in Schemes 4 and 5 starting from the commercially 
available L-tyrosine. 
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4.3.5 Synthesis of compound O1 and derivatives thereof 
The synthesis of compound O1 started with the protection of D-glutamic acid with 
benzyl chloroformate to give N-Cbz-glutamic acid 19. The protected compound was 
reacted with paraformaldehyde in the presence of p-toluensulfonic acid to obtain 20, which 
was converted into 1-methyl-N-Cbz-glutamic ester (21) by reacting it with NaOMe. The 
monomethyl ester 21 was then coupled to ethanolamine in the presence of DCC and HOBt 
to give N-ethanol-1-methyl-N-Cbz-glutamic ester (22). The primary alcohol in compound 
22 was oxidized to aldehyde O2. In order to achieve the desired compound O1, the Cbz 
protected compound 22 was deprotected and reacted with phenyl choloroformate obtaining 
alcohol O3, which was subsequently oxidized in the presence of DMP affording the final 
aldehyde O1.  
Scheme 6a 
aReagents and conditions: a) Benzyl chloroformate, 4M NaOH, 60 °C, 15 min, 38% 
; b) Paraformaldehyde, p-TsOH, toluene, reflux, 3 h, 91%; c) 1M NaOMe, MeOH, 0 
°C, 30 min, 80%; d) Ethanolamine, DCC, HOBt, DMF, 25 °C, 12 h, 41%; e) DMP, 
DCM, 25 °C, 1 h, 41%; f) 10% Pd/C, H2, MeOH, 25 °C, 81 %; g) Phenyl 
chloroformate, Et3N, dioaxane, 25 °C, 12 h, 18%; h) DMP, DCM,  0 °C, 1 h, 46%. 
The corresponding enantiomers of O1-O3, referred to as O4-O6, were prepared in an 
analogous manner to that shown in Scheme 6 starting from the commercially available L-
glutamic acid.………………………………………………………………………………………………………………………………………
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4.4 Biological evaluation 
An overview of the tested molecules is given in Figure 22.  
 Figure 22. Overview of the tested compounds. 
First, cell viability in the presence of these compounds was conducted in four different 
cell lines: 3T3 NIH mouse fibroblasts, HT-29 colon adenocarcinoma, MDA-MD-231 breast 
carcinoma and A549 lung adenocarcinoma cells. Cell viability was studied by measuring 
the ability of the cells to process resazurin, which becomes fluorescent under mitochondrial 
reduction and its emission directly correlates with the metabolic viability of the cells. No 
toxicity was observed for any of the tested molecules (Figure 22) upon incubation of the 
inhibitors for 4, 24 or 48 hours at concentrations as high as 100 μM, confirming their safe 
toxicity profile.  
Next, the effects of the molecules on the actin cytoskeleton were studied. For this 
purpose, a well-established assay involves the incubation of NIH/3T3 fibroblasts with the 
drug of choice. Morphological changes can easily be monitored by fluorescence marked 
phalloidin staining of actin that provides a straightforward read-out of the impact of such 
molecules on the actin network by fluorescence microscopy. The compounds showing an 
impact on the actin cytoskeleton and their effects are given in Figure 23. 
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Figure 23. Effect of compounds K1, K2, N2, N3 and O2 on mouse fibroblasts 
after 4 hours of incubation. Fluorescence micrographs (40x) of the actin 
cytoskeleton of NIH/3T3 cells: actin cytoeskeleton is stained with FITC-phalloidin 
(yellow) and nuclei with 2-(4-amidinophenyl)-6-indolecarbamidine hydrochloride 
(DAPI) (blue).  The value in (%) indicates the percentage of viable cells.   
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At low micromolar concentrations the compounds shown in Figure 23 elicited 
considerable morphological changes in cells starting only 4 hours after compound 
application. The inhibitors caused rounding of NIH/3T3 cells and loss of cell contacts. 
Moreover, well spread cells lost their smooth contour and a diminution of the 
microfilament bundles (stress fibers), together with cell shrinkage, was also observed. At 
higher concentrations of the drug (4 and 10 μM), depletion of F-actin from the central 
region and formation of actin bundles at the cell margins was observed (Figure 23). 
Interestingly, many of the cells became binuclear, indicating that the molecules did not 
affect mitosis but most likely inhibit cytokinesis. Thus, the molecules shown in Figure 23 
were able to modify the actin cytoskeleton of fibroblast cells at non-toxic concentrations, 
provoking morphological changes that resemble that of actin binding natural products.  
To confirm the binding of the design inhibitors towards actin, an in vitro actin 
polymerization fluorescence assay was conducted with pyrene labelled actin monomers. The 
time course of polymerization can be monitored by the fluorescence increase of pyrene 
during the copolymerization of actin with fluorescence labelled (pyrene) actin.84 Generally, 
a lag time is observed (nucleation step) followed by an exponential phase (elongation) and 
a plateau when the steady state is reached. At a concentration of 10 μM, the tested 
compounds were able to slightly inhibit the polymerization of actin by decreasing the 
extent of polymerization. Unfortunately, their inhibition values lied far away to those of 
the natural product latrunculin (Figure 24).  
 
Figure 24. Effect of compounds J-O on actin polymerization in vitro. 
Actin/pyrenyl-labeled actin (2.5 µM) was incubated with the corresponding 
compounds (10 µM) or DMSO as control (shown in black squares). Polymerization 
was started by the addition of inducing salts (50 mM KCl, 2 mM MgCl2, 1 mM 
ATP) and drugs dissolved in DMSO. Latrunculin is given as a reference compound 
at 1 µM concentration.  
We succeeded in recording a dose response curve for compound O1 (Figure 25), 
confirming its over 100 fold weaker inhibition in comparison to latrunculin. However, it is 
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worth underlying the ease of synthesis of the designed actin inhibitors in respect to the 
complex natural product latrunculin (26 steps with an overall yield of 0.21%),85 making our 
compounds readily accessible in high quantities.  
 
Figure 25. Concentration dependent effect of compound O1 on actin 
polymerization in vitro. Actin/pyrenyl-labeled actin (2.5 µM) was incubated with 
O1 at 1 and 100 µM or DMSO as control (shown in black squares). Polymerization 
was started by the addition of inducing salts (50 mM KCl, 2 mM MgCl2, 1 mM 
ATP) and drugs dissolved in DMSO. Latrunculin is given as a reference compound 
at 1 µM concentration.…………………………………………………………………………………………………………
4.5 Conclusions and outlook 
We have designed and validated a new computational approach to discover novel 
actin leads targeting the ATP binding site of actin. Several fragments were selected from 
an in house constructed library and ranked by means of consensus scoring. The best 
ranking compounds of five different consensus scorings were visually analyzed and fifteen 
fragments were selected and subjected to MD simulations, where the binding behavior was 
studied. From those fifteen fragments, five scaffolds were chemically synthesized.  
Cytotoxicity studies on NIH/3T3 fibroblasts and several human cancer cells by the 
colorimetric rezazurin assay revealed low toxicity values for the tested molecules. The actin 
cytoskeleton of the NIH/3T3 cells was then stained with TRITC-Phalloidin to visualize the 
morphological changes in the actin cytoskeleton. The molecules were able to alter the 
morphology of the actin cytoskeleton at low micromolar concentrations and after a short 
incubation time (4 hours) by reducing the microfilament bundles (stress fibers), inducing 
cell shrinkage and actin aggregation. To confirm the binding of the design inhibitors 
towards actin, an in vitro actin polymerization fluorescence assay was conducted with 
pyrene labelled actin monomers, obtaining a weak inhibition of actin polymerization.  
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As a result, the developed small organic molecules constitute valuable tools for the 
study of actin dynamics and are promising starting hits for the development of more 
potent actin inhibitors. The next steps of the project include the design and synthesis of 
more potent derivatives of the mentioned scaffolds, as well as the implementation of 
computer based de novo design aiming to develop novel actin binding molecules. 
4.6 Experimental section 
4.6.1 Chemistry. General methods 
All reactions, unless otherwise stated, were carried out under a nitrogen atmosphere 
using standard Schlenk-techniques. All reagents were used as received unless otherwise 
noted. Solvents were purchased in the best quality available, degassed by purging 
thoroughly with nitrogen and dried over activated molecular sieves of appropriate size. 
Alternatively, they were purged with argon and passed through alumina columns in a 
solvent purification system (Innovative Technology). Reactions were monitored by thin 
layer chromatography (TLC) using Merck TLC silica gel 60 F254. Flash column 
chromatography was performed over silica gel (230-400 mesh). NMR spectra were recorded 
on AV 300, AV2 400 or AV2 500 MHz Bruker spectrometers. Chemical shifts are given in 
ppm. The spectra are calibrated to the residual 1H and 13C signals of the solvents. 
Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), 
doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and broad (br). Melting 
points were determined on a Buchi melting point B-540 instrument. High-resolution 
electrospray ionization mass spectrometry was performed on a Finnigan MAT 900 (Thermo 
Finnigan, San Jose, CA, USA) double-focusing magnetic sector mass spectrometer. Ten 
spectra were acquired. A mass accuracy ≤2 ppm was obtained in the peak matching 
acquisition mode by using a solution containing 2 µL PEG200, 2 µL PPG450, and 1.5 mg 
NaOAc (all obtained from Sigma-Aldrich, Buchs, Switzerland) dissolved in 100 mL MeOH 
(HPLC Supra grade, Scharlau, E-Barcelona) as internal standard. The purity of all tested 
compounds was determined by HPLC on a Waters Acquity UPLC (Waters, Milford, MA) 
Top spectrometer using an Acquity BEH C18 HPLC column (1.7 μm, 1× 50 mm, Waters) 
with a mixture of H2O + 0.1% HCOOH (A) and CH3CN + 0.1% HCOOH (B) solvent (0.1 
mL flow rate, linear gradient from 5% to 98% B within 4 min followed by flushing with 
98% B for 1 min). Unless otherwise stated, all compounds showed ≥ 95 % purity.  
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Ethyl 2-(3-hydroxyphenoxy)acetate (1)86  
To a mixture of resorcinol (0.50 g, 4.54 mmol) and K2CO3 (0.63 g, 
4.54 mmol) in DMF (8.0 mL), ethyl bromoacetate (0.51 mL, 4.54 
mmol) was added dropwise at 0 °C. The mixture was stirred at 25 °C 
for 12 hours, concentrated and redissolved in EtOAc. The insoluble solid was filtered off 
and the solution was extracted with 10 % citric acid, 5 % sodium bicarbonate and brine. 
The organic phase was dried over MgSO4 and evaporated under reduced pressure. The 
product was purified by flash column chromatography on silica gel (hexane/EtOAc, 7:1) to 
provide a  colorless oil (0.27 g, 30 % yield). 1H NMR (500 MHz, CDCl3): δ= 6.97 (t, J = 
8.2 Hz, 1H), 6.72 (br, 1H), 6.40 (ddd, J = 8.1, 2.2, 0.7 Hz, 1H), 6.36 (t, J = 2.2 Hz, 1H), 
6.32-6.35 (m, 1H), 4.48 (s, 2H), 4.17 (q, J = 7.1 Hz, 2H), 1.20 (t, J = 7.1 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ= 169.6, 158.7, 157.1, 130.1, 109.2, 106.1, 102.6, 65.2, 61.6, 
14.0; IR (neat): ῦ = 3422, 2988, 2908, 1749, 1603, 1594, 1514, 1464, 1435, 1223, 1161, 1092, 
1021, 951, 864, 762, 686, 599 cm-1 ; HRMS (ESI), m/z: calcd for C10H12NaO4, 219.0628; 
found, 219.0628 [M + Na]+. 
 
2-(3-Hydroxyphenoxy)acetic acid (2)  
Ethyl 2-(3-hydroxyphenoxy)acetate (0.77 g, 3.93 mmol) was dissolved 
in methanol (7.0 mL) and a 2M NaOH aqueous solution (4.0 mL) was 
added at 0 °C. The mixture was stirred at 25 °C until the dissapearance of the starting 
material. The reaction mixture was neutralized by the addition of 1M HCl solution and 
extracted with DCM. The pH was adjusted to 2 by 1M HCl addition and extracted with 
EtOAc. The organic phases were dried over MgSO4 and evaporated to afford the product 
as a white solid (88 % yield). 1H NMR (500 MHz, DMSO-d6): δ= 12.94 (br, 1H), 9.41 (s, 
1H), 7.04 (t, J = 8.1 Hz, 1H), 6.36 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H), 6.32 (ddd, J = 8.2 , 2.5, 
0.8 Hz, 1H), 6.28 (t, J = 2.3 Hz, 1H), 4.57 (s, 2H); 13C NMR (125 MHz, DMSO-d6): δ= 
170.2, 158.8, 158.4, 129.8, 108.2, 104.9, 101.6, 64.3; IR (neat): ῦ = 3479, 2970, 1714, 1589, 
1499, 1455, 1431, 1272, 1246, 1175, 1146, 1088, 966, 818, 687 cm-1; HRMS (ESI), m/z: calcd 
for C8H8NaO4, 191.0315; found, 191.0314 [M + Na]+. 
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L-Valine tert-butyl ester (3)87  
To a solution of L-valine (1.00 g, 17.07 mmol) in tBuAc (20.0 mL), HClO4 
(2.51 g, 25.00 mmol)  were added dropwise at 0 °C and the mixture was 
stirred at 25 °C for 12 hours. The reaction mixture was washed with water 
and 1M HCl solution. The aqueous solution was adjusted to pH 9 by adding a 10 % K2CO3 
solution and it was extracted with DCM. The combined organic extracts were dried over 
MgSO4. Purification by column chromatography on silica gel (hexanes/EtOAc, 3:1) 
afforded the desired compound as a colorless oil (63 %). 1H NMR (400 MHz, CDCl3): δ= 
3.13 (d, J = 4.8 Hz, 1H), 1.92-2.00 (m, 1H), 1.43 (s, 9H), 1.36 (s, 2H), 0.94 (dd, J = 6.7, 
5.2 Hz, 3H), 0.87 (dd, J = 6.7, 5.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ= 174.8, 80.7, 
60.3, 32.1, 28.0, 19.2, 17.0; IR (film): ῦ = 3391, 3316, 2964, 2933, 2875, 1725, 1460, 1391, 
1367, 1251, 1147, 973, 850 cm-1; MS (ESI): m/z: calcd for C9H19NNaO4: 196.1, found: 196.0 
[M + Na]+. 
 
N-2-(3-Hydroxyphenoxy)acetoyl-L-valine tert-butyl ester (4)  
To a solution of 2-(3-hydroxyphenoxy)acetic acid (2) (0.17 g, 
1.00 mmol) in THF (10.0 mL) was added L-valine tert-butyl 
ester (3) (0.17 g, 1.00 mmol), HOBt (0.14 g, 1.00 mmol) and 
Et3N (138 μL, 1.00 mmol) in 20.0 mL THF. After stirring the solution for 15 min, DCC 
(0.25 g, 1.20 mmol) was added in 4.0 mL THF. The reaction mixture was stirred at 25 °C 
for 24 hours. The dicyclohexyl urea formed was filtered off and the residue was purified by 
flash column chromatography (3:1 hexane/EtOAc) to afford the desired product as an 
orange oil (64 % yield). 1H NMR (500 MHz, CDCl3): δ= 7.10-7.15 (m, 2H), 6.53 (dd, J = 
7.8, 1.2 Hz, 1H), 6.46 (dd, J = 10.5, 2.2 Hz, 2H), 4.48-4.53 (m, 3H), 2.19 (qd, J = 13.5, 6.8 
Hz, 1H), 1.46 (s, 9H), 0.93 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (125 
MHz, CDCl3): δ= 170.6, 168.7, 158.2, 157.9, 130.3, 109.4, 106.4, 102.3, 82.5, 67.0, 57.2, 
31.5, 28.0, 18.8, 17.5; IR (neat): ῦ = 3338, 2969, 2933, 1729, 1665, 1597, 1530, 1489, 1369, 
1285, 1145, 911, 842, 731, 686 cm-1; HRMS (ESI), m/z: calcd for C17H25NNaO5, 346.1625; 
found, 346.1622 [M + Na]+; [α]D26 + 16.1 (c 1.00, DCM). 
 
N-2-(3-Hydroxyphenoxy)acetoyl-L-valine (J1)  
To a solution of N-2-(3-hydroxyphenoxy)acetoyl-L-valine tert-butyl 
ester (4, 119 mg, 0.37 mmol) in DCM (2.0 mL) was added TFA  in 
excess (0.73 mL, 9.60 mmol) at 0 °C. The reaction was stirred at 
25 °C for 4h. It was concentrated and the residue was dissolved in water, which was 
extracted with DCM. The pH of the aqueous phase was adjusted to 2 by the addition of 
1M HCl and it was extracted with EtOAc. The EtOAc extracts were dried over MgSO4 
and concentrated in vaccuo to afford the product in a 52 % yield as a yellow solid. 1H 
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NMR (500 MHz, MeOD): δ= 7.09 (t, J = 8.3 Hz, 1H), 6.46 (ddd, J = 8.2, 2.3, 0.9 Hz, 
1H), 6.42-6.45 (m, 2H), 4.54 (s, 2H), 4.38 (d, J = 5.0 Hz, 1H), 2.18-2.24 (m, 1H), 0.94 (d, J 
= 6.9 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H); 13C NMR (125 MHz, MeOD): δ= 171.0, 160.3, 
160.0, 131.2, 110.2, 106.7, 103.4, 68.1, 32.3, 19.7, 18.1, one carbon is missing due to 
overlapping; IR (neat): ῦ = 3326, 2965, 1715, 1658, 1597, 1536, 1284, 1173, 1147, 1059, 
837, 762, 684 cm-1; HRMS (ESI), m/z: calcd for C13H17NNaO5, 290.0999; found, 290.0997 
[M + Na]+; [α]D26 + 3.5 (c 0.67, MeOH). 
Ethyl P,P-bischloro phosphonoacetate (5)88  
Triethyl phosphonoacetate (2.00 g, 8.92 mmol) was cooled to 0 °C and 
phosphorus (V) pentachloride (4.64 g, 22.30 mmol) was added. The reaction 
mixture was stirred for 1 hour at 25 °C and heated to 75 °C for 12 hours. The excess of 
PCl5 and POCl3 were removed under vacuum and the bischloro phosphonoacetate  (yellow 
oil, 84 % yield) was used without further purification in the next step.  
 
Ethyl P,P-bis(2,2,2-trifluoroethyl) phosphonoacetate (6)88  
Dichloride 5 (0.50 g, 2.44 mmol) was dissolved in benzene (3.0 mL) and 
a solution of trifluoroethanol  (0.35 mL, 4.87 mmol) and diisopropyl 
amine (0.85 mL, 4.87 mmol) in benzene (4.30 mL) was added at 0 °C. 
The solution was stirred at 25 °C for 2 hours. Evaporation of the solvent and column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded the desired compound as a 
colorless oil (49 % yield). 1H NMR (400 MHz, CDCl3): δ= 4.43 (quint, J = 8.3 Hz, 4H), 
4.19 (q, J = 7.1 Hz, 2H), 3.12 (d, J = 21.2 Hz, 2H), 1.26 (t, J = 7.2 Hz, 3H); 13C NMR 
(100 MHz, CDCl3): δ= 164.6 (d, J = 4.3 Hz), 122.4 (qd, J = 277.3, 8.4 Hz), 62.5 (qd, J = 
38.2, 5.5 Hz), 62.2, 33.9 (d, J = 143.9 Hz), 13.8; IR (film): 2985, 2927, 1737, 1420, 1287, 
1260, 1163, 1096, 1065, 1028, 961, 897, 843, 652, 553, 471 cm-1; MS (ESI), m/z: calcd for 
C8H11F6NaO5P, 355.0; found, 355.0 [M + Na]+. 
Cis-4-Methoxycinnamate (7) 
A solution of the phosphonoacetate 6 (0.80 g, 2.41 mmol) and 15-crown-
5 (0.43 g, 1.61 mmol) in dry THF (12.0 mL) was cooled to -78 °C under 
nitrogen. 1 hour after adding a 0.5 M solution of KHMDS in toluene (4.8 
mL), freshly distilled p-anysaldehyde (0.33 g, 2.41 mmol) was added by slow dropwise. The 
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reaction was stirred at -20 °C for 1 hour and at 25 °C for 3 hours. The reaction was 
quenched by addition of saturated ammonium chloride. The aqueous layer was then 
extracted with Et2O three times, the combined organic phases were dried over MgSO4 and 
the diastereoisomers were separated by flash column chromatography (toluene, 47 % yield).  
1H NMR (400 MHz, CDCl3): δ= 7.69 (d, J = 8.6 Hz, 2H), 6.87 (d, J = 8.9 Hz, 2H), 6.83 
(d, J = 12.8 Hz, 1H), 5.82 (d, J = 12.7 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 
1.28 (t, J = 7.1 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ= 166.3, 160.3, 143.0, 132.1, 127.3, 
117.1, 113.3, 60.0, 55.1, 14.1; IR (film): 2979, 2904, 2839, 1713, 1624, 1601, 1509, 1462, 
1441, 1306, 1255, 1190, 1028, 947, 846, 519 cm-1; HRMS (ESI), m/z: calcd for C12H14NaO3, 
229.0835; found, 229.0835 [M + Na]+. 
 
Cis-4-Methoxycinnamic acid (8)  
Cis-4-methoxycinnamate 7 (0.20 g, 0.97 mmol) was dissolved in 1M 
aqueous NaOH (4.0 mL) solution and ethanol (8.0 mL). The reaction 
mixture was stirred for 2 hours. The pH was neutralized and the solvent evaporated. The 
ressidue was redissolved in water. The pH was acidified to 2 by addition of 1M HCl and it 
was then extracted with EtOAc. The combined organic phases were dried over MgSO4 and 
the acid 8 was obtained in 92 % yield. 1H NMR (400 MHz, CDCl3): δ= 7.63 (d, J = 8.7 
Hz, 2H), 6.89 (d, J = 12.8 Hz, 1H), 6.81 (d, J = 8.7 Hz, 2H), 5.77 (d, J = 12.8 Hz, 1H), 
3.76 (s, 3H); 13C NMR (100 MHz, CDCl3): δ= 171.5, 160.7, 145.9, 132.6, 127.0, 115.9, 
113.5, 55.3; IR (film): 2956, 2936, 2838, 2574, 1684, 1618, 1597, 1509, 1453, 1442, 1306, 
1250, 1223, 1168, 1117, 1028, 919, 841, 774, 705, 590, 515 cm-1; HRMS (ESI), m/z: calcd for 
C10H10NaO3, 201.0522; found, 201.0520 [M + Na]+. 
 
N-(cis-p-Methoxycinnamoyl)-D-alanine (K1) 
DCC (66.0 mg, 0.320 mmol) was added to a solution of cis-4-
methoxycinnamic acid (52.0 mg, 0.294 mmol) and N-
hydroxysuccinimide (37 mg, 1.24 mmol) in dioxane (0.5 mL) at 0 °C. 
The reaction mixture was warmed up to 25 °C and stirred for 5 hours. The insoluble solid 
was filtered off and washed with cold dioxane. The filtrate was added to a solution of D-
alanine (29.0 mg, 0.326 mmol) and sodium bicarbonate (25.0 mg) in water (0.4 mL) and it 
was stirred at 25 °C for 24 hours. The solvent was evaporated and the residue redissolved 
in water. The solid was filtered off and the aqueous phase was extracted with EtOAc. The 
organic extracts were discarded, the aqueous phase was adjusted to pH2 by addition of 
concentrated HCl and it was extracted with EtOAc. The combined organic extracts were 
dried over MgSO4. The desired compound was purified by flash column chromatography 
(Et2O), obtaining a white solid in 60% yield. 1H NMR (500 MHz, CDCl3): δ= 7.49 (d, J = 
8.8 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.79 (d, J = 12.5 Hz, 1H), 6.07 (d, J = 6.6 Hz, 1H), 
5.86 (d, J = 12.5 Hz, 1H), 4.60 (quint, J = 7.1 Hz, 1H), 3.81 (s, 3H), 1.39 (d, J = 7.2 Hz, 
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3H); 13C NMR (125 MHz, CDCl3): δ= 175.4, 167.5, 160.2, 138.7, 131.1, 127.0, 120.9, 113.8, 
55.3, 48.3, 17.4; IR (film): 3330, 2936, 1734, 1646, 1604, 1511, 1456, 1257, 1175, 1030, 838, 
750 cm-1; HRMS (ESI), m/z: calcd for C13H15NNaO4, 272.0893; found, 272.0889 [M + Na]+; 
[α]D26 + 49.6 (c 1.14, DCM). 
 
N-(Trans-p-methoxycinnamoyl)-D-alanine (K2)89  
Following an identical procedure to the one described for 
compound K1, starting from trans-4-methoxycinnamic acid (0.20 
g, 1.12 mmol), K2 was obtained as a white solid (63 % yield). 1H 
NMR (400 MHz, DMSO-d6): δ= 12.57 (br, 1H), 8.28 (d, J = 7.4 Hz, 1H), 7.51 (d, J = 8.6 
Hz, 2H), 7.38 (d, J = 15.8 Hz, 1H), 6.98 (d, J = 8.5 Hz, 2H), 6.55 (d, J = 15.8 Hz, 1H), 
4.33 (quint, J = 7.3 Hz, 1H), 3.79 (s, 3H), 1.31 (d, J = 7.3 Hz, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ= 174.1, 164.8, 160.3, 138.7, 129.0, 127.3, 119.2, 114.3, 55.2, 47.5, 17.2; IR 
(neat): 3374, 2985, 2945, 1716, 1650, 1595, 1523, 1509, 1459, 1389, 1320, 1249, 1207, 1176, 
1154, 1110, 1040, 994, 895, 827, 648, 577, 538, 513, 422 cm-1; MS (ESI), m/z: calcd for 
C13H14NO4, 248.1; found, 247.9 [M -H]-; [α]D26 – 27.1 (c 0.95, MeOH). 
 
N-Fmoc-L-alanine (9)90  
L-alanine (1.00 g, 11.22 mmol) was dissolved in water (44.0 mL) and 
Na2CO3 (3.0 g) was added. The solution was cooled to 0 °C and dioxane 
(26.0 mL) was added. Fmoc-Cl (3.19 g, 12.35 mmol), dissolved in 26.0 mL of dioxane, was 
added dropwise. The reaction mixture was stirred at 0 °C for two hours and at 25 °C for 
12 hours. The solvent was evaporated under reduced preassure and the obtained solid was 
redissolved in water. The aqueous phase was extracted with diethyl ether. Then, the 
aqueous phase was adicified to pH 2 by the addition of 1M HCl solution and it was 
extracted with ethyl acetate three times. The combined EtOAc phases were dried over 
MgSO4 and concentrated under vacuum. The obtained product was recrystallized from 
DCM/hexanes to afford a white solid (81 % yield). 1H NMR (400 MHz, DMSO-d6): δ= 
12.52 (br, 1H), 7.89 (d, J = 7.5 Hz, 2H), 7.72 (dd, J = 7.3, 3.8 Hz, 2H), 7.65 (d, J = 7.5 
Hz, 1H), 7.42 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 4.20-4.29 (m, 3H), 4.00 (quint, 
J = 7.2 Hz, 1H), 1.28 (d, J = 7.4 Hz, 3H); 13C NMR (100 MHz, DMSO-d6): δ= 174.2, 
4.6 EXPERIMENTAL SECTION 
203 
 
155.7, 143.7, 143.7, 140.6, 127.5, 127.0, 125.1, 120.0, 65.5, 49.1, 46.5, 17.0; IR (neat): ῦ = 
3513, 3414, 3340, 2985, 1717, 1702, 1678, 1528, 1449, 1307, 1246, 1082, 1032, 765, 743 cm-1; 
MS (ESI): m/z: calcd for C18H17O4: 310.1, found: 310.0 [M - H]-. 
 
N-Fmoc-L-alanine acid chloride (10)91  
To a solution of N-Fmoc-L-alanine (9, 1.00 g, 3.24 mmol) in DCM (13.0 
mL) was added SOCl2 (2.3 mL, 32.40 mmol). The reaction was stirred at 
25 °C for 17 hours.The excess of SOCl2 was removed under vacuo and the obtained solid 
was used in the next step without further purification. (71 % yield).  
 
Trans-4-(aminomethyl)cyclohexanecarboxyl-L-alanine (11)  
Trans-4-(aminomethyl)cyclohexanecarboxylic acid (172 mg, 1.09 
mmol) was dissolved in 10% NaOH aqueous solution (3.0 mL). N-
Fmoc-L-alanine chloride (10, 359 mg, 1.09 mmol) was added and 
the solution was stirred for 12 hours. The white precitate was filtered off and the pH of the 
solution was neutralized by addition of 1M HCl solution. The solvent was evaporated, the 
obtained solid was dissolved in methanol and the salts were filtered off. The solvent was 
removed under reduced pressure to afford a white solid (77 % yield). 1H NMR (500 MHz, 
MeOD): δ= 3.58 – 3.79 (m, 1H), 3.06 (dd, J = 6.7, 3.3 Hz, 1H), 2.77 (d, J = 7.0 Hz, 1H), 
2.08 (ddd, J = 12.1, 10.9, 6.7 Hz, 1H), 1.94-2.01 (m, 2H), 1.80 – 1.87 (m, 2H), 1.61 (ddq, J 
= 11.1, 7.1, 3.7 Hz, 1H), 1.36-1.48 (m, 6H), 0.94 – 1.08 (m, 2H); 13C NMR (125 MHz, 
MeOD): δ= 184.7, 184.4, 173.3, 51.8, 50.7, 48.0, 47.7, 46.7, 46.4, 38.9, 37.1, 31.5, 31.4, 
30.9, 30.8, 30.5, 19.1, 17.4, presence of rotamers; IR (neat): ῦ = 3466, 3281, 3072, 2928, 
2850, 1651, 1550, 1448, 1405, 1212, 928, 779 cm-1; HRMS (ESI), m/z: calcd for C11H21N2O3, 
229.1547; found, 229.1544 [M + H]+; [α]D27 - 1.42 (c 1.02, MeOH). 
 
N-Formyl-trans-4-(aminomethyl)cyclohexanecarboxyl-L-alanine (L1’) 
To a solution of 11 (0.10 g, 0.44 mmol) in formic acid (2.3 mL) 
acetic anhydride (1.3 mL) was added dropwise at 0 °C. The 
solution was warmed to 25 °C and stirred for 12 hours. The 
solvent was removed under reduced pressure. The desired compound precipitated in water 
when the pH was adicified to 2 and it was washed with pentane to afford a white solid (62 
% yield).  1H NMR (500 MHz, MeOD): δ= 8.08 (s, 1H), 3.94 – 4.50 (m, 1H), 3.09 (dd, J = 
6.7, 2.1 Hz, 1H), 3.05 (dd, J = 6.9, 1.9 Hz, 1H), 2.18 – 2.26 (m, 1H), 1.98 – 2.01 (m, 2H), 
1.81 – 1.86 (m, 2H), 1.35 – 1.52 (m, 6H), 0.95 – 1.06 (m, 2H); 13C NMR (125 MHz, 
MeOD): δ= 179.9, 179.8, 175.4, 174.6, 171.1, 164.0, 163.5, 163.4, 50.3, 48.0, 46.5, 46.4, 
45.1, 44.4, 44.4, 38.6, 38.5, 30.8, 29.8, 18.6, 18.0, 17.9, presence of rotamers; IR (neat): ῦ = 
3270, 3060, 2929, 2864, 1715, 1651, 1540, 1451, 1381,1232, 1193, 1087, 667 cm-1; HRMS 
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(ESI), m/z: calcd for C12H20N2NaO4, 279.1315; found, 279.1313 [M + Na]+; [α]D26 -12.6 (c 
1.18, MeOH). 
 
Boc-D-tyrosine (12)92  
To a dispersion of D-tyrosine (2.00 g, 11.04 mmol) in 1/1 
dioxane/water (28.0 mL) Et3N (2.31 mL, 16.56 mmol) was added. The 
round bottomed flask was cooled to 0 °C and (Boc)2O (3.61 g, 16.56 
mmol) was added. The reaction mixture was stirred at 0 °C for 1 hour and at 25 °C for 12 
hours. It was concentrated under reduced pressure and diluted with water. The aqueous 
layer was first extracted with EtOAc three times and then adjusted to pH 2 with a 1M 
HCl solution. It was extracted with EtOAc three times and brine. The organic extracts 
were dried over MgSO4 and evaporation of the solvent gave the desired product as a white 
solid (97 % yield). 1H NMR (500 MHz, DMSO-d6): δ= 12.50 (br, 1H), 9.16 (s, 1H), 7.02 (d, 
J = 8.3 Hz, 2H), 6.97 (d, J = 8.3 Hz, 1H), 6.64 (d, J = 8.4 Hz, 2H), 3.99 (dt, J = 9.8, 4.7 
Hz, 1H), 2.88 (dd, J = 13.9, 4.6 Hz, 1H), 2.70 (dd, J = 13.8, 10.1 Hz, 1H), 1.33 (s, 9H); 13C 
NMR (125 MHz, DMSO-d6): δ= 173.7, 155.8, 155.4, 129.9, 128.0, 114.8, 77.9, 55.5, 35.6, 
28.1; IR (neat): ῦ = 3380, 3162, 1725, 1669, 1612, 16001, 1515, 1402, 1370, 1242, 1162, 
1136, 1055, 1032, 822, 783, 653, 595, 532, 490 cm-1; MS (ESI), m/z: calcd for C14H18NO5, 
280.1; found, 280.0 [M - H]-; [α]D23 -16.3 (c 1.02, MeOH). 
 
Boc-D-Tyr-D-Gly-OMe (13)93  
N-Methylmorpholine (2.25 g, 22.22 mmol ) was dropwise added 
to a 0 °C solution of Boc-D-tyrosine (2.50 g, 8.89 mmol), glycine 
hydrochloride (1.12 g, 8.89 mmol) and CDMT (1.56 g, 8.89 
mmol) in EtOAc (25.0 mL). The reaction was stirred at 25 °C for 4 hours. It was then 
diluted with EtOAc and extracted with water (1x), 1M HCl (2x), saturated NaHCO3 (2x), 
water (1x) and brine (1x). The organic phase was dried over MgSO4 and concentrated. The 
residue was purified by flash chromatography on silica gel (2-4 % MeOH in DCM) to 
afford the desired compound as a white solid (78 % yield). 1H NMR (500 MHz, DMSO-d6): 
δ= 9.12 (s, 1H), 8.30 (t, J = 5.8 Hz, 1H), 7.04 (d, J = 8.3 Hz, 2H), 6.80 (d, J = 8.7 Hz, 
1H), 6.64 (d, J = 8.4 Hz, 2H), 4.11 (dt, J = 9.9, 4.2 Hz, 1H), 3.86 (ddd, J = 23.1, 17.6, 6.0 
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Hz, 2H), 3.63 (s, 3H), 2.87 (dd, J = 14.0, 4.1 Hz, 1H), 2.62 (dd, J = 13.8, 10.3 Hz, 1H), 
1.30 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ= 172.3, 170.1, 155.6, 155.1, 130.0, 128.1, 
114.7, 77.8, 55.7, 51.5, 40.5, 36.6, 28.0;  IR (neat): ῦ = 3330, 2979, 2937, 1745, 1687, 1660, 
1515, 1439, 1365, 1214, 1163, 1019, 826, 541, 445 cm-1; MS (ESI), m/z: calcd for 
C17H24N2NaO6, 375.1; found, 375.1 [M + Na]+; [α]D24 +0.37 (c 0.98, MeOH). 
 
Boc-D-Tyr-Gly (14)94  
Dipeptide 13 (1.50 g, 4.26 mmol) was dissolved in MeOH (7.5 
mL) and cooled to 0 °C. 2M NaOH (4.5 mL) was added dropwise. 
The reaction mixture was stirred for 3 hours, it was diluted with 
water and extracted with DCM. The aqueous phase was adicified to pH 2 by 1M HCl 
addition and extracted it with EtOAc. The organic phase was dried over MgSO4 and the 
solvent was evaporated under reduced pressure to afford 14 has a white solid (98 % yield). 
1H NMR (500 MHz, DMSO-d6): δ= 12.54 (br, 1H), 9.11 (s, 1H), 8.15 (t, J = 5.5 Hz, 1H), 
7.04 (d, J = 8.3 Hz, 2H), 6.78 (d, J = 8.7 Hz, 1H), 6.63 (d, J = 8.3 Hz, 2H), 4.10 (dt, J = 
9.3, 9.4, 3.7 Hz, 1H), 3.77 (dq, J = 17.4, 5.5 Hz, 2H), 2.88 (dd, J = 14.1, 3.8 Hz, 1H), 2.58-
2.64 (m, 1H), 1.30 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ= 172.2, 171.2, 155.6, 155.2, 
130.0, 128.2, 114.7, 77.8, 55.8, 54.9, 40.6, 36.6, 28.1; IR (neat): ῦ = 3325, 2974, 2937, 1652, 
1515, 1443, 1393, 1367, 1225, 1159, 1050, 1022, 828, 544 cm-1; MS (ESI), m/z: calcd for 
C16H21N2O6, 337.1; found, 337.1 [M - H]-; [α]D24 +0.29 (c 0.98, MeOH). 
 
Boc-D-Tyr-Gly-aminoethanol (15)  
Boc-D-Tyr-Gly (14, 1.30 g, 3.85 mmol), DCC (0.95 g, 4.61 
mmol) and HOBt (0.62 g, 4.61 mmol) were stirred in DMF 
(10.0 mL) at   25 °C for 30 minutes. Ethanolamine (0.23 mL, 
3.85 mmol) was added and it was stirred for 12 hours. The reaction mixture was 
concentrated under reduced pressure and the residue dissolved in water. The dicyclohexyl 
urea was filtered off and the aqueous layer was extracted with DCM three times. The 
aqueous layer was then extracted with EtOAc (3x). Finally, the EtOAc phase was washed 
with 10 % NaHCO3 solution and it was dried over MgSO4. Evaporation of the solvent 
afforded the desired compound as a white solid in pure form (69 % yield). 1H NMR (500 
MHz, D2O-d6): δ= 7.14 (d, J = 8.0 Hz, 2H), 6.84 (d, J = 8.1 Hz, 2H), 4.25 (t, J = 7.9 Hz, 
1H), 3.79-3.88 (m, 2H), 3.62 (t, J = 5.4 Hz, 2H), 3.32 (t, J = 5.0 Hz, 2H), 2.04 (dd, J = 
14.0, 6.2 Hz, 1H), 2.85 (dd, J = 16.0, 7.4 Hz, 1H), 1.34 (s, 9H);        13C NMR (125 MHz, 
D2O-d6): δ= 175.0, 171.3, 157.5, 154.3, 130.5, 128.3, 115.4, 81.6, 59.8, 56.5, 42.4, 41.4, 36.2, 
27.4; IR (neat): ῦ = 3308, 2974, 2926, 1651, 1515, 1452, 1392, 1366, 1242, 1161, 1055, 828, 
541, 424 cm-1; HRMS (ESI), m/z: calcd for C18H27N3NaO6, 404.1792; found, 404.1790 [M + 
Na]+; [α]D24 -16.3 (c 0.99, MeOH). 
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D-Tyr-Gly-aminoethanol (16)  
15 (0.85 g, 2.22 mmol) was dissolved in EtOH/water 50:50 
v/v (6.9 mL) and 20 % aqueous HCl solution (2.8 mL) was 
added dropwise. After stirring the reaction for 12 hours, it 
was neutralized with a 10 % NaOH solution. It was extracted with EtOAc and the organic 
phase was discarded. The aqueous phase was concentrated under reduced pressure, the 
residue was dissolved in MeOH, and the salts were filtered off to obtain the desired 
compound as a white solid (98 % yield).  1H NMR (400 MHz, D2O-d6): δ= 7.24 (d, J = 8.4 
Hz, 2H), 6.96 (d, J = 8.5 Hz, 2H), 4.30 (t, J = 7.2 Hz, 1H), 3.95 (dd, J = 49.0, 16.7 Hz, 
2H), 3.70 (t, J = 5.5 Hz, 2H), 3.39 (t, J = 5.5 Hz, 2H), 3.21 (d, J = 7.3 Hz, 2H); 13C NMR 
(100 MHz, D2O-d6): δ= 171.4, 170.4, 155.7, 131.4, 126.1, 116.4, 60.4, 55.1, 42.9, 42.0, 36.5. 
IR (neat): ῦ = 3263, 3069, 2931, 1652, 1539, 1514, 1444, 1227, 1051, 1017, 825, 549, 498 
cm-1; HRMS (ESI), m/z: calcd for C13H19N3NaO4, 304.1268; found, 304.1265 [M + Na]+; 
[α]D25 -42.6 (c 1.08, MeOH). 
 
N-Formyl-D-Tyr-Gly-aminoethanyl acetate (17)  
To a solution of 16 (0.20 g, 0.712 mmol) in formic acid 
(4.0 mL), acetic anhydride was added dropwise at 0 °C and 
the solution was stirred at 25 °C for 12 hours. The reaction 
mixture was concentrated, dissolved in DCM and filtrated. 
The product was purified by flash column chromatography (DCM/10% MeOH) to obtain 
it in 41% yield as a white solid. 1H NMR (400 MHz, CDCl3): δ= 8.11 (s, 1H), 8.04 (s, 
0.6H), 7.20 (d, J = 8.4 Hz, 2H), 7.01 (d, J = 8.4 Hz, 2H), 6.95 (dd, J = 10.9, 5.8 Hz, 1H), 
6.71 (t, J = 5.5 Hz, 0.6H), 6.61 (t, J = 8.1Hz, 1.4H), 4.70 (quint, J = 7.2, 7.0 Hz, 1H), 
4.22-4.25 (m, 1H),  4.12-4.16 (m, 1H), 3.93 (ddd, J = 16.7, 5.9, 2.2 Hz, 1H), 3.76 (dd, J = 
16.6, 5.5 Hz, 1H), 3.50 (dt, J = 11.0, 5.6 Hz, 2H), 3.09 (ddd, J = 29.3, 13.9, 7.1 Hz, 2H), 
2.29 (s, 3H), 2.06 (s, 1.6H), presence of rotamers; 13C NMR (125 MHz, CDCl3): δ= 171.3, 
170.9, 169.7, 168.8, 168.7, 161.6, 161.5, 161.1, 149.8, 133.6, 133.6, 130.3, 121.9, 62.8, 62.4, 
53.5, 53.4, 43.1, 43.1, 38.8, 38.5, 37.1, 37.1, 21.1, 20.9; IR (neat): ῦ = 3272, 3083, 2932, 
1760, 1720, 1637, 1551, 1508, 1438, 1390, 1371, 1220, 1201, 1182, 1165, 1054, 1018, 916, 
719, 554 cm-1; HRMS (ESI), m/z: calcd for C16H21N3NaO6, 374.1323; found, 374.1321 [M + 
Na]+; [α]D26 -26.5 (c 0.36, MeOH). 
 
N-formyl-D-Tyr-Gly-aminoethanol (18)  
Ester 17 (125 mg, 0.405 mmol) was dissolved in MeOH 
(1.50 mL) and K2CO3 was added (0.1 g, 0.724mmol). The 
reaction mixture was stirred at 25 °C for 1 hour, it was 
filtrated and concentrated obtaining alcohol 18 in 
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quantitative yield. 1H NMR (500 MHz, MeOD): δ= 8.04 (s, 1H), 6.91 (d, J = 8.4 Hz, 2H), 
6.58 (d, J = 8.4 Hz, 2H), 4.44 (t, J = 7.4 Hz, 1H), 3.76 (dd, J = 46.6, 17.0 Hz, 2H), 3.56 
(t, J = 6.0 Hz, 2H), 3.35 (s, 2H), 2.87 (ddd, J = 39.3, 13.7, 7.5 Hz, 2H); 13C NMR (500 
MHz, MeOD): δ= 174.4, 171.7, 170.4, 170.4, 166.0, 164.0, 130.9, 122.8, 119.7, 61.4, 56.4, 
43.7, 43.0, 38.0, 24.3, presence of rotamers; IR (neat): ῦ = 3272, 3078, 2932, 2807, 1760, 
1719, 1638, 1596, 1557, 1499, 1439, 1389, 1372, 1221, 1166, 1020, 916, 844, 759, 718, 668, 
634, 554, 531 cm-1; HRMS (ESI), m/z: calcd for C14H19N3NaO5, 332.1217; found, 332.1215 
[M + Na]+; [α]D26 -16.6 (c 0.54, MeOH). 
 
Boc-L-Tyrosine (24) 
Following an identical procedure to the one described for compound 12, 
starting from D-glutamic acid (3.00 g, 16.56 mmol), protected 
compound 24 was obtained as a white solid (4.04 g, 87 % yield). 1H 
NMR (500 MHz, DMSO-d6): δ= 12.53 (br, 1H), 9.20 (s, 1H), 7.02 (d, J = 8.4 Hz, 2H), 6.65 
(d, J = 8.4 Hz, 2H), 3.98 (ddd, J = 10.0, 8.5, 4.6 Hz, 1H), 2.87 (dd, J = 13.9, 4.6 Hz, 1H), 
2.69 (dd, J = 13.8, 10.2 Hz, 1H), 1.32 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ= 173.7, 
155.8, 155.4, 129.9, 128.0, 114.8, 77.9, 55.5, 35.6, 28.1; IR (neat): ῦ = 3381, 3147, 1725, 
1668, 1515, 1402, 1370, 1242, 1201, 1163, 1136, 1055, 822, 783, 654, 595, 533, 491, 456 cm-1; 
MS (ESI), m/z: calcd for C14H19NNaO5, 304.1; found, 304.1 [M + Na]+; [α]D23 +17.3 (c 1.06, 
MeOH). 
 
Boc-L-Tyr-D-Gly-OMe (25)  
Following an identical procedure to the one described for 
compound 13, starting from Boc-L-tyrosine (2.00 g, 7.11 mmol) , 
ester 25 was obtained as a white solid (2.02 g, 80 % yield). 1H 
NMR (500 MHz, DMSO-d6): δ= 9.12 (s, 1H), 8.29 (t, J = 5.5 Hz, 1H), 7.04 (d, J = 8.1 Hz, 
2H), 6.80 (d, J = 8.7 Hz, 1H), 6.64 (d, J = 8.1 Hz, 2H), 4.11 (dt, J = 9.4, 9.1, 4.2 Hz, 1H), 
3.79-3.92 (m, 2H), 3.63 (s, 3H), 2.87 (dd, J = 13.9, 3.4 Hz, 1H), 2.58-2.67 (m, 1H), 1.30 (s, 
9H); 13C NMR (125 MHz, DMSO-d6): δ= 172.4, 170.2, 155.6, 155.2, 130.0, 128.2, 114.7, 
77.9, 55.8, 54.9, 51.6, 40.5, 36.6, 28.1; IR (neat): ῦ = 3366, 3332, 2979, 2952, 1688, 1636, 
1515, 1439, 1358, 1223, 1164, 1048, 985, 812, 670, 564 cm-1; MS (ESI), m/z: calcd for 
C17H24N2NaO6, 375.2; found, 375.2 [M + Na]+; [α]D24 -0.29 (c 1.02, MeOH). 
 
Boc-L-Tyr-Gly (26)  
Following an identical procedure to the one described for 
compound 14, starting from ester 25 (1.839 g, 5.221 mmol), acid 
26 was obtained as a white solid (1.730 g, 98 % yield). 1H NMR 
(500 MHz, DMSO-d6): δ= 12.54 (br, 1H), 9.11 (s, 1H), 8.15 (t, J = 5.7 Hz, 1H), 7.04 (d, J 
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= 8.3 Hz, 2H), 6.78 (d, J = 8.8 Hz, 1H), 6.63 (d, J = 8.3 Hz, 2H), 4.10 (dt, J = 10.0, 3.9 
Hz, 1H), 3.77 (dq, J = 17.6, 17.5, 5.9 Hz, 2H), 2.88 (dd, J = 13.9, 3.9 Hz, 1H),  2.58 – 2.64 
(m, 1H), 1.30 (s, 9H); 13C NMR (125 MHz, DMSO-d6): δ= 172.2, 171.2, 155.6, 155.2, 130.0, 
128.2, 114.7, 77.9, 55.8, 40.6, 36.6, 28.1; IR (neat): ῦ = 3344, 2979, 2932, 1722, 1679, 1646, 
1517, 1429, 1366, 1247, 1227, 1163, 1050, 822, 577, 547 cm-1; MS (ESI), m/z: calcd for 
C16H22N2O6, 337.1; found, 337.1 [M - H]-. 
 
Boc-L-Tyr-Gly-aminoethanol (27)  
Following an identical procedure to the one described for 
compound 15, starting from Boc-L-Tyr-Gly (0.200 g, 0.595 
mmol), alcohol 27 was obtained as a white solid (0.186 g, 
82% yield). 1H NMR (500 MHz, D2O-d6): δ= 7.21 (d, J = 7.9 Hz, 2H), 6.91 (d, J = 8.2 Hz, 
2H), 4.33 (t, J = 7.5 Hz, 1H), 3.87-3.95 (m, 2H), 3.69 (t, J = 5.5 Hz, 2H), 3.39 (t, J = 5.2 
Hz, 2H), 3.11 (dd, J = 13.7, 6.0 Hz, 1H),  2.92 (dd, J = 15.6, 7.1 Hz, 1H), 1.41 (s, 9H); 13C 
NMR (125 MHz, D2O-d6): δ= 175.0, 171.3, 157.5, 154.3, 130.5, 128.3, 115.4, 81.6, 59.8, 
56.5, 42.4, 41.4, 36.2, 27.4; IR (neat): ῦ = 3296, 2974, 1651, 1515, 1451, 1366, 1244, 1161, 
1055, 1019, 827, 543, 424, 416 cm-1; MS (ESI), m/z: calcd for C18H27N3NaO6, 404.2; found, 
404.2 [M + Na]+; [α]D25 +17.8 (c 1.07, MeOH). 
 
L-Tyr-Gly-aminoethanol (28)  
Following an identical procedure to the one described for 
compound 16, starting from 27 (0.186 g, 0.487 mmol), 
amine 28 was obtained in quantitative yield (0.185 g). 1H 
NMR (400 MHz, D2O-d6): δ= 7.28 (d, J = 8.4 Hz, 2H), 6.99 (d, J = 8.2 Hz, 2H), 4.36 (t, J 
= 7.2 Hz, 1H), 3.98 (dd, J = 49.0, 16.7 Hz, 2H), 3.73 (t, J = 5.5 Hz, 2H), 3.43 (t, J = 5.5 
Hz, 2H), 3.24 (d, J = 7.2 Hz, 2H); 13C NMR (125 MHz, D2O-d6): δ= 170.9, 169.9, 155.1, 
130.9, 125.5, 115.9, 59.9, 54.6, 42.5, 41.5, 35.9; IR (neat): ῦ = 3263, 3082, 2932, 2811, 2775, 
2682, 1653, 1548, 1515, 1367, 1351, 1246, 1020, 826, 764, 553 cm-1; MS (ESI), m/z: calcd for 
C13H19N3NaO4, 304.1; found, 304.1 [M + Na]+; [α]D25 +20.3 (c 0.96, MeOH). 
 
N-Formyl-L-Tyr-Gly-aminoethanyl acetate (29)  
Following an identical procedure to the one described for 
compound 17, starting from L-Tyr-Gly-aminoethanol (200 
mg, 0.712 mmol), formamide 29 was obtained (108 mg, 
43 % yield). 1H NMR (500 MHz, CDCl3): δ= 8.00 (d, J = 4.1 Hz, 1.5H), 7.64 (t, J = 5.5 
Hz, 0.53H),  7.60 (t, J = 5.4Hz, 0.33H), 7.29 (d, J = 7.3 Hz, 0.56H), 7.24 (d, J = 7.4 Hz, 
0.35H),  7.17 (d, J = 8.5 Hz, 2H), 7.14 (t, J = 5.6Hz, 0.53H), 7.03 (t, J = 5.6Hz, 0.36H), 
6.96 (d, J = 8.5 Hz, 2H), 4.73-4.79 (m, 1H), 4.19 (t, J = 5.5 Hz, 1.20H), 4.10 (t, J = 5.7 
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Hz, 0.71H), 3.84-3.89 (m, 1H), 3.76 (dd, J = 16.7, 5.4 Hz, 1H), 3.45 (td, J = 19.3, 5.6 Hz, 
2H), 3.08-3.12 (m, 1H), 2.99 (dd, J = 14.0, 7.6 Hz, 2H), 2.26 (s, 3H). presence of rotamers; 
13C NMR (125 MHz, CDCl3): δ= 171.3/171.3/171.2, 169.9/169.9, 169.2, 169.1, 162.0, 161.2, 
149.5, 133.9, 130.3, 121.7, 62.7, 62.2, 53.3, 53.2, 42.9, 38.5, 38.3, 37.2, 37.1, 21.1, 20.9, 
presence of rotamers; IR (neat): ῦ = 3308, 2937, 1764, 1723, 1650, 1507, 1370, 1220, 1193, 
1167, 1018, 913, 545 cm-1; MS (ESI), m/z: calcd for C16H21N3NaO6, 374.1; found, 374.3 [M 
+ Na]+; [α]D25 -4.44 (c 1.02, MeOH). 
 
N-Formyl-L-Tyr-Gly-aminoethanol (N5) 
29 (50 mg, 0.143 mmol) was dissolved in MeOH (0.6 mL) 
and K2CO3 (40 mg, 0.289 mmol) was added. It was stirred 
at 25 °C until dissapearance of the starting material. The 
reaction mixture was filtrated and concentrated. The residue was dissolved in MeOH and 
K2CO3 was filtered off to obtain N5 in quantitative yield. 1H NMR (500 MHz, D2O): δ= 
7.96 (s, 1H), 6.94 (d, J = 8.5 Hz, 2H), 6.55 (d, J = 8.5 Hz, 2H), 4.46 (t, J = 7.2 Hz, 1H), 
3.83 (dd, J = 32.4, 17.0 Hz, 2H), 3.62 (t, J = 5.5Hz, 2H), 3.52 (t, J = 5.5 Hz, 2H), 3.22 (t, 
J =5.5 Hz, 2H), 2.87 (dd, J = 7.4, 2.1 Hz, 2H); 13C NMR (125 MHz, D2O): δ= 173.9, 
171.2, 170.9, 165.6, 164.1, 162.6, 130.3, 122.5, 117.9, 59.7, 54.4, 42.4, 41.3, 36.0, presence of 
rotamers; IR (neat): ῦ = 3272, 2941, 2822, 1651, 1597, 1496, 1441, 1380, 1269, 1169, 1076, 
1026, 829, 554 cm-1; MS (ESI), m/z: calcd for C14H19N3NaO5, 332.1; found, 332.1 [M + 
Na]+; [α]D25 +0.17 (c 1.40, MeOH). 
 
N-Formyl-D-Tyr (30)  
D-Tyrosine (1.50 g, 0.83 mmol) was dissolved in formic acid (9.8 mL) 
and acetic anhydride (5.0 mL, 52.9 mmol) was added in excess. The 
reaction mixture was stirred at 10 °C for 1 hour and then at 25 °C for 
30 minutes. Water (6.50 mL) was added at 10 °C, it was stirred for 30 minutes and the 
reaction mixture was then concentrated under reduced pressure. The residue was dissolved 
in 1M HCl solution and extracted with EtOAc. The combined organic phases were dried 
over MgSO4 to afford acid 18 as a white solid in 85 % yield. 1H NMR (500 MHz, DMSO-
d6): δ= 12.77 (br, 1H), 9.23 (s, 1H), 8.31 (d, J = 8.0 Hz, 1H), 7.96 (s, 1H), 6.99 (d, J = 8.4 
Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 4.42 (dt, J = 8.5, 5.1 Hz, 1H), 2.94 (dd, J = 13.9, 4.9 
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Hz, 1H), 2.74 (dd, J = 13.9, 9.0 Hz, 1H); 13C NMR (125 MHz, DMSO-d6):δ= 172.6, 160.9, 
155.9, 129.0, 127.1, 114.9, 52.1, 35.6; IR (neat): ῦ = 3336, 3058, 3025, 2919, 2815, 1713, 
1625, 1611, 1601, 1536, 1513, 1445, 1427, 1376, 1344, 1272, 1221, 1173, 1109, 1071, 950, 
828, 790, 661, 546, 471 cm-1; MS (ESI), m/z: calcd for C10H10NO4, 208.0; found, 207.9 [M - 
H]-; [α]D24 -49.6 (c 1.22, MeOH). 
 
N-Formyl-D-Tyr-Gly-OMe (31)  
N-formyl-D-tyrosine (18, 1.30 g, 6.24 mmol) was dissolved in 
DMF (25.0 mL). HOBt (1.01 g, 7.49 mmol) and DCC (1.55 g, 
7.49 mmol) were added and the reaction mixture was stirred at 
25 °C for 30 minutes. Glycine methyl ester (1.57 g, 12.50 mmol) and triethyl amine (1.0 
mL, 7.49 mmol) were added and it was stirred for 12 hours at 25 °C. The reaction mixture 
was then filtered and concentrated. The desired coupled peptide was purified by flash 
column chromatography (acetonitrile/water 1:0.05) to obtain it as a white solid in 71 % 
yield. 1H NMR (500 MHz, MeOH): δ= 8.01 (s, 1H), 7.07 (d, J = 8.4 Hz, 2H), 6.70 (d, J = 
8.4 Hz, 2H), 4.68 (dd, J = 8.3, 5.7 Hz, 1H), 3.89-3.96 (m, 2H), 3.72 (s, 3H), 3.08 (dd, J = 
14.0, 5.8 Hz, 1H), 2.82 (dd, J = 13.9, 8.6 Hz, 1H); 13C NMR (125 MHz, MeOH): δ= 174.3, 
173.8, 171.5, 163.5, 157.5, 157.4, 131.4, 128.7, 128.6, 116.2, 54.7, 53.9, 52.7, 41.9, 38.4, 37.7, 
presence of rotamers; IR (neat): ῦ = 3293, 3161, 2954, 2916, 1742, 1633, 1591, 1564, 1539, 
1516, 1435, 1389, 1354, 1219, 1172, 1113, 1053, 1026, 984, 909, 830, 752, 723, 680, 560, 472 
cm-1; HRMS (ESI), m/z: calcd for C13H16N2NaO5, 303.0951; found, 303.0948 [M + 
Na]+;[α]D25 -6.1 (c 1.09, MeOH). 
 
N-Formyl-D-Tyr-Gly (18)  
N-formyl-D-Tyr-Gly-OMe (31, 1.00 g, 3.58 mmol) was dissolved 
in MeOH (16.0 mL) and a 2M NaOH solution (3.7 mL) was 
added. The reaction mixture was stirred at 25 °C for 2.5 hours. 
1M HCl was added to neutralize the reaction mixture and it was extracted with DCM. The 
organic phases were discarded and the aqueous phase was concentrated. The residue was 
dissolved in MeOH and the salts were filtered out. The desired acid was obtain in 
quantitative yield as a white solid after evaporating the MeOH. 1H NMR (400 MHz, 
MeOH): δ= 8.29 (t, J = 5.9 Hz, 1H), 8.03 (s, 1H), 7.07 (d, J = 8.4 Hz, 2H), 6.71 (d, J = 
8.5 Hz, 2H), 4.67 (dd, J = 8.7, 5.5 Hz, 1H), 3.87 (d, J = 5.5 Hz, 2H), 3.10 (dd, J = 14.1, 
5.3 Hz, 1H), 2.83 (dd, J = 14.0, 8.9 Hz, 1H); 13C NMR (100 MHz, MeOH): δ= 173.7, 
172.7, 163.5, 157.4, 131.4, 128.8, 116.3, 54.7, 41.8, 38.4; IR (neat): ῦ = 3326, 3031, 2926, 
2822, 1658, 1613, 1514, 1447, 1384, 1235, 1174, 1101, 1021, 830, 782, 741, 551, 516 cm-1; 
HRMS (ESI), m/z: calcd for C12H14N2NaO5, 289.0795; found, 289.0793 [M + Na]+; [α]D25 -6.8 
(c 1.05, MeOH). 
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N-Formyl-D-Tyr-Gly-aminoacetaldehyde (N3)  
N-formyl-D-Tyr-Gly (18, 0.50 g, 1.89 mmol) was dissolved 
in DMF (5.0 mL). HOBt (0.51 g, 3.78 mmol) and DCC 
(0.78 g, 3.78 mmol) were added and stirred at 25 °C for 30 
minutes. Acetaldehyde (0.41 mL, 3.78 mmol) was then added and the reaction mixture was 
stirred for 12 hours. The reaction mixture was concentrated and the desired acetaldehyde 
was  purified by flash column chromatography (acetonitrile/water 1:0.05). The product 
was obtained as a white solid in 49 % yield (0.29 g, 0.82 mmol).  1H NMR (500 MHz, 
MeOH): δ= 8.03 (s, 1H), 7.06 (d, J = 8.6 Hz, 2H), 6.71 (d, J = 8.6 Hz, 2H), 4.53 (t, J = 
7.4 Hz, 1H), 4.42 (t, J = 5.4 Hz, 1H), 3.79 (dd, J = 74.8, 16.8 Hz, 2H), 3.36 (d, J = 0.8 
Hz, 6H), 3.05 (dd, J = 13.9, 6.5 Hz, 2H), 2.85 (dd, J = 13.9, 8.3 Hz, 2H); 13C NMR (100 
MHz, MeOH): δ= 173.9, 171.6, 163.9, 157.5, 131.3, 128.6, 116.3, 97.1, 55.6, 45.5, 43.5, 37.9, 
1 carbon is missing due to overlapping; IR (neat): ῦ = 3285, 3088, 2943, 2838, 1633, 1557, 
1541, 1515, 1392, 1234, 1219, 1136, 1106, 1069, 1025, 835, 722, 697, 683, 555, 413 cm-1; 
HRMS (ESI), m/z: calcd for C16H23N3NaO6, 376.1479; found, 376.1480 [M + Na]+; [α]D25 -
26.8 (c 1.16, MeOH). 
 
N-Formyl-L-Tyr (32)  
Following an identical procedure to the one described for compound 
30, starting from L-tyrosine (2.00 g, 11.04 mmol), formamide 32 was 
obtained as a white solid (1.91 g, 83% yield). 1H NMR (500 MHz, 
DMSO-d6): δ= 12.81 (br, 1H), 9.23 (s, 1H), 8.31 (d, J = 8.4 Hz, 1H), 7.96 (s, 1H), 6.99 (d, 
J = 8.3 Hz, 2H), 6.65 (d, J = 8.4 Hz, 2H), 4.42 (dt, J = 8.6, 5.4 Hz, 1H), 2.94 (dd, J = 
13.9, 4.8 Hz, 1H), 2.74 (dd, J = 13.8, 8.9 Hz, 1H); 13C NMR (125 MHz, DMSO-d6):δ = 
172.6, 160.9, 155.9, 130.0, 127.2, 114.9, 52.2, 35.9; IR (neat): ῦ = 3335, 3067, 3026, 2922, 
2807, 1713, 1625, 1611, 1601, 1535, 1513, 1445, 1427, 1376, 1345, 1271, 1221, 1173, 1109, 
1071, 950, 828, 790, 661, 546, 470 cm-1; MS (ESI), m/z: calcd for C10H10NO4, 208.0; found, 
207.9 [M - H]-; [α]D24 +50.3 (c 0.97, MeOH). 
 
N-Formyl-L-Tyr-Gly (33)  
Following an identical procedure to the one described for 
compound 31, starting from 32 (1.00 g, 3.58 mmol), acid 33 was 
obtained as a white solid (80 % yield over two steps). 1H NMR 
(500 MHz, MeOH): δ= 8.02 (s, 1H), 7.66-7.61 (m, 1H), 7.25-7.31 (m, 1H), 7.06 (d, J = 8.3 
Hz, 2H), 6.70 (d, J = 8.3 Hz, 2H), 4.66 (dd, J = 8.8, 5.3 Hz, 1H), 3.75 (dd, J = 55.5, 17.3 
Hz, 2H), 3.11 (dd, J = 14.1, 5.2 Hz, 1H), 2.82 (dd, J = 14.0, 9.1 Hz, 1H); 13C NMR (125 
MHz, MeOH): δ= 175.7, 172.9, 163.6, 157.3, 131.4, 129.0, 116.2, 55.0, 44.3, 38.2; IR (neat): 
ῦ = 3274, 2939, 2826, 1660, 1596, 1515, 1447, 1385, 1241, 1174, 1102, 1022, 832, 782, 743, 
N
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549, 516 cm-1; MS (ESI), m/z: calcd for C12H13N2O5, 265.1; found, 264.9 [M - H]-; [α]D25 +6.9 
(c 1.07, MeOH). 
 
N-Formyl-L-Tyr-Gly-aminoacetaldehyde (N6)  
Following an identical procedure to the one described for 
compound N3, starting from acid 33 (0.50 g, 1.89 mmol),  
acetaldehyde N6 was obtained as a white solid (0.11 g, 17 
% yield). 1H NMR (500 MHz, MeOH): δ= 8.04 (s, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.07 (d, J 
= 8.5 Hz, 2H), 6.72 (d, J = 8.5 Hz, 2H), 4.57 (t, J = 7.4 Hz, 1H), 4.42 (t, J = 5.4 Hz, 1H), 
3.81 (ddd, J = 67.5, 16.8 Hz, 4.5 Hz, 2H), 3.36 (s, 6H), 3.06 (dd, J = 13.9, 6.4 Hz, 2H), 
2.87 (dd, J = 13.9, 8.3 Hz, 2H); 13C NMR (100 MHz, MeOH): δ= 173.9, 171.637, 163.9, 
157.4, 131.3, 128.6, 116.3, 103.7, 55.5, 43.5, 42.2, 42.1, 37.9; IR (neat): ῦ = 3343, 2929, 
2943, 1645, 1613, 1515, 1467, 1343, 1257, 1228, 1175, 1103, 1061, 980, 905, 811, 665, 487, 
440, 421 cm-1. MS (ESI), m/z: calcd for C16H23N3NaO6, 376.1; found, 376.1 [M + Na]+; [α]D25 
+10.2 (c 1.09, MeOH). 
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N-Benzyloxycarbonyl-D-glutamic acid (19)95  
To a solution of L-glutamic acid (5.00 g, 33.98 mmol) in 17.0 mL 
of 4M NaOH, benzyl chloroformate (7.76 mL, 54.37 mmol) was 
added dropwise at 0 °C. The reaction mixture was heated at 60 °C 
for 15 minutes and cooled to 25 °C. It was extracted with diethyl ether, the aqueous phase 
was acidified to pH 2 by 1M HCl addition and extracted with EtOAc (3x). The combined 
EtOAc phases were dried with MgSO4 to obtained the protected glutamic acid in 38 % 
yield. 1H NMR (500 MHz, DMSO-d6): δ= 12.25 (br, 2H), 7.47 (d, J = 7.4 Hz, 1H), 7.31-
7.38 (m, 5H), 5.04 (s, 2H), 4.02 (dt, J = 8.9, 5.1 Hz, 1H), 2.30 (dd, J =14.1, 6.6 Hz, 2H), 
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1.98 (dq, J = 7.6, 5.4 Hz, 1H), 1.79 (dq, J = 9.0, 6.4 Hz, 1H); 13C NMR (125 MHz, DMSO-
d6): δ= 173.3, 136.8, 128.0, 127.5, 127.4, 65.2, 52.9, 29.9, 26.0, two carbons are missing due 
to overlapping; IR (neat): ῦ = 3303, 3037, 2945, 1700, 1685, 1547, 1525, 1418, 1256, 1169, 
1051, 1014, 951, 910, 869, 779, 734, 694, 649, 599, 573 cm-1; MS (ESI), m/z: calcd for 
C13H15NNaO6, 304.1; found, 304.1 [M + Na]+; [α]D24 + 11.8 (c 0.65, MeOH). 
 
4-(R)-(2-Carboxy-ethyl)-5-oxo-oxazolidine-3-carboxylic acid benzyl ester (20)96  
To 19 (3.63 g, 12.92 mmol) in toluene (85.0 mL), 1.5 equivalents of 
paraformaldehyde and 1% of toluensulfonic acid (wt/wt) were added. 
The reaction mixture was refluxed under Dean-Stark conditions for 3 
hours. The mixture was diluted with EtOAc, washed with brine and dried over MgSO4. 
The solvent was evaporated under reduced pressure to give the azalactone 20 in 91 % 
yield, which was used without further purification. 1H NMR (500 MHz, DMSO-d6): δ= 
12.24 (br, 1H), 7.32-7.41 (m, 5H),  5.44 (d, J =2.8 Hz, 1H), 5.29 (s, 1H), 5.12-5.18 (m, 2H),  
4.38-4.45 (m, 1H), 2.22-2.39 (m, 2H), 2.09-2.19 (m, 2H), 1.96-2.06 (m, 1H); 13C NMR (125 
MHz, DMSO-d6): δ= 173.4, 172.3, 136.0, 128.4, 128.0/128.0, 127.7/127.6, 77.8/77.7, 66.7/ 
66.7, 53.9, 51.3, 28.9, 28.7, presence of rotamers; IR (neat): ῦ = 3304, 3026, 2951, 1799, 
1702, 1546, 1525, 1417, 1356, 1254, 1167, 1131, 1051, 1015, 951, 913, 752, 735, 696 cm-1; 
HRMS (ESI), m/z: calcd for C14H15NNaO6, 316.0792; found, 316.0790 [M + Na]+; [α]D29 - 
38.3 (c 1.07, MeOH). 
 
1-Methyl-N-Cbz-D-glutamic ester (21)97  
Azalactone 20 (1.21g, 4.11 mmol) was dissolved in dried MeOH 
(96.0 mL) and 5.8 mL of an in situ prepared NaOMe 1.75M 
solution (2eq.) was added at 0 °C. The reaction was run for 30 
minutes at 0 °C. 1M HCl solution was added to the reaction mixture in order to acidify the 
reaction to pH 2 and it was extracted with EtOAc. The combined organic phases were 
dried over MgSO4 and concentrated under reduced pressure to obtain the monomethyl 
ester 21 in 80 % yield. 1H NMR (500 MHz, DMSO-d6): δ= 12.22 (br, 1H), 7.78 (t, J = 
6.3Hz, 1H), 7.26-7.39 (m, 5H), 5.03 (s, 2H), 4.09 (dd, J = 13.3, 8.1 Hz, 1H), 2.37-2.43 (m, 
1H), 2.26-2.34 (m, 1H), 1.92-2.03 (m, 1H),  1.73-1.85 (m, 1H); 13C NMR (125 MHz, DMSO-
d6) (2 rotamers): δ= 173.6, 172.4, 156.1, 136.8, 128.4, 128.3, 127.8, 127.7, 127.6, 65.5/65.5, 
53.0/52.9, 51.9/51.9, 51.3, 29.8/29.6, 25.9/25.8; IR (neat): ῦ = 3303, 3032, 2956, 1701, 
1524, 1436, 1418, 1345, 1256, 1212, 1178, 1050, 1015, 951, 912, 778, 735, 696, 599 cm-1; 
HRMS (ESI), m/z: calcd for C14H17NNaO6, 318.0948; found, 318.0945 [M + Na]+; [α]D25 
+22.7 (c 1.05, MeOH). 
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1-Methyl-4-hydroxyethylcarbamoyl-N-Cbz-D-glutamic ester (22)  
0.90 g (3.05 mmol) of methyl ester 21, DCC (0.76 g, 3.66 
mmol) and HOBt (0.49 g, 3.66 mmol) were dissolved in DMF 
(8.0 mL) at 25 °C. Ethanolamine (0.19 g, 3.05 mmol) was 
added after 30 minutes and the reaction was stirred for 12 
hours. The reaction mixture was filtered, concentrated and the desired product was 
purified by flash column chromatography (DCM/5 % MeOH) to get it as a white solid in 
41% yield. 1H NMR (400 MHz, CDCl3): δ= 7.29-7.37 (m, 5H), 6.42 (s, 1H), 5.84 (d, J = 
7.4 Hz, 1H), 5.09 (s, 2H), 4.34 (t, J = 6.9 Hz, 1H), 3.73 (s, 3H), 3.61-3.69 (m, 2H), 3.41-
3.48 (m, 1H), 3.23-3.33 (m, 1H), 2.89 (br, 1H), 2.19-2.30 (m, 3H), 1.88-1.97 (m, 1H); 13C 
NMR (125 MHz, CDCl3): δ= 172.8, 172.5, 156.4, 136.0, 128.5, 128.2, 128.1, 67.1, 61.7, 
53.3, 52.6, 42.4, 32.2, 28.5; IR (film): ῦ = 3308, 3067, 3031, 2943, 1707, 1650, 1536, 1454, 
1438, 1339, 1262, 1216, 1177, 1057, 746, 698 cm-1; HRMS (ESI), m/z: calcd for 
C16H22N2NaO6, 361.1370; found, 361.1369 [M + Na]+; [α]D26 +13.3 (c 1.00, MeOH). 
 
1-Methyl-4-hydroxyethylcarbamoyl -D-glutamic ester (23)   
Alcohol 22 (0.199 g, 0.561 mmol) was dissolved in dried MeOH 
(2.0 mL). 10% Pd on activated charcoal (19.9 mg) were added and 
the reaction was carried out under a H2 atmosphere at 25 °C until 
disappearance of the starting material. The reaction mixture was filtered through celite 
and washed with MeOH to obtain 30 (0.139 g, 81% yield), which was used without further 
purification. 1H NMR (500 MHz, MeOD): δ= 3.73 (s, 3H), 3.59 (t, J = 5.8 Hz, 2H), 3.52 
(dd, J = 7.2, 5.9 Hz, 1H), 3.29 (t, J =5.8 Hz,  2H), 2.32 (ddd, J = 8.1, 4.8, 1.8 Hz,  2H), 
2.00-2.07 (m, 1H), 1.85-1.92 (m, 1H); 13C NMR (125 MHz, MeOD): δ= 176.3, 175.3, 61.6, 
54.6, 52.7, 43.0, 33.0, 31.1; IR (film): ῦ = 3288, 3078, 2936, 2865, 1732, 1644, 1551, 1438, 
1380, 1210, 1176, 1065 cm-1; HRMS (ESI), m/z: calcd for C8H17N2O4, 205.1183; found, 
205.1184 [M + H]+; [α]D26 -10.5. (c 0.76, MeOH). 
 
Phenyl (R)-3-(2-hydroxyethylcarbamoyl)-1(methoxycarbonyl)propylcarbamate 
(O3) 
Amine 30 (105 mg, 0.51 mmol) was dissolved in dioxane (2.0 
mL) and Et3N was added (143 μL). The solution was cooled to 
0 °C and phenyl chloroformate (71 μL, 0.51 mmol) was added 
dropwise. The reaction was run at 25 °C for 12 hours. It was 
diluted with water and extracted with EtOAc. The residue was purified by flash column 
chromatography (DCM/5 % MeOH) obtaining the desired product in pure form (32.1mg, 
18% yield). 1H NMR (500 MHz, CDCl3): δ= 7.34 (t, J = 7.6 Hz, 2H), 7.19 (t, J = 7.4 Hz, 
1H), 7.10 (d, J = 7.8 Hz, 2H), 6.60 (t, J = 5.5 Hz, 1H), 6.43 (d, J = 8.0 Hz, 1H), 4.38 (dt, 
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J = 8.5, 4.1 Hz, 1H), 3.75 (s, 3H), 3.59-3.67 (m, 2H), 3.36-3.42 (m, 1H), 3.25-3.31 (m, 1H), 
2.22-2.33 (m, 3H), 1.97-2.05 (m, 1H); 13C NMR (125 MHz, CDCl3): δ= 172.9, 172.3, 154.8, 
150.7, 129.3, 125.5, 121.5, 61.6, 53.6, 52.7, 42.3, 32.1, 28.1; IR (film): ῦ = 3323, 3052, 2948, 
1726, 1650, 1538, 1490, 1442, 1354, 1207, 1066, 1025, 688, 482, 418 cm-1; HRMS (ESI), 
m/z: calcd for C15H20N2NaO6, 347.1214; found, 347.1216 [M + Na]+; [α]D26 + 0.36 (c 0.65, 
MeOH). 
 
Phenyl-(R)-3-(formylmethylcarbamoyl)-1-(methoxycarbonyl)propylcarbamate 
(O1) 
To a solution of alcohol O3 (21.3 mg, 0.060 mmol) in DCM (0.6 
mL), DMP (30.6 mg, 0.072 mmol) was added at 0 °C. The 
reaction mixture was stirred for 15 minutes at 0 °C and at 25 °C 
for 2 hours. The reaction was quenched with an aqueous basic 
Na2S2O3 solution in saturated sodium bicarbonate, it was stirred for 15 minutes and 
extracted with EtOAc. The combined organic phases were dried over MgSO4, concentrated, 
and the desired product O1 was purified by flash column chromatography (EtOAc). (10.0 
mg, 45% yield). 1H NMR (500 MHz, CDCl3): δ= 9.64  (s, 1H), 7.36 (t, J = 7.9 Hz, 2H), 
7.20 (t, J = 7.4 Hz, 1H), 7.12 (t, J = 7.9 Hz, 2H), 6.62 (br, 1H), 6.07 (d, J = 7.7 Hz, 1H), 
4.49 (dt, J = 8.4, 4.2 Hz, 1H), 4.19 (ddd, J = 39.7, 20.4, 5.1 Hz, 2H), 3.79 (s, 3H), 2.44 
(dd, J = 13.3, 6.6 Hz, 1H), 2.28-2.34 (m, 1H), 2.03-2.10 (m, 1H), 1.23-1.27 (m, 1H), 0.83-
0.89 (m, 1H); 13C NMR (125 MHz, CDCl3): δ= 196.4, 172.3, 172.2, 154.7, 150.7, 129.3, 
125.6 121.5 53.5 52.7, 50.3, 32.0, 28.6; IR (film): ῦ = 3327, 3062, 2958, 2922, 2859, 1732, 
1654, 1530, 1489, 1438, 1262, 1205, 1025, 734, 690, 476, 438, 406 cm-1;  HRMS (ESI), m/z: 
calcd for C15H18N2NaO6, 345.1057; found, 345.1052 [M + Na]+;[α]D25 + 2.90 (c 0.55, DCM). 
 
1-Methyl-4-formylmethylcarbamoyl-N-Cbz-D-glutamic ester (O2)   
Methyl ester 22 (48.5 mg, 0.14 mmol) was dissolved in 1.0 mL 
of non-dried DCM. It was cooled to 0 °C and DMP (0.072 g) 
was added. The reaction mixture was stirred for 15 minutes at 
0 °C and at 25 °C for 1 hour. The reaction was quenched with 
an aqueous basic Na2S2O3 solution in saturated sodium bicarbonate, it was stirred for 15 
minutes and extracted with EtOAc. The combined organic phases were dried over MgSO4, 
concentrated, and the desired product O2 was purified by flash column chromatography 
(EtOAc). (19.8 mg, 41% yield). 1H NMR (500 MHz, CDCl3): δ= 9.63 (s, 1H), 7.30-7.36 (m, 
5H), 6.54 (br, 1H), 5.60 (d, J = 7.0 Hz, 1H), 5.07-5.14 (m, 2H), 4.44 (dt, J = 8.6, 8.2, 4.0 
Hz, 1H), 4.17 (dq, J = 20.4, 20.3, 4.9 Hz, 2H), 3.75 (s, 3H),  2.32-2.41 (m, 2H), 2.21-2.30 
(m, 1H), 1.93-2.02 (m, 1H); 13C NMR (125 MHz, CDCl3): δ= 196.3, 172.3, 172.2, 156.3, 
136.1, 128.6, 128.3, 128.1, 67.2, 53.3, 52.6, 50.9, 50.3, 32.0, 28.7; IR (film): ῦ = 3307, 3062, 
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3031, 2952, 1716, 1655, 1530, 1454, 1438, 1260, 1214, 1053, 739, 699, 411 cm-1; HRMS 
(ESI), m/z: calcd for C16H20N2NaO6, 359.1214; found, 359.1210 [M + Na]+; [α]D25 -4.38 (c 
0.34, MeOH). 
 
N-Benzyloxycarbonyl-L-glutamic acid (34)  
Following an identical procedure to the one described for 
compound 19, starting from L-glutamic acid (5.00 g, 33.98 mmol), 
diacid 34 was obtained as a white solid (3.69 g, 38 % yield). 1H 
NMR (400 MHz, DMSO-d6): δ= 12.37 (br, 2H), 7.58 (d, J = 8.1 Hz, 1H), 7.29-7.36 (m, 
5H), 5.03 (s, 2H), 4.00 (dt, J = 9.4, 5.0 Hz, 1H), 2.28-2.32 (m, 2H), 1.97 (dq, J = 7.6, 7.7, 
5.0 Hz, 1H),  1.71-1.81 (m, 1H);    13C NMR (100 MHz, DMSO-d6): δ= 173.6, 173.5, 156.1, 
136.9, 128.3, 127.7, 127.6, 65.3, 53.0, 30.0, 26.0; IR (neat): ῦ = 3302, 3037, 2945, 1701, 
1685, 1547, 1525, 1418, 1257, 1169, 1051, 1015, 951, 909, 779, 734, 694, 651, 599 cm-1; MS 
(ESI), m/z: calcd for C13H14NO6, 280.1; found, 279.9 [M - H]-; [α]D25 = - 16.3 (c = 1.01 in 
MeOH). 
 
4-(S)-(2-Carboxy-ethyl)-5-oxo-oxazolidine-3-carboxylic acid benzyl ester (35)  
Following an identical procedure as the one described for compound 
20, starting from diacid 34 (3.40 g, 12.09 mmol), azalactone 35 was 
obtained (2.86 g, 91% yield). 1H NMR (400 MHz, DMSO-d6): δ= 
12.21 (br, 1H), 7.31-7.41 (m, 5H),  5.45 (d, J = 4.0 Hz, 1H), 5.29 (s, 1H), 5.12-5.18 (m, 
2H),  4.41 (t, J = 5.6 Hz, 1H), 2.21-2.38 (m, 2H), 2.09-2.17 (m, 1H), 1.96-2.05 (m, 1H); 13C 
NMR (125 MHz, DMSO-d6) : δ= 173.4, 172.4, 136.1, 128.4, 128.0, 127.6, 77.8, 66.7, 53.9, 
48.6, 28.9, 25.6; IR (neat): ῦ = 3299, 3032, 2951, 1798, 1702, 1524, 1416, 1358, 1252, 1212, 
1166, 1130, 1051, 1015, 916, 750, 735, 696, 614, 568, 493 cm-1; MS (ESI), m/z: calcd for 
C14H14NO6, 292.1; found, 292.0 [M - H]-; [α]D25 = + 41.6 (c = 1.04 in MeOH). 
 
1-Methyl-N-Cbz-L-glutamic ester (36)  
Following an identical procedure as the one described for compound 
21, starting from acid 35 (0.75 g, 2.55 mmol), mono-ester 36 was 
obtained (0.64 g, 85% yield). 1H NMR (300 MHz, DMSO-d6): δ= 
11.99 (br, 1H), 7.77 (d, J = 7.7 Hz, 1H), 7.31-7.40 (m, 5H), 5.04 (s, 2H), 4.10 (dd, J = 
13.2, 8.0 Hz, 1H), 3.63 (s, 3H), 2.31 (t, J = 7.1 Hz, 2H), 1.91-2.03 (m, 1H),  1.78 (dt, J = 
14.5, 7.4 Hz, 1H); 13C NMR (125 MHz, DMSO-d6): δ= 173.6, 172.5, 156.1, 136.8, 128.3, 
127.8, 127.7, 65.5, 53.0, 51.9, 29.8, 25.9; IR (neat): ῦ = 3513, 3345, 3032, 2956, 1711, 1529, 
1454, 1438, 1258, 1210, 1176, 1047, 1024, 992, 818, 741, 698, 608, 580, 458 cm-1; MS (ESI), 
m/z: calcd for C14H17NNaO6, 318.1; found, 318.1 [M + Na]+.; [α]D26 = - 12.4 (c = 1.09 in 
MeOH). 
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1-Methyl-4-hydroxyethylcarbamoyl-N-Cbz-D-glutamic ester (37)   
Following an identical procedure as the one described for 
compound 22, starting from the mono-ester 36 (0.86 g, 2.71 
mmol), alcohol 37 was obtained (0.54 g, 56% yield). 1H NMR 
(400 MHz, CDCl3): δ= 7.19-7.27 (m, 5H), 6.72 (t, J = 5.5 Hz, 
1H), 6.13 (d, J = 8.0 Hz, 1H), 4.99 (s, 2H), 4.23 (dt, J = 8.3, 4.5 Hz, 1H), 3.61 (s, 3H), 
3.49-3.57 (m, 2H), 3.15-3.32 (m, 2H),  2.04-2.21 (m, 3H), 1.87 (dt, J = 15.3, 15.1, 6.8 Hz, 
1H); 13C NMR (125 MHz, CDCl3): δ= 172.7, 172.4, 156.4 136.0, 128.6, 128.3, 128.1, 67.2, 
62.0, 53.1, 52.6, 42.5, 32.3, 28.8; IR (neat): ῦ = 3414, 3296, 3060, 3032, 2956, 1747, 1684, 
1629, 1528, 1453, 1351, 1284, 1247, 1217, 1168, 1049, 864, 783, 756, 736, 697, 656, 613, 589, 
428 cm-1; MS (ESI), m/z: calcd for C16H22N2NaO6, 361.1; found, 361.2 [M + Na]+; [α]D27 = - 
15.4 (c = 1.09 in MeOH). 
 
1-Methyl-4-hydroxyethylcarbamoyl -D-glutamic ester (38)  
Following an identical procedure as the one described for 
compound 23, starting from alcohol 36 (0.269 g, 0.76 mmol), 
amine 38  was obtained (0.137 g, 89 % yield). 1H NMR (500 MHz, 
MeOD): δ= 3.86 (s, 3H), 3.73 (t, J = 5.7 Hz, 2H), 3.61 (t, J = 6.9 Hz,1H), 3.43 (t, J = 5.7 
Hz,  2H), 2.45 (t, J = 6.7 Hz,  2H), 2.12-2.21 (m, 1H), 1.96-2.07 (m, 1H); 13C NMR (100 
MHz, MeOD): δ= 176.8, 175.3, 61.6, 54.7, 52.6, 43.0, 33.0, 31.5; IR (film): ῦ = 3362, 3281, 
3078, 2933, 2864, 1732, 1644, 1547, 1437, 1368, 1205, 1176, 1060, 666, 574, 499 cm-1; MS 
(ESI), m/z: calcd for C8H16N2 NaO4, 227.1; found, 227.0 [M + Na]+;[α]D27 = - 5.2 (c = 1.06 
in MeOH). 
 
Phenyl-(S)-3-(2-hydroxyethylcarbamoyl)-1-(methoxycarbonyl)propylcarbamate 
(O6)  
Following an identical procedure as the one described for 
compound O3, starting from amine 38 (49.8 mg, 0.244 mmol), 
carbamate O6  was obtained (37.1 mg, 45 % yield). As a side 
product (11 %), the alcohol also reacted with phenyl 
cholorformate. 1H NMR (500 MHz, CDCl3): δ= 7.35 (t, J = 7.9 Hz, 2H), 7.20 (t, J = 7.4 
Hz, 1H), 7.12 (d, J = 7.8 Hz, 2H), 6.46 (br, 1H), 6.26 (d, J = 7.9 Hz, 1H), 4.40 (dt, J = 
8.4, 3.8 Hz, 1H), 3.77 (s, 3H), 3.62-3.71 (m, 2H), 3.41-3.47 (m, 1H), 3.27-3.33 (m, 1H), 2.66 
(br, 1H), 2.26-2.38 (m, 3H), 1.98-2.05 (m, 1H); 13C NMR (125 MHz, CDCl3): δ= 172.9, 
172.3, 154.8, 150.7, 129.3, 125.6, 121.5, 61.8, 53.5, 52.7, 42.5, 32.2, 28.4; IR (film): ῦ = 
3330, 3286, 3055, 2945, 1720, 1649, 1535, 1488, 1437, 1351, 1260, 1201, 1140, 1068, 1025, 
764, 756, 688, 496 cm-1; MS (ESI), m/z: calcd for C15H20N2 NaO6, 347.1; found, 347.1 [M + 
Na]+; [α]D28 = - 2.9 (c = 1.23 in DCM). 
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Phenyl (S)-3-(formylmethylcarbamoyl)-1-(methoxycarbonyl)propylcarbamate 
(O4) 
Following an identical procedure as the one described for 
compound O1, starting from alcohol O6 (13.0 mg, 0.038 mmol), 
aldehyde O4 was obtained (6.3 mg, 49 % yield). 1H NMR (400 
MHz, CDCl3): δ= 9.64 (s, 1H), 7.36 (t, J = 7.9 Hz, 2H), 7.20 (t, 
J = 7.4 Hz, 1H), 7.13 (d, J = 7.9 Hz, 2H), 6.54 (s, 1H), 6.02 (d, J = 7.4 Hz, 1H), 4.49 (td, 
J = 8.3, 4.3 Hz, 1H), 4.19 (qd, J = 20.4, 5.1 Hz, 2H), 3.79 (s, 3H), 2.47-2.40 (m, 2H), 2.36-
2.25 (m, 1H), 2.13-2.03 (m, 1H); 13C NMR (125 MHz, CDCl3): δ= 196.4, 172.3, 172.2, 
154.7, 150.7, 129.3, 125.6 121.5 53.5 52.7, 50.3, 32.0, 28.6; IR (film): ῦ = 3333, 3055, 2956, 
2927, 2852, 1723, 1652, 1530, 1488, 1455, 1438, 1345, 1202, 1141, 1025, 759, 689, 490, 403 
cm-1; MS (ESI), m/z: calcd for C15H18N2NaO6, 345.1; found, 345.1 [M + Na]+; [α]D29 = - 4.9 
(c = 0.27 in DCM). 
 
1-Methyl-4-formylmethylcarbamoyl-N-Cbz-L-glutamic ester (O5) 
Following an identical procedure as the one described for 
compound O2, starting from alcohol 37 (34.6 mg, 0.098 mmol), 
aldehyde O5 was obtained (22.2 mg, 65 % yield). 1H NMR (500 
MHz, CDCl3): δ= 9.61 (s, 1H), 7.31-7.36 (m, 5H), 6.58 (br, 1H), 5.65 (d, J = 7.8 Hz, 1H), 
5.07-5.13 (m, 2H), 4.43 (dt, J = 8.5, 4.5 Hz, 1H), 4.16 (dq, J = 20.2, 4.9 Hz, 2H), 3.75 (s, 
3H), 2.31-2.41 (m, 2H), 2.24 (td, J = 19.2, 7.1 Hz, 1H), 1.94-2.01 (m, 1H); 13C NMR (125 
MHz, CDCl3): δ= 196.5, 172.7, 172.5, 173.3, 156.4, 136.0, 128.5, 128.3, 128.2, 128.1, 67.2, 
67.1, 61.8, 53.3, 53.2, 52.6, 50.3, 42.5, 32.2, 32.0, 28.7, 28.7, 28.6, presence of rotamers; IR 
(film): ῦ = 3325, 3060, 3032, 2956, 1715, 1654, 1531, 1454, 1438, 1340, 1259, 1216, 1055, 
740, 698, 592 cm-1; MS (ESI), m/z: calcd for C16H20N2NaO6, 359.1; found, 359.1 [M + Na]+; 
[α]D29 =  + 3.6 (c = 1.04 in DCM). 
4.6.2 Cellular proliferation assays 
Muscle NIH/3T3 (myc-), HT29 and MDA-MB-231 cells obtained from the UZH 
Cancer Institute and A498 cells obtained from Prof. Krek (Institute of Cell Biology, ETH) 
were cultured in DMEM supplemented with 10 % (v/v) fetal bovine serum, 100 units/mL 
of penicillin, 100 g/mL of streptomycin, 4.5 g/L glucose, 0.11g/L sodium pyrubate and 
2mM glutamine and the cells were grown at 37 ºC in 5% CO2 atmosphere with 80% 
relative humidity. A 5mM stock solution of the compounds in DMSO was prepared and 
kept at -20 °C. 
The cells were plated at 5,000 cells per well (100 μL per well) in 96-well culture dishes 
and allowed to incubate for 24 h. The old media was removed, cells were washed with PBS 
(phosphate-buffered saline) and fresh media was added. A 5 mM solution of inhibitor (in 
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100% DMSO) was serially diluted in the culture media (12 different concentrations were 
used) and allowed to incubate for 24, 48 or 72 h. Control cells were treated with the same 
DMSO concentrations. After the incubation period the media was once more removed and 
the cells were washed with PBS to then be incubated with fresh media containing 86 nM 
resazurin. After 4 hours, the fluorescence was quantified using a fluorescence microplate 
reader (Biotek, FLx800TM) at the respective excitation and emission wavelength of 560 and 
590 nm. Resazurin becomes fluorescent under mitochondrial reduction and its emission 
directly correlates with the metabolic viability of the cells.  The measured fluorescence 
values were corrected from the control samples containing DMSO and IC50 values were 
determined by plotting the fraction of metabolically active cells against the log of the drug 
concentration. All measurements were performed at least in triplicate.   
4.6.3 Fluorescent visualization of F-actin 
10 000 cells per well in 90uL cell culture media were seeded in MEZEL diagnostic 
slides (PTFE coating around 10 wells of 6.7mm diameter each) and grown overnight. The 
cells were incubated with 4uM, 1uM and 250nM for 2 h or 8 h of the corresponding 
compound. For the recovery experiments, the cells were incubated for 2 h and allowed to 
recover in fresh media for 22 h.  
The cells were washed with PBS and fixed with a solution of 4% paraformaldehyde in 
PBS for 10 minutes. Actin filaments were stained for 1h with a solution of 0.1 M 
tetramethyl rhodamine isothiocyanate TRITC labelled phalloidin (P1951, Sigma Aldrich) 
in PBS and cell nuclei were stained with a 1 g/mL DAPI (2-(4-amidinophenyl)-6-
indolecarbamidine dihydrochloride) solution in PBS. The cells were mounted in Glycergel® 
mounting medium (Dako) after several PBS washes. Cells were visualized and 
photographed using a 40 x oil objective, A4 (nuclei) and TX2 (actin) filter cubes in a Leica 
wide field microscope (Hamamatsu EM-CCD).  
4.6.4  In vitro actin polymerization experiments 
In the polymerization experiments pyrene labeled muscle actin (Cytoeskeleton) was 
depolymerized on ice cold G-buffer (5 mM Tris-HCl pH 8.0, 0.2 mM CaCl2 and 0.2 mM 
ATP) at a concentration of 2.5 µM for two days.  
Actin was polymerized at 24 °C at 2.5 µM of the corresponding actin concentrations in 
a 96 well-plate (150 µL/well) and with 10 µM compound concentration.  All the wells 
contained the same DMSO concentration (less than 5%). The fluorescence of pyrene 
labeled actin with the drug was monitored for 20 min to establish a baseline. Actin 
polymerization was induced by the addition of actin polymerization buffer (50 mM KCl, 2 
mM MgCl2 and 1 mM ATP, final concentrations). The polymerization process was 
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measured by monitoring the fluorescence once every 30 s for a total of 1 h-1.5 h in a Tecan 
Infinite® M1000 microplate reader with an excitation and emission wavelength of 350 nm 
and 407 nm respectively. Plotting and statistical analysis was performed using Origin. 
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5 
CONCLUSIONS AND OUTLOOK 
 
Modern drug discovery involves the identification of hits for a particular target, 
medicinal chemistry optimization of those hits to increase the affinity, selectivity, efficacy 
and drug-like properties, followed by in vivo efficacy studies preceding clinical 
development. In this Ph.D. thesis, three independent projects dealing with in silico 
fragment-based hit discovery and medicinal chemistry optimization campaigns are 
presented for the discovery of kinase, bromodomain and actin inhibitors.  
First, single digit nanomolar potent kinase inhibitors were designed based on X-ray 
structures of EphA3 kinase in complex with in silico identified hits. Different binding 
modes were designed, which resulted in the development of a total of 25 type I, I1/2 and II 
kinase inhibitors. These inhibitors were characterized by an array of biophysical techniques 
including enzymatic assays, differential scanning fluorimetry and surface plasmon 
resonance. Some of these compounds presented good selectivity profiles against a panel of 
453 kinases and their antiproliferation activity against a panel of cancer cells revealed 
remarkable growth inhibition values in the low nanomolar range, especially against a 
leukemia cell line. Finally, in vivo assays (mice xenografted with human breast cancer) 
confirmed the cytostatic activity of one of our inhibitors, which makes it a promising 
candidate lead for further preclinical development. Further steps to be carried out include 
the evaluation of solubility and metabolic stability of the designed inhibitors, as well as 
their study on a leukemia mouse model due to the high antiproliferative activities observed 
in a leukemia cell line for several derivatives.  
The next project presented in this thesis aimed to identify and optimize CREBBP 
bromodomain ligands. Bromodomains have recently been recognized as potential 
therapeutic targets, and thus, there is a big need for the development of potent and 
selective bromodomain ligands that could validate this approach. During this thesis, novel 
ligands of the CREBBP bromodomain were identified by fragment-based docking. The in 
silico hits were optimized by chemical synthesis resulting in 24 derivatives, some of which 
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turned out to be selective nanomolar ligands achieving an almost 30 fold improvement in 
binding affinity. The synthesized analogues presented unprecedented selectivity values for 
the CREBBP bromodomain over other human bromodomain sub-families, as a result of 
establishing electrostatic interactions between the designed ligands and the Arg1173 side 
chain of the protein. The mentioned interaction was confirmed by solving the high-
resolution crystal structure of the CREBBP bromodomain in complex with one of the 
synthesized ligands. A preliminary cell based screening revealed that our CREBBP ligands 
are able to inhibit the proliferation of leukemia cell lines in the low micromolar level. 
Future research will concentrate on the study of properties such as water solubility, by the 
addition of water solubilizing groups (e.g. morpholine, piperazine, etc.) and membrane 
permeability, by the substitution of the benzoic acid moiety present in the compounds by 
isosters (e. g. tetrazole, sulfonamides etc.) in order to develop promising lead candidates 
whose efficacy will be evaluated on in vivo models. 
Another aspect of this Ph. D. work dealt with the in silico design, synthesis and 
biological evaluation of actin binders. Actin is a novel and attractive protein target that 
has so far remained unexplored in the context of small organic molecule ligands.  During 
this work, we have designed and validated a new computational approach to discover novel 
actin leads targeting the ATP binding site of actin. The in silico campaign resulted in the 
selection of fifteen fragments, from which five scaffolds were chemically synthesized. Cell 
based studies revealed that the compounds were able to alter the morphology of the actin 
cytoskeleton at low micromolar concentrations by reducing the microfilament bundles 
(stress fibers) and inducing cell shrinkage and actin aggregation. Moreover, moderate 
inhibition of actin polymerization was obtained in an in vitro actin polymerization assay. 
As a result, the developed small organic molecules are promising starting hits for the 
development of more potent actin inhibitors. In the future we aim to design and synthesize 
more potent derivatives of the mentioned scaffolds, as well as to implement a computer 
based de novo design campaign aiming to develop novel actin binding molecules.  
To sum up, we can conclude that the combination of computer-based drug design, 
X-ray crystallography, chemical synthesis and in vitro and cell based assays performed 
during this work has proven to be an efficient strategy for the development of promising 
kinase and bromodomain ligands as well as for the identification of actin inhibitor hits with 
moderate potency.  
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